rearrangement	amino_acid	frame_type	rearrangement_type	templates	reads	frequency	productive_frequency	cdr3_length	v_family	v_gene	v_allele	d_family	d_gene	d_allele	j_family	j_gene	j_allele	v_deletions	d5_deletions	d3_deletions	j_deletions	n2_insertions	n1_insertions	v_index	n1_index	n2_index	d_index	j_index	v_family_ties	v_gene_ties	v_allele_ties	d_family_ties	d_gene_ties	d_allele_ties	j_family_ties	j_gene_ties	j_allele_ties	sequence_tags	v_shm_count	v_shm_indexes	antibody	bio_identity	v_resolved	d_resolved	j_resolved	sample_name	species	locus	product_subtype	kit_pool	sku	test_name	sample_catalog_tags	sample_rich_tags	sample_rich_tags_json	kit_control	total_templates	productive_templates	outofframe_templates	stop_templates	dj_templates	total_rearrangements	productive_rearrangements	outofframe_rearrangements	stop_rearrangements	dj_rearrangements	total_reads	total_productive_reads	total_outofframe_reads	total_stop_reads	total_dj_reads	productive_clonality	productive_entropy	sample_clonality	sample_entropy	sample_amount_ng	sample_cells_mass_estimate	fraction_productive_of_cells_mass_estimate	sample_cells	fraction_productive_of_cells	max_productive_frequency	max_frequency	counting_method	primer_set	sequence_result_status	release_date	upload_date	sample_tags	fraction_productive	order_name	kit_id	total_t_cells	total_templates_agg
GACTCGGCCATGTATCGCTGTGCCAGCAGCTTAGTTGGGGCAGGCCCGACCGGGGAGCTGTTTTTTGGAGAA	CASSLVGAGPTGELFF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	48	TCRBV07	TCRBV07-06	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	1	7	0	5	2	7	18	34	41	36	48														CASSLVGAGPTGELFF+TCRBV07-06+TCRBJ02-02	TCRBV07-06*01	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCATGTATCGCTGTGCCAGCAGCATCCTGGCTAGCGCGAGTTTCTACAATGAGCAGTTCTTCGGGCCA	CASSILASASFYNEQFF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	51	TCRBV07	TCRBV07-06	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	4	6	3	7	7	18	30	43	37	50						01,02								CASSILASASFYNEQFF+TCRBV07-06+TCRBJ02-01	TCRBV07-06*01	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCATGTATCGCTGTGCCAGCAGCTTAGCTAGCGGGGGAAAGACCCAGTACTTCGGGCCA	CASSLASGGKTQYF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	42	TCRBV07	TCRBV07-06	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	0	5	2	6	0	2	18	-1	44	35	46														CASSLASGGKTQYF+TCRBV07-06+TCRBJ02-05	TCRBV07-06*01	TCRBD02-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCATGTATCGCTGTGCCAGCAGCTGGTGGCGGGGGGGCCGTACAGATACGCAGTATTTTGGCCCA	CASSWWRGGRTDTQYF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	48	TCRBV07	TCRBV07-06	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	4	7	0	3	4	4	18	31	44	35	48														CASSWWRGGRTDTQYF+TCRBV07-06+TCRBJ02-03	TCRBV07-06*01	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCATGTATCGCTGTGCCAGAAGCTTGGCCGGGACAGGGTTAAACACTGAAGCTTTCTTTGGACAA	CARSLAGTGLNTEAFF	In	VDJ	1	19	3.358789421581106E-4	4.066084574559151E-4	48	TCRBV07	TCRBV07-06	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	0	3	2	4	3	18	32	45	36	48														CARSLAGTGLNTEAFF+TCRBV07-06+TCRBJ01-01	TCRBV07-06*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCATGTATCGCTGTGCCAGCAGCTTGACGGGTCTTAATGAAAAACTGTTTTTTGGCAGT	CASSLTGLNEKLFF	In	VDJ	1	22	3.8891245934097015E-4	4.7080979284369113E-4	42	TCRBV07	TCRBV07-06	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-04	01	3	8	4	4	2	3	18	32	38	34	41						01,02								CASSLTGLNEKLFF+TCRBV07-06+TCRBJ01-04	TCRBV07-06*01	TCRBD02-01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCATGTATCGCTGTGCCAGCAGCTTGGGGGTTAGTATTAACACTGAAGCTTTCTTTGGACAA	CASSLGVSINTEAFF	In	VDJ	1	25	4.4194597652382975E-4	5.350111282314672E-4	45	TCRBV07	TCRBV07-06	01				TCRBJ01	TCRBJ01-01	01	3	6	1	2	0	8	18	-1	37	32	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGVSINTEAFF+TCRBV07-06+TCRBJ01-01	TCRBV07-06*01		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCATGTATCGCTGTGCCAGCAGCGCGTCAGGGATGTGGAATGAAAAACTGTTTTTTGGCAGT	CASSASGMWNEKLFF	In	VDJ	2	46	8.131805968038467E-4	9.844204759458996E-4	45	TCRBV07	TCRBV07-06	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	5	4	3	5	4	6	18	30	39	34	45														CASSASGMWNEKLFF+TCRBV07-06+TCRBJ01-04	TCRBV07-06*01	TCRBD01-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGACTCGGCTGTGTATCTCTGTGCCAGCAGCTTGGGGGCCTCTGGAAACACCATATATTTTGGAGAG	CASSLGASGNTIYF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	42	TCRBV07	TCRBV07-05	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	2	6	0	0	0	0	19	-1	-1	33	39														CASSLGASGNTIYF+TCRBV07-05+TCRBJ01-03	TCRBV07-05*01	TCRBD01-01*01	TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGACTCGGCTGTGTATCTCTGTGCCAGTAGCTTAGATCCCAGCGGGGGGTACAATGAGCAGTTCTTCGGGCCA	CASSLDPSGGYNEQFF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	48	TCRBV07	TCRBV07-05	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	0	6	1	4	5	0	19	35	-1	40	49														CASSLDPSGGYNEQFF+TCRBV07-05+TCRBJ02-01	TCRBV07-05*01	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGACTCGGCTGTGTATCTCTGTGCCAGCAGCCCGACAACCGGGACTAGCGGGAGTCAGTTCTTCGGGCCA	CASSPTTGTSGSQFF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	45	TCRBV07	TCRBV07-05	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	4	0	2	13	9	1	19	31	54	40	55														CASSPTTGTSGSQFF+TCRBV07-05+TCRBJ02-01	TCRBV07-05*01	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGACTCGGCTGTGTATCTCTGTGCCAGCAGTACAGGGCCAGGGTTCTACGAGCAGTACTTCGGGCCG	CASSTGPGFYEQYF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	42	TCRBV07	TCRBV07-05	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	8	3	3	3	4	8	19	27	37	31	45														CASSTGPGFYEQYF+TCRBV07-05+TCRBJ02-07	TCRBV07-05*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGACTCGGCTGTGTATCTCTGTGCCAGCAGCCAGCGCCAGTTAGGGACCTCTGGAAACACCATATATTTTGGAGAG	CASSQRQLGTSGNTIYF	In	VDJ	1	21	3.71234620280017E-4	4.4940934771443245E-4	51	TCRBV07	TCRBV07-05	01				TCRBJ01	TCRBJ01-03	01	4	0	7	0	12	0	19	31	-1	43	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQRQLGTSGNTIYF+TCRBV07-05+TCRBJ01-03	TCRBV07-05*01		TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGACTCGGCTGTGTATCTCTGTGCCAGCAGCTTAGTCGACAGGGGTGGCTACGAGCAGTACTTCGGGCCG	CASSLVDRGGYEQYF	In	VDJ	1	25	4.4194597652382975E-4	5.350111282314672E-4	45	TCRBV07	TCRBV07-05	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	2	2	3	2	3	19	35	45	37	48														CASSLVDRGGYEQYF+TCRBV07-05+TCRBJ02-07	TCRBV07-05*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGACTCGGCTGTGTATCTCTGTGCCAGCAGCTTAGGGGGACCGAAGCTCCTATAATTCACCCCTCCACTTTGGGAAC		Out	VDJ	1	30	5.303351718285957E-4		52	TCRBV07	TCRBV07-05	01				TCRBJ01	TCRBJ01-06	01	0	0	7	0	1	5	19	35	41	36	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV07-05+TCRBJ01-06	TCRBV07-05*01		TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGAGGGGACAGCCAATGAGCAGTTCTTCGGGCCA	CASSEGTANEQFF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	39	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	0	5	6	2	1	23	36	45	38	46			01,02										Vb 1	CASSEGTANEQFF+TCRBV09-01+TCRBJ02-01	TCRBV09-01	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCACCCCCCCCGGGGACAACTACGAGTCGACTAACTATGGCTACACCTTCGGTTCG	CATPPGDNYESTNYGYTF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	54	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	9	0	6	0	9	12	23	30	45	39	57			01,02										Vb 1	CATPPGDNYESTNYGYTF+TCRBV09-01+TCRBJ01-02	TCRBV09-01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGTGGGTGCACGCTGAAGCTTTCTTTGGACAA		Out	VDJ	1	11	1.9445622967048507E-4		40	TCRBV09	TCRBV09-01					TCRBJ01	TCRBJ01-01	01	0	0	9	6	1	6	23	39	43	40	49			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	X+TCRBV09-01+TCRBJ01-01	TCRBV09-01		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGGCGTGAGGGGAGCACAGATACGCAGTATTTTGGCCCA	CASRREGSTDTQYF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	42	TCRBV09	TCRBV09-01					TCRBJ02	TCRBJ02-03	01	5	5	2	0	5	0	23	34	-1	39	44			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASRREGSTDTQYF+TCRBV09-01+TCRBJ02-03	TCRBV09-01		TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGTGCGGCTAGGGCTAGCGGGCGATCCTACGAGCAGTACTTCGGGCCG	CASSAARASGRSYEQYF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	51	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	4	4	1	11	3	23	34	53	45	56			01,02			01,02							Vb 1	CASSAARASGRSYEQYF+TCRBV09-01+TCRBJ02-07	TCRBV09-01	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGAGCAGACAGGCAACTATGGCTACACCTTCGGTTCG	CASSVEQTGNYGYTF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	45	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	2	4	2	4	1	23	39	49	43	50			01,02										Vb 1	CASSVEQTGNYGYTF+TCRBV09-01+TCRBJ01-02	TCRBV09-01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCTCGCGACCCGTAACCTACGAGCAGTACTTCGGGCCG	CASSSRPVTYEQYF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	42	TCRBV09	TCRBV09-01					TCRBJ02	TCRBJ02-07	01	4	2	7	2	4	6	23	35	42	39	48			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSSRPVTYEQYF+TCRBV09-01+TCRBJ02-07	TCRBV09-01		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGCCGACTAGCGGGAAAGGGAGCACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	19	3.358789421581106E-4		52	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	3	2	3	4	2	7	23	36	49	38	56			01,02										Vb 1	X+TCRBV09-01+TCRBJ02-02	TCRBV09-01	TCRBD02-01*02	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAAGTAGCGGGAGAGGCTACAATGAGCAGTTCTTCGGGCCA	CASSVSSGRGYNEQFF	In	VDJ	1	19	3.358789421581106E-4	4.066084574559151E-4	48	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	1	5	2	3	2	3	23	38	49	40	52			01,02										Vb 1	CASSVSSGRGYNEQFF+TCRBV09-01+TCRBJ02-01	TCRBV09-01	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGGTAGCGGGAGAGGCGCAGATACGCAGTATTTTGGCCCA	CASSGSGRGADTQYF	In	VDJ	1	22	3.8891245934097015E-4	4.7080979284369113E-4	45	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	3	5	2	4	1	5	23	36	46	37	51			01,02										Vb 1	CASSGSGRGADTQYF+TCRBV09-01+TCRBJ02-03	TCRBV09-01	TCRBD02-01*02	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGTGATTTTGGGGGAACGGGCGAGCAGTACTTCGGGCCG	CASSDFGGTGEQYF	In	VDJ	1	25	4.4194597652382975E-4	5.350111282314672E-4	42	TCRBV09	TCRBV09-01					TCRBJ02	TCRBJ02-07	01	5	6	1	6	7	6	23	34	46	41	52			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSDFGGTGEQYF+TCRBV09-01+TCRBJ02-07	TCRBV09-01		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCCCTCGGGAGAGCTCCTACGAGCAGTACTTCGGGCCG	CASSPRESSYEQYF	In	VDJ	1	29	5.126573327676425E-4	6.20612908748502E-4	42	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	4	8	2	0	3	2	23	35	44	38	46			01,02										Vb 1	CASSPRESSYEQYF+TCRBV09-01+TCRBJ02-07	TCRBV09-01	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGCGTAGGGATACAAACCGGCGGGGAGCTGTTTTTTGGAGAA	CASSVGIQTGGELFF	In	VDJ	2	49	8.662141139867063E-4	0.0010486218113336758	45	TCRBV09	TCRBV09-01					TCRBJ02	TCRBJ02-02	01	0	1	8	7	0	10	23	-1	42	39	52			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 1	CASSVGIQTGGELFF+TCRBV09-01+TCRBJ02-02	TCRBV09-01		TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAAAGGGAGGTCGGACACCGGGGAGCTGTTTTTTGGAGAA	CASKGRSDTGELFF	In	VDJ	2	50	8.838919530476595E-4	0.0010700222564629343	42	TCRBV09	TCRBV09-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	6	9	1	3	2	4	23	33	41	35	45			01,02										Vb 1	CASKGRSDTGELFF+TCRBV09-01+TCRBJ02-02	TCRBV09-01	TCRBD02-01*02	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGGGGGACTCAGCTTTGTATTTCTGTGCCAGCAGTGGACAGGGAAATTTTAGGGACATTCAGTACTTCGGCGCC	CASSGQGNFRDIQYF	In	VDJ	3	88	0.0015556498373638806	0.0018832391713747645	45	TCRBV09	TCRBV09-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	5	1	3	8	1	11	23	34	43	35	54			01,02										Vb 1	CASSGQGNFRDIQYF+TCRBV09-01+TCRBJ02-04	TCRBV09-01	TCRBD01-01*01	TCRBJ02-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCATGTATCTCTGTGCCAGCAGCTTAGAGCCAGGGGTGGGCGAGCAGTACTTCGGGCCG	CASSLEPGVGEQYF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	42	TCRBV11	TCRBV11-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	4	2	6	3	4	19	35	44	38	48														CASSLEPGVGEQYF+TCRBV11-01+TCRBJ02-07	TCRBV11-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCATGTATCTCTGTGCCAGCAGCTTCCCGGGGGCTAGTGGAAACACCATATATTTTGGAGAG	CASSFPGASGNTIYF	In	VDJ	1	27	4.7730165464573613E-4	5.778120184899846E-4	45	TCRBV11	TCRBV11-01	01				TCRBJ01	TCRBJ01-03	01	3	6	0	3	3	3	19	33	42	36	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSFPGASGNTIYF+TCRBV11-01+TCRBJ01-03	TCRBV11-01*01		TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCATGTATCTCTGTGCCAGCAGCTTGAGTGTGGGCATCACAGATACGCAGTATTTTGGCCCA	CASSLSVGITDTQYF	In	VDJ	1	30	5.303351718285957E-4	6.420133538777606E-4	45	TCRBV11	TCRBV11-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	3	8	0	2	6	2	19	33	43	39	45														CASSLSVGITDTQYF+TCRBV11-01+TCRBJ02-03	TCRBV11-01*01	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCATGTATCTCTGTGCCAGCAGCTTAGATTCATCCTGGACTAGCGGGTCCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	2	47	8.308584358647998E-4		55	TCRBV11	TCRBV11-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	1	1	4	2	9	2	19	35	55	44	57						01,02								X+TCRBV11-01+TCRBJ02-07	TCRBV11-01*01	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGATCAGCAGCTAGCCAAAAACATTCAGTACTTCGGCGCC	CASSQDQQLAKNIQYF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	48	TCRBV14	TCRBV14-01	01				TCRBJ02	TCRBJ02-04	01	0	4	5	0	1	5	29	46	50	47	55				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	CASSQDQQLAKNIQYF+TCRBV14-01+TCRBJ02-04	TCRBV14-01*01		TCRBJ02-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGCGAGCGCCGGCTACGAGCAGTACTTCGGGCCG	CASSQASAGYEQYF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	42	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	1	6	6	3	2	4	29	45	51	47	55						01,02							Vb 16	CASSQASAGYEQYF+TCRBV14-01+TCRBJ02-07	TCRBV14-01*01	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAACTCGGGCGGGGGGCGCACGTTACGCAGTATTTTGGCCCA	CASSQLGRGAHVTQYF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	48	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	2	7	1	8	5	7	29	44	57	49	64													Vb 16	CASSQLGRGAHVTQYF+TCRBV14-01+TCRBJ02-03	TCRBV14-01*01	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGCTCTCACAAAAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	11	1.9445622967048507E-4		44	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	3	6	2	5	2	29	45	53	50	55													Vb 16	X+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCCTAGGACTAGCGGGGGACACAATGAGCAGTTCTTCGGGCCA	CASSPRTSGGHNEQFF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	48	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	4	1	2	14	3	11	29	42	58	45	69													Vb 16	CASSPRTSGGHNEQFF+TCRBV14-01+TCRBJ02-01	TCRBV14-01*01	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCCTAGGACTAGCGGGGGACACAATGAGTAGTTCTTCGGGCCA	CASSPRTSGGHNE*FF	Stop	VDJ	1	11	1.9445622967048507E-4		48	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	4	1	2	14	3	11	29	42	58	45	69													Vb 16	CASSPRTSGGHNE*FF+TCRBV14-01+TCRBJ02-01	TCRBV14-01*01	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGACCGGGGTTGTAGGGGGCGCATGGCTACACCTTCGGTTCG	CASRPGL*GAHGYTF	Stop	VDJ	1	12	2.1213406873143826E-4		45	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	5	0	6	11	2	29	40	58	51	60													Vb 16	CASRPGL*GAHGYTF+TCRBV14-01+TCRBJ01-02	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCATTACGTCAGGACAATCGGCAATGAGCAGTTCTTCGGGCCA	CASSHYVRTIGNEQFF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	48	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	1	6	6	8	5	29	43	56	51	61													Vb 16	CASSHYVRTIGNEQFF+TCRBV14-01+TCRBJ02-01	TCRBV14-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCCATTACCCGGGACAGGGGGCCTAAACGATGAGCAGTTCTTCGGGCCA	CASSPLPGTGGLNDEQFF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	54	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	4	0	0	8	8	7	27	40	60	48	67													Vb 16	CASSPLPGTGGLNDEQFF+TCRBV14-01+TCRBJ02-01	TCRBV14-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGATTTGCGCACTGAAGCTTTCTTTGGACAA	CASSQDLRTEAFF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	39	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	0	7	6	4	3	0	29	46	-1	49	52						01,02							Vb 16	CASSQDLRTEAFF+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01	TCRBD02-01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGTGGACCCTGTGAGCAGTTCTTCGGGCCA		Out	VDJ	1	16	2.82845424975251E-4		38	TCRBV14	TCRBV14-01	01				TCRBJ02	TCRBJ02-01	01	1	1	7	9	1	4	29	45	50	46	54				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	X+TCRBV14-01+TCRBJ02-01	TCRBV14-01*01		TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAATTGGGACAGGAGAATGAGCAGTTCTTCGGGCCA	CASSQLGQENEQFF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	42	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	2	0	4	7	2	2	29	44	54	46	56													Vb 16	CASSQLGQENEQFF+TCRBV14-01+TCRBJ02-01	TCRBV14-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGAACGGGGGGCAACTGAAGCTTTCTTTGGACAA	CASSQERGATEAFF	In	VDJ	1	19	3.358789421581106E-4	4.066084574559151E-4	42	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	0	8	1	5	1	2	29	46	54	47	56													Vb 16	CASSQERGATEAFF+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01	TCRBD02-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGATAGGACAGGTGGTTACACCTTCGGTTCG	CASSQDRTGGYTF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	39	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	1	4	11	2	4	29	46	55	48	59													Vb 16	CASSQDRTGGYTF+TCRBV14-01+TCRBJ01-02	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCGATGGGAAGGGAGAGGCTCCTACGAGCAGTACTTCGGGCCG	CASSRWEGRGSYEQYF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	48	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	4	9	2	0	8	3	29	42	55	50	58													Vb 16	CASSRWEGRGSYEQYF+TCRBV14-01+TCRBJ02-07	TCRBV14-01*01	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGATGAAGGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	21	3.71234620280017E-4		37	TCRBV14	TCRBV14-01	01				TCRBJ01	TCRBJ01-04	01	0	2	8	8	1	2	29	46	49	47	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	X+TCRBV14-01+TCRBJ01-04	TCRBV14-01*01		TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCGTACTAGCGGGGGCGCCAGCGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	22	3.8891245934097015E-4		53	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	4	3	2	1	2	7	28	41	54	43	61													Vb 16	X+TCRBV14-01+TCRBJ02-03	TCRBV14-01*01	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAGGGGATAACCCTCGGGGAGACCCAGTACTTCGGGCCA	CASSQGITLGETQYF	In	VDJ	1	23	4.0659029840192336E-4	4.922102379729498E-4	45	TCRBV14	TCRBV14-01	01				TCRBJ02	TCRBJ02-05	01	3	0	8	5	1	11	29	43	48	44	59				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	CASSQGITLGETQYF+TCRBV14-01+TCRBJ02-05	TCRBV14-01*01		TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TTTATTTCTGTGCCAGCAGCCAAGTTTAACTAGCGGGAGGCAAGTCACCAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	24	4.2426813746287653E-4		62	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	1	3	1	2	4	9	8	24	40	28	49													Vb 16	X+TCRBV14-01+TCRBJ02-02	TCRBV14-01*01	TCRBD02-01*02	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCCCTTGGACGGATTCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSPLDGFSGANVLTF	In	VDJ	1	25	4.4194597652382975E-4	5.350111282314672E-4	51	TCRBV14	TCRBV14-01	01				TCRBJ02	TCRBJ02-06	01	4	1	7	0	4	5	29	42	50	46	55				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	CASSPLDGFSGANVLTF+TCRBV14-01+TCRBJ02-06	TCRBV14-01*01		TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCTTGGACTAGCGGCCTTCTACAATGAGCAGTTCTTCGGGCCA	CASSLGLAAFYNEQFF	In	VDJ	1	25	4.4194597652382975E-4	5.350111282314672E-4	48	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	4	1	5	3	2	4	29	42	54	44	58						01,02							Vb 16	CASSLGLAAFYNEQFF+TCRBV14-01+TCRBJ02-01	TCRBV14-01*01	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCGGATCTAGCAGATGGGGCGAGCAGTACTTCGGGCCG	CASSGSSRWGEQYF	In	VDJ	1	25	4.4194597652382975E-4	5.350111282314672E-4	42	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	4	7	6	4	8	29	41	50	45	58						01,02							Vb 16	CASSGSSRWGEQYF+TCRBV14-01+TCRBJ02-07	TCRBV14-01*01	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGGGGACAAAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	29	5.126573327676425E-4		44	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	1	0	6	2	0	1	29	-1	51	45	52													Vb 16	X+TCRBV14-01+TCRBJ02-02	TCRBV14-01*01	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCCCGGCATTGGTTTGGATACGCAGTATTTTGGCCCA	CASSPGIGLDTQYF	In	VDJ	1	29	5.126573327676425E-4	6.20612908748502E-4	42	TCRBV14	TCRBV14-01	01				TCRBJ02	TCRBJ02-03	01	4	9	0	6	2	9	29	42	47	44	56				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	CASSPGIGLDTQYF+TCRBV14-01+TCRBJ02-03	TCRBV14-01*01		TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCCGAGGATAGAGGGACGAAGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	30	5.303351718285957E-4		50	TCRBV14	TCRBV14-01	01				TCRBJ01	TCRBJ01-01	01	4	0	7	1	10	3	29	42	57	52	60				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	X+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAAACCTGGGACACCCTAGCCTTAACACTGAAGCTTTCTTTGGACAA	CASSQNLGHPSLNTEAFF	In	VDJ	1	35	6.187243671333617E-4	7.490155795240541E-4	54	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	0	6	2	5	10	27	42	53	47	63													Vb 16	CASSQNLGHPSLNTEAFF+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCGACTGAACAAGCCGAACACTGAAGCTTTCTTTGGACAA	CASSRLNKPNTEAFF	In	VDJ	1	38	6.717578843162212E-4	8.132169149118302E-4	45	TCRBV14	TCRBV14-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	4	2	10	1	0	9	29	-1	46	42	55						01,02							Vb 16	CASSRLNKPNTEAFF+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01	TCRBD02-01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCGTATGACGGGGACAGTGAACACTGAAGCTTTCTTTGGACAA	CASSRMTGTVNTEAFF	In	VDJ	2	42	7.42469240560034E-4	8.988186954288649E-4	48	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	0	5	0	8	0	29	42	-1	50	57													Vb 16	CASSRMTGTVNTEAFF+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCTACGGACAGTCTAGCACAGATACGCAGTATTTTGGCCCA	CASSYGQSSTDTQYF	In	VDJ	2	50	8.838919530476595E-4	0.0010700222564629343	45	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	1	5	0	3	3	29	41	50	44	53													Vb 16	CASSYGQSSTDTQYF+TCRBV14-01+TCRBJ02-03	TCRBV14-01*01	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCGGTGGCAAGCAATCTGACAAAGTCGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	2	54	9.546033092914723E-4		56	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	5	2	6	5	15	5	25	37	56	52	61													Vb 16	X+TCRBV14-01+TCRBJ02-06	TCRBV14-01*01	TCRBD01-01*01	TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAAGCAGGACAGGGGGCTTCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	2	55	9.722811483524254E-4		47	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	7	1	0	1	4	1	29	39	54	43	55													Vb 16	X+TCRBV14-01+TCRBJ02-01	TCRBV14-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCTTGGGGCCGGGTTATGGAAACACCATATATTTTGGAGAG	CASSLGPGYGNTIYF	In	VDJ	2	63	0.001113703860840051	0.0013482280431432975	45	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	5	7	0	3	2	7	29	41	48	43	55													Vb 16	CASSLGPGYGNTIYF+TCRBV14-01+TCRBJ01-03	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCACCCGACGGGACATCCCACTGAAGCTTTCTTTGGACAA	CASSHPTGHPTEAFF	In	VDJ	3	70	0.0012374487342667233	0.0014980311590481082	45	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	0	6	4	6	3	29	43	55	49	58													Vb 16	CASSHPTGHPTEAFF+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGGGACCGGGACAACACTGAAGCTTTCTTTGGACAA	CASRDRDNTEAFF	In	VDJ	3	71	0.0012551265733276764	0.001519431604177367	39	TCRBV14	TCRBV14-01	01				TCRBJ01	TCRBJ01-01	01	6	0	7	2	5	0	29	40	-1	45	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 16	CASRDRDNTEAFF+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCGTGGGGACAGGGGGCATTACAGATACGCAGTATTTTGGCCCA	CASSVGTGGITDTQYF	In	VDJ	3	79	0.001396549285815302	0.0016906351652114363	48	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	0	0	3	3	3	29	41	56	44	59													Vb 16	CASSVGTGGITDTQYF+TCRBV14-01+TCRBJ02-03	TCRBV14-01*01	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGAAGGCAGGTGGAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	4	109	0.0019268844576438976		44	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	0	4	4	3	3	3	29	46	53	49	56													Vb 16	X+TCRBV14-01+TCRBJ02-05	TCRBV14-01*01	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAAGGGGGGCTACACCTTCGGTTCG		Out	VDJ	4	110	0.0019445622967048507		32	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	5	2	8	0	0	29	-1	-1	44	49													Vb 16	X+TCRBV14-01+TCRBJ01-02	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAACAGGGGGCCCTGAGCACTGAAGCTTTCTTTGGACAA	CASSQQGALSTEAFF	In	VDJ	17	453	0.008008061094611794	0.009694401643554186	45	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	4	0	4	0	6	29	-1	52	44	58													Vb 16	CASSQQGALSTEAFF+TCRBV14-01+TCRBJ01-01	TCRBV14-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAACTGGAGGATTCTGGAGTTTATTTCTGTGCCAGCAGCCAAGGTTTAGGCCAGGGTCACGACGAGCAGTACTTCGGGCCG	CASSQGLGQGHDEQYF	In	VDJ	23	607	0.010730448309998586	0.012990070193460023	48	TCRBV14	TCRBV14-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	4	3	5	8	5	29	45	58	53	63													Vb 16	CASSQGLGQGHDEQYF+TCRBV14-01+TCRBJ02-07	TCRBV14-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGAAAGGGGGCTAGCCAAAAACATTCAGTACTTCGGCGCC		Out	VDJ	1	9	1.591005515485787E-4		40	TCRBV21	TCRBV21-or09_02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	10	5	0	0	3	1	24	31	41	34	42														X+TCRBV21-or09_02+TCRBJ02-04	TCRBV21-or09_02*01	TCRBD01-01*01	TCRBJ02-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGACGAACAGGGGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	9	1.591005515485787E-4		41	TCRBV21	TCRBV21-or09_02	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	3	3	2	4	0	24	35	-1	39	45														X+TCRBV21-or09_02+TCRBJ01-05	TCRBV21-or09_02*01	TCRBD01-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCCGGGGGTTTGGACGGGGAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	9	1.591005515485787E-4		50	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	5	8	2	1	0	10	24	-1	42	36	52														X+TCRBV21-or09_02+TCRBJ02-02	TCRBV21-or09_02*01	TCRBD02-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCGTCCATACTAGCGGCGGCACAGATACGCAGTATTTTGGCCCA	CASSVHTSGGTDTQYF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	48	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	5	3	5	1	6	2	24	36	50	42	52						01,02								CASSVHTSGGTDTQYF+TCRBV21-or09_02+TCRBJ02-03	TCRBV21-or09_02*01	TCRBD02-01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGTCCCGAGGGGCGGACAGGGACCTTGGGGCAGTACTTCGGGCCG	CASSPEGRTGTLGQYF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	48	TCRBV21	TCRBV21-or09_02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	1	3	9	11	8	24	35	54	46	62														CASSPEGRTGTLGQYF+TCRBV21-or09_02+TCRBJ02-07	TCRBV21-or09_02*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGTGTGGGAGCGGGAGGACAGCCCCAGCATTTTGGTGAT	CASSVGAGGQPQHF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	42	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-05	01	6	6	1	7	6	1	24	35	50	41	51														CASSVGAGGQPQHF+TCRBV21-or09_02+TCRBJ01-05	TCRBV21-or09_02*01	TCRBD02-01*02	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAAGGGGGACAATCAGCCCCAGCATTTTGGTGAT	CASKGDNQPQHF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	36	TCRBV21	TCRBV21-or09_02	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	10	5	1	3	3	1	24	31	40	34	41														CASKGDNQPQHF+TCRBV21-or09_02+TCRBJ01-05	TCRBV21-or09_02*01	TCRBD01-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCTTGGACCTAGCGACTTTAAATGAGCAGTTCTTCGGGCCA	CASSLDLATLNEQFF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	45	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	4	6	7	6	6	24	36	48	42	54						01,02								CASSLDLATLNEQFF+TCRBV21-or09_02+TCRBJ02-01	TCRBV21-or09_02*01	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGTGGGAAAAGGGTCAACTACAGGTTCAGTACTTCGGGCCG		Out	VDJ	1	11	1.9445622967048507E-4		44	TCRBV21	TCRBV21-or09_02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	3	4	10	17	2	24	35	57	52	59														X+TCRBV21-or09_02+TCRBJ02-07	TCRBV21-or09_02*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCGGCGGGAGGGCCGTCGGGGAGCTGTTTTTTGGAGAA	CASSGGRAVGELFF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	42	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	5	7	0	7	1	4	24	36	46	37	50														CASSGGRAVGELFF+TCRBV21-or09_02+TCRBJ02-02	TCRBV21-or09_02*01	TCRBD02-01*02	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCCCGGGCCGCTCCAATCTGGGCGATGCCAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	14	2.474897468533447E-4		55	TCRBV21	TCRBV21-or09_02	01				TCRBJ02	TCRBJ02-03	01	5	8	0	4	2	20	24	36	42	38	62				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV21-or09_02+TCRBJ02-03	TCRBV21-or09_02*01		TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCGTAGCTAATATCAACTAGCGGTGACTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	14	2.474897468533447E-4		55	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	3	5	0	13	3	24	36	57	49	60						01,02								X+TCRBV21-or09_02+TCRBJ02-07	TCRBV21-or09_02*01	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCTCCGCAGGGGGGGTGGCTAATGAAAAACTGTTTTTTGGCAGT	CASSAGGVANEKLFF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	45	TCRBV21	TCRBV21-or09_02	01				TCRBJ01	TCRBJ01-04	01	10	4	1	3	6	5	24	31	44	37	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSAGGVANEKLFF+TCRBV21-or09_02+TCRBJ01-04	TCRBV21-or09_02*01		TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGTTTAGGATCCCTTGGGAGCAATCAGCCCCAGCATTTTGGTGAT	CASSLGSLGSNQPQHF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	48	TCRBV21	TCRBV21-or09_02	01				TCRBJ01	TCRBJ01-05	01	6	0	9	1	13	0	24	35	-1	48	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGSLGSNQPQHF+TCRBV21-or09_02+TCRBJ01-05	TCRBV21-or09_02*01		TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGTTTCCCCCCGAGCTCCTACAATGAGCAGTTCTTCGGGCCA	CASSFPPSSYNEQFF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	45	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	6	11	2	0	9	0	24	35	-1	44	47														CASSFPPSSYNEQFF+TCRBV21-or09_02+TCRBJ02-01	TCRBV21-or09_02*01	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGTGAACAACGGCGACAAGAGACCCAGTACTTCGGGCCA	CASSEQRRQETQYF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	42	TCRBV21	TCRBV21-or09_02	01				TCRBJ02	TCRBJ02-05	01	6	3	6	2	3	7	24	35	41	38	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSEQRRQETQYF+TCRBV21-or09_02+TCRBJ02-05	TCRBV21-or09_02*01		TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCACTCAGACTAGCGGGGAATACAATGAGCAGTTCTTCGGGCCA	CASSTQTSGEYNEQFF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	48	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	4	2	3	4	4	2	24	37	52	41	54														CASSTQTSGEYNEQFF+TCRBV21-or09_02+TCRBJ02-01	TCRBV21-or09_02*01	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGTCCCCGCCGGCCAGGCCTACAGAATTCACCCCTCCACTTTGGGAAC	CASSPRRPGLQNSPLHF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	51	TCRBV21	TCRBV21-or09_02	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	6	3	5	7	18	0	24	35	-1	53	57														CASSPRRPGLQNSPLHF+TCRBV21-or09_02+TCRBJ01-06	TCRBV21-or09_02*01	TCRBD01-01*01	TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCCTGAGCGTCGGGACAGGATCACACGAGCAGTACTTCGGGCCG	CASSLSVGTGSHEQYF	In	VDJ	1	19	3.358789421581106E-4	4.066084574559151E-4	48	TCRBV21	TCRBV21-or09_02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	0	4	5	9	5	24	36	53	45	58														CASSLSVGTGSHEQYF+TCRBV21-or09_02+TCRBJ02-07	TCRBV21-or09_02*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCCTGGCGCCGGGACAGGGTTCTCTGGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	1	19	3.358789421581106E-4		53	TCRBV21	TCRBV21-or09_02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	10	0	3	0	10	2	24	31	50	41	52														X+TCRBV21-or09_02+TCRBJ02-06	TCRBV21-or09_02*01	TCRBD01-01*01	TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCGTAGCAGAGTATTCTGGAAACACCATATATTTTGGAGAG	CASSVAEYSGNTIYF	In	VDJ	1	29	5.126573327676425E-4	6.20612908748502E-4	45	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-03	01	5	5	7	1	1	7	24	36	41	37	48						01,02								CASSVAEYSGNTIYF+TCRBV21-or09_02+TCRBJ01-03	TCRBV21-or09_02*01	TCRBD02-01	TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGACCACGGAACGGACTAGGCAATGAGCAGTTCTTCGGGCCA	CASRPRNGLGNEQFF	In	VDJ	1	34	6.010465280724084E-4	7.276151343947955E-4	45	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	1	8	6	10	1	24	35	52	45	53						01,02								CASRPRNGLGNEQFF+TCRBV21-or09_02+TCRBJ02-01	TCRBV21-or09_02*01	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCGTAGCTAATGGACAGCCTAATGAAAAACTGTTTTTTGGCAGT	CASSVANGQPNEKLFF	In	VDJ	1	34	6.010465280724084E-4	7.276151343947955E-4	48	TCRBV21	TCRBV21-or09_02	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	5	1	5	3	9	1	24	36	51	45	52														CASSVANGQPNEKLFF+TCRBV21-or09_02+TCRBJ01-04	TCRBV21-or09_02*01	TCRBD01-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGTGAAGCATTAGCGGGGGGCTCCTACGAGCAGTACTTCGGGCCG	CASSEALAGGSYEQYF	In	VDJ	1	34	6.010465280724084E-4	7.276151343947955E-4	48	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	6	5	1	0	8	0	24	35	-1	43	53														CASSEALAGGSYEQYF+TCRBV21-or09_02+TCRBJ02-07	TCRBV21-or09_02*01	TCRBD02-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCCTAGACTAGCGGGAGGTGGGCGAGCAGTACTTCGGGCCG	CASSLD*REVGEQYF	Stop	VDJ	1	39	6.894357233771744E-4		45	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	5	2	1	6	3	4	24	36	52	39	56														CASSLD*REVGEQYF+TCRBV21-or09_02+TCRBJ02-07	TCRBV21-or09_02*01	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGGCGTTGTATAGCTACACGTGTTGACGAGCAGTACTTCGGGCCG	CASRRCIATRVDEQYF	In	VDJ	2	46	8.131805968038467E-4	9.844204759458996E-4	48	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	6	5	7	5	8	11	24	35	47	43	58						01,02								CASRRCIATRVDEQYF+TCRBV21-or09_02+TCRBJ02-07	TCRBV21-or09_02*01	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGGAGACACAGCACGGTATTTCTGTGCCAGCAGGTTACCCTACAAGACAGGGGGCTGAACATGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	2	50	8.838919530476595E-4		59	TCRBV21	TCRBV21-or09_02	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	2	0	0	12	6	22	33	55	45	61														X+TCRBV21-or09_02+TCRBJ01-01	TCRBV21-or09_02*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCCCAGACAGGGGGCTTGAAGCTTTCTTTGGACAA	CASSPDRGLEAFF	In	VDJ	2	57	0.0010076368264743318	0.0012198253723677453	39	TCRBV21	TCRBV21-or09_02	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	2	0	7	3	1	24	36	49	39	50														CASSPDRGLEAFF+TCRBV21-or09_02+TCRBJ01-01	TCRBV21-or09_02*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCGTAGAAGGGAAAGCCTACGAGCAGTACTTCGGGCCG	CASSVEGKAYEQYF	In	VDJ	3	81	0.0014319049639372084	0.0017334360554699538	42	TCRBV21	TCRBV21-or09_02	01				TCRBJ02	TCRBJ02-07	01	5	0	8	2	6	3	24	36	46	42	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSVEGKAYEQYF+TCRBV21-or09_02+TCRBJ02-07	TCRBV21-or09_02*01		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCTTAGGTGGTCAGGGGGCACGCGAGCAGTACTTCGGGCCG	CASSLGGQGAREQYF	In	VDJ	7	175	0.0030936218356668083	0.0037450778976202705	45	TCRBV21	TCRBV21-or09_02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	4	0	6	9	3	24	36	53	45	56														CASSLGGQGAREQYF+TCRBV21-or09_02+TCRBJ02-07	TCRBV21-or09_02*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAAGCAAGGTGGAGGGACAGGCGCGGCTACACCTTCGGTTCG	CASSEARWRDRRGYTF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	48	TCRBV06	TCRBV06-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	0	4	8	8	3	23	40	56	48	59														CASSEARWRDRRGYTF+TCRBV06-01+TCRBJ01-02	TCRBV06-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAAGGGGGGTCGTTCGACACCGGGGAGCTGTTTTTTGGAGAA	CASSEGGSFDTGELFF	In	VDJ	1	23	4.0659029840192336E-4	4.922102379729498E-4	48	TCRBV06	TCRBV06-01	01				TCRBJ02	TCRBJ02-02	01	1	6	1	3	0	7	23	-1	44	39	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSEGGSFDTGELFF+TCRBV06-01+TCRBJ02-02	TCRBV06-01*01		TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAAGCCTCAGAGAACACTGAAGCTTTCTTTGGACAA	CASSEASENTEAFF	In	VDJ	2	45	7.955027577428935E-4	9.63020030816641E-4	42	TCRBV06	TCRBV06-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	4	5	1	2	1	23	40	45	42	46														CASSEASENTEAFF+TCRBV06-01+TCRBJ01-01	TCRBV06-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGGGGACTCAGCTGTGTATCTCTGTGCCAGCAGCGTAGTGGCAGGGGGACGAACTGAAGCTTTCTTTGGACAA	CASSVVAGGRTEAFF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	45	TCRBV07	TCRBV07-04	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	4	1	5	3	4	22	38	48	41	52														CASSVVAGGRTEAFF+TCRBV07-04+TCRBJ01-01	TCRBV07-04*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGGGGACTCAGCTGTGTATCTCTGTGCCAGCAGCTTACGACTAGCGGGGAATGAGCAGTTCTTCGGGCCA	CASSLRLAGNEQFF	In	VDJ	1	25	4.4194597652382975E-4	5.350111282314672E-4	42	TCRBV07	TCRBV07-04	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	2	2	3	7	1	0	22	37	-1	38	49														CASSLRLAGNEQFF+TCRBV07-04+TCRBJ02-01	TCRBV07-04*01	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGAAATGCGCGGGAGTCCTACGAGCAGTACTTCGGGCCG	CAWRNARESYEQYF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	42	TCRBV30	TCRBV30-01	02	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	3	7	2	1	6	0	26	37	-1	43	50													Vb 20	CAWRNARESYEQYF+TCRBV30-01+TCRBJ02-07	TCRBV30-01*02	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTCCACAGAGCAATCAGCCCCAGCATTTTGGTGAT	CAWSPQSNQPQHF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	39	TCRBV30	TCRBV30-01	02	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	2	3	5	1	2	0	26	38	-1	40	44													Vb 20	CAWSPQSNQPQHF+TCRBV30-01+TCRBJ01-05	TCRBV30-01*02	TCRBD01-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGGCACCTCCGGGACAGTGGAGTGAAAAACTGTTTTTTGGCAGT	CAWAPPGQWSEKLFF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	45	TCRBV30	TCRBV30-01	02	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	5	0	5	7	8	5	26	35	50	43	55													Vb 20	CAWAPPGQWSEKLFF+TCRBV30-01+TCRBJ01-04	TCRBV30-01*02	TCRBD01-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTGGGGGCATATTCCTACGAGCAGTACTTCGGGCCG	CAWSVGAYSYEQYF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	42	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	6	0	1	0	4	26	-1	46	40	50													Vb 20	CAWSVGAYSYEQYF+TCRBV30-01+TCRBJ02-07	TCRBV30-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTACATAAATGTGACAGGGATGGACAGATACGCAGTATTTTGGCCCA	CAWST*M*QGWTDTQYF	Stop	VDJ	1	11	1.9445622967048507E-4		51	TCRBV30	TCRBV30-01	02	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	2	2	3	3	10	4	26	38	55	48	59			unresolved										Vb 20	CAWST*M*QGWTDTQYF+TCRBV30-01+TCRBJ02-03	TCRBV30-01*02	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGCCGACAGGGGAGTGGCTACACCTTCGGTTCG		Out	VDJ	1	13	2.2981190779239146E-4		34	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	2	2	7	2	2	26	35	45	37	47													Vb 20	X+TCRBV30-01+TCRBJ01-02	TCRBV30-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGCTTACAGGGGAATGAAAAACTGTTTTTTGGCAGT	CAWSLQGNEKLFF	In	VDJ	1	19	3.358789421581106E-4	4.066084574559151E-4	39	TCRBV30	TCRBV30-01	02	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	3	3	2	5	3	0	26	37	-1	40	47													Vb 20	CAWSLQGNEKLFF+TCRBV30-01+TCRBJ01-04	TCRBV30-01*02	TCRBD01-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTCGGGGAAAATACGAGCAGTACTTCGGGCCG	CAWSRGKYEQYF	In	VDJ	1	21	3.71234620280017E-4	4.4940934771443245E-4	36	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	2	8	3	4	0	4	26	-1	43	38	47			unresolved										Vb 20	CAWSRGKYEQYF+TCRBV30-01+TCRBJ02-07	TCRBV30-01*01	TCRBD02-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGATCCGAGACTGGGGGACTGACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	22	3.8891245934097015E-4		43	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	4	0	10	5	11	1	26	36	53	47	54			unresolved			01,02							Vb 20	X+TCRBV30-01+TCRBJ01-01	TCRBV30-01*01	TCRBD02-01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGGATCGGGACTAGCGGGAGAAGGGGCAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	25	4.4194597652382975E-4		52	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	3	0	2	4	4	6	26	37	55	41	61													Vb 20	X+TCRBV30-01+TCRBJ02-03	TCRBV30-01*01	TCRBD02-01*02	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGCAATGGGGGATTCACCCCTCCACTTTGGGAAC	CAWSAMGDSPLHF	In	VDJ	1	26	4.596238155847829E-4	5.564115733607259E-4	39	TCRBV30	TCRBV30-01	02				TCRBJ01	TCRBJ01-06	01	1	6	1	8	4	0	26	39	-1	43	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWSAMGDSPLHF+TCRBV30-01+TCRBJ01-06	TCRBV30-01*02		TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTGGGACAGTTTAGCTCCTACGAGCAGTACTTCGGGCCG	CAWSVGQFSSYEQYF	In	VDJ	1	28	4.949794937066893E-4	5.992124636192433E-4	45	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	0	5	0	0	5	26	-1	47	40	52													Vb 20	CAWSVGQFSSYEQYF+TCRBV30-01+TCRBJ02-07	TCRBV30-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCCTCAGTGACTCTGGCTTCTATCTCTGTGCCGGTAACAGGGGCTACGAGCAGTACTTCGGGCCG	CAGNRGYEQYF	In	VDJ	1	30	5.303351718285957E-4	6.420133538777606E-4	33	TCRBV30	TCRBV30-01	02	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	8	3	2	3	4	0	26	32	-1	36	43													Vb 20	CAGNRGYEQYF+TCRBV30-01+TCRBJ02-07	TCRBV30-01*02	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGCGTCGGCCTTTACGAGCAGTACTTCGGGCCG	CAWSVGLYEQYF	In	VDJ	1	31	5.480130108895489E-4	6.634137990070194E-4	36	TCRBV30	TCRBV30-01	01				TCRBJ02	TCRBJ02-07	01	3	9	0	4	4	3	26	37	44	41	47			unresolved	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWSVGLYEQYF+TCRBV30-01+TCRBJ02-07	TCRBV30-01*01		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GCTTCTATCTCTGTGCCTGGAGTGGTATCGCGTCCTTGGACTAGCGGTTACCGTCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	33	5.833686890114552E-4		62	TCRBV30	TCRBV30-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	1	1	5	2	13	7	11	24	47	37	54			01,02			01,02							Vb 20	X+TCRBV30-01+TCRBJ02-03	TCRBV30-01	TCRBD02-01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTACGGGACTGGCATATCAGGGCCCCAGCATTTTGGTGAT	CAYGTGISGPQHF	In	VDJ	1	34	6.010465280724084E-4	7.276151343947955E-4	39	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	7	0	10	9	2	11	26	33	41	35	52						01,02							Vb 20	CAYGTGISGPQHF+TCRBV30-01+TCRBJ01-05	TCRBV30-01*01	TCRBD02-01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTATCGGCGGGAGATCACGGGGAGCTGTTTTTTGGAGAA	CAWSVSAGDHGELFF	In	VDJ	1	35	6.187243671333617E-4	7.490155795240541E-4	45	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	0	7	2	7	4	4	26	40	51	44	55													Vb 20	CAWSVSAGDHGELFF+TCRBV30-01+TCRBJ02-02	TCRBV30-01*01	TCRBD02-01*02	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTAAACATGAGTACGAGCAGTACTTCGGGCCG	CAWSKHEYEQYF	In	VDJ	2	40	7.071135624381275E-4	8.560178051703475E-4	36	TCRBV30	TCRBV30-01	01				TCRBJ02	TCRBJ02-07	01	2	3	6	4	2	4	26	38	43	40	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWSKHEYEQYF+TCRBV30-01+TCRBJ02-07	TCRBV30-01*01		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTATATACTAGCGGGGGGAAAAACATTCAGTACTTCGGCGCC	CAWSVYTSGGKNIQYF	In	VDJ	2	42	7.42469240560034E-4	8.988186954288649E-4	48	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-04	01	0	3	1	4	4	0	26	40	-1	44	56													Vb 20	CAWSVYTSGGKNIQYF+TCRBV30-01+TCRBJ02-04	TCRBV30-01*01	TCRBD02-01*01	TCRBJ02-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTCGGTGACGTGTCGGACGAGCAGTACTTCGGGCCG	CAWSVGDVSDEQYF	In	VDJ	2	42	7.42469240560034E-4	8.988186954288649E-4	42	TCRBV30	TCRBV30-01	01				TCRBJ02	TCRBJ02-07	01	0	2	7	5	4	7	26	40	47	44	54				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWSVGDVSDEQYF+TCRBV30-01+TCRBJ02-07	TCRBV30-01*01		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTAGGGGGCAATGAGCAGTTCTTCGGGCCA	CAWSVGGNEQFF	In	VDJ	2	43	7.601470796209872E-4	9.202191405581236E-4	36	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	0	5	1	6	0	0	26	-1	-1	40	46													Vb 20	CAWSVGGNEQFF+TCRBV30-01+TCRBJ02-01	TCRBV30-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGGGAACTCTGGAAACACCATATATTTTGGAGAG	CAWSGNSGNTIYF	In	VDJ	2	47	8.308584358647998E-4	0.0010058209210751584	39	TCRBV30	TCRBV30-01	01				TCRBJ01	TCRBJ01-03	01	1	1	8	0	0	1	26	-1	42	39	43			unresolved	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWSGNSGNTIYF+TCRBV30-01+TCRBJ01-03	TCRBV30-01*01		TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGGACGAGGGAGTAGCCCAAGAGACCCAGTACTTCGGGCCA	CAWDEGVAQETQYF	In	VDJ	6	159	0.0028107764106915572	0.0034026707755521316	42	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	5	9	2	1	5	4	26	35	45	40	49													Vb 20	CAWDEGVAQETQYF+TCRBV30-01+TCRBJ02-05	TCRBV30-01*01	TCRBD02-01*02	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGCCCCAGGGAAAACAACTATGGCTACACCTTCGGTTCG	CAWSPRENNYGYTF	In	VDJ	7	184	0.003252722387215387	0.0039376819037835985	42	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	4	3	2	3	5	26	37	45	40	50													Vb 20	CAWSPRENNYGYTF+TCRBV30-01+TCRBJ01-02	TCRBV30-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCATGCCAGGGGGGGCACTGAAGCTTTCTTTGGACAA	CASSHARGGTEAFF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	42	TCRBV01	TCRBV01-01	01				TCRBJ01	TCRBJ01-01	01	3	4	1	4	3	2	23	37	47	40	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSHARGGTEAFF+TCRBV01-01+TCRBJ01-01	TCRBV01-01*01		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AAGAAGACTCAGCTGCGTATCTCTGCACCAGCAGCCAAGTCACGGATGGGGGGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	12	2.1213406873143826E-4		49	TCRBV01	TCRBV01-01	01				TCRBJ02	TCRBJ02-03	01	1	6	1	1	8	0	23	39	-1	47	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV01-01+TCRBJ02-03	TCRBV01-01*01		TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGACATCGGCGGGGGGGTGCTGGATGAGCAGTTCTTCGGGCCA	CASSQDIGGGVLDEQFF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	51	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	0	7	0	8	5	6	23	40	54	45	60														CASSQDIGGGVLDEQFF+TCRBV01-01+TCRBJ02-01	TCRBV01-01*01	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGAATCCCAACAGGGTTTCGGCACAGATACGCAGTATTTTGGCCCA	CASSQESQQGFGTDTQYF	In	VDJ	1	21	3.71234620280017E-4	4.4940934771443245E-4	54	TCRBV01	TCRBV01-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	0	3	3	1	6	5	23	40	52	46	57														CASSQESQQGFGTDTQYF+TCRBV01-01+TCRBJ02-03	TCRBV01-01*01	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAGGAACCTCTAGCGGGGATACGTACAGATACGCAGTATTTTGGCCCA	CASSQEPLAGIRTDTQYF	In	VDJ	1	22	3.8891245934097015E-4	4.7080979284369113E-4	54	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	3	4	3	3	7	6	23	37	53	44	59														CASSQEPLAGIRTDTQYF+TCRBV01-01+TCRBJ02-03	TCRBV01-01*01	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGATGGGGCTAGCGGGGGGACAGATACGCAGTATTTTGGCCCA	CASSQDGASGGTDTQYF	In	VDJ	1	26	4.596238155847829E-4	5.564115733607259E-4	51	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	0	4	1	3	5	0	23	40	-1	45	56														CASSQDGASGGTDTQYF+TCRBV01-01+TCRBJ02-03	TCRBV01-01*01	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AAGAAGACTCAGCTGCGTATCTCTGCACCAGCAGCCAAGTTACAGGGCAGAAGACCGAAGCTTTCTTTGGACAA	CTSSQVTGQKTEAFF	In	VDJ	1	29	5.126573327676425E-4	6.20612908748502E-4	45	TCRBV01	TCRBV01-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	3	3	8	2	9	23	39	47	41	56														CTSSQVTGQKTEAFF+TCRBV01-01+TCRBJ01-01	TCRBV01-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AAGAAGACTCAGCTGCGTATCTCTGCGCCAGCAGCCAAGATCCGGGACTTAACTACAATGAGCAGTTCTTCGGGCCA	CASSQDPGLNYNEQFF	In	VDJ	2	41	7.247914014990807E-4	8.774182502996063E-4	48	TCRBV01	TCRBV01-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	0	0	10	3	3	3	23	40	49	43	52						01,02								CASSQDPGLNYNEQFF+TCRBV01-01+TCRBJ02-01	TCRBV01-01*01	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AAGAAGACTCAGCTGCGTATCTCTGCACCAGTATCCGTTAACTACAGGCCCGGAGAACGAACACTGAAGCTTTCTTTGGACAA	CTSIR*LQARRTNTEAFF	Stop	VDJ	6	161	0.0028461320888134634		54	TCRBV01	TCRBV01-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	9	3	4	1	12	10	23	31	48	43	58														CTSIR*LQARRTNTEAFF+TCRBV01-01+TCRBJ01-01	TCRBV01-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGAGGTGGGATGACTAGCGGGGGCCTCTCCTACGAGCAGTACTTCGGGCCG	CASRGGMTSGGLSYEQYF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	54	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	5	2	2	0	9	3	19	30	51	39	54													Vb 5.1	CASRGGMTSGGLSYEQYF+TCRBV05-01+TCRBJ02-07	TCRBV05-01*01	TCRBD02-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCCACGGACTAGGTTCGACAGATACGCAGTATTTTGGCCCA	CASSHGLGSTDTQYF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	45	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	4	1	8	3	3	5	19	31	41	34	46						01,02							Vb 5.1	CASSHGLGSTDTQYF+TCRBV05-01+TCRBJ02-03	TCRBV05-01*01	TCRBD02-01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCGGACAGGGGGCTGGTGAGACCCAGTACTTCGGGCCA	CASSGQGAGETQYF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	42	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	4	1	0	5	0	4	19	-1	42	31	46													Vb 5.1	CASSGQGAGETQYF+TCRBV05-01+TCRBJ02-05	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGAGGGGAGAGTTCTCGGGAAACTGTTTTTTGGCAGT	CASSLEGRVLGKLFF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	45	TCRBV05	TCRBV05-01	01				TCRBJ01	TCRBJ01-04	01	0	5	2	11	0	12	19	-1	40	35	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 5.1	CASSLEGRVLGKLFF+TCRBV05-01+TCRBJ01-04	TCRBV05-01*01		TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCTATTCGGCCTAGTAAAGCGGGGAAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	8	1.414227124876255E-4		49	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	7	6	3	3	15	1	19	28	50	43	51													Vb 5.1	X+TCRBV05-01+TCRBJ02-05	TCRBV05-01*01	TCRBD02-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCACCTCGAGGGGCCAGGTCACAGATACGCAGTATTTTGGCCCA	CATSRGQVTDTQYF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	42	TCRBV05	TCRBV05-01	01				TCRBJ02	TCRBJ02-03	01	9	5	2	2	5	6	19	26	36	31	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 5.1	CATSRGQVTDTQYF+TCRBV05-01+TCRBJ02-03	TCRBV05-01*01		TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTGTGGGCTCCCCACCGGCGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	9	1.591005515485787E-4		44	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	3	8	0	9	2	11	19	32	38	34	49													Vb 5.1	X+TCRBV05-01+TCRBJ02-02	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGACAGACTTCCCCAGGATAAGCAGTATTTTGGCCCA	CASSLDRLPQDKQYF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	45	TCRBV05	TCRBV05-01	01				TCRBJ02	TCRBJ02-03	01	0	3	5	11	0	15	19	-1	39	35	54				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 5.1	CASSLDRLPQDKQYF+TCRBV05-01+TCRBJ02-03	TCRBV05-01*01		TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGGAGGGAGGCGGCCCTAGCCAAAAACATTCAGTACTTCGGCGCC	CASRREAALAKNIQYF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	48	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-04	01	5	9	1	0	2	7	19	30	38	32	45													Vb 5.1	CASRREAALAKNIQYF+TCRBV05-01+TCRBJ02-04	TCRBV05-01*01	TCRBD02-01*02	TCRBJ02-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCGAACAGCCGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSEQPNTGELFF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	42	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	4	3	5	0	2	1	19	31	37	33	38													Vb 5.1	CASSEQPNTGELFF+TCRBV05-01+TCRBJ02-02	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCGCCGGGACAGGGGGCAGAGGAGATGGAAACACCATATATTTTGGAGAG	CASSAGTGGRGDGNTIYF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	54	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	4	0	0	3	3	8	19	31	46	34	54													Vb 5.1	CASSAGTGGRGDGNTIYF+TCRBV05-01+TCRBJ01-03	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGCCAGGGGGCTTGAGTCACCCCTCCACTTTGGGAAC	CASSLARGLESPLHF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	45	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	0	4	0	10	1	5	19	35	44	36	49													Vb 5.1	CASSLARGLESPLHF+TCRBV05-01+TCRBJ01-06	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGGGGGACAGGGAGTAGTAACAGATACGCAGTATTTTGGCCCA	CASSLGGQGVVTDTQYF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	51	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	0	0	3	3	1	7	19	35	45	36	52													Vb 5.1	CASSLGGQGVVTDTQYF+TCRBV05-01+TCRBJ02-03	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCAGGAAGTCAGGACAGGGCAAGTGAAGCTTTCTTTGGACAA		Out	VDJ	1	11	1.9445622967048507E-4		40	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	8	1	3	7	7	4	19	27	42	34	46													Vb 5.1	X+TCRBV05-01+TCRBJ01-01	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCGTCCGTCGGGGGCTAAAAAAACATTCAGTACTTCGGCGCC		Out	VDJ	1	11	1.9445622967048507E-4		40	TCRBV05	TCRBV05-01	01				TCRBJ02	TCRBJ02-04	01	10	6	0	4	7	3	19	25	38	32	41				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 5.1	X+TCRBV05-01+TCRBJ02-04	TCRBV05-01*01		TCRBJ02-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGAAAATCCGGGACTAGCGGTTCGGATACGCAGTATTTTGGCCCA		Out	VDJ	1	12	2.1213406873143826E-4		53	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	0	0	5	6	7	4	19	35	53	42	57						01,02							Vb 5.1	X+TCRBV05-01+TCRBJ02-03	TCRBV05-01*01	TCRBD02-01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTACGACAGACTCTCCTACGAGCAGTACTTCGGGCCG	CASSYDRLSYEQYF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	42	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	2	5	0	2	3	19	32	39	34	42													Vb 5.1	CASSYDRLSYEQYF+TCRBV05-01+TCRBJ02-07	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTCCTGCTCTCCGGAAACACAGATACGCAGTATTTTGGCCCA	CASSFLLSGNTDTQYF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	48	TCRBV05	TCRBV05-01	01				TCRBJ02	TCRBJ02-03	01	2	1	8	2	10	2	19	33	46	43	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 5.1	CASSFLLSGNTDTQYF+TCRBV05-01+TCRBJ02-03	TCRBV05-01*01		TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGCCTCAGGGGAGGGCTACGAGCAGTACTTCGGGCCG	CASSLASGEGYEQYF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	45	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	0	9	0	3	6	0	19	35	-1	41	48													Vb 5.1	CASSLASGEGYEQYF+TCRBV05-01+TCRBJ02-07	TCRBV05-01*01	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGTCAGCAGTCCAGCGGAGTACACAGATACGCAGTATTTTGGCCCA	CVSSPAEYTDTQYF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	42	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	5	6	5	2	3	4	19	30	38	33	42						01,02							Vb 5.1	CVSSPAEYTDTQYF+TCRBV05-01+TCRBJ02-03	TCRBV05-01*01	TCRBD02-01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTCGGGGGGCAGCGGGTGAATGAAAAACTGTTTTTTGGCAGT	CASSFGGQRVNEKLFF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	48	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-04	01	2	8	1	5	0	9	19	-1	40	33	49													Vb 5.1	CASSFGGQRVNEKLFF+TCRBV05-01+TCRBJ01-04	TCRBV05-01*01	TCRBD02-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGACAACAGGCTGACTGAAGCTTTCTTTGGACAA	CASSLDNRLTEAFF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	42	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	3	4	5	3	3	19	35	43	38	46													Vb 5.1	CASSLDNRLTEAFF+TCRBV05-01+TCRBJ01-01	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTCTCCCAGGGCCCCTTCTTAGCTAACTATGGCTACACCTTCGGTTCG	CASSFSQGPFLANYGYTF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	54	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	4	3	0	4	11	19	33	42	37	53													Vb 5.1	CASSFSQGPFLANYGYTF+TCRBV05-01+TCRBJ01-02	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTGGGGCGGGGGAGGTAATGAGCAGTTCTTCGGGCCA	CASSWGGGGNEQFF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	42	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	3	7	2	7	3	4	19	32	42	35	46													Vb 5.1	CASSWGGGGNEQFF+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGGGGGACAGGGAAAATCTCTGAAGCTTTCTTTGGACAA	CASRGTGKISEAFF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	42	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	0	3	6	1	7	19	30	40	31	47													Vb 5.1	CASRGTGKISEAFF+TCRBV05-01+TCRBJ01-01	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCCAAGTCCCGGCAGGGGGGATCCAAGAGACCCAGTACTTCGGGCCA	CASSQVPAGGIQETQYF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	51	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	4	4	1	1	10	3	19	31	48	41	51													Vb 5.1	CASSQVPAGGIQETQYF+TCRBV05-01+TCRBJ02-05	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGATATCAGGTACAGGACGGTGGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	1	20	3.5355678121906376E-4		56	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	0	3	4	3	9	4	19	35	49	44	53													Vb 5.1	X+TCRBV05-01+TCRBJ02-06	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCACCGACCTACAGGGGGCAGGATACAATGAGCAGTTCTTCGGGCCA	CASSTDLQGAGYNEQFF	In	VDJ	1	23	4.0659029840192336E-4	4.922102379729498E-4	51	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	4	3	0	4	8	4	19	31	48	39	52													Vb 5.1	CASSTDLQGAGYNEQFF+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGAACGTGATCTAAACACCGGGGAGCTGTTTTTTGGAGAA	CASSLERDLNTGELFF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	48	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	0	4	9	2	8	0	19	35	-1	43	46						01,02							Vb 5.1	CASSLERDLNTGELFF+TCRBV05-01+TCRBJ02-02	TCRBV05-01*01	TCRBD02-01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTGGTGTGCCAGGCAACTAATGAAAAACTGTTTTTTGGCAGT	CASSLVCQATNEKLFF	In	VDJ	1	27	4.7730165464573613E-4	5.778120184899846E-4	48	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	0	4	4	0	5	0	19	35	-1	40	44													Vb 5.1	CASSLVCQATNEKLFF+TCRBV05-01+TCRBJ01-04	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTTTTACAGGCCCTATACTGAGCGGGTGAACACTGAAGCTTTCTTTGGACAA	CASSFYRPYTERVNTEAFF	In	VDJ	1	36	6.364022061943148E-4	7.704160246533128E-4	57	TCRBV05	TCRBV05-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	2	6	4	0	17	0	19	33	-1	50	56						01,02							Vb 5.1	CASSFYRPYTERVNTEAFF+TCRBV05-01+TCRBJ01-01	TCRBV05-01*01	TCRBD02-01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCCAAGCAGACAGGGTAGGGAGCCAGCCCCAGCATTTTGGTGAT	CASSQADRVGSQPQHF	In	VDJ	2	42	7.42469240560034E-4	8.988186954288649E-4	48	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	4	2	3	7	6	8	19	31	44	37	52													Vb 5.1	CASSQADRVGSQPQHF+TCRBV05-01+TCRBJ01-05	TCRBV05-01*01	TCRBD01-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCCCCCCGCCCGGGGCCTCCTACAATGAGCAGTTCTTCGGGCCA	CASSPPPGASYNEQFF	In	VDJ	2	54	9.546033092914723E-4	0.0011556240369799693	48	TCRBV05	TCRBV05-01	01				TCRBJ02	TCRBJ02-01	01	4	7	0	0	9	0	19	31	-1	40	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 5.1	CASSPPPGASYNEQFF+TCRBV05-01+TCRBJ02-01	TCRBV05-01*01		TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTTTATCTTTGCGCCAGCAGCTCGGCAGAGCAGGGTAGCTACGAGCAGTACTTCGGGCCG	CASSSAEQGSYEQYF	In	VDJ	3	82	0.0014495828029981615	0.0017548365005992125	45	TCRBV05	TCRBV05-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	4	3	3	8	3	19	32	45	40	48													Vb 5.1	CASSSAEQGSYEQYF+TCRBV05-01+TCRBJ02-07	TCRBV05-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTCAACGGACAGGGGAAGCTATGGCTACACCTTCGGTTCG	CASSSTDRGSYGYTF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	1	2	4	4	3	25	38	51	42	54													Vb 3	CASSSTDRGSYGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTAAACCCACACAGGGGGTATGGCTACACCTTCGGTTCG	CASSLNPHRGYGYTF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	3	1	5	7	0	25	40	-1	47	55													Vb 3	CASSLNPHRGYGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCTCGGGAGGGACCTATGGCTACACCTTCGGTTCG	CASSGGTYGYTF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	36	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	8	8	0	4	1	2	25	34	43	35	45													Vb 3	CASSGGTYGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD02-01*02	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCCCCCTACAATCAACTCCTACAATGAGCAGTTCTTCGGGCCA	CASSPPTINSYNEQFF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	48	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-01	01	5	3	6	0	6	5	25	37	46	43	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSPPTINSYNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01		TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTGTAGGGGCTCGGGGCTACACCTTCGGTTCG	CASSVGARGYTF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	36	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	5	2	8	2	5	25	37	44	39	49													Vb 3	CASSVGARGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAATCCTGCGGCGGGCCGAGGATGGGGACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	11	1.9445622967048507E-4		53	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	7	7	4	5	8	12	25	35	48	43	60						01,02							Vb 3	X+TCRBV28-01+TCRBJ02-02	TCRBV28-01*01	TCRBD02-01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCCGACGAAGGACAGGGAACACTGAAGCTTTCTTTGGACAA	CASSRRRTGNTEAFF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	1	4	1	8	0	25	36	-1	44	51													Vb 3	CASSRRRTGNTEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCGCTCACGGAACACTGAAGCTTTCTTTGGACAA	CASSRSRNTEAFF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	39	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-01	01	5	3	7	1	5	1	25	37	44	42	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSRSRNTEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCTCGAGCATACGCGGGAGAAGCTCCTACGAGCAGTACTTCGGGCCG	CASSIRGRSSYEQYF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	11	7	2	0	10	3	25	31	48	41	51													Vb 3	CASSIRGRSSYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCACCGGGACGTCCGATTACGAGCAGTACTTCGGGCCG	CATGTSDYEQYF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	36	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-07	01	10	0	7	4	2	7	25	32	39	34	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CATGTSDYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAAAGGCCCACTGGAATCCTACGAGCAGTACTTCGGGCCG	CASKGPLESYEQYF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	42	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-07	01	7	1	8	1	10	1	25	35	48	45	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASKGPLESYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTAATGGCACAGGCTAACAAAGCTTTCTTTGGACAA	CASSLMAQANKAFF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	3	4	9	5	6	25	40	50	45	56													Vb 3	CASSLMAQANKAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGGGCAAGCGGGTTCGGCCTCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASRASGFGLSGANVLTF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	54	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-06	01	6	6	4	0	4	8	25	36	46	40	54						01,02							Vb 3	CASRASGFGLSGANVLTF+TCRBV28-01+TCRBJ02-06	TCRBV28-01*01	TCRBD02-01	TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGGAACCTTGGGCGGGCCGCGAACACCGGGGAGCTGTTTTTTGGAGAA	CASRNLGRAANTGELFF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	51	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	6	7	4	0	9	3	25	36	50	45	53						01,02							Vb 3	CASRNLGRAANTGELFF+TCRBV28-01+TCRBJ02-02	TCRBV28-01*01	TCRBD02-01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGGGAAAGGGACCACAGGGTCCGGGTCAATGAGCAGTTCTTCGGGCCA	CASRERDHRVRVNEQFF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	51	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	3	3	6	11	7	25	36	53	47	60													Vb 3	CASRERDHRVRVNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCATCTCCTCCGGGACAGGGGCTTCTCTCTATGGCTACACCTTCGGTTCG	CASISSGTGASLYGYTF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	51	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	7	0	2	4	8	7	25	35	53	43	60													Vb 3	CASISSGTGASLYGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCACGGCTTTCCTGGATAATTCACCCCTCCACTTTGGGAAC	CASTAFLDNSPLHF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	42	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-06	01	7	9	0	5	1	8	25	35	39	36	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASTAFLDNSPLHF+TCRBV28-01+TCRBJ01-06	TCRBV28-01*01		TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCACTGAGAGGGGGGGGCCCACAGATACGCAGTATTTTGGCCCA	CASTERGGPTDTQYF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	7	9	0	2	6	3	25	35	48	41	51													Vb 3	CASTERGGPTDTQYF+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCACTTCATTCGGGACAGCGAAGTCCTCCTACGAGCAGTACTTCGGGCCG	CASTSFGTAKSSYEQYF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	51	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	7	0	5	0	8	7	25	35	50	43	57													Vb 3	CASTSFGTAKSSYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCCCACTCGACAGGGCTATGGCTACACCTTCGGTTCG	CASSPTRQGYGYTF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	2	3	4	7	0	25	37	-1	44	51													Vb 3	CASSPTRQGYGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTGACAGGATTAGCAATCAGCCCCAGCATTTTGGTGAT	CASSDRISNQPQHF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	2	4	0	0	2	25	-1	43	37	45													Vb 3	CASSDRISNQPQHF+TCRBV28-01+TCRBJ01-05	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCGCCAAGGGACTAAGACCTACACCTTCGGTTCG		Out	VDJ	1	17	3.005232640362042E-4		35	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	8	0	9	10	5	4	25	34	46	39	50						01,02							Vb 3	X+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD02-01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTACGGCCTTTCTTGACACAAAGTCGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	1	18	3.182011030971574E-4		55	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	5	2	6	5	12	7	25	37	53	49	60													Vb 3	X+TCRBV28-01+TCRBJ02-06	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTCCGGGACAAACACCGGGGAGCTGTTTTTTGGAGAA	CASSSGTNTGELFF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	4	0	6	2	2	0	25	38	-1	40	46													Vb 3	CASSSGTNTGELFF+TCRBV28-01+TCRBJ02-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCATAGGGGGCCCGAACACTGAAGCTTTCTTTGGACAA	CASIGGPNTEAFF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	39	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	7	5	0	1	1	2	25	35	43	36	45													Vb 3	CASIGGPNTEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTATTCGGTGGGGAGACCCAGTACTTCGGGCCA	CASSLFGGETQYF	In	VDJ	1	19	3.358789421581106E-4	4.066084574559151E-4	39	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-05	01	1	0	9	5	5	0	25	41	-1	46	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSLFGGETQYF+TCRBV28-01+TCRBJ02-05	TCRBV28-01*01		TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTGCCGGGACGAAACTATGGCTACACCTTCGGTTCG	CASSLPGRNYGYTF	In	VDJ	1	19	3.358789421581106E-4	4.066084574559151E-4	42	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-02	01	3	0	7	2	3	2	25	39	47	42	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSLPGRNYGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01		TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTTCTGCACAACTATGGCTACACCTTCGGTTCG	CASSFLHNYGYTF	In	VDJ	1	19	3.358789421581106E-4	4.066084574559151E-4	39	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-02	01	3	3	7	2	5	0	25	39	-1	44	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSFLHNYGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01		TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGGCAGGGGCGGCCTATGGYTACACCTTCGGTTCG		Out	VDJ	1	20	3.5355678121906376E-4		38	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	4	2	11	1	11	25	36	43	37	54													Vb 3	X+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTCCCAGACACCCAAACTGCGGGCTACACCTTCGGTTCG		Out	VDJ	1	20	3.5355678121906376E-4		44	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	2	6	8	4	11	25	38	46	42	57													Vb 3	X+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTTGATCCCCTGACATATAAGGGGATAAACAATGAGCAGTTCTTCGGGCCA	CASSFDPLTYKGINNEQFF	In	VDJ	1	21	3.71234620280017E-4	4.4940934771443245E-4	57	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	5	2	5	17	4	24	38	60	55	64													Vb 3	CASSFDPLTYKGINNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTAGCGGGACAGGGTGGGGCAGATACGCAGTATTTTGGCCCA	CASSLAGQGGADTQYF	In	VDJ	1	21	3.71234620280017E-4	4.4940934771443245E-4	48	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	2	0	3	4	2	5	25	40	51	42	56													Vb 3	CASSLAGQGGADTQYF+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCCCAGGCCAAGAGACCCAGTACTTCGGGCCA	CASSPGQETQYF	In	VDJ	1	22	3.8891245934097015E-4	4.7080979284369113E-4	36	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	6	4	4	1	2	0	25	36	-1	38	42													Vb 3	CASSPGQETQYF+TCRBV28-01+TCRBJ02-05	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCCCCGGCCAGGAGACCCAGTACTTCGGGCCA	CASSPGQETQYF	In	VDJ	1	23	4.0659029840192336E-4	4.922102379729498E-4	36	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-05	01	6	4	5	5	7	0	25	36	-1	43	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSPGQETQYF+TCRBV28-01+TCRBJ02-05	TCRBV28-01*01		TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTCCTACAGGGGGTGAGTTGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	23	4.0659029840192336E-4		49	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	3	1	0	3	5	25	38	49	41	54													Vb 3	X+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCCTAGACAGGGGTCGGGGCTACACCTTCGGTTCG	CASSLDRGRGYTF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	39	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	2	2	8	4	4	25	36	48	40	52													Vb 3	CASSLDRGRGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGGCTGGGACTAGCGGGAGAGAATGAGCAGTTCTTCGGGCCA	CASRLGLAGENEQFF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	6	0	2	7	3	2	25	36	53	39	55													Vb 3	CASRLGLAGENEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGGGGCGGTTCGGGGACAGGGACTGGGGCCAACGTCCTGACTTTCGGGGCC	CASRGGSGTGTGANVLTF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	54	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	6	0	3	2	10	1	25	36	55	46	56													Vb 3	CASRGGSGTGTGANVLTF+TCRBV28-01+TCRBJ02-06	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCGACTAGCGGGAGACACCGGGGAGCTGTTTTTTGGAGAA	CASSRLAGDTGELFF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	5	2	2	3	1	0	25	37	-1	38	50													Vb 3	CASSRLAGDTGELFF+TCRBV28-01+TCRBJ02-02	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTGTCGGACGGGAGAACACTGAAGCTTTCTTTGGACAA	CASSVGRENTEAFF	In	VDJ	1	26	4.596238155847829E-4	5.564115733607259E-4	42	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	5	8	3	1	6	0	25	37	-1	43	48													Vb 3	CASSVGRENTEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD02-01*02	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTCGGGCCTCTATAATTCACCCCTCCACTTTGGGAAC	CASSSGLYNSPLHF	In	VDJ	1	26	4.596238155847829E-4	5.564115733607259E-4	42	TCRBV28	TCRBV28-01	01				TCRBJ01	TCRBJ01-06	01	4	8	0	3	1	2	25	38	43	39	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSSGLYNSPLHF+TCRBV28-01+TCRBJ01-06	TCRBV28-01*01		TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTGGGGGCAGGGCCTTACAATGAGCAATTCTTCGGGCCA		Out	VDJ	1	28	4.949794937066893E-4		43	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	6	0	16	0	19	25	-1	43	37	62													Vb 3	X+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCTCCTCCCCGGTCGGGAGCAGTACTTCGGGCCG	CASSLLPGREQYF	In	VDJ	1	29	5.126573327676425E-4	6.20612908748502E-4	39	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	8	5	7	8	4	25	37	48	45	52						01,02							Vb 3	CASSLLPGREQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTGTGGACACCGGCACTGAAGCTTTCTTTGGACAA	CASSVDTGTEAFF	In	VDJ	1	29	5.126573327676425E-4	6.20612908748502E-4	39	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	1	6	4	2	4	25	37	44	39	48													Vb 3	CASSVDTGTEAFF+TCRBV28-01+TCRBJ01-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCCATTGGACAGTTAACTATGGCTACACCTTCGGTTCG	CASHWTVNYGYTF	In	VDJ	1	29	5.126573327676425E-4	6.20612908748502E-4	39	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	8	1	5	1	4	1	25	34	44	38	45													Vb 3	CASHWTVNYGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCTTTGACAGGGGGCCCGAGACCCAGTACTTCGGGCCA	CASSFDRGPETQYF	In	VDJ	1	31	5.480130108895489E-4	6.634137990070194E-4	42	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	6	2	0	5	4	2	25	36	50	40	52													Vb 3	CASSFDRGPETQYF+TCRBV28-01+TCRBJ02-05	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTGTGTGGGGGGCCCAAGAGACCCAGTACTTCGGGCCA	CASSVWGAQETQYF	In	VDJ	1	31	5.480130108895489E-4	6.634137990070194E-4	42	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-05	01	5	6	0	1	5	0	25	37	-1	42	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	CASSVWGAQETQYF+TCRBV28-01+TCRBJ02-05	TCRBV28-01*01		TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGTGTCCGGGACAGGGGCCGGGCCGGGGAGCTGTTTTTTGGAGAA	CASVRDRGRAGELFF	In	VDJ	1	32	5.65690849950502E-4	6.84814244136278E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	9	0	2	6	5	5	25	33	48	38	53													Vb 3	CASVRDRGRAGELFF+TCRBV28-01+TCRBJ02-02	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGTGCCAGCAGTTCAGGTTAGAACGGGCAGGAAACAGGGGCTTCCATCTGACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	34	6.010465280724084E-4		67	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	4	3	2	5	20	10	0	13	40	33	50													Vb 3	X+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAAGCAGCGGGGGAGCACAGATACGCAGTATTTTGGCCCA	CASKQRGSTDTQYF	In	VDJ	1	35	6.187243671333617E-4	7.490155795240541E-4	42	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	7	6	2	0	3	0	25	35	-1	38	46													Vb 3	CASKQRGSTDTQYF+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCGCACAGGGGGACGAGGAGGAAACACCATATATTTTGGAGAG	CASSRTGGRGGNTIYF	In	VDJ	1	37	6.54080045255268E-4	7.918164697825714E-4	48	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	5	3	1	4	3	7	25	37	48	40	55													Vb 3	CASSRTGGRGGNTIYF+TCRBV28-01+TCRBJ01-03	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCGCTCTATCACAGGGTCCCCTAAAGAAAAACTGTTTTTTGGCAGT	CASSRSITGSPKEKLFF	In	VDJ	1	37	6.54080045255268E-4	7.918164697825714E-4	51	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	5	3	3	8	9	9	25	37	52	46	61													Vb 3	CASSRSITGSPKEKLFF+TCRBV28-01+TCRBJ01-04	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTACGGTACCACAAAGTCGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	1	38	6.717578843162212E-4		49	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-06	01	4	3	6	5	8	5	25	38	49	46	54				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	X+TCRBV28-01+TCRBJ02-06	TCRBV28-01*01		TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTATTTGGGCTTAACACAGATACGCAGTATTTTGGCCCA	CASSLFGLNTDTQYF	In	VDJ	1	38	6.717578843162212E-4	8.132169149118302E-4	45	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	1	8	0	2	2	4	25	41	47	43	51													Vb 3	CASSLFGLNTDTQYF+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTGACTCGACTCTTGACACAAAGTCGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	1	39	6.894357233771744E-4		55	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-06	01	5	2	6	5	12	7	25	37	53	49	60				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	X+TCRBV28-01+TCRBJ02-06	TCRBV28-01*01		TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCCGGACAGGGGGCAGGGGAGGAAACACCATATATTTTGGAGAG	CASSRTGGRGGNTIYF	In	VDJ	2	40	7.071135624381275E-4	8.560178051703475E-4	48	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	6	1	0	4	2	6	25	36	49	38	55													Vb 3	CASSRTGGRGGNTIYF+TCRBV28-01+TCRBJ01-03	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTGCCCCCCGTGGGAAGTGGAACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	2	40	7.071135624381275E-4		49	TCRBV28	TCRBV28-01	01				TCRBJ02	TCRBJ02-02	01	5	0	8	5	9	6	25	37	50	46	56				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 3	X+TCRBV28-01+TCRBJ02-02	TCRBV28-01*01		TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAAAACCTCGGGGGGCGAGAATCAGCCCCAGCATTTTGGTGAT	CASKTSGGENQPQHF	In	VDJ	2	41	7.247914014990807E-4	8.774182502996063E-4	45	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-05	01	7	8	1	4	6	4	25	35	48	41	52													Vb 3	CASKTSGGENQPQHF+TCRBV28-01+TCRBJ01-05	TCRBV28-01*01	TCRBD02-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTAACACAGGGGACCAGTACAGATACGCAGTATTTTGGCCCA	CASSLTQGTSTDTQYF	In	VDJ	2	41	7.247914014990807E-4	8.774182502996063E-4	48	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	2	3	2	3	2	6	25	40	49	42	55													Vb 3	CASSLTQGTSTDTQYF+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCTATGTACCTCTGTGCCAGCAGTTTATGCACCGGGACAGGCACCCATTCTAGCCAAAAACATTCAGTACTTCGGCGCC		Out	VDJ	2	47	8.308584358647998E-4		61	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	0	0	4	0	4	10	12	29	41	33	51													Vb 3	X+TCRBV28-01+TCRBJ02-04	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTATTGGGGACTAGCGTCTACAATGAGCAGTTCTTCGGGCCA	CASSLLGTSVYNEQFF	In	VDJ	3	75	0.001325837929571489	0.0016050333846944016	48	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	1	0	6	3	2	1	25	41	53	43	54						01,02							Vb 3	CASSLLGTSVYNEQFF+TCRBV28-01+TCRBJ02-01	TCRBV28-01*01	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGCCAAAYTAGCGGGAGGAGGGAACAGTACTTCGGGCCG	CASSQXSGRREQYF	In	VDJ	4	96	0.0016970725498515061	0.002054442732408834	42	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	6	5	1	10	6	6	25	36	52	42	58													Vb 3	CASSQXSGRREQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCAGCGGACTAGCGGGAGGGCCTACGAGCAGTACTTCGGGCCG	CASSQRTSGRAYEQYF	In	VDJ	4	98	0.0017324282279734125	0.0020972436226673516	48	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	5	1	0	2	4	0	25	37	-1	41	56													Vb 3	CASSQRTSGRAYEQYF+TCRBV28-01+TCRBJ02-07	TCRBV28-01*01	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTACAGGGGCTTGAGTTTCAAGATACGCAGTATTTTGGCCCA		Out	VDJ	4	103	0.0018208174232781785		46	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	3	2	5	0	11	25	-1	44	37	55													Vb 3	X+TCRBV28-01+TCRBJ02-03	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTAGGGTCCCGGACAACCCAGCATTTTGGTGAT	CASSLGSRTTQHF	In	VDJ	13	350	0.0061872436713336166	0.007490155795240541	39	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	2	1	6	11	7	1	25	40	52	47	53													Vb 3	CASSLGSRTTQHF+TCRBV28-01+TCRBJ01-05	TCRBV28-01*01	TCRBD01-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCAAGTCGCTCCCGAACCCCCTGCAGGGTAGGAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	11	1.9445622967048507E-4		56	TCRBV12	TCRBV12-02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	4	4	3	1	13	3	18	31	49	44	52														X+TCRBV12-02+TCRBJ02-02	TCRBV12-02*01	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCAAGTCGCTCCCCTGGGAGGGGAACCCCGACTACACCCCTCCACTTTGGGAAC	CASRSPGRGTPTTPLHF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	51	TCRBV12	TCRBV12-02	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-06	01	4	9	0	11	5	12	18	31	43	36	55														CASRSPGRGTPTTPLHF+TCRBV12-02+TCRBJ01-06	TCRBV12-02*01	TCRBD02-01*02	TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCACCCCGGGGGTCTACAAGTTAAAGAGCAGTTCTTCGGGCCA		Out	VDJ	1	24	4.2426813746287653E-4		41	TCRBV12	TCRBV12-02	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	12	8	2	10	5	13	18	23	34	28	47														X+TCRBV12-02+TCRBJ02-01	TCRBV12-02*01	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCACCGCGAACCTACAGGGGGCGACCGGGGAGCTGTTTTTTGGAGAA	CATANLQGATGELFF	In	VDJ	7	178	0.003146655352849668	0.0038092792330080465	45	TCRBV12	TCRBV12-02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	12	3	0	5	12	1	18	23	44	35	45														CATANLQGATGELFF+TCRBV12-02+TCRBJ02-02	TCRBV12-02*01	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCAACCAGACCTCTCTGTACTTCTGTGCCAGCAGTTCCGGACTATTCACCGAGGAGCTGTTTTTTGGAGAA	CASSSGLFTEELFF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	42	TCRBV27	TCRBV27-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	4	1	9	10	2	8	23	36	44	38	52						01,02							Vb 14	CASSSGLFTEELFF+TCRBV27-01+TCRBJ02-02	TCRBV27-01*01	TCRBD02-01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCAACCAGACCTCTCTGTACTTCTGTGCCAGCAGTTCCTCGGTCATGGACTATGGCTACACCTTCGGTTCG	CASSSSVMDYGYTF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	42	TCRBV27	TCRBV27-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	4	8	5	3	3	6	23	36	42	39	48						01,02							Vb 14	CASSSSVMDYGYTF+TCRBV27-01+TCRBJ01-02	TCRBV27-01*01	TCRBD02-01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCAACCAGACCTCTCTGTACTTCTGTGCCAGCAGTCCCTCCAGAGTCGCTGGAAACACCATATATTTTGGAGAG	CASSPSRVAGNTIYF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	45	TCRBV27	TCRBV27-01	01				TCRBJ01	TCRBJ01-03	01	5	4	5	2	5	5	23	35	43	40	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 14	CASSPSRVAGNTIYF+TCRBV27-01+TCRBJ01-03	TCRBV27-01*01		TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCAACCAGACCTCTCTGTACTTCTGTGCCAGCAGTCTTTACGGCCCTAGGGGAGACCTCGGGTCCTACGAGCAGTACTTCGGGCCA	CASSLYGPRGDLGSYEQYF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	57	TCRBV27	TCRBV27-01	01				TCRBJ02	TCRBJ02-05	01	5	5	2	11	12	19	23	35	52	47	71				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 14	CASSLYGPRGDLGSYEQYF+TCRBV27-01+TCRBJ02-05	TCRBV27-01*01		TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCAACCAGACCTCTCTGTACTTCTGTGCCACCAGTGATACAGGGGAAAATGCCTACAATGAGCAGTTCTTCGGGCCA	CATSDTGENAYNEQFF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	48	TCRBV27	TCRBV27-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	3	2	2	3	6	23	35	45	38	51													Vb 14	CATSDTGENAYNEQFF+TCRBV27-01+TCRBJ02-01	TCRBV27-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCAACCAGACCTCTCTGTACTTCTGTGCCAGCAGAACCTGGGCTAGCCATAGGAGTGAGCAGTTCTTCGGGCCA	CASRTWASHRSEQFF	In	VDJ	1	21	3.71234620280017E-4	4.4940934771443245E-4	45	TCRBV27	TCRBV27-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	4	7	9	8	8	23	34	47	42	55						01,02							Vb 14	CASRTWASHRSEQFF+TCRBV27-01+TCRBJ02-01	TCRBV27-01*01	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCAACCAGACCTCTCTGTACTTCTGTGCCAGCAGTCCCCACAGATCTACTAATGAAAAACTGTTTTTTGGCAGT	CASSPHRSTNEKLFF	In	VDJ	1	21	3.71234620280017E-4	4.4940934771443245E-4	45	TCRBV27	TCRBV27-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	5	3	5	2	4	4	23	35	43	39	47													Vb 14	CASSPHRSTNEKLFF+TCRBV27-01+TCRBJ01-04	TCRBV27-01*01	TCRBD01-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCAACCAGACCTCTCTGTACTTCTGTGCCAGCAGTTACCTCAGGGGGCCCCGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	25	4.4194597652382975E-4		43	TCRBV27	TCRBV27-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	4	4	0	8	4	3	23	36	48	40	51													Vb 14	X+TCRBV27-01+TCRBJ01-04	TCRBV27-01*01	TCRBD01-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCAACCAGACCTCTCTGTACTTCTGTGCCAGCAGTTCGGAGGGAAAGAGGTACGAGCAGTACTTCGGGCCG	CASSSEGKRYEQYF	In	VDJ	3	88	0.0015556498373638806	0.0018832391713747645	42	TCRBV27	TCRBV27-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	4	10	0	4	1	7	23	36	43	37	50													Vb 14	CASSSEGKRYEQYF+TCRBV27-01+TCRBJ02-07	TCRBV27-01*01	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTCGAACTCGACCGTGTGAACACTGAAGCTTTCTTTGGACAA	CSVELDRVNTEAFF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	42	TCRBV29	TCRBV29-01	01				TCRBJ01	TCRBJ01-01	01	2	2	7	0	3	4	25	37	43	40	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 4	CSVELDRVNTEAFF+TCRBV29-01+TCRBJ01-01	TCRBV29-01*01		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGATGCGGGCTCAATCACAGATACGCAGTATTTTGGCCCA	CSVDAGSITDTQYF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	42	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	3	7	4	2	1	6	25	36	42	37	48						01,02							Vb 4	CSVDAGSITDTQYF+TCRBV29-01+TCRBJ02-03	TCRBV29-01*01	TCRBD02-01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGCTCAGCGGGGAGACAATGAGCAGTTCTTCGGGCCA	CSAQRGDNEQFF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	36	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	7	6	3	5	3	2	25	32	42	35	44													Vb 4	CSAQRGDNEQFF+TCRBV29-01+TCRBJ02-01	TCRBV29-01*01	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTAGGGAAGGGGCGCAATCACCCCTCCACTTTGGGAAC	CSVREGAQSPLHF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	39	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	5	5	2	10	5	5	25	34	44	39	49													Vb 4	CSVREGAQSPLHF+TCRBV29-01+TCRBJ01-06	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGCTCACAAGAACACCGGGGAGCTGTTTTTTGGAGAA	CSAHKNTGELFF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	36	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	7	3	6	1	3	1	25	32	38	35	39													Vb 4	CSAHKNTGELFF+TCRBV29-01+TCRBJ02-02	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTCGATGGTCCTTTGGACAGATATGGCTACACCTTCGGTTCG	CSVDGPLDRYGYTF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	42	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	1	5	5	12	1	25	33	51	45	52													Vb 4	CSVDGPLDRYGYTF+TCRBV29-01+TCRBJ01-02	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTAGGACAGGGGTTGAGACCCAGTACTTCGGGCCA	CSVRTGVETQYF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	36	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	1	2	5	1	2	25	34	44	35	46													Vb 4	CSVRTGVETQYF+TCRBV29-01+TCRBJ02-05	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGATGGAAGGGGAGGGGGTTCTAGCCAAAAACATTCAGTACTTCGGCGCC		Out	VDJ	1	12	2.1213406873143826E-4		52	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-04	01	3	9	0	0	6	6	25	36	49	42	55													Vb 4	X+TCRBV29-01+TCRBJ02-04	TCRBV29-01*01	TCRBD02-01*02	TCRBJ02-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGTCCCGAGGCCCGGGACTAGCGAGCAGTACTTCGGGCCG	CSVVPRPGTSEQYF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	42	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	4	0	8	6	11	0	25	35	-1	46	54						01,02							Vb 4	CSVVPRPGTSEQYF+TCRBV29-01+TCRBJ02-07	TCRBV29-01*01	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGCCCCCCGTTTTGAAGCAACTAATGAAAAACTGTTTTTTGGCAGT	CSAPRFEATNEKLFF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	45	TCRBV29	TCRBV29-01	01				TCRBJ01	TCRBJ01-04	01	7	2	8	0	11	2	25	32	45	43	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 4	CSAPRFEATNEKLFF+TCRBV29-01+TCRBJ01-04	TCRBV29-01*01		TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTCCAGGACTAGCAGTTAGCGTGGGTAATGAGCAGTTCTTCGGGCCA	CSVPGLAVSVGNEQFF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	48	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	1	7	7	3	13	25	34	45	37	58						01,02							Vb 4	CSVPGLAVSVGNEQFF+TCRBV29-01+TCRBJ02-01	TCRBV29-01*01	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGAAGGGTAGCATCCGCCAGATACGCAGTATTTTGGCCCA	CSVEG*HPPDTQYF	Stop	VDJ	1	13	2.2981190779239146E-4		42	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	1	5	7	4	2	6	25	38	44	40	50						01,02							Vb 4	CSVEG*HPPDTQYF+TCRBV29-01+TCRBJ02-03	TCRBV29-01*01	TCRBD02-01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGATAGCGGCAGGGGGGGGGAGACCCAGTACTTCGGGCCA	CSVDSGRGGETQYF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	42	TCRBV29	TCRBV29-01	01				TCRBJ02	TCRBJ02-05	01	3	4	1	5	6	3	25	36	49	42	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 4	CSVDSGRGGETQYF+TCRBV29-01+TCRBJ02-05	TCRBV29-01*01		TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGGAAGTACGGCAGGACAAAGCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CSVGSTAGQSSGANVLTF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	54	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	4	1	6	0	11	3	25	35	51	46	54													Vb 4	CSVGSTAGQSSGANVLTF+TCRBV29-01+TCRBJ02-06	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGCGACCTCTAAAAGGGACATTCAGTACTTCGGCGCC	CSVATSKRDIQYF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	39	TCRBV29	TCRBV29-01	01				TCRBJ02	TCRBJ02-04	01	4	5	3	8	11	0	25	35	-1	46	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 4	CSVATSKRDIQYF+TCRBV29-01+TCRBJ02-04	TCRBV29-01*01		TCRBJ02-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGCTGAAGAAGGGGGATACGAGCAGTACTTCGGGCCG	CSAEEGGYEQYF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	36	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	5	1	4	0	1	25	-1	45	39	46													Vb 4	CSAEEGGYEQYF+TCRBV29-01+TCRBJ02-07	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGCCCCGGGACAGGGGGTTAGAGAGCAGTACTTCGGGCCG	CSVAPGQGVREQYF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	42	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	0	1	7	4	5	25	35	50	39	55													Vb 4	CSVAPGQGVREQYF+TCRBV29-01+TCRBJ02-07	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGCTCAAGACTCTAACACTGAAGCTTTCTTTGGACAA	CSAQDSNTEAFF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	36	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	0	4	10	2	0	2	25	-1	41	39	43						01,02							Vb 4	CSAQDSNTEAFF+TCRBV29-01+TCRBJ01-01	TCRBV29-01*01	TCRBD02-01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGCTAAGGGGCGGACTGAAGCTTTCTTTGGACAA	CSVAKGRTEAFF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	36	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	5	2	5	3	3	25	35	43	38	46													Vb 4	CSVAKGRTEAFF+TCRBV29-01+TCRBJ01-01	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGCCTGGGATTTGAGCAGCTCCTACAATGAGCAGTTCTTCGGGCCA	CSAWDLSSSYNEQFF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	45	TCRBV29	TCRBV29-01	01				TCRBJ02	TCRBJ02-01	01	7	0	8	0	3	9	25	32	39	35	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 4	CSAWDLSSSYNEQFF+TCRBV29-01+TCRBJ02-01	TCRBV29-01*01		TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGAAGGGGGACAGGGGATCAACTATGGCTACACCTTCGGTTCG	CSVEGGQGINYGYTF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	45	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	1	0	2	2	1	3	25	38	49	39	52													Vb 4	CSVEGGQGINYGYTF+TCRBV29-01+TCRBJ01-02	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGAATATGGGGAAGGCACTGAAGCTTTCTTTGGACAA	CSVEYGEGTEAFF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	39	TCRBV29	TCRBV29-01	01				TCRBJ01	TCRBJ01-01	01	2	0	8	4	4	3	25	37	45	41	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 4	CSVEYGEGTEAFF+TCRBV29-01+TCRBJ01-01	TCRBV29-01*01		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGCCCGGTCCAGGGAGGCTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	18	3.182011030971574E-4		41	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	7	9	1	0	9	0	25	32	-1	41	47													Vb 4	X+TCRBV29-01+TCRBJ02-07	TCRBV29-01*01	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGCTCACCGGGCTAGCGGGGGTACTAGCATAGATTTTGGCCCA	CSAHRASGGTSIDF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	42	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	7	4	2	16	9	11	25	32	51	41	62													Vb 4	CSAHRASGGTSIDF+TCRBV29-01+TCRBJ02-03	TCRBV29-01*01	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGAAGTGGGGGCGGATGAGCAGTTCTTCGGGCCA	CSVEVGADEQFF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	36	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	1	6	0	8	1	2	25	38	45	39	47													Vb 4	CSVEVGADEQFF+TCRBV29-01+TCRBJ02-01	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGCCGTTCTCCCCTCGATTGCCTACGAGCAGTACTTCGGGCCG	CSVAVLPSIAYEQYF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	45	TCRBV29	TCRBV29-01	01				TCRBJ02	TCRBJ02-07	01	4	2	8	2	13	3	25	35	50	48	53				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 4	CSVAVLPSIAYEQYF+TCRBV29-01+TCRBJ02-07	TCRBV29-01*01		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTAGGGGACAGGGGGCGAAGTTGTGGCTACACCTTCGGTTCG		Out	VDJ	1	23	4.0659029840192336E-4		43	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	0	0	7	2	7	25	34	48	36	55													Vb 4	X+TCRBV29-01+TCRBJ01-02	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGCTCGCGACAGCTCCCTCTACGAGCAGTACTTCGGGCCG	CSARDSSLYEQYF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	39	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	7	2	5	3	5	6	25	32	42	37	48													Vb 4	CSARDSSLYEQYF+TCRBV29-01+TCRBJ02-07	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGAAGATAGCCGTGCGGGAGGGTTGGCCAAAAACATTCAGTACTTCGGCGCC	CSVEDSRAGGLAKNIQYF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	54	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-04	01	0	7	0	1	7	3	25	39	55	46	58													Vb 4	CSVEDSRAGGLAKNIQYF+TCRBV29-01+TCRBJ02-04	TCRBV29-01*01	TCRBD02-01*02	TCRBJ02-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGGATCAGGGGGGACTAATGAAAAACTGTTTTTTGGCAGT	CSVGSGGTNEKLFF	In	VDJ	1	25	4.4194597652382975E-4	5.350111282314672E-4	42	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	4	4	1	2	3	1	25	35	45	38	46													Vb 4	CSVGSGGTNEKLFF+TCRBV29-01+TCRBJ01-04	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAAGACAGCAGCATATATCTCTGCAGCGCCCCTCCGGTACTAGTGGGGGGCCGCCCGAGTAGCACAGATACGCAGTATTTTGGCCCA	CSAPPVLVGGRPSSTDTQYF	In	VDJ	1	25	4.4194597652382975E-4	5.350111282314672E-4	60	TCRBV29	TCRBV29-01	01				TCRBJ02	TCRBJ02-03	01	7	6	0	0	17	9	21	28	51	45	60				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 4	CSAPPVLVGGRPSSTDTQYF+TCRBV29-01+TCRBJ02-03	TCRBV29-01*01		TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGAAGGTGGGACAGGGCGGGAGACCCACTACTATGGCTACACCTTCGGTTCG	CSVEGGTGRETHYYGYTF	In	VDJ	1	27	4.7730165464573613E-4	5.778120184899846E-4	54	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	1	0	3	3	2	13	25	38	49	40	62													Vb 4	CSVEGGTGRETHYYGYTF+TCRBV29-01+TCRBJ01-02	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGAAGAACCCCTATATGGCTACACCTTCGGTTCG	CSVEEPLYGYTF	In	VDJ	1	29	5.126573327676425E-4	6.20612908748502E-4	36	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	0	4	9	5	4	0	25	39	-1	43	46						01,02							Vb 4	CSVEEPLYGYTF+TCRBV29-01+TCRBJ01-02	TCRBV29-01*01	TCRBD02-01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGGACAGAGGTTAAACAATGAGCAGTTCTTCGGGCCA	CSVGQRLNNEQFF	In	VDJ	1	29	5.126573327676425E-4	6.20612908748502E-4	39	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	4	2	5	5	0	7	25	-1	40	35	47													Vb 4	CSVGQRLNNEQFF+TCRBV29-01+TCRBJ02-01	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGGCCAGGGGGCCCCCGAGCAGTACTTCGGGCCG	CSVGQGAPEQYF	In	VDJ	1	29	5.126573327676425E-4	6.20612908748502E-4	36	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	4	0	6	2	3	25	35	45	37	48													Vb 4	CSVGQGAPEQYF+TCRBV29-01+TCRBJ02-07	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTAAGGGACAGAAATAAAGCGAATACCGGGGAGCTGTTTTTTGGAGAA	CSVRDRNKANTGELFF	In	VDJ	1	33	5.833686890114552E-4	7.062146892655367E-4	48	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	6	0	5	5	2	13	25	33	42	35	55													Vb 4	CSVRDRNKANTGELFF+TCRBV29-01+TCRBJ02-02	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGAGGCGACAGGGGCTTCCGAGCAGTACTTCGGGCCG	CSVEATGASEQYF	In	VDJ	1	35	6.187243671333617E-4	7.490155795240541E-4	39	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	2	2	6	3	4	25	36	47	39	51													Vb 4	CSVEATGASEQYF+TCRBV29-01+TCRBJ02-07	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGAAGAGTCGACACGGAGCTCTGGAAACACCATATATTTTGGAGAG	CSVEESTRSSGNTIYF	In	VDJ	1	36	6.364022061943148E-4	7.704160246533128E-4	48	TCRBV29	TCRBV29-01	01				TCRBJ01	TCRBJ01-03	01	0	2	6	0	3	5	25	39	46	42	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 4	CSVEESTRSSGNTIYF+TCRBV29-01+TCRBJ01-03	TCRBV29-01*01		TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTGAAGACAGCAGCATATATCTCTGCAGCGTTGTTCGGAGACCAGGGGCCGGGGCCAGCTCCTACAATGAGCAGTTCTTCGGGCCA	CSVVRRPGAGASSYNEQFF	In	VDJ	1	37	6.54080045255268E-4	7.918164697825714E-4	57	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	4	4	2	0	9	10	24	34	49	43	59													Vb 4	CSVVRRPGAGASSYNEQFF+TCRBV29-01+TCRBJ02-01	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGGTGTGGCAGCGGGACACCAACCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	38	6.717578843162212E-4		50	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	4	6	3	2	7	6	25	35	49	42	55													Vb 4	X+TCRBV29-01+TCRBJ02-01	TCRBV29-01*01	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGACTCTATGAACACTGAAGCTTTCTTTGGACAA	CSVDSMNTEAFF	In	VDJ	1	39	6.894357233771744E-4	8.346173600410888E-4	36	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	3	4	9	0	2	0	25	36	-1	38	41						01,02							Vb 4	CSVDSMNTEAFF+TCRBV29-01+TCRBJ01-01	TCRBV29-01*01	TCRBD02-01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGGCCAGAGGGTCTCTGGAAACACCATATATTTTGGAGAG	CSVGQRVSGNTIYF	In	VDJ	2	45	7.955027577428935E-4	9.63020030816641E-4	42	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-03	01	4	11	0	0	4	1	25	35	44	39	45													Vb 4	CSVGQRVSGNTIYF+TCRBV29-01+TCRBJ01-03	TCRBV29-01*01	TCRBD02-01*02	TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGAAGATCAGGCAGGCCTCTCTGGAAACACCATATATTTTGGAGAG	CSVEDQAGLSGNTIYF	In	VDJ	2	47	8.308584358647998E-4	0.0010058209210751584	48	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	0	4	4	0	1	7	25	39	44	40	51													Vb 4	CSVEDQAGLSGNTIYF+TCRBV29-01+TCRBJ01-03	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGACAAGGTCAGCTCTGGAAACACCATATATTTTGGAGAG	CSVDKVSSGNTIYF	In	VDJ	3	70	0.0012374487342667233	0.0014980311590481082	42	TCRBV29	TCRBV29-01	01				TCRBJ01	TCRBJ01-03	01	3	4	5	0	6	0	25	36	-1	42	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 4	CSVDKVSSGNTIYF+TCRBV29-01+TCRBJ01-03	TCRBV29-01*01		TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTGCAGGGTATGAACCTTGAAAAACTGTTTTTTGGCAGT	CSVQGMNLEKLFF	In	VDJ	3	82	0.0014495828029981615	0.0017548365005992125	39	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	6	4	3	7	1	9	25	33	39	34	48													Vb 4	CSVQGMNLEKLFF+TCRBV29-01+TCRBJ01-04	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGGGACAGGCGGAACTAATGAAAAACTGTTTTTTGGCAGT	CSVGTGGTNEKLFF	In	VDJ	6	147	0.0025986423419601186	0.0031458654340010272	42	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	4	1	4	1	0	3	25	-1	42	35	45													Vb 4	CSVGTGGTNEKLFF+TCRBV29-01+TCRBJ01-04	TCRBV29-01*01	TCRBD01-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGGGCAGGCGCTATACAATGAGCAGTTCTTCGGGCCA	CSVGQALYNEQFF	In	VDJ	24	619	0.010942582378730024	0.013246875535011127	39	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	4	4	4	4	2	5	25	35	41	37	46													Vb 4	CSVGQALYNEQFF+TCRBV29-01+TCRBJ02-01	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGTGTCGACAGCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSVDSSGANVLTF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	45	TCRBV02	TCRBV02-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	4	2	5	0	2	0	23	36	-1	38	43													Vb 22	CASSVDSSGANVLTF+TCRBV02-01+TCRBJ02-06	TCRBV02-01*01	TCRBD01-01*01	TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGTGATTTCGGGACAGCTAACTATGGCTACACCTTCGGTTCG	CASSDFGTANYGYTF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	45	TCRBV02	TCRBV02-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	0	5	0	4	0	23	37	-1	41	48													Vb 22	CASSDFGTANYGYTF+TCRBV02-01+TCRBJ01-02	TCRBV02-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCCGAGCCCAGGGGCCCATCTATGGCTACACCTTCGGTTCG	CASRAQGPIYGYTF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	42	TCRBV02	TCRBV02-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	8	4	2	4	6	5	23	32	44	38	49													Vb 22	CASRAQGPIYGYTF+TCRBV02-01+TCRBJ01-02	TCRBV02-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGGAGGACTCAGCCATGTACTTCTGTGCCAGCAGGGCTACCTTAGGGACTAGCGGGAGAAGGGAGACCCAGTACTTCGGGCCA	CASRATLGTSGRRETQYF	In	VDJ	3	75	0.001325837929571489	0.0016050333846944016	54	TCRBV02	TCRBV02-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	6	0	2	5	10	4	23	34	58	44	62													Vb 22	CASRATLGTSGRRETQYF+TCRBV02-01+TCRBJ02-05	TCRBV02-01*01	TCRBD02-01*02	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGTACCCTCTCAGACATCTGTGTACTTCTGTGCCAGCAGTTACTCCCCCGGGAATCGAATAACTGAAGCTTTCTTTGGACAA	CASSYSPGNRITEAFF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	48	TCRBV06	TCRBV06-04		TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	0	8	3	5	3	8	28	45	53	48	61			01,02											CASSYSPGNRITEAFF+TCRBV06-04+TCRBJ01-01	TCRBV06-04	TCRBD02-01*02	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAGCCTCCTGGGGGGAACCCAAGAGACCCAGTACTTCGGGCCA	CASSLLGGTQETQYF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	45	TCRBV06	TCRBV06-07	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	6	9	1	1	6	3	26	37	49	43	52														CASSLLGGTQETQYF+TCRBV06-07+TCRBJ02-05	TCRBV06-07*01	TCRBD02-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCTGTGATTACGGAGGGGCCGGATACAATGAGCAGTTCTTCGGGCCA	CASCDYGGAGYNEQFF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	48	TCRBV06	TCRBV06-07	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	8	10	0	4	9	6	26	35	50	44	56														CASCDYGGAGYNEQFF+TCRBV06-07+TCRBJ02-01	TCRBV06-07*01	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAGCGGGACTACCCGTTTGAACACTGAAGCTTTCTTTGGACAA	CASSGTTRLNTEAFF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	45	TCRBV06	TCRBV06-07	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	6	0	9	0	1	6	26	37	45	38	51						01,02								CASSGTTRLNTEAFF+TCRBV06-07+TCRBJ01-01	TCRBV06-07*01	TCRBD02-01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCACCCTTAAGGGGTCGGACTAGCCCTACAATGAGCAGTTCTTCGGGCCA	CASTLKGSD*PYNEQFF	Stop	VDJ	1	16	2.82845424975251E-4		51	TCRBV06	TCRBV06-07	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	7	1	7	2	13	0	26	36	-1	49	57						01,02								CASTLKGSD*PYNEQFF+TCRBV06-07+TCRBJ02-01	TCRBV06-07*01	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAACAGTGACTCCCAGGGGGCACGTCGCGGCTACACCTTCGGTTCG	CANSDSQGARRGYTF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	45	TCRBV06	TCRBV06-07	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	4	0	8	1	7	26	43	52	44	59														CANSDSQGARRGYTF+TCRBV06-07+TCRBJ01-02	TCRBV06-07*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAGTTCCTACAATGAGCAGTTCTTCGGGCCA	CASSSYNEQFF	In	VJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	33	TCRBV06	TCRBV06-07	01				TCRBJ02	TCRBJ02-01	01	5	0	0	1	0	0	26	-1	-1	-1	38														CASSSYNEQFF+TCRBV06-07+TCRBJ02-01	TCRBV06-07*01		TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAGGGGGACTTACACCTCCTACGAGCAGTACTTCGGGCCG	CASRGTYTSYEQYF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	42	TCRBV06	TCRBV06-07	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	6	0	10	0	1	5	26	37	44	38	49						01,02								CASRGTYTSYEQYF+TCRBV06-07+TCRBJ02-07	TCRBV06-07*01	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAGTTAGGCAGAAGCTTACTATGGCTACACCTTCGGTTCG	CASS*AEAYYGYTF	Stop	VDJ	1	22	3.8891245934097015E-4		42	TCRBV06	TCRBV06-07	01				TCRBJ01	TCRBJ01-02	01	3	4	5	3	2	6	26	40	45	42	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASS*AEAYYGYTF+TCRBV06-07+TCRBJ01-02	TCRBV06-07*01		TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TTCTGTTTACTTCTGTGCCAGCAGTTACTCGCGGGACTAGCGGGGGGCCGAACCAATCTACGAGCAGTACTTCGGGCCG	CASSYSRD*RGAEPIYEQYF	Stop	VDJ	1	22	3.8891245934097015E-4		60	TCRBV06	TCRBV06-07	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	0	0	1	3	2	10	13	30	47	32	57														CASSYSRD*RGAEPIYEQYF+TCRBV06-07+TCRBJ02-07	TCRBV06-07*01	TCRBD02-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAGCCACCGCCGGTCAGACAGGGGGGATAGGAACACTGAAGCTTTCTTTGGACAA	CASSHRRSDRGDRNTEAFF	In	VDJ	1	23	4.0659029840192336E-4	4.922102379729498E-4	57	TCRBV06	TCRBV06-07	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	2	1	1	13	5	24	35	57	48	62														CASSHRRSDRGDRNTEAFF+TCRBV06-07+TCRBJ01-01	TCRBV06-07*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAGTCGCACTAGCGGGGGGCCAAGGGAGCAGTACTTCGGGCCG	CASSRTSGGPREQYF	In	VDJ	1	23	4.0659029840192336E-4	4.922102379729498E-4	45	TCRBV06	TCRBV06-07	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	5	3	1	7	3	6	26	38	53	41	59														CASSRTSGGPREQYF+TCRBV06-07+TCRBJ02-07	TCRBV06-07*01	TCRBD02-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAGCCCAAAATACAGGGTTTTAACCGGGGAGCTGTTTTTTGGAGAA	CASSPKYRVLTGELFF	In	VDJ	1	28	4.949794937066893E-4	5.992124636192433E-4	48	TCRBV06	TCRBV06-07	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	6	3	3	5	8	5	26	37	51	45	56														CASSPKYRVLTGELFF+TCRBV06-07+TCRBJ02-02	TCRBV06-07*01	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CTCCCTCTCAGACTTCTGTTTACTTCTGTGCCAGCAGCGCGGGTCCTTACAATTCACCCCTCCACTTTGGGAAC	CASSAGPYNSPLHF	In	VDJ	1	30	5.303351718285957E-4	6.420133538777606E-4	42	TCRBV06	TCRBV06-07	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-06	01	6	7	4	7	1	7	26	37	43	38	50						01,02								CASSAGPYNSPLHF+TCRBV06-07+TCRBJ01-06	TCRBV06-07*01	TCRBD02-01	TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCAGCCATGTATCGCTGTGCCAGCAGCTTAGTGTCCTTTCAAGAGACCCAGTACTTCGGGCCA	CASSLVSFQETQYF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	42	TCRBV07	TCRBV07-07	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	1	4	10	2	4	2	19	35	41	39	43						01,02								CASSLVSFQETQYF+TCRBV07-07+TCRBJ02-05	TCRBV07-07*01	TCRBD02-01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCAGCCATGTATCGCTGTGCCAGCAGCAGGAACGGGACAGGGGATAAGAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	13	2.2981190779239146E-4		49	TCRBV07	TCRBV07-07	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	0	2	5	6	5	19	31	47	37	52														X+TCRBV07-07+TCRBJ02-03	TCRBV07-07*01	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCAGCCATGTATCGCTGTGCCAGCAGCCACCTAACTCAGAAGCGGGGTCAGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	20	3.5355678121906376E-4		55	TCRBV07	TCRBV07-07	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	5	6	3	0	13	2	19	31	51	44	53														X+TCRBV07-07+TCRBJ02-03	TCRBV07-07*01	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCAGCCATGTATCGCTGTGCCAGCAGCTTACGGACTAGCCTAAACACCGGGGAGCTGTTTTTTGGAGAA	CASSLRTSLNTGELFF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	48	TCRBV07	TCRBV07-07	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	2	1	7	2	1	3	19	34	43	35	46						01,02								CASSLRTSLNTGELFF+TCRBV07-07+TCRBJ02-02	TCRBV07-07*01	TCRBD02-01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAAGCTTGAGGATTCAGCAGTGTATTTTTGTGCCAGCAGCCAACCGGACAGGGGCAATCAGCCCCAGCATTTTGGTGAT	CASSQPDRGNQPQHF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	45	TCRBV16	TCRBV16-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	2	1	3	2	2	0	29	44	-1	46	54			01,02											CASSQPDRGNQPQHF+TCRBV16-01+TCRBJ01-05	TCRBV16-01	TCRBD01-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAAGCTTGAGGATTCAGCAGTGTATTTTTGTGCCAGCAGCCCAGACACAGATACGCAGTATTTTGGCCCA	CASSPDTDTQYF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	36	TCRBV16	TCRBV16-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	4	4	5	2	0	1	29	-1	45	42	46			01,02											CASSPDTDTQYF+TCRBV16-01+TCRBJ02-03	TCRBV16-01	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCACCAACCAGACATCTGTGTATCTCTATGCCAGCAGTTTGAGGGCCGAGCAGTACTTCGGGCCG	YASSLRAEQYF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	33	TCRBV26	TCRBV26-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	4	11	0	6	1	1	27	40	46	41	47														YASSLRAEQYF+TCRBV26-01+TCRBJ02-07	TCRBV26-01*01	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCACCAACCAGACATCTGTGTATCTCTATGCCAGCAGTCCTCCTGGGGGAGGGATCAATGAGCAGTTCTTCGGGCCA	YASSPPGGGINEQFF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	45	TCRBV26	TCRBV26-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	5	9	0	6	8	2	27	39	54	47	56														YASSPPGGGINEQFF+TCRBV26-01+TCRBJ02-01	TCRBV26-01*01	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCTCYCAGACATCTGTGTACTTSTGTGCCAGCAGTGAAGAGTCGGTCCTTATCAGCTCCTATAATTCACCCCTCCACTTTGGGAAC	CASSEESVLISSYNSPLHF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	57	TCRBV06	unresolved					TCRBJ01	TCRBJ01-06	01	3	4	5	0	15	0	24	38	-1	53	56		TCRBV06-01,TCRBV06-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSEESVLISSYNSPLHF+TCRBV06-X+TCRBJ01-06	unresolved		TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGCAGTTACCAGGGGGCGCAGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	8	1.414227124876255E-4		46	TCRBV06	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	2	4	0	1	0	2	26	-1	49	41	51		TCRBV06-07,TCRBV06-08												X+TCRBV06-X+TCRBJ01-05	unresolved	TCRBD01-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCCCTCCCARACATCTGTGTACTTSTGTGCCAGCAGGCAGATGACCGGGGAGCTGTTTTTTGGAGAA	CASRQMTGELFF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	36	TCRBV06	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	6	4	5	5	1	3	25	36	40	37	43		TCRBV06-02,TCRBV06-03,TCRBV06-08												CASRQMTGELFF+TCRBV06-X+TCRBJ02-02	unresolved	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCAGTTACGGAGGAGAAACGAAGCAGTACTTCGGGCCG	CASSYGGETKQYF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	39	TCRBV06	unresolved		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	2	10	1	8	0	8	23	-1	43	38	51		TCRBV06-05,TCRBV06-06,TCRBV06-08												CASSYGGETKQYF+TCRBV06-X+TCRBJ02-07	unresolved	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCRTGTATSTCTGTGCCAGCAGCTGGGGGACAGGGGGCCGTCGGGAGCAGTACTTCGGGCCG	CASSWGTGGRREQYF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	45	TCRBV11	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	0	0	7	2	6	18	31	45	33	51		TCRBV11-01,TCRBV11-03												CASSWGTGGRREQYF+TCRBV11-X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTSTATCTCTGTGCCAGCAGCTCAGGGACAGTCAAAAGGACTCGTGGCTACACCTTCGGTTCG	CASSSGTVKRTRGYTF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	48	TCRBV05	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	0	5	7	2	13	19	32	41	34	54		TCRBV05-05,TCRBV05-06,TCRBV05-07												CASSSGTVKRTRGYTF+TCRBV05-X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGYWCCCTCTCAGACWTCTGTKTACTTCTGTGCCAGCAGTTACTTTGGGACAGGGGACTATGGCTACACCTTCGGTTCG	CASSYFGTGDYGYTF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	45	TCRBV06	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	1	0	2	3	2	0	28	44	-1	46	56		TCRBV06-04,TCRBV06-07												CASSYFGTGDYGYTF+TCRBV06-X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGYWCCCTCTCAGACWTCTGTKTACTTCTGTGCCAGCATAAAGGGAGGGGTTGCTTTCTTTGGACAA	CASIKGGVAFF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	33	TCRBV06	unresolved		TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	7	9	0	11	4	3	28	38	49	42	52		TCRBV06-04,TCRBV06-07												CASIKGGVAFF+TCRBV06-X+TCRBJ01-01	unresolved	TCRBD02-01*02	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGACTCGGCYGTGTATCTCTGTGCCAGCAGCCCCGGGACGTACAGCACAGATACGCAGTATTTTGGCCCA	CASSPGTYSTDTQYF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	45	TCRBV07	unresolved					TCRBJ02	TCRBJ02-03	01	4	0	7	0	3	4	19	31	39	34	43		TCRBV07-02,TCRBV07-05		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPGTYSTDTQYF+TCRBV07-X+TCRBJ02-03	unresolved		TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
SGACTCRGCYRTGTATCKCTGTGCCAGCAGCCAGACCCTGGACAGGGGTTTGCAGTACTTCGGGCCG	CASSQTLDRGLQYF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	42	TCRBV07	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	1	2	9	8	3	19	31	48	39	51		TCRBV07-05,TCRBV07-07												CASSQTLDRGLQYF+TCRBV07-X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGGGGACTYGGCYRTGTATCKCTGTGCCAGCAGCTTAGGGACAGGGACTAGCACAGATACGCAGTATTTTGGCCCA	CASSLGTGTSTDTQYF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	48	TCRBV07	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	1	1	3	0	0	3	18	-1	42	34	45		TCRBV07-01,TCRBV07-06												CASSLGTGTSTDTQYF+TCRBV07-X+TCRBJ02-03	unresolved	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTSCTCCCAGACATCTGTRTATTTCTGCGCCAGGACACCCACCCCGGGTCTGGAAAGGAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	14	2.474897468533447E-4		49	TCRBV10	unresolved					TCRBJ02	TCRBJ02-03	01	9	2	6	5	0	21	26	-1	38	34	59		TCRBV10-01,TCRBV10-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV10-X+TCRBJ02-03	unresolved		TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGGGGACTYGGCYGTGTATCTCTGTGCCAGCAAGGAGGGACTCTCCTACGAGCAGTACTTCGGGCCG	CASKEGLSYEQYF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	39	TCRBV07	unresolved		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	7	0	10	0	4	0	22	32	-1	36	42		TCRBV07-01,TCRBV07-02				01,02								CASKEGLSYEQYF+TCRBV07-X+TCRBJ02-07	unresolved	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCAGTTACGTAGCGGGGGGGCTCAATGAGCAGTTCTTCGGGCCA	CASSYVAGGLNEQFF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	45	TCRBV06	unresolved		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	2	5	0	6	1	2	23	38	50	39	52		TCRBV06-05,TCRBV06-06,TCRBV06-08												CASSYVAGGLNEQFF+TCRBV06-X+TCRBJ02-01	unresolved	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CTCCCTCYCAGACWTCTGTWTACTTCTGTGCCATCAGTGGAACTAGCGGGGGGACCCAAGAGACCCAGTACTTCGGGCCA	CAISGTSGGTQETQYF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	48	TCRBV06	unresolved		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	5	3	1	1	3	2	26	38	53	41	55		TCRBV06-07,TCRBV06-09												CAISGTSGGTQETQYF+TCRBV06-X+TCRBJ02-05	unresolved	TCRBD02-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGCAGCCCTCCTAGGGGGCCGAAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	17	3.005232640362042E-4		49	TCRBV06	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	6	5	0	2	7	3	26	37	51	44	54		TCRBV06-07,TCRBV06-08												X+TCRBV06-X+TCRBJ02-02	unresolved	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTSTATCTCTGTGCCAGCAGGGGGACCGTTAGCTCCTACGAGCAGTACTTCGGGCCG	CASRGTVSSYEQYF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	42	TCRBV05	unresolved					TCRBJ02	TCRBJ02-07	01	5	0	7	0	1	6	19	30	36	31	42		TCRBV05-05,TCRBV05-06,TCRBV05-07		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRGTVSSYEQYF+TCRBV05-X+TCRBJ02-07	unresolved		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCRTGTATCTCTGTGCCAGCAGCGCTCTAGCGGGGGGCCTTAATGAGCAGTTCTTCGGGCCA	CASSALAGGLNEQFF	In	VDJ	1	19	3.358789421581106E-4	4.066084574559151E-4	45	TCRBV11	unresolved		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	5	4	1	7	3	4	18	30	44	33	48		TCRBV11-01,TCRBV11-03												CASSALAGGLNEQFF+TCRBV11-X+TCRBJ02-01	unresolved	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCRTGTATSTCTGTGCCAGCAGCTTAACTAGCGGGGGGCAGGGTACGCAGTATTTTGGCCCA	CASSLTSGGQGTQYF	In	VDJ	1	19	3.358789421581106E-4	4.066084574559151E-4	45	TCRBV11	unresolved		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	2	3	1	8	0	5	18	-1	45	33	50		TCRBV11-01,TCRBV11-03												CASSLTSGGQGTQYF+TCRBV11-X+TCRBJ02-03	unresolved	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTSCTCCCAGACATCTGTRTATTTCTGCGCCAGCAGTGACAGGGGGGGCAACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	19	3.358789421581106E-4		43	TCRBV10	unresolved					TCRBJ02	TCRBJ02-02	01	3	4	1	5	0	4	23	-1	44	37	48		TCRBV10-01,TCRBV10-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV10-X+TCRBJ02-02	unresolved		TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCRTGTATSTCTGTGCCAGCAGCTTAGGCCACCTATCCTACGAGCAGTACTTCGGGCCG	CASSLGHLSYEQYF	In	VDJ	1	22	3.8891245934097015E-4	4.7080979284369113E-4	42	TCRBV11	unresolved		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	1	4	9	1	5	0	19	35	-1	40	43		TCRBV11-01,TCRBV11-03				01,02								CASSLGHLSYEQYF+TCRBV11-X+TCRBJ02-07	unresolved	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGACTCGGCYRTGTATCKCTGTGCCAGAAGCAACCCGGGACCGCGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	24	4.2426813746287653E-4		44	TCRBV07	unresolved					TCRBJ01	TCRBJ01-01	01	5	0	7	1	5	3	18	30	40	35	43		TCRBV07-05,TCRBV07-06		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV07-X+TCRBJ01-01	unresolved		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTSTATCTCTGTGCCAGCAGCCCCCTCCCCCGACAGTCGTTCTATAATTCACCCCTYCACTTTGGGAAC	CASSPLPRQSFYNSPLHF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	54	TCRBV05	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	4	2	5	3	10	5	19	31	46	41	51		TCRBV05-05,TCRBV05-06,TCRBV05-07												CASSPLPRQSFYNSPLHF+TCRBV05-X+TCRBJ01-06	unresolved	TCRBD01-01*01	TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGGGGACTCRGCYGTGTATCTCTGTGCCAGCAGCTTGCGACTAGCGGGAGGCCCCACAGATACGCAGTATTTTGGCCCA	CASSLRLAGGPTDTQYF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	51	TCRBV07	unresolved		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	3	2	1	2	2	3	22	36	51	38	54		TCRBV07-02,TCRBV07-04												CASSLRLAGGPTDTQYF+TCRBV07-X+TCRBJ02-03	unresolved	TCRBD02-01*02	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGTAMSCTCYCAGACATCTGTGTACTTCTGTGCCAGCAGTTACCAGGGAGGGAGCTCTGGAAACACCATATATTTTGGAGAG	CASSYQGGSSGNTIYF	In	VDJ	1	25	4.4194597652382975E-4	5.350111282314672E-4	48	TCRBV06	unresolved		TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-03	01	2	9	0	0	2	2	24	39	48	41	50		TCRBV06-04,TCRBV06-05,TCRBV06-06												CASSYQGGSSGNTIYF+TCRBV06-X+TCRBJ01-03	unresolved	TCRBD02-01*02	TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGTACCCTCYCAGACATCTGTGTACTTSTGTGCCAGCATTGGCCTAGTACCCGGGGAGCTGTTTTTTGGAGAA	CASIGLVPGELFF	In	VDJ	1	39	6.894357233771744E-4	8.346173600410888E-4	39	TCRBV06	unresolved		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	7	4	8	6	5	3	23	33	42	38	45		TCRBV06-04,TCRBV06-08				01,02								CASIGLVPGELFF+TCRBV06-X+TCRBJ02-02	unresolved	TCRBD02-01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGCAGTTACCCCCGGGACGGAGAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	2	40	7.071135624381275E-4		49	TCRBV06	unresolved					TCRBJ02	TCRBJ02-02	01	2	0	7	1	4	3	23	38	47	42	50		TCRBV06-07,TCRBV06-08		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV06-X+TCRBJ02-02	unresolved		TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTSCTCCCAGACATCTGTRTATTTCTGCGCCAGCAGTCCGTAGCGGGAGCTTTCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	2	46	8.131805968038467E-4		47	TCRBV10	unresolved		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	5	5	2	3	3	4	23	35	47	38	51		TCRBV10-01,TCRBV10-02												X+TCRBV10-X+TCRBJ02-01	unresolved	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTYTATCTYTGYGCCAGCAAGAAACAGGGGGCTGATTTTGGCTACACCTTCGGTTCG	CASKKQGADFGYTF	In	VDJ	2	56	9.899589874133787E-4	0.0011984249272384865	42	TCRBV05	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	3	0	7	4	6	19	29	42	33	48		TCRBV05-01,TCRBV05-06,TCRBV05-07												CASKKQGADFGYTF+TCRBV05-X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAAGACTCRGCCCTGTATCTCTGCGCCAGCAGCCGGGGACAGGGGGCCGAGCAGTACTTCGGGCCG	CASSRGQGAEQYF	In	VDJ	2	63	0.001113703860840051	0.0013482280431432975	39	TCRBV04	unresolved		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	0	0	6	1	0	23	36	-1	37	49		TCRBV04-01,TCRBV04-03												CASSRGQGAEQYF+TCRBV04-X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGGGGACTTGGCTGTGTATCTCTGTGCCAGCAGCGTCAAGATGAACACTGAAGCTTTCTTTGGACAA	CASSVKMNTEAFF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	39	TCRBV07	TCRBV07-01	01				TCRBJ01	TCRBJ01-01	01	5	2	8	0	5	0	22	34	-1	39	41				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSVKMNTEAFF+TCRBV07-01+TCRBJ01-01	TCRBV07-01*01		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGGGGACTTGGCTGTGTATCTCTGTGCCAGCAGCTCTAGCCCCGTCGACAGCTACACAGATACGCAGTATTTTGGCCCA	CASSSSPVDSYTDTQYF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	51	TCRBV07	TCRBV07-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	3	2	5	2	10	3	22	36	51	46	54														CASSSSPVDSYTDTQYF+TCRBV07-01+TCRBJ02-03	TCRBV07-01*01	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGGACTCCGCCGTGTATCTCTGTGCCAGCAGCTTGTCGGCGGACTATTACAATGAGCAGTTCTTCGGGCCA	CASSLSADYYNEQFF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	45	TCRBV07	TCRBV07-08		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	3	1	9	4	6	1	20	34	46	40	47			01,02			01,02								CASSLSADYYNEQFF+TCRBV07-08+TCRBJ02-01	TCRBV07-08	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCAGCAGTGAGAGGACGGGTCATAACTATGGCTACACCTTCGGTTCG	CASSERTGHNYGYTF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	45	TCRBV10	TCRBV10-02	01				TCRBJ01	TCRBJ01-02	01	2	1	7	1	1	6	23	38	43	39	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 12	CASSERTGHNYGYTF+TCRBV10-02+TCRBJ01-02	TCRBV10-02*01		TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCAGCAGTGAGTCGTTCTAGCGGGGGATTGGGATACGCAGTATTTTGGCCCA		Out	VDJ	1	17	3.005232640362042E-4		50	TCRBV10	TCRBV10-02	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	0	4	2	6	3	5	23	40	53	43	58													Vb 12	X+TCRBV10-02+TCRBJ02-03	TCRBV10-02*01	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCAGCAGTGGCCCTCAGCTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	19	3.358789421581106E-4		40	TCRBV10	TCRBV10-02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	4	5	0	5	0	23	36	-1	41	44													Vb 12	X+TCRBV10-02+TCRBJ02-07	TCRBV10-02*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TTTCTGCGCCAGCAGTGAGATCATAAGGACAGGATAAATTGTAACCTTACTTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	19	3.358789421581106E-4		65	TCRBV10	TCRBV10-02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	2	1	4	4	7	18	4	19	33	26	51													Vb 12	X+TCRBV10-02+TCRBJ02-01	TCRBV10-02*01	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCACCCGCTTCGGTCGTCTCCTCTACGAGCAGTACTTCGGGCCG	CATRFGRLLYEQYF	In	VDJ	1	21	3.71234620280017E-4	4.4940934771443245E-4	42	TCRBV10	TCRBV10-02	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	10	8	5	3	7	9	23	30	40	37	49						01,02							Vb 12	CATRFGRLLYEQYF+TCRBV10-02+TCRBJ02-07	TCRBV10-02*01	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCAGCAGTGAGCCGACAGGCAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	22	3.8891245934097015E-4		40	TCRBV10	TCRBV10-02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	2	2	4	4	2	0	23	38	-1	40	46													Vb 12	X+TCRBV10-02+TCRBJ02-03	TCRBV10-02*01	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCAGCACCCGGGACAGCCCGGAACGTGAAGCTTTCTTTGGACAA	CASTRDSPEREAFF	In	VDJ	2	47	8.308584358647998E-4	0.0010058209210751584	42	TCRBV10	TCRBV10-02	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	7	0	5	7	3	9	23	33	43	36	52													Vb 12	CASTRDSPEREAFF+TCRBV10-02+TCRBJ01-01	TCRBV10-02*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GCTCCCAGACATCTGTGTATTTCTGCGCCAGCACCAAGACAGAAAGGGGAGACCCAGTACTTCGGGCCA		Out	VDJ	3	69	0.00121977089520577		40	TCRBV10	TCRBV10-02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	7	2	5	5	4	6	23	33	42	37	48													Vb 12	X+TCRBV10-02+TCRBJ02-05	TCRBV10-02*01	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTCCCAGACATCTGTGTACTTCTGTGCCATCCAGCAGAGTCTCACTGAAGCTTTCTTTGGACAA	CAIQQSLTEAFF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	36	TCRBV10	TCRBV10-03	01				TCRBJ01	TCRBJ01-01	01	8	4	5	4	0	8	24	-1	36	33	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 12	CAIQQSLTEAFF+TCRBV10-03+TCRBJ01-01	TCRBV10-03*01		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACATCTGTGTACTTCTGTGCCATCAGTGAGTCATTGAAGGTAGCGGGCGGCGTGCTTTACAATGAGCAGTTCTTCGGGCCA	CAISESLKVAGGVLYNEQFF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	60	TCRBV10	TCRBV10-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	0	5	4	4	8	10	16	33	48	41	58						01,02							Vb 12	CAISESLKVAGGVLYNEQFF+TCRBV10-03+TCRBJ02-01	TCRBV10-03*01	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTCCCAGACATCTGTGTACTTCTGTGCCATCAGAAGAGACTTTTCGACAGGGAGGGATGAGCAGTTCTTCGGGCCA	CAIRRDFSTGRDEQFF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	48	TCRBV10	TCRBV10-03	01				TCRBJ02	TCRBJ02-01	01	6	2	3	8	12	4	24	35	54	47	58				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 12	CAIRRDFSTGRDEQFF+TCRBV10-03+TCRBJ02-01	TCRBV10-03*01		TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTCCCAGACATCTGTGTACTTCTGTGCCAGCCGGGACAGGGGTTGGAAGCTCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	11	1.9445622967048507E-4		49	TCRBV10	TCRBV10-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	10	0	2	0	3	7	24	31	44	34	51													Vb 12	X+TCRBV10-03+TCRBJ02-01	TCRBV10-03*01	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGAGAACGGATCTCCTGTTGACACTGAAGCTTTCTTTGGACAA	CAISENGSPVDTEAFF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	48	TCRBV10	TCRBV10-03	01				TCRBJ01	TCRBJ01-01	01	2	1	8	3	3	10	23	38	44	41	54				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 12	CAISENGSPVDTEAFF+TCRBV10-03+TCRBJ01-01	TCRBV10-03*01		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTCCCAGACATCTGTGTACTTCTGTGCCAGCCCCGTTAATCTCCAGGGGGCGGTCTGGACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	15	2.6516758591429784E-4		53	TCRBV10	TCRBV10-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	10	4	0	3	14	7	24	31	53	45	60													Vb 12	X+TCRBV10-03+TCRBJ01-01	TCRBV10-03*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTCCCAGACATCTGTGTACTTCTGTGCCATCGCTCTGCAGGGAGGGTCCTACAATGAGCAGTTCTTCGGGCCA	CAIALQGGSYNEQFF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	45	TCRBV10	TCRBV10-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	8	9	0	1	8	0	24	33	-1	41	48													Vb 12	CAIALQGGSYNEQFF+TCRBV10-03+TCRBJ02-01	TCRBV10-03*01	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTCCCAGACATCTGTGTACTTCTGTGCCATCAGTCCTCACAGGGGTGTGGTAACTGAAGCTTTCTTTGGACAA	CAISPHRGVVTEAFF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	45	TCRBV10	TCRBV10-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	3	2	5	4	7	24	36	47	40	54													Vb 12	CAISPHRGVVTEAFF+TCRBV10-03+TCRBJ01-01	TCRBV10-03*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGAGCCCCCCGAAACTAGCGGCCGCACAGATACGCAGTATTTTGGCCCA	CAISEPPETSGRTDTQYF	In	VDJ	1	34	6.010465280724084E-4	7.276151343947955E-4	54	TCRBV10	TCRBV10-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	2	3	5	1	9	2	23	38	55	47	57						01,02							Vb 12	CAISEPPETSGRTDTQYF+TCRBV10-03+TCRBJ02-03	TCRBV10-03*01	TCRBD02-01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTCCCAGACATCTGTGTACTTCTGTGCCATCAGAGAACAGGGTAATCAGCCCCAGCATTTTGGTGAT	CAIREQGNQPQHF	In	VDJ	2	44	7.778249186819403E-4	9.416195856873823E-4	39	TCRBV10	TCRBV10-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	3	3	4	3	1	24	35	44	38	45													Vb 12	CAIREQGNQPQHF+TCRBV10-03+TCRBJ01-05	TCRBV10-03*01	TCRBD01-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTAGGGCGGGACAGGGGGACTATATTGGCAATCAGCCCCAGCATTTTGGTGAT	CASSRAGQGDYIGNQPQHF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	57	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	4	0	1	2	4	9	24	37	52	41	61			01,02										Vb 17	CASSRAGQGDYIGNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTACCCTGACAGGGGGAGGAACTGAAGCTTTCTTTGGACAA	CASTLTGGGTEAFF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	7	2	1	5	4	4	27	37	50	41	54			01,02										Vb 17	CASTLTGGGTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGACAGCCTGTATAGCAATCAGCCCCAGCATTTTGGTGAT	CASSIDSLYSNQPQHF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	48	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-05	01	0	4	5	0	0	6	27	-1	47	44	53			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSIDSLYSNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01		TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTACAGGGGACACTGAAGCTTTCTTTGGACAA	CASTGDTEAFF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	33	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	7	4	2	3	0	0	27	-1	-1	37	43			01,02										Vb 17	CASTGDTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGAATAGGAGAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	9	1.591005515485787E-4		40	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-02	01	1	2	8	1	0	0	27	-1	-1	43	45			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	X+TCRBV19-01+TCRBJ02-02	TCRBV19-01		TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGCTTAGGGTTGACGGAGGAGACCCAGTACTTCGGGCCA	CASSLGLTEETQYF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	42	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-05	01	6	5	3	5	3	9	27	38	45	41	54			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSLGLTEETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01		TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGGCTCGCGGGACAGCCCTCCTACGAGCAGTACTTCGGGCCG	CASRLAGQPSYEQYF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	0	5	0	6	2	27	38	51	44	53			01,02										Vb 17	CASRLAGQPSYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCGGACAGGGTTCCTACGAGCAGTACTTCGGGCCG	CASSIGQGSYEQYF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	1	3	1	1	1	27	41	50	42	51			01,02										Vb 17	CASSIGQGSYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCGGCAGGGGGCGTGGGGAGACCCAGTACTTCGGGCCA	CASSIGRGRGETQYF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	3	4	0	5	3	5	27	41	52	44	57			01,02										Vb 17	CASSIGRGRGETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTAGGTCACTTACTTAACTCTGGAAACACCATATATTTTGGAGAG		Out	VDJ	1	11	1.9445622967048507E-4		49	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-03	01	4	3	10	0	4	7	27	40	47	44	54			01,02			01,02							Vb 17	X+TCRBV19-01+TCRBJ01-03	TCRBV19-01	TCRBD02-01	TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCCGGGGAGGGCTCGAGCAGTACTTCGGGCCG	CASSIRGGLEQYF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	39	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	3	9	0	6	3	2	27	41	51	44	53			01,02										Vb 17	CASSIRGGLEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTGGCAGCAGGGCCCAGCCCCAGCATTTTGGTGAT	CASSGSRAQPQHF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	39	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	4	3	7	5	2	27	39	49	44	51			01,02										Vb 17	CASSGSRAQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTACCTAGACCCTCGGACAGGGGTACTGTTCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	12	2.1213406873143826E-4		53	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	7	1	2	3	11	7	27	37	57	48	64			01,02										Vb 17	X+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTACCCGTGAGCCGCTGGGTTCCCAACTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	12	2.1213406873143826E-4		52	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-07	01	4	0	9	3	13	7	27	40	56	53	63			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	X+TCRBV19-01+TCRBJ02-07	TCRBV19-01		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTGGTTTAAAGGGGGCTCGGGGCAATGAGCAGTTCTTCGGGCCA	CASSGLKGARGNEQFF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	48	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	5	0	6	7	6	27	39	53	46	59			01,02										Vb 17	CASSGLKGARGNEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTTCTCGTTCTCAGCCCCAGCATTTTGGTGAT	CASSRSQPQHF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	33	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	8	4	10	6	1	5	27	36	39	37	44			01,02			01,02							Vb 17	CASSRSQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD02-01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTACTTCAGGGGTGTCACCAGATTTTAACTATGGCTACACCTTCGGTTCG	CASSTSGVSPDFNYGYTF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	54	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	4	2	1	3	13	27	40	49	43	62			01,02										Vb 17	CASSTSGVSPDFNYGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGCGCCCCGACAGAGGGAGGCGGTTACACCTTCGGTTCG	CASSAPTEGGGYTF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	42	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	6	9	1	11	12	4	27	38	56	50	60			01,02										Vb 17	CASSAPTEGGGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD02-01*02	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCCGGGACAGGTCTACGAGCAGTACTTCGGGCCG	CASSPGQVYEQYF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	39	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	0	4	3	2	1	27	39	49	41	50			01,02										Vb 17	CASSPGQVYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCACCACGGGACAGGGCACAGATACGCAGTATTTTGGCCCA	CATTGQGTDTQYF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	39	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	10	0	4	1	4	0	27	34	-1	38	46			01,02										Vb 17	CATTGQGTDTQYF+TCRBV19-01+TCRBJ02-03	TCRBV19-01	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAATATAGATCTCCAGAACACTGAAGCTTTCTTTGGACAA	CASNIDLQNTEAFF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	42	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-01	01	0	4	6	1	4	0	27	44	-1	48	50			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASNIDLQNTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGCCGAACTAGCTCTGGGACAGATACGCAGTATTTTGGCCCA	CASSRTSSGTDTQYF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	45	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	6	3	7	3	4	6	27	38	48	42	54			01,02			01,02							Vb 17	CASSRTSSGTDTQYF+TCRBV19-01+TCRBJ02-03	TCRBV19-01	TCRBD02-01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAAATGGGGGGGAGCAGTTCTTCGGGCCA	CASSINGGEQFF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	36	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	2	9	1	10	3	0	27	42	-1	45	51			01,02										Vb 17	CASSINGGEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCTCGGTCTATGGCTACACCTTCGGTTCG	CASSISVYGYTF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	36	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	3	8	5	4	2	1	27	41	46	43	47			01,02			01,02							Vb 17	CASSISVYGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD02-01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTATCAGGTGAGACAGGGAATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	15	2.6516758591429784E-4		43	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	7	2	3	5	8	0	27	37	-1	45	52			01,02										Vb 17	X+TCRBV19-01+TCRBJ01-04	TCRBV19-01	TCRBD01-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGAGGGACAGGGGAAAGAGACCCAGTACTTCGGGCCA	CASSIEGQGKETQYF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	0	0	2	3	0	1	27	-1	54	44	55			01,02										Vb 17	CASSIEGQGKETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTGCCCCTGAGAACACTGAAGCTTTCTTTGGACAA	CASAPENTEAFF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	36	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-01	01	8	2	8	1	6	0	27	36	-1	42	44			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASAPENTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGGGCCGTCCTGGGGGGCAATCAGCCCCAGCATTTTGGTGAT	CASRAVLGGNQPQHF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	45	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-05	01	6	6	1	2	9	0	27	38	-1	47	52			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASRAVLGGNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01		TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTCGTACAGGGCATAGCAATCAGCCCCAGCATTTTGGTGAT	CASRTGHSNQPQHF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	4	4	3	0	0	2	27	-1	45	40	47			01,02										Vb 17	CASRTGHSNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGGGGAACAAGAGACCCAGTACTTCGGGCCA	CASSIGEQETQYF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	39	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-05	01	1	0	8	2	0	1	27	-1	47	43	48			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSIGEQETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01		TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATTGCGGGGGGGCAAGATACGCAGTATTTTGGCCCA	CASSIAGGQDTQYF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	42	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	3	7	0	5	1	2	27	41	51	42	53			01,02										Vb 17	CASSIAGGQDTQYF+TCRBV19-01+TCRBJ02-03	TCRBV19-01	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATTTGGGGACACGCGCAAGAGACCCAGTACTTCGGGCCA	CASSIWGHAQETQYF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	3	0	6	2	3	4	27	41	50	44	54			01,02										Vb 17	CASSIWGHAQETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTGAATACAGGAACACTGAAGCTTTCTTTGGACAA	CASSEYRNTEAFF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	39	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	3	5	1	4	0	27	39	-1	43	47			01,02										Vb 17	CASSEYRNTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGCTCCAGGGTTAAATATGGCTACACCTTCGGTTCG	CASSRVKYGYTF	In	VDJ	1	19	3.358789421581106E-4	4.066084574559151E-4	36	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	9	4	3	5	3	5	27	35	43	38	48			01,02										Vb 17	CASSRVKYGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAAGTCGGGGTTTGAAATTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	19	3.358789421581106E-4		49	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	2	8	3	1	3	8	27	42	50	45	58			01,02										Vb 17	X+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD02-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTACCTCCGTTTTGAACACCGGGGAGCTGTTTTTTGGAGAA	CASTSVLNTGELFF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	42	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	7	4	10	1	1	7	27	37	40	38	47			01,02			01,02							Vb 17	CASTSVLNTGELFF+TCRBV19-01+TCRBJ02-02	TCRBV19-01	TCRBD02-01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGCCCACATAACACAGTGACCTATGGCTACACCTTCGGTTCG	CASSPHNTVTYGYTF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	3	5	4	10	4	27	38	52	48	56			01,02										Vb 17	CASSPHNTVTYGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGAGGGACAGGGATGGGGCAATCAGCCCCAGCATTTTGGTGAT	CASSIEGQGWGNQPQHF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	51	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	0	0	3	2	0	5	27	-1	53	44	58			01,02										Vb 17	CASSIEGQGWGNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGTTGTAGGAACTTATAGCAATCAGCCCCAGCATTTTGGTGAT	CASSIVVGTYSNQPQHF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	51	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-05	01	1	1	8	0	5	5	27	43	51	48	56			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSIVVGTYSNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01		TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTGCACAGGGAGGCGGGGAGCTGTTTTTTGGAGAA	CASSAQGGGELFF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	39	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-02	01	5	3	3	7	2	3	27	39	47	41	50			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSAQGGGELFF+TCRBV19-01+TCRBJ02-02	TCRBV19-01		TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTGGAGGACAGGGGGAATTCAATCCCCAGCATTTTGGTGAT	CASGGQGEFNPQHF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	8	1	1	10	3	8	27	36	49	39	57			01,02										Vb 17	CASGGQGEFNPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTACCTGCGGGATTAGCGGGAACCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	21	3.71234620280017E-4		46	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	7	5	3	2	10	1	27	37	55	47	56			01,02										Vb 17	X+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGCCAACTCGGGTCTGGCAATCAGCCCCAGCATTTTGGTGAT	CASSQLGSGNQPQHF	In	VDJ	1	21	3.71234620280017E-4	4.4940934771443245E-4	45	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	6	8	4	2	6	4	27	38	48	44	52			01,02			01,02							Vb 17	CASSQLGSGNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD02-01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGGTGGGAGCTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	21	3.71234620280017E-4		37	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	6	9	2	0	2	0	27	38	-1	40	45			01,02										Vb 17	X+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCAACAGCTATGGCTACATCTTCGGTTCG	CASSINSYGYIF	In	VDJ	1	21	3.71234620280017E-4	4.4940934771443245E-4	36	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	3	5	16	2	12	27	41	47	43	59			01,02										Vb 17	CASSINSYGYIF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTTTTCATATGGCTACACCTTCGGTTCG	CASSFSYGYTF	In	VDJ	1	21	3.71234620280017E-4	4.4940934771443245E-4	33	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	4	6	5	4	0	27	39	-1	43	45			01,02										Vb 17	CASSFSYGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCACGGACAGGCATATGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	23	4.0659029840192336E-4		46	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	1	4	0	3	4	27	39	49	42	53			01,02										Vb 17	X+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTACCCCACCAGGGAGAGCTAACTATGGCTACACCTTCGGTTCG	CASTPPGRANYGYTF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	45	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-02	01	7	4	3	0	6	4	27	37	48	43	52			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASTPPGRANYGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01		TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATATGGGGGAGGGGATTCACAGATACGCAGTATTTTGGCCCA	CASSIWGRGFTDTQYF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	48	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	2	9	0	2	3	4	27	42	52	45	56			01,02										Vb 17	CASSIWGRGFTDTQYF+TCRBV19-01+TCRBJ02-03	TCRBV19-01	TCRBD02-01*02	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCGGACTAACGCCTACACAGATACGCAGTATTTTGGCCCA	CASSRTNAYTDTQYF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	45	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	5	1	9	2	1	7	27	39	46	40	53			01,02			01,02							Vb 17	CASSRTNAYTDTQYF+TCRBV19-01+TCRBJ02-03	TCRBV19-01	TCRBD02-01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTTTCTAGCGATCAATGAGCAGTTCTTCGGGCCA	CASSFLAINEQFF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	39	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	4	6	6	3	2	27	39	48	42	50			01,02			01,02							Vb 17	CASSFLAINEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGATGGGACATCCTACGAGCAGTACTTCGGGCCG	CASSIDGTSYEQYF	In	VDJ	1	26	4.596238155847829E-4	5.564115733607259E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	0	6	1	1	0	27	44	-1	45	51			01,02										Vb 17	CASSIDGTSYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCACAGGGGGAGGCTACGAGCAGTACTTCGGGCCG	CASSITGGGYEQYF	In	VDJ	1	26	4.596238155847829E-4	5.564115733607259E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	3	1	3	1	3	27	41	50	42	53			01,02										Vb 17	CASSITGGGYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCCGCCGATCGGGACTAGCGAACTCTACAATGAGCAGTTCTTCGGGCCA	CASSPPIGTSELYNEQFF	In	VDJ	1	26	4.596238155847829E-4	5.564115733607259E-4	54	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	0	6	3	9	4	27	39	58	48	62			01,02			01,02							Vb 17	CASSPPIGTSELYNEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTCACCTTTTGGGACGCAGTATTTTGGCCCA	CASSSPFGTQYF	In	VDJ	1	26	4.596238155847829E-4	5.564115733607259E-4	36	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-03	01	5	0	9	9	9	0	27	39	-1	48	51			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSSPFGTQYF+TCRBV19-01+TCRBJ02-03	TCRBV19-01		TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCACCGTTAACAGGGCTATGAACACTGAAGCTTTCTTTGGACAA	CATVNRAMNTEAFF	In	VDJ	1	27	4.7730165464573613E-4	5.778120184899846E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	10	3	3	0	6	3	27	34	46	40	49			01,02										Vb 17	CATVNRAMNTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATTGGACTAGCGGGAGGGCCGGTCGAGCAGTACTTCGGGCCG	CASSIGLAGGPVEQYF	In	VDJ	1	28	4.949794937066893E-4	5.992124636192433E-4	48	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	3	1	0	6	1	5	27	41	57	42	62			01,02										Vb 17	CASSIGLAGGPVEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCACCCACCGGACCTGAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	29	5.126573327676425E-4		37	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-05	01	10	1	7	3	6	3	27	34	44	40	47			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	X+TCRBV19-01+TCRBJ02-05	TCRBV19-01		TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTGTCTTGGCTAGCGGTGGCAATGAGCAGTTCTTCGGGCCA	CASSVLASGGNEQFF	In	VDJ	1	29	5.126573327676425E-4	6.20612908748502E-4	45	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	4	5	6	7	3	27	39	53	46	56			01,02			01,02							Vb 17	CASSVLASGGNEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGGGGGGAGTTTCTGACTGAAGCTTTCTTTGGACAA	CASRGEFLTEAFF	In	VDJ	1	31	5.480130108895489E-4	6.634137990070194E-4	39	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-01	01	6	6	1	5	0	8	27	-1	43	38	51			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASRGEFLTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTACCACAGGGGGCATGAACACTGAAGCTTTCTTTGGACAA	CASSTTGGMNTEAFF	In	VDJ	1	31	5.480130108895489E-4	6.634137990070194E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	3	0	0	2	1	27	40	51	42	52			01,02										Vb 17	CASSTTGGMNTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATACAGGGGATCGGCTACGAGCAGTACTTCGGGCCG	CASSIQGIGYEQYF	In	VDJ	1	31	5.480130108895489E-4	6.634137990070194E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	4	2	3	0	5	27	-1	48	42	53			01,02										Vb 17	CASSIQGIGYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCACCACGAGACAGGGACAAGAGACCCAGTACTTCGGGCCA	CATTRQGQETQYF	In	VDJ	1	32	5.65690849950502E-4	6.84814244136278E-4	39	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	10	2	3	2	6	1	27	34	47	40	48			01,02										Vb 17	CATTRQGQETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTAAACCCCGGTCGGGAGCTTCGGAACGAGCAGTACTTCGGGCCG		Out	VDJ	1	32	5.65690849950502E-4		49	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	4	8	2	5	9	7	27	40	55	49	62			01,02										Vb 17	X+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTACGTCCGGTGGAGAGCAGTACTTCGGGCCG	CASSTSGGEQYF	In	VDJ	1	32	5.65690849950502E-4	6.84814244136278E-4	36	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-07	01	4	1	8	7	8	0	27	40	-1	48	51			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSTSGGEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGTTCATCTTAACAGTGAAGCTTTCTTTGGACAA	CASSIVHLNSEAFF	In	VDJ	1	32	5.65690849950502E-4	6.84814244136278E-4	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	3	5	7	9	0	27	43	-1	52	56			01,02										Vb 17	CASSIVHLNSEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTTCGACAGGGGGATGGGGTGAAGCTTTCTTTGGACAA	CASSTGGWGEAFF	In	VDJ	1	32	5.65690849950502E-4	6.84814244136278E-4	39	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	8	2	1	7	2	6	27	36	47	38	53			01,02										Vb 17	CASSTGGWGEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGCCTGACAGGGCTGAACACTGAAGCTTTCTTTGGACAA	CASLTGLNTEAFF	In	VDJ	1	33	5.833686890114552E-4	7.062146892655367E-4	39	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	9	2	3	0	3	1	27	35	45	38	46			01,02										Vb 17	CASLTGLNTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTACGGGACAGGGGAGAGATGAGCAGTTCTTCGGGCCA	CASTGQGRDEQFF	In	VDJ	1	33	5.833686890114552E-4	7.062146892655367E-4	39	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	7	0	2	8	1	4	27	37	48	38	52			01,02										Vb 17	CASTGQGRDEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCGAGGGTAGCAATCAGCCCCAGCATTTTGGTGAT	CASSIEGSNQPQHF	In	VDJ	1	33	5.833686890114552E-4	7.062146892655367E-4	42	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-05	01	3	11	0	0	1	0	27	41	-1	42	47			01,02										Vb 17	CASSIEGSNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD02-01*02	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCGTATGACAGGGGGGTTGGACGAGCAGTACTTCGGGCCG	CASSRMTGGLDEQYF	In	VDJ	1	33	5.833686890114552E-4	7.062146892655367E-4	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	2	1	5	5	5	27	39	53	44	58			01,02										Vb 17	CASSRMTGGLDEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTCTCACAGGCCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	33	5.833686890114552E-4		35	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	8	3	4	2	3	1	27	36	44	39	45			01,02										Vb 17	X+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATGGGGGGCGGCTACGAGCAGTACTTCGGGCCG	CASSMGGGYEQYF	In	VDJ	1	36	6.364022061943148E-4	7.704160246533128E-4	39	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-07	01	3	6	0	3	1	2	27	41	48	42	50			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSMGGGYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTACTCTCGGACGGACCCAAGAGACCCAGTACTTCGGGCCA	CASSTLGRTQETQYF	In	VDJ	1	38	6.717578843162212E-4	8.132169149118302E-4	45	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-05	01	4	1	7	1	5	4	27	40	49	45	53			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSTLGRTQETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01		TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTACAGGAGCCTACGAGCAGTACTTCGGGCCG	CASSTGAYEQYF	In	VDJ	1	39	6.894357233771744E-4	8.346173600410888E-4	36	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-07	01	4	4	4	2	0	2	27	-1	44	40	46			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSTGAYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATATACGTGAGGGGCAATGAGCAGTTCTTCGGGCCA	CASSIYVRGNEQFF	In	VDJ	2	41	7.247914014990807E-4	8.774182502996063E-4	42	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-01	01	2	5	2	6	6	0	27	42	-1	48	53			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSIYVRGNEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01		TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCGGCGGAGGGCCCACAGATACGCAGTATTTTGGCCCA	CASSIGGGPTDTQYF	In	VDJ	2	46	8.131805968038467E-4	9.844204759458996E-4	45	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	3	10	0	2	4	2	27	41	51	45	53			01,02										Vb 17	CASSIGGGPTDTQYF+TCRBV19-01+TCRBJ02-03	TCRBV19-01	TCRBD02-01*02	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGACCCCTTTTGGGGAGCAATCAGCCCCAGCATTTTGGTGAT	CASRPLLGSNQPQHF	In	VDJ	2	47	8.308584358647998E-4	0.0010058209210751584	45	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-05	01	6	6	2	1	9	0	27	38	-1	47	51			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASRPLLGSNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01		TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTGCGACAGGGGAATTCACAGATACGCAGTATTTTGGCCCA	CASATGEFTDTQYF	In	VDJ	2	47	8.308584358647998E-4	0.0010058209210751584	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	8	2	2	2	2	4	27	36	46	38	50			01,02										Vb 17	CASATGEFTDTQYF+TCRBV19-01+TCRBJ02-03	TCRBV19-01	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGAACTCCAGGGATGGAGCAATCAGCCCCAGCATTTTGGTGAT	CASSIELQGWSNQPQHF	In	VDJ	2	48	8.485362749257531E-4	0.001027221366204417	51	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	0	4	3	1	4	4	27	44	53	48	57			01,02										Vb 17	CASSIELQGWSNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGGGTGGGCTGATGTGGGCAGCTTTCTTTGGACAA		Out	VDJ	2	48	8.485362749257531E-4		43	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	8	0	10	3	10	27	43	50	46	60			01,02										Vb 17	X+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGGGAAGGGCCAGGGGATCGCTGAAGCTTTCTTTGGACAA	CASSIGKGQGIAEAFF	In	VDJ	2	50	8.838919530476595E-4	0.0010700222564629343	48	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	4	2	6	8	4	27	43	57	51	61			01,02										Vb 17	CASSIGKGQGIAEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCAATTGGGGGGCTAGGGAGACCCAGTACTTCGGGCCA	CASSINWGARETQYF	In	VDJ	2	53	9.36925470230519E-4	0.0011342235918507105	45	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-05	01	3	6	0	5	6	4	27	41	53	47	57			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSINWGARETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01		TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTACAGACTTCGGAATGAAAAACTGTTTTTTGGCAGT	CASSYRLRNEKLFF	In	VDJ	2	53	9.36925470230519E-4	0.0011342235918507105	42	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-04	01	5	3	5	5	1	7	27	39	44	40	51			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSYRLRNEKLFF+TCRBV19-01+TCRBJ01-04	TCRBV19-01		TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTCAGGGATCCACGAGCAGTACTTCGGGCCG	CASSSGIHEQYF	In	VDJ	2	54	9.546033092914723E-4	0.0011556240369799693	36	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	4	3	5	1	4	27	39	45	40	49			01,02										Vb 17	CASSSGIHEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTAGGGACTAGCGGGGGGGCCTAAAAGAGACCCAGTACTTCGGGCCA	CASSRD*RGGLKETQYF	Stop	VDJ	2	62	0.0010960260217790978		51	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	4	0	0	3	0	5	27	-1	56	40	61			01,02										Vb 17	CASSRD*RGGLKETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01	TCRBD02-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGAGGGGGGACAGCGAACACCGGGGAGCTGTTTTTTGGAGAA	CASRGGTANTGELFF	In	VDJ	2	65	0.0011490595389619573	0.0013910289334018147	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	6	0	5	0	4	0	27	38	-1	42	49			01,02										Vb 17	CASRGGTANTGELFF+TCRBV19-01+TCRBJ02-02	TCRBV19-01	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTCCCGGACAGAAGAATCAGCCCCAGCATTTTGGTGAT	CASSPGQKNQPQHF	In	VDJ	3	68	0.0012020930561448169	0.001455230268789591	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	1	5	4	3	3	27	39	48	42	51			01,02										Vb 17	CASSPGQKNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTACACGGGCCCCCTCCTACAATGAGCAGTTCTTCGGGCCA	CASTRAPSYNEQFF	In	VDJ	3	78	0.0013788714467543488	0.0016692347200821776	42	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-01	01	7	8	0	0	3	3	27	37	44	40	47			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASTRAPSYNEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01		TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATGACGGACAGGACGATCAACTATGGCTACACCTTCGGTTCG	CASSMTDRTINYGYTF	In	VDJ	3	79	0.001396549285815302	0.0016906351652114363	48	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	1	4	2	3	6	27	41	51	44	57			01,02										Vb 17	CASSMTDRTINYGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTGGATCAGTGATTTTTGGCTACACCTTCGGTTCG	CASGSVIFGYTF	In	VDJ	3	81	0.0014319049639372084	0.0017334360554699538	36	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-02	01	8	1	8	7	0	11	27	-1	39	36	50			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASGSVIFGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01		TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTTTACAGGGGGAGACCCAGTACTTCGGGCCA	CASLQGETQYF	In	VDJ	3	82	0.0014495828029981615	0.0017548365005992125	33	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	8	3	2	5	2	0	27	36	-1	38	45			01,02										Vb 17	CASLQGETQYF+TCRBV19-01+TCRBJ02-05	TCRBV19-01	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTAGCGAAGGACAAGGCTACACCTTCGGTTCG	CASSSEGQGYTF	In	VDJ	3	88	0.0015556498373638806	0.0018832391713747645	36	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	1	6	8	5	1	27	40	50	45	51			01,02										Vb 17	CASSSEGQGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGYCAGTAGTATCAACAGCTATGGCTACACCTTCGGTTCG	CXSSINSYGYTF	In	VDJ	3	91	0.0016086833545467401	0.0019474405067625407	36	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	3	5	4	2	0	27	41	-1	43	47			01,02										Vb 17	CXSSINSYGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATGGAAGGGGTGCTCAATCAGCCCCAGCATTTTGGTGAT	CASSMEGVLNQPQHF	In	VDJ	4	94	0.0016617168717295997	0.0020116418421503167	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	3	5	2	3	3	4	27	41	49	44	53			01,02										Vb 17	CASSMEGVLNQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATCAGACCCAAAAAGATATGGTATGGCTACACCTTCGGTTCG	CASSIRPKKIWYGYTF	In	VDJ	4	97	0.0017147503889124594	0.0020758431775380927	48	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-02	01	3	2	7	5	2	14	27	41	46	43	60			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSIRPKKIWYGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01		TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTGGGGGCTAGACAAAGTCGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	4	97	0.0017147503889124594		49	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	5	6	0	5	0	11	27	-1	45	39	56			01,02										Vb 17	X+TCRBV19-01+TCRBJ02-06	TCRBV19-01	TCRBD01-01*01	TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGTGGCAGGGAGAACTGAAGCTTTCTTTGGACAA	CASSIVAGRTEAFF	In	VDJ	4	99	0.0017501060670343657	0.00211864406779661	42	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-01	01	1	4	3	5	3	3	27	43	51	46	54			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSIVAGRTEAFF+TCRBV19-01+TCRBJ01-01	TCRBV19-01		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTCGGGGGACAGCATATACGAGCAGTACTTCGGGCCG	CASSSGDSIYEQYF	In	VDJ	4	99	0.0017501060670343657	0.00211864406779661	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	0	5	4	4	4	27	39	50	43	54			01,02										Vb 17	CASSSGDSIYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAAAGTCGGTCTAGGGCCATTCACGCAGTATTTTGGCCCA	CASKVGLGPFTQYF	In	VDJ	4	102	0.0018031395842172252	0.002182845403184386	42	TCRBV19	TCRBV19-01					TCRBJ02	TCRBJ02-03	01	7	5	3	9	10	6	27	37	51	47	57			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASKVGLGPFTQYF+TCRBV19-01+TCRBJ02-03	TCRBV19-01		TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGCTCCACAGGGGAAGGGCAGCCCCAGCATTTTGGTGAT	CASSSTGEGQPQHF	In	VDJ	4	109	0.0019268844576438976	0.002332648519089197	42	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	3	2	7	4	5	27	38	49	42	54			01,02										Vb 17	CASSSTGEGQPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01	TCRBD01-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGACACCTACAAGCCCCAGCATTTTGGTGAT	CASSIDTYKPQHF	In	VDJ	4	113	0.0019975958138877103	0.002418250299606232	39	TCRBV19	TCRBV19-01					TCRBJ01	TCRBJ01-05	01	0	3	6	8	5	0	27	44	-1	49	52			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 17	CASSIDTYKPQHF+TCRBV19-01+TCRBJ01-05	TCRBV19-01		TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGATTTCGGGACAGATTCCTACGAGCAGTACTTCGGGCCG	CASSIDFGTDSYEQYF	In	VDJ	31	801	0.014159949087823505	0.01714175654853621	48	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	0	5	1	4	2	27	44	55	48	57			01,02										Vb 17	CASSIDFGTDSYEQYF+TCRBV19-01+TCRBJ02-07	TCRBV19-01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATGGCAGGGTCTCGAGCCAAAAACATTCAGTACTTCGGCGCC	CASSMAGSRAKNIQYF	In	VDJ	35	919	0.016245934097015982	0.019667009073788735	48	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	3	4	3	0	2	5	27	41	48	43	53			01,02										Vb 17	CASSMAGSRAKNIQYF+TCRBV19-01+TCRBJ02-04	TCRBV19-01	TCRBD01-01*01	TCRBJ02-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCATACCTACGGATCACTTCTCCTATAATGAGCAGTTCTTCGGGCCA	CASIPTDHFSYNEQFF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	48	TCRBV25	TCRBV25-01	01				TCRBJ02	TCRBJ02-01	01	7	1	8	7	7	13	23	33	43	40	56				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 11	CASIPTDHFSYNEQFF+TCRBV25-01+TCRBJ02-01	TCRBV25-01*01		TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGAATATCTGACAGGGAATGAGCAATTCTTCGGGCCA	CASSEYLTGNEQFF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	42	TCRBV25	TCRBV25-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	0	2	3	16	3	9	23	40	50	43	59													Vb 11	CASSEYLTGNEQFF+TCRBV25-01+TCRBJ02-01	TCRBV25-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTTTACAGGGGGCCCCCGGGGAGCTGTTTTTTGGAGAA	CASSLQGAPGELFF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	42	TCRBV25	TCRBV25-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	5	3	0	6	2	2	23	35	46	37	48													Vb 11	CASSLQGAPGELFF+TCRBV25-01+TCRBJ02-02	TCRBV25-01*01	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGCGGGACAGGGGGCAGATACGCAGTATTTTGGCCCA	CASSAGQGADTQYF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	42	TCRBV25	TCRBV25-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	4	0	1	4	1	0	23	36	-1	37	48													Vb 11	CASSAGQGADTQYF+TCRBV25-01+TCRBJ02-03	TCRBV25-01*01	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGAAGGCAGGTACGAGCAGTACTTCGGGCCG	CASSEGRYEQYF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	36	TCRBV25	TCRBV25-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	4	4	4	2	0	23	38	-1	40	44													Vb 11	CASSEGRYEQYF+TCRBV25-01+TCRBJ02-07	TCRBV25-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGGGCTAGCGTGGAGACCCAGTACTTCGGGCCA	CASRASVETQYF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	36	TCRBV25	TCRBV25-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	6	4	6	5	2	2	23	34	42	36	44						01,02							Vb 11	CASRASVETQYF+TCRBV25-01+TCRBJ02-05	TCRBV25-01*01	TCRBD02-01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGGTGGACACATGACACTGAAGCTTTCTTTGGACAA	CASRWTHDTEAFF	In	VDJ	1	34	6.010465280724084E-4	7.276151343947955E-4	39	TCRBV25	TCRBV25-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	1	6	3	2	4	23	34	41	36	45													Vb 11	CASRWTHDTEAFF+TCRBV25-01+TCRBJ01-01	TCRBV25-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGCCCATCTCCCGGGGTACGATAATTCACCCCTCCACTTTGGGAAC	CASSAHLPGYDNSPLHF	In	VDJ	2	42	7.42469240560034E-4	8.988186954288649E-4	51	TCRBV25	TCRBV25-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-06	01	4	8	3	5	9	4	23	36	50	45	54													Vb 11	CASSAHLPGYDNSPLHF+TCRBV25-01+TCRBJ01-06	TCRBV25-01*01	TCRBD02-01*01	TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGAAGGGTACACTGAAGCTTTCTTTGGACAA	CASSEGYTEAFF	In	VDJ	2	56	9.899589874133787E-4	0.0011984249272384865	36	TCRBV25	TCRBV25-01	01				TCRBJ01	TCRBJ01-01	01	2	0	9	3	0	1	23	-1	41	38	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 11	CASSEGYTEAFF+TCRBV25-01+TCRBJ01-01	TCRBV25-01*01		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCACATACCTCTCAGTACCTCTGTGCCAGCAGTGACTACAGGATCGCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	3	66	0.0011667373780229104		41	TCRBV25	TCRBV25-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	3	3	4	7	2	4	23	37	44	39	48													Vb 11	X+TCRBV25-01+TCRBJ02-02	TCRBV25-01*01	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCAGCCAAACAGCTTTGTACTTCTGTGCCAGCAGCTCCGACGGGGGCGGCTGAACTAACCAAAGCAGTACTTCGGGCCG		Out	VDJ	1	11	1.9445622967048507E-4		50	TCRBV22	TCRBV22-01	01				TCRBJ02	TCRBJ02-07	01	13	6	0	8	15	15	25	28	49	43	64				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV22-01+TCRBJ02-07	TCRBV22-01*01		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CRRRRGACTCAGCCSTGTATCTCTRCGCCAGCAGCCAAGATCGCTTCTATGGCTACACCTTCGGTTCG	XASSQDRFYGYTF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	39	TCRBV04	TCRBV04-01	01				TCRBJ01	TCRBJ01-02	01	0	10	0	4	2	2	22	39	43	41	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 7.1	XASSQDRFYGYTF+TCRBV04-01+TCRBJ01-02	TCRBV04-01*01		TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCAGCCCTGACAGGGTCGGGACTGAAGCTTTCTTTGGACAA	CASSPDRVGTEAFF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	42	TCRBV04	TCRBV04-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	2	3	5	2	5	23	36	45	38	50													Vb 7.1	CASSPDRVGTEAFF+TCRBV04-01+TCRBJ01-01	TCRBV04-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAAGACTCAGCCCTGTATCTCTGCACCAGCAGCCAAGTATAGGCCTAGCGGGAGTGATCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	13	2.2981190779239146E-4		56	TCRBV04	TCRBV04-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	1	4	2	2	7	4	23	39	56	46	60													Vb 7.1	X+TCRBV04-01+TCRBJ02-03	TCRBV04-01*01	TCRBD02-01*02	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCAGCCAAGATCGTGGGGGGAGCTCCTACAATGAGCAGTTCTTCGGGCCA	CASSQDRGGSSYNEQFF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	51	TCRBV04	TCRBV04-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	0	9	1	0	4	2	23	40	50	44	52													Vb 7.1	CASSQDRGGSSYNEQFF+TCRBV04-01+TCRBJ02-01	TCRBV04-01*01	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCAGCCAAGATCCCCAGGGGCAGAGGTACGAGCAGTACTTCGGGCCG	CASSQDPQGQRYEQYF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	48	TCRBV04	TCRBV04-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	4	2	4	4	6	23	40	50	44	56													Vb 7.1	CASSQDPQGQRYEQYF+TCRBV04-01+TCRBJ02-07	TCRBV04-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AAGACTCAGCCCTGTATCTCTGCGCCAGCAGCCAAGAGAATCAAGCGGGAGGACCGACAGGCCAAAAACATTCAGTACTTCGGCGCC		Out	VDJ	1	24	4.2426813746287653E-4		61	TCRBV04	TCRBV04-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-04	01	0	6	1	1	6	8	20	37	52	43	60													Vb 7.1	X+TCRBV04-01+TCRBJ02-04	TCRBV04-01*01	TCRBD02-01*02	TCRBJ02-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGGGACTCAGCCGTGTATCTCTACGCCAGCAGCCAAGCCGGGGGGAGGACTGAAGCTTTCTTTGGACAA	YASSQAGGRTEAFF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	42	TCRBV04	TCRBV04-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	1	8	1	5	1	3	22	38	46	39	49													Vb 7.1	YASSQAGGRTEAFF+TCRBV04-01+TCRBJ01-01	TCRBV04-01*01	TCRBD02-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCAGCCAAGAGGCCAGGGGCTCCAAACGGGGCTACACCTTCGGTTCG	CASSQEARGSKRGYTF	In	VDJ	1	25	4.4194597652382975E-4	5.350111282314672E-4	48	TCRBV04	TCRBV04-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	4	2	8	3	10	23	40	49	43	59													Vb 7.1	CASSQEARGSKRGYTF+TCRBV04-01+TCRBJ01-02	TCRBV04-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCAGCGCAGCGGGAGGGCGGGAGACCCAGTACTTCGGGCCA	CASSAAGGRETQYF	In	VDJ	1	31	5.480130108895489E-4	6.634137990070194E-4	42	TCRBV04	TCRBV04-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	5	6	0	5	2	3	23	35	47	37	50													Vb 7.1	CASSAAGGRETQYF+TCRBV04-01+TCRBJ02-05	TCRBV04-01*01	TCRBD02-01*02	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCAGCCAAGATCAGGGGGCCTACGAGCAGTACTTCGGGCCG	CASSQDQGAYEQYF	In	VDJ	1	32	5.65690849950502E-4	6.84814244136278E-4	42	TCRBV04	TCRBV04-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	4	1	2	1	0	23	40	-1	41	48													Vb 7.1	CASSQDQGAYEQYF+TCRBV04-01+TCRBJ02-07	TCRBV04-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCAGCCCCCCGAGAAAATCGGATACGCAGTATTTTGGCCCA	CASSPPRKSDTQYF	In	VDJ	1	32	5.65690849950502E-4	6.84814244136278E-4	42	TCRBV04	TCRBV04-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	4	11	2	6	4	7	23	36	43	40	50													Vb 7.1	CASSPPRKSDTQYF+TCRBV04-01+TCRBJ02-03	TCRBV04-01*01	TCRBD02-01*02	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCAGCCAACAACCCGACAGGGAAGCTTTCTTTGGACAA	CASSQQPDREAFF	In	VDJ	1	33	5.833686890114552E-4	7.062146892655367E-4	39	TCRBV04	TCRBV04-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	2	4	8	6	0	23	38	-1	44	50													Vb 7.1	CASSQQPDREAFF+TCRBV04-01+TCRBJ01-01	TCRBV04-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CRRRRGACTCAGCCSTGTATCTCTRCGCCAGCAGCCAACCGACAGGGGCCTCCTATGAAAAACTGTTTTTTGGCAGT	XASSQPTGASYEKLFF	In	VDJ	1	36	6.364022061943148E-4	7.704160246533128E-4	48	TCRBV04	TCRBV04-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	2	2	2	6	2	6	22	37	47	39	53													Vb 7.1	XASSQPTGASYEKLFF+TCRBV04-01+TCRBJ01-04	TCRBV04-01*01	TCRBD01-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCAGTCAAGATGGGCTAGCAGGTGTCAAAAACATTCAGTACTTCGGCGCC	CASSQDGLAGVKNIQYF	In	VDJ	1	39	6.894357233771744E-4	8.346173600410888E-4	51	TCRBV04	TCRBV04-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-04	01	0	4	7	3	4	6	23	40	49	44	55						01,02							Vb 7.1	CASSQDGLAGVKNIQYF+TCRBV04-01+TCRBJ02-04	TCRBV04-01*01	TCRBD02-01	TCRBJ02-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGAAGACTCAGCCCTGTATCTCTGCGCCAGCAGCCAAGACCCCCCGACAGGGGTCGGAAACACCATATATTTTGGAGAG	CASSQDPPTGVGNTIYF	In	VDJ	2	46	8.131805968038467E-4	9.844204759458996E-4	51	TCRBV04	TCRBV04-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	0	2	2	4	6	2	23	40	54	46	56													Vb 7.1	CASSQDPPTGVGNTIYF+TCRBV04-01+TCRBJ01-03	TCRBV04-01*01	TCRBD01-01*01	TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CTCCCTCCCAGACATCTGTATACTTCTGTGCCAGCAGCCCTTATAATGAGCAGTTCTTCGGGCCA	CASSPYNEQFF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	33	TCRBV06	TCRBV06-09	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	4	10	7	2	3	26	37	41	39	44						01,02							Vb 13.1	CASSPYNEQFF+TCRBV06-09+TCRBJ02-01	TCRBV06-09*01	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CTCCCTCCCAGACATCTGTATACTTCTGTGCCAGCAGTGTTAACAGAGGAGATAATTCACCCCTCCACTTTGGGAAC	CASSVNRGDNSPLHF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	45	TCRBV06	TCRBV06-09	01				TCRBJ01	TCRBJ01-06	01	5	3	5	5	4	5	26	38	46	42	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 13.1	CASSVNRGDNSPLHF+TCRBV06-09+TCRBJ01-06	TCRBV06-09*01		TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CTCCCTCCCAGACATCTGTATACTTCTGTGCCAGCAGTTACGGAGCCTCAGGGGACACTGAAGCTTTCTTTGGACAA	CASSYGASGDTEAFF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	45	TCRBV06	TCRBV06-09	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	4	2	3	8	0	26	40	-1	48	54													Vb 13.1	CASSYGASGDTEAFF+TCRBV06-09+TCRBJ01-01	TCRBV06-09*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CTCCCTCCCAGACATCTGTATACTTCTGTGCCAGCAGTCCCGCCGCCCAAACAGATACGCAGTATTTTGGCCCA	CASSPAAQTDTQYF	In	VDJ	1	19	3.358789421581106E-4	4.066084574559151E-4	42	TCRBV06	TCRBV06-09	01				TCRBJ02	TCRBJ02-03	01	5	4	6	3	9	1	26	38	49	47	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 13.1	CASSPAAQTDTQYF+TCRBV06-09+TCRBJ02-03	TCRBV06-09*01		TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCTCCCAGACATCTGTATATTTCTGCGCCAGCAGGGAGACATCCTCTGGCGAGCAGTACTTCGGGCCG	CASRETSSGEQYF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	39	TCRBV10	TCRBV10-01		TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	3	6	6	0	8	26	-1	44	41	52			01,02										Vb 12	CASRETSSGEQYF+TCRBV10-01+TCRBJ02-07	TCRBV10-01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCTCCCAGACATCTGTATATTTCTGCGCCAGCAGCCGATACAATGCCCCGGGAGTTCACCCCTCCACTTTGGGAAC		Out	VDJ	1	25	4.4194597652382975E-4		47	TCRBV10	TCRBV10-01		TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-06	01	6	8	2	9	14	0	26	37	-1	51	57			01,02										Vb 12	X+TCRBV10-01+TCRBJ01-06	TCRBV10-01	TCRBD02-01*02	TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCTCCCAGACATCTGTATATTTCTGCGCCAGCAGTGACCGGGACCACTGAAGCTTTCTTTGGACAA		Out	VDJ	2	44	7.778249186819403E-4		37	TCRBV10	TCRBV10-01					TCRBJ01	TCRBJ01-01	01	3	0	7	4	2	0	26	40	-1	42	47			01,02	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 12	X+TCRBV10-01+TCRBJ01-01	TCRBV10-01		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGGGACTTGGGCCTATATTTCTGTGCCAGCAGCTGGGAGAGCGGGAGCTCCTACAATGAGCAGTTCTTCGGGCCA	CASSWESGSSYNEQFF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	48	TCRBV12	TCRBV12-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	4	6	2	0	5	0	22	35	-1	40	48														CASSWESGSSYNEQFF+TCRBV12-01+TCRBJ02-01	TCRBV12-01*01	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGGGACTTGGGCCTATATTTCTGTGCCAGCAGCTTCGGGTCTGGCGGCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	17	3.005232640362042E-4		43	TCRBV12	TCRBV12-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	3	7	5	2	8	0	22	36	-1	44	48						01,02								X+TCRBV12-01+TCRBJ02-07	TCRBV12-01*01	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGGGACTTGGGCCTATATTTCTGTGCCAGCAGCTTCGGGGACTAGCGGCAAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	28	4.949794937066893E-4		50	TCRBV12	TCRBV12-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	3	0	5	2	2	2	22	36	49	38	51						01,02								X+TCRBV12-01+TCRBJ02-02	TCRBV12-01*01	TCRBD02-01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGGGACTTGGGCCTATATTTCTGTGCCAGCAGGTTATGACAGGGGAGGAAAACTGAAGCTTTCTTTGGACAA	CASRL*QGRKTEAFF	Stop	VDJ	1	34	6.010465280724084E-4		45	TCRBV12	TCRBV12-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	2	2	5	5	6	22	33	46	38	52														CASRL*QGRKTEAFF+TCRBV12-01+TCRBJ01-01	TCRBV12-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACGCAGCCATGTACCTGTGTGCCACCAGACTAGCGGGGCTCCAAGAGACCCAGTACTTCGGGCCA	CATRLAGLQETQYF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	42	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	6	3	3	1	0	2	18	-1	39	29	41														CATRLAGLQETQYF+TCRBV15-01+TCRBJ02-05	TCRBV15-01*01	TCRBD02-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCATGCCCCCGGGGTGCACAGATACGCAGTATTTTGGCCCA	CATSMPPGCTDTQYF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	45	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	4	8	3	1	6	1	18	31	42	37	43														CATSMPPGCTDTQYF+TCRBV15-01+TCRBJ02-03	TCRBV15-01*01	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCGCTAGCAGGGGAACAGATACGCAGTATTTTGGCCCA	CATSASRGTDTQYF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	42	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	4	2	3	5	1	18	30	41	35	42														CATSASRGTDTQYF+TCRBV15-01+TCRBJ02-03	TCRBV15-01*01	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGGGGGTAAAGGGAACTATGGCTACACCTTCGGTTCG	CATSRGGKGNYGYTF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	45	TCRBV15	TCRBV15-01	01				TCRBJ01	TCRBJ01-02	01	1	5	3	2	7	0	18	34	-1	41	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CATSRGGKGNYGYTF+TCRBV15-01+TCRBJ01-02	TCRBV15-01*01		TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACGCAGCCATGTACCTGTGTGCCACCATAGCCGACAGCTCTGGAAACACCATATATTTTGGAGAG	CATIADSSGNTIYF	In	VDJ	1	26	4.596238155847829E-4	5.564115733607259E-4	42	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	7	2	5	0	5	0	18	28	-1	33	38														CATIADSSGNTIYF+TCRBV15-01+TCRBJ01-03	TCRBV15-01*01	TCRBD01-01*01	TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCGCCCGAACCGGGACTAGCGGGAGCACAGATACGCAGTATTTTGGCCCA	CATSARTGTSGSTDTQYF	In	VDJ	1	29	5.126573327676425E-4	6.20612908748502E-4	54	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	5	0	4	0	9	0	18	30	-1	39	51						01,02								CATSARTGTSGSTDTQYF+TCRBV15-01+TCRBJ02-03	TCRBV15-01*01	TCRBD02-01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGGGGGCGGGGCCATCCAAGAGACCCAGTACTTCGGGCCA	CATSRGGGAIQETQYF	In	VDJ	1	35	6.187243671333617E-4	7.490155795240541E-4	48	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	1	7	3	1	3	4	18	34	43	37	47														CATSRGGGAIQETQYF+TCRBV15-01+TCRBJ02-05	TCRBV15-01*01	TCRBD02-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGACCCCGGACTAGCGGGGTCTACGAGCAGTACTTCGGGCCG	CATSRPRTSGVYEQYF	In	VDJ	1	39	6.894357233771744E-4	8.346173600410888E-4	48	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	2	1	3	3	4	1	18	33	49	37	50														CATSRPRTSGVYEQYF+TCRBV15-01+TCRBJ02-07	TCRBV15-01*01	TCRBD02-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGAAAATGCAGGGAATAATCAGCCCCAGCATTTTGGTGAT	CATSRENAGNNQPQHF	In	VDJ	2	45	7.955027577428935E-4	9.63020030816641E-4	48	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	0	4	3	4	5	3	18	35	45	40	48														CATSRENAGNNQPQHF+TCRBV15-01+TCRBJ01-05	TCRBV15-01*01	TCRBD01-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGAGGTTCCCGGTGGTGAGCAGTTCTTCGGGCCA	CATSREVPGGEQFF	In	VDJ	2	48	8.485362749257531E-4	0.001027221366204417	42	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	0	8	5	9	6	3	18	35	44	41	47						01,02								CATSREVPGGEQFF+TCRBV15-01+TCRBJ02-01	TCRBV15-01*01	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGAACTCGAGGTTGACACCATATATTTTGGAGAG	CATSRELEVDTIYF	In	VDJ	2	58	0.001025314665535285	0.001241225817497004	42	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-03	01	0	11	1	8	4	3	18	35	43	39	46														CATSRELEVDTIYF+TCRBV15-01+TCRBJ01-03	TCRBV15-01*01	TCRBD02-01*02	TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAAATTCATAGGGCCTGTATAATTCACCCCTCCACTTTGGGAAC	CATSRNS*GLYNSPLHF	Stop	VDJ	2	64	0.001131381699901004		51	TCRBV15	TCRBV15-01	01				TCRBJ01	TCRBJ01-06	01	2	5	3	4	7	4	18	33	44	40	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CATSRNS*GLYNSPLHF+TCRBV15-01+TCRBJ01-06	TCRBV15-01*01		TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGGCAGGGCGAACACCGGGGAGCTGTTTTTTGGAGAA	CATSRGRANTGELFF	In	VDJ	27	709	0.012533587894215811	0.01517291559664441	45	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	1	4	3	0	1	0	18	34	-1	35	40														CATSRGRANTGELFF+TCRBV15-01+TCRBJ02-02	TCRBV15-01*01	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACYSRGGGACTCAGCTKTGTATTTYTGTGCCACCGACAGGGAAGGAGGGGGCTACACCTTCGGTTCG	CATDREGGGYTF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	36	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	12	2	3	8	4	8	26	31	42	35	50	TCRBV09,TCRBV12													CATDREGGGYTF+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCRGCYSTSTATYTYTGTGCCAGCAACGAACTAGCGGGAGGCCACAATGAGCAGTTCTTCGGGCCA	CASNELAGGHNEQFF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	45	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	12	3	1	5	9	2	26	31	52	40	54	TCRBV05,TCRBV12													CASNELAGGHNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGGACAGGGCAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	8	1.414227124876255E-4		35	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	6	2	3	4	0	0	26	-1	-1	37	44		TCRBV12-03,TCRBV12-04,TCRBV12-05												X+TCRBV12-X+TCRBJ02-03	TCRBV12	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGGCGACAGGGATCTGGAAACACCATATATTTTGGAGAG	CASRRQGSGNTIYF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	42	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	6	2	3	1	2	1	26	37	46	39	47		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASRRQGSGNTIYF+TCRBV12-X+TCRBJ01-03	TCRBV12	TCRBD01-01*01	TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTGGCCGGGTTGGATGGCTACACCTTCGGTTCG	CASSLAGLDGYTF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	39	TCRBV12			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	3	8	4	6	3	4	26	40	47	43	51		TCRBV12-03,TCRBV12-04				01,02								CASSLAGLDGYTF+TCRBV12-X+TCRBJ01-02	TCRBV12	TCRBD02-01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGCCCTTTTCCGGGACAGGGGTACAGATACGCAGTATTTTGGCCCA	CASSQALFRDRGTDTQYF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	54	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	1	0	2	3	9	1	26	42	61	51	62		TCRBV03-01,TCRBV03-02												CASSQALFRDRGTDTQYF+TCRBV03-X+TCRBJ02-03	TCRBV03	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCATCCTTAATCCTTTGAATTTTGATAAGGGTTTACTTCGGGCCG		Out	VDJ	1	8	1.414227124876255E-4		50	TCRBV03						TCRBJ02	TCRBJ02-07	01	3	5	3	13	24	2	26	40	68	64	70		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV03-X+TCRBJ02-07	TCRBV03		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCTCCCGACTAGCGGGAGAACGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSLPTSGRTNTGELFF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	54	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	4	2	2	0	4	2	26	39	55	43	57		TCRBV03-01,TCRBV03-02												CASSLPTSGRTNTGELFF+TCRBV03-X+TCRBJ02-02	TCRBV03	TCRBD02-01*02	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
MRGGGACTYRGSCCTRTATYTCTGTGCCAGCAGCGCCGCGGGCGGGTGGGGTACTAACTATGGCTACACCTTCGGTTCG	CASSAAGGWGTNYGYTF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	51	unresolved			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	6	7	4	0	5	11	22	32	42	37	53	TCRBV05,TCRBV12					01,02								CASSAAGGWGTNYGYTF+X+TCRBJ01-02	unresolved	TCRBD02-01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCAGATCGCGGACAGTTCTGGGCACAGATACGCAGTATTTTGGCCCA	CSARSRTVLGTDTQYF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	48	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	2	1	5	1	4	6	26	38	48	42	54		TCRBV20-01,TCRBV20-or09_02												CSARSRTVLGTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCACGACAGGCAAAGCTACGAGCAGTACTTCGGGCCG	CSAHDRQSYEQYF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	2	4	3	4	5	26	34	44	38	49		TCRBV20-01,TCRBV20-or09_02												CSAHDRQSYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATTGGGTAGGCAATCAGCCCCAGCATTTTGGTGAT	CSARDWVGNQPQHF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	42	TCRBV20						TCRBJ01	TCRBJ01-05	01	0	0	9	2	2	3	26	40	45	42	48		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARDWVGNQPQHF+TCRBV20-X+TCRBJ01-05	TCRBV20		TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGCGAGGGATCGGTAATGAAAAACTGTTTTTTGGCAGT	CSARRGIGNEKLFF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	42	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-04	01	3	11	0	4	2	5	26	37	44	39	49		TCRBV20-01,TCRBV20-or09_02												CSARRGIGNEKLFF+TCRBV20-X+TCRBJ01-04	TCRBV20	TCRBD02-01*02	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTCAGGTGACCTACGAGCAGTACTTCGGGCCG	CSASQVTYEQYF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	36	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	4	4	2	1	3	26	37	42	38	45		TCRBV20-01,TCRBV20-or09_02												CSASQVTYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGAGGACAGGGGGTTAGCGACGGATACGCAGTATTTTGGCCCA	CSAEDRGLATDTQYF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	45	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	1	1	6	2	9	26	35	47	37	56		TCRBV20-01,TCRBV20-or09_02												CSAEDRGLATDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CMCCARCCARACAGCTYTKTACTTCTGTGCCAGCAGTTTCTGACTAGCGGGAGATTGCTGGGAGCTGTTTTTTGGAGAA	CASSF*LAGDCWELFF	Stop	VDJ	1	8	1.414227124876255E-4		48	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	13	2	2	9	13	6	25	28	53	41	59	TCRBV22,TCRBV24													CASSF*LAGDCWELFF+X+TCRBJ02-02	unresolved	TCRBD02-01*02	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAAGATCAGAGGGGCCAACGTCCTGACTTTCGGGGCC	CASKIRGANVLTF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	39	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	7	4	5	4	4	1	23	33	40	37	41	TCRBV01,TCRBV04													CASKIRGANVLTF+X+TCRBJ02-06	unresolved	TCRBD01-01*01	TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CTCCCWSKSASWCWKCTGTKTACTTCTGTGCCAGCAGTTACTCAGGGATGGCCAATCAGCTCCAGCATTTTGGTGAT	CASSYSGMANQLQHF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	45	unresolved			unresolved			TCRBJ01	TCRBJ01-05	01	4	4	3	12	3	14	22	35	43	38	57	TCRBV06,TCRBV12			TCRBD01,TCRBD02										CASSYSGMANQLQHF+X+TCRBJ01-05	unresolved	unresolved	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCWSSSASWCAKCTGTGTACTTSTGTGCCAGCAGTTACTGGACAGCGCAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	8	1.414227124876255E-4		41	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	4	1	5	4	3	2	22	35	44	38	46	TCRBV06,TCRBV12													X+X+TCRBJ02-03	unresolved	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCWSSSASWCAKCTGTGTACTTSTGTGCCAGCATTGATAGCGGGAKCGTGGGCCCCTACAATGAGCAGTTCTTCGGGCCA	CASIDSGXVGPYNEQFF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	51	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	7	5	3	2	4	9	22	32	44	36	53	TCRBV06,TCRBV12													CASIDSGXVGPYNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTCTAGCTCGGAACCCCTGCGAGCAGTACTTCGGGCCG		Out	VDJ	1	8	1.414227124876255E-4		46	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	2	4	7	6	0	12	24	-1	45	40	57		TCRBV24-01,TCRBV24-or09_02				01,02								X+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTCCCCGACTAGCGGGAGTCCCCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	8	1.414227124876255E-4		53	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	1	2	2	6	4	3	24	41	57	45	60		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ02-02	TCRBV24	TCRBD02-01*02	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTAGCCCGGAGGGACACTGAAGCTTTCTTTGGACAA	CASSLARRDTEAFF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	42	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	6	10	0	3	7	0	24	36	-1	43	49		TCRBV24-01,TCRBV24-or09_02												CASSLARRDTEAFF+TCRBV24-X+TCRBJ01-01	TCRBV24	TCRBD02-01*02	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCGGTTCGGACAGGGTCCCCGGGGAGCTGTTTTTTGGAGAA	CASGSDRVPGELFF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	11	1	3	6	7	3	24	31	46	38	49		TCRBV24-01,TCRBV24-or09_02												CASGSDRVPGELFF+TCRBV24-X+TCRBJ02-02	TCRBV24	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CMCCAACCAGACAKCTMTKTACYTCTGTGCCAGGCCAGGAATACCTTCGGCCGAGCAGTACTTCGGGCCG	CARPGIPSAEQYF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	39	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	11	4	4	6	3	12	24	31	38	34	50	TCRBV24,TCRBV28													CARPGIPSAEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCWSCCARACAKCTKTGTACTTSTGTGCCAGCAGAATCTACCCCCTTACTGAAGCTTTCTTTGGACAA	CASRIYPLTEAFF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	39	unresolved			unresolved			TCRBJ01	TCRBJ01-01	01	6	4	9	5	3	7	23	34	40	37	47	TCRBV06,TCRBV22			TCRBD01,TCRBD02										CASRIYPLTEAFF+X+TCRBJ01-01	unresolved	unresolved	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAAACAGGGGGGAGTTATACGCAGTATTTTGGCCCA	CASSETGGSYTQYF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	42	TCRBV06			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	2	3	1	7	0	5	23	-1	46	38	51		TCRBV06-01,TCRBV06-08												CASSETGGSYTQYF+TCRBV06-X+TCRBJ02-03	TCRBV06	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CTCYSKMKSASWCWKCYRTKTACTTCTGTGCCAGCAGGCTCTTTGGCACTGAAGCTTTCTTTGGACAA	CASRLFGTEAFF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	36	unresolved						TCRBJ01	TCRBJ01-01	01	6	0	10	4	7	0	26	37	-1	44	46	TCRBV02,TCRBV06			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRLFGTEAFF+X+TCRBJ01-01	unresolved		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CTCCCWMYCAGACWKCTSTTTACTTCTGTGCCAGCAGTGCCGTGGGCAGGAAACTTTCTTTGGACAA		Out	VDJ	1	8	1.414227124876255E-4		35	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	4	4	12	8	3	26	38	50	46	53	TCRBV06,TCRBV24													X+X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCRGCYRTGTATYKYTGTGCCACCAGCGCACAAATACAGGGTGTGAATGCTTTCTTTGGACAA	CATSAQIQGVNAFF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	3	3	11	8	7	18	30	44	38	51	TCRBV07,TCRBV12													CATSAQIQGVNAFF+X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAAGACTCGGCCSTGTATSTCTGTGCCAGCAGCCCGAATGAGGGATCCGATCAGCCCCAGCATTTTGGTGAT	CASSPNEGSDQPQHF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	45	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-05	01	5	11	0	5	6	5	18	30	41	36	46	TCRBV04,TCRBV11													CASSPNEGSDQPQHF+X+TCRBJ01-05	unresolved	TCRBD02-01*02	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCCTGCAGATTAAGTGCCGAAAGACCTATGGCCGGTTCG		Out	VDJ	1	8	1.414227124876255E-4		43	unresolved						TCRBJ01	TCRBJ01-02	01	5	2	7	19	20	7	18	30	53	50	60	TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+X+TCRBJ01-02	unresolved		TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATSTCTGTGCCAGCAGCTTAAGGTTACCGGCGACTAGCGGGATTTCGTGCGAGCAGTAYTTCGGGCCG	CASSLRLPATSGISCEQYF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	57	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	2	2	3	16	11	17	18	33	55	44	72	TCRBV07,TCRBV11													CASSLRLPATSGISCEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTATTTGGGGGGGCCGGGGTAGCAGATACGCAGTATTTTGGCCCA	CASSLFGGAGVADTQYF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	51	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	2	9	0	4	3	9	18	33	43	36	52	TCRBV07,TCRBV11													CASSLFGGAGVADTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGACWCGGCMSTGTATCTCTGYGCCAGCAGCTCCTGGGCGCTAGCGGGGCTCCAAGAGACCCAGTACTTCGGGCCA	CASSSWALAGLQETQYF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	51	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	6	4	3	1	10	2	20	31	50	41	52	TCRBV11,TCRBV23													CASSSWALAGLQETQYF+X+TCRBJ02-05	unresolved	TCRBD02-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGACWCGGCMSTGTATCTCTGYGCCAGCAGCTTGGTGGTAGCCCCAGATACGCAGTATTTTGGCCCA	CASSLVVAPDTQYF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	42	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	6	5	7	4	8	2	20	31	43	39	45	TCRBV05,TCRBV07,TCRBV23					01,02								CASSLVVAPDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGACWCGGCMSTGTATCTCTGYGCCAGCAGCTTTACTAGCGTTGAGACCCAGTACTTCGGGCCA	CASSFTSVETQYF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	39	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	6	3	6	5	4	2	20	31	42	35	44	TCRBV07,TCRBV23					01,02								CASSFTSVETQYF+X+TCRBJ02-05	unresolved	TCRBD02-01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGGGGGACTCAGCYWTGTATYKCTGTGCCAGCAGCTTTTCCGGGACCCCTAACACCGGGGAGCTGTTTTTTGGAGAA	CASSFSGTPNTGELFF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	48	unresolved						TCRBJ02	TCRBJ02-02	01	3	0	7	2	4	4	19	33	42	37	46	TCRBV07,TCRBV09			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSFSGTPNTGELFF+X+TCRBJ02-02	unresolved		TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCCCGAGGACAGGGGGGTATCAAGAGACCCAGTACTTCGGGCCA	CASSPRTGGYQETQYF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	4	1	1	2	4	4	19	31	45	35	49	TCRBV05,TCRBV11													CASSPRTGGYQETQYF+X+TCRBJ02-05	unresolved	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
SGACTCGGCYSTGTATCTCTGTGCCAGCAGCTTGGGGGGGACAGGGTCGACAGATACGCAGTATTTTGGCCCA	CASSLGGTGSTDTQYF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	0	0	3	3	2	3	19	35	46	37	49	TCRBV05,TCRBV07													CASSLGGTGSTDTQYF+X+TCRBJ02-03	unresolved	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGGCAAGCCACGTTTGGTGRASCYWGGKRMYYMKCTGTGTATTTYTGTGCCAGCAGTTTAGCGGGGGGGACCCAGTACTTCGGGCCA	CASSLAGGTQYF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	36	TCRBV12			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	0	9	1	7	0	0	45	-1	-1	62	68		TCRBV12-03,TCRBV12-04												CASSLAGGTQYF+TCRBV12-X+TCRBJ02-05	TCRBV12	TCRBD02-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGCACCTCGGTAGCAAACGGGCGGACTGAAGCTTTCTTTGGACAA	CASSTSVANGRTEAFF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	48	TCRBV12						TCRBJ01	TCRBJ01-01	01	6	8	0	5	16	2	26	37	57	53	59		TCRBV12-03,TCRBV12-04,TCRBV12-05		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSTSVANGRTEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGCGTAGCTCCAACTAGCTCCTACAATGAGCAGTTCTTCGGGCCA	CASSVAPTSSYNEQFF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	48	TCRBV12			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	3	8	0	10	0	26	37	-1	47	52		TCRBV12-03,TCRBV12-04,TCRBV12-05				01,02								CASSVAPTSSYNEQFF+TCRBV12-X+TCRBJ02-01	TCRBV12	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTAAAACACAGGGGCCGATTAACTATGGCTACACTTTCGGTTCG	CASSKTQGPINYGYTF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	48	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	3	2	17	5	21	26	38	50	43	71		TCRBV12-03,TCRBV12-04												CASSKTQGPINYGYTF+TCRBV12-X+TCRBJ01-02	TCRBV12	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTCCCAGAGAGGGGCTTTCTTTGGACAA	CASSSQRGAFF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	33	TCRBV12			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	4	11	0	11	6	0	26	39	-1	45	50		TCRBV12-03,TCRBV12-04												CASSSQRGAFF+TCRBV12-X+TCRBJ01-01	TCRBV12	TCRBD02-01*02	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTAGTGGTCGGGGAGCAGTACTTCGGGCCG	CASSLVVGEQYF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	36	TCRBV12			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	1	8	4	7	4	0	26	42	-1	46	50		TCRBV12-03,TCRBV12-04				01,02								CASSLVVGEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTCGGTTCTCGGCGGAGCGCCTACGAGCAGTACTTCGGGCCG	CASSFGSRRSAYEQYF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	48	TCRBV12			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	3	6	6	2	13	0	26	40	-1	53	57		TCRBV12-03,TCRBV12-04				01,02								CASSFGSRRSAYEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTCCCAGACATCTGTGTACTTCTGTGCCAGCACCAGACAGGGACGTCAGCCCCAGCATTTTGGTGAT	CASTRQGRQPQHF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	39				TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	7	2	3	6	3	3	24	34	44	37	47	TCRBV06,TCRBV10	TCRBV06-01,TCRBV06-05,TCRBV06-06,TCRBV10-03												CASTRQGRQPQHF+X+TCRBJ01-05		TCRBD01-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTCCCAGACATCTGTGTACTTCTGTGCCAGCAGTTACTCCCGATTTACCACTGAAGCTTTCTTTGGACAA	CASSYSRFTTEAFF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	42	TCRBV06						TCRBJ01	TCRBJ01-01	01	0	2	8	4	2	5	24	41	45	43	50		TCRBV06-05,TCRBV06-06		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYSRFTTEAFF+TCRBV06-X+TCRBJ01-01	TCRBV06		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGGCCGGGGTTTTCGGAACATTCAGTACTTCGGCGCC	CASSQGRGFRNIQYF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	45	TCRBV03			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-04	01	1	8	3	7	2	7	26	42	49	44	56		TCRBV03-01,TCRBV03-02												CASSQGRGFRNIQYF+TCRBV03-X+TCRBJ02-04	TCRBV03	TCRBD02-01*01	TCRBJ02-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCCTCAACGAACACTGAAGCTTTCTTTGGACAA	CASSPSTNTEAFF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	39	TCRBV03						TCRBJ01	TCRBJ01-01	01	4	3	7	1	5	0	26	39	-1	44	46		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPSTNTEAFF+TCRBV03-X+TCRBJ01-01	TCRBV03		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCCCCCCGGGAGGGGAGGAGAGCAGTACTTCGGGCCG		Out	VDJ	1	9	1.591005515485787E-4		38	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	8	8	0	7	4	5	26	35	47	39	52		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCTCGGGCATGGAGACCCAGTACTTCGGGCCA	CASSGMETQYF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	33	TCRBV03						TCRBJ02	TCRBJ02-05	01	8	8	0	5	2	3	26	35	41	37	44		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSGMETQYF+TCRBV03-X+TCRBJ02-05	TCRBV03		TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGCGCTGGGACTAGGTACAATGAGCAGTTCTTCGGGCCA	CSAGTRYNEQFF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	36	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	0	8	4	0	1	26	-1	43	35	44		TCRBV20-01,TCRBV20-or09_02				01,02								CSAGTRYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAAGAGCGGGACTCCAAACACTGAAGCTTTCTTTGGACAA	CSAKSGTPNTEAFF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	42	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	4	6	3	2	2	5	26	36	45	38	50		TCRBV20-01,TCRBV20-or09_02												CSAKSGTPNTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD02-01*02	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTACCGGACAGGAGAACACAGATACGCAGTATTTTGGCCCA	CSATGQENTDTQYF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	4	1	4	2	2	4	26	36	45	38	49		TCRBV20-01,TCRBV20-or09_02												CSATGQENTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGACCTAGGGACAGCCACGCGATAGATACGCAGTATTTTGGCCCA	CSARPRDSHAIDTQYF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	48	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	2	0	5	5	4	9	26	38	49	42	58		TCRBV20-01,TCRBV20-or09_02												CSARPRDSHAIDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATAATCAGGGAGGTTCACCCCTCCACTTTGGGAAC	CSARDNQGGSPLHF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	42	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-06	01	0	9	1	9	6	0	26	40	-1	46	52		TCRBV20-01,TCRBV20-or09_02												CSARDNQGGSPLHF+TCRBV20-X+TCRBJ01-06	TCRBV20	TCRBD02-01*02	TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATCCGAGGGACTCCTACAATGAGCAGTTCTTCGGGCCA	CSARDPRDSYNEQFF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	45	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	0	11	0	0	3	1	26	40	48	43	49		TCRBV20-01,TCRBV20-or09_02												CSARDPRDSYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCCACTCCCGGGAGGGGGCACTGAAGCTTTCTTTGGACAA	CSAPLPGGGTEAFF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	42	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	5	8	0	4	7	2	26	35	50	42	52		TCRBV20-01,TCRBV20-or09_02												CSAPLPGGGTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD02-01*02	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCCCCACGGGGGGGCAGATACGCAGTATTTTGGCCCA	CSAPHGGADTQYF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	39	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	5	8	0	4	5	0	26	35	-1	40	48		TCRBV20-01,TCRBV20-or09_02												CSAPHGGADTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCAGCTTAATGGGACAGGGGAGCTCCTACAATGAGCAGTTCTTCGGGCCA	CASSLMGQGSSYNEQFF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	51	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	2	0	2	0	2	2	22	37	49	39	51		TCRBV12-03,TCRBV12-04												CASSLMGQGSSYNEQFF+TCRBV12-X+TCRBJ02-01	TCRBV12	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCAGTAAAGGGACTAGCGAGGGGAATGAGCAGTTCTTCGGGCCA	CASSKGTSEGNEQFF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	45	TCRBV12			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	0	6	7	3	5	22	34	47	37	52		TCRBV12-03,TCRBV12-04				01,02								CASSKGTSEGNEQFF+TCRBV12-X+TCRBJ02-01	TCRBV12	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCGTGCGGCTAGCGGGAGGATCGGACTACAATGAGCAGTTCTTCGGGCCA	CASVRLAGGSDYNEQFF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	51	TCRBV12			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	8	4	1	3	6	6	22	31	48	37	54		TCRBV12-03,TCRBV12-04												CASVRLAGGSDYNEQFF+TCRBV12-X+TCRBJ02-01	TCRBV12	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGCTCCGACAGGGGTTCTGACAGATACGCAGTATTTTGGCCCA	CATSAPTGVLTDTQYF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	48	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	2	2	3	4	5	24	37	49	41	54		TCRBV24-01,TCRBV24-or09_02												CATSAPTGVLTDTQYF+TCRBV24-X+TCRBJ02-03	TCRBV24	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGACTGGGCCCTGGGGATGGCTACACCTTCGGTTCG	CASRLGPGDGYTF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	39	TCRBV24						TCRBJ01	TCRBJ01-02	01	7	6	2	6	10	0	24	35	-1	45	49		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRLGPGDGYTF+TCRBV24-X+TCRBJ01-02	TCRBV24		TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGAACCGCCCGGACGACAGGGGGCGCAAAACTATGGCTACACCTTCGGTTCG	CSAREPPGRQGAQNYGYTF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	57	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	2	0	2	11	4	24	38	59	49	63		TCRBV20-01,TCRBV20-or09_02												CSAREPPGRQGAQNYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTCTATCTCTGTGCCAGCAGCATGAGTAGCGGGAGGGCCAACACCGGGGAGCTGTTTTTTGGAGAA	CASSMSSGRANTGELFF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	51	TCRBV05			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	4	5	0	2	5	2	19	31	47	36	49		TCRBV05-06,TCRBV05-07												CASSMSSGRANTGELFF+TCRBV05-X+TCRBJ02-02	TCRBV05	TCRBD02-01*02	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTCTATCTCTGTGCCAGCAGCTTGGTAGGGGGCTCCAATCAGCCCCAGCATTTTGGTGAT	CASSLVGGSNQPQHF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	45	TCRBV05			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	0	5	0	3	1	2	19	35	43	36	45		TCRBV05-06,TCRBV05-07												CASSLVGGSNQPQHF+TCRBV05-X+TCRBJ01-05	TCRBV05	TCRBD01-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTGATGGACGTCCTGACTTTCGGGGCC	CASSLMDVLTF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	33	TCRBV12						TCRBJ02	TCRBJ02-06	01	3	0	10	11	3	0	26	40	-1	43	45		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLMDVLTF+TCRBV12-X+TCRBJ02-06	TCRBV12		TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTTAGCGGGGGGGTAGATACGCAGTATTTTGGCCCA	CASSFSGGVDTQYF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	42	TCRBV12			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	3	5	0	5	0	1	26	-1	51	40	52		TCRBV12-03,TCRBV12-04												CASSFSGGVDTQYF+TCRBV12-X+TCRBJ02-03	TCRBV12	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGATGCGAGGCCAAATGGCTACACCTTCGGTTCG	CASSQDARPNGYTF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	42	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	0	11	1	6	3	4	26	43	50	46	54		TCRBV03-01,TCRBV03-02												CASSQDARPNGYTF+TCRBV03-X+TCRBJ01-02	TCRBV03	TCRBD02-01*02	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCGCCTAGTACCGACTCCTACTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	10	1.7677839060953188E-4		47	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	4	2	10	3	10	4	26	39	53	49	57		TCRBV03-01,TCRBV03-02				01,02								X+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGGGGACTCRGCCSTGTATSTCTGTGCCAGCAGCCACAGGGCCGGCGGACAAGAGACCCAGTACTTCGGGCCA	CASSHRAGGQETQYF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	6	3	3	2	3	8	22	32	41	35	49	TCRBV05,TCRBV11													CASSHRAGGQETQYF+X+TCRBJ02-05	unresolved	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGACTCTGGACTAGCGGTGACAATGAGCAGTTCTTCGGGCCA	CSARLWTSGDNEQFF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	45	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	2	1	5	5	4	2	26	38	52	42	54		TCRBV20-01,TCRBV20-or09_02				01,02								CSARLWTSGDNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTGATTACAGGGCTGGCTACACCTTCGGTTCG	CSASDYRAGYTF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	36	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	3	3	7	5	1	26	37	48	42	49		TCRBV20-01,TCRBV20-or09_02												CSASDYRAGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGGCAGGGACCCCCGGGCCGACATTCAGTACTTCGGCGCC	CSGRDPRADIQYF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	39	TCRBV20						TCRBJ02	TCRBJ02-04	01	7	0	7	8	3	10	26	33	41	36	51		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSGRDPRADIQYF+TCRBV20-X+TCRBJ02-04	TCRBV20		TCRBJ02-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCTCCTGTGGGGGCTGGACTGAAGCTTTCTTTGGACAA	CSCGGWTEAFF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	33	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	11	6	0	5	6	3	26	29	41	35	44		TCRBV20-01,TCRBV20-or09_02												CSCGGWTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCCTCCTACTAGCAAGGGATACAATGAGCAGTTCTTCGGGCCA	CASSPPTSKGYNEQFF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	48	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	4	3	7	4	5	6	23	36	47	41	53	TCRBV01,TCRBV04					01,02								CASSPPTSKGYNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGTTTCACCTCAGGGGCGGGAAAGACCCAGTACTTCGGGCCA	CASSFTSGAGKTQYF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	45	unresolved						TCRBJ02	TCRBJ02-05	01	3	4	2	6	5	6	23	37	48	42	54	TCRBV24,TCRBV27			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSFTSGAGKTQYF+X+TCRBJ02-05	unresolved		TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTCCGGACTAGCGGAAATACAGATACGCAGTATTTTGGCCCA	CATSDFRTSGNTDTQYF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	51	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	1	1	5	3	2	4	24	41	53	43	57		TCRBV24-01,TCRBV24-or09_02				01,02								CATSDFRTSGNTDTQYF+TCRBV24-X+TCRBJ02-03	TCRBV24	TCRBD02-01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGGCTAGGGAGAGGCGGCCCGTGGACATTTAGTACTTCGGCGCC		Out	VDJ	1	10	1.7677839060953188E-4		49	TCRBV24						TCRBJ02	TCRBJ02-04	01	5	1	6	14	20	3	24	37	62	57	65		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV24-X+TCRBJ02-04	TCRBV24		TCRBJ02-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGGTGGGCCAGGGCTATCTTACGAGCAGTACTTCGGGCCG	CATSGGPGLSYEQYF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	45	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	4	3	4	6	6	24	37	48	43	54		TCRBV24-01,TCRBV24-or09_02												CATSGGPGLSYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCWMCCAGACMTCTSTGTACTTSTGTGCCATCAGAGAATGTAGCGGGAGGGAAGAACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	10	1.7677839060953188E-4		50	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	6	5	0	3	6	4	23	34	51	40	55	TCRBV06,TCRBV27													X+X+TCRBJ02-03	unresolved	TCRBD02-01*02	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCGAACGAGTCCAGGGTCGGGACACTGAAGCTTTCTTTGGACAA	CASSERVQGRDTEAFF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	4	3	3	9	5	19	31	45	40	50	TCRBV07,TCRBV11													CASSERVQGRDTEAFF+X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGGGGGACTCRGCYKTGTATKTCTGTGCCAGCAGCCCACGGACAGGGGGCGCCGAGACCCAGTACTTCGGGCCA	CASSPRTGGAETQYF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	1	0	5	4	3	18	30	45	34	48	TCRBV09,TCRBV11													CASSPRTGGAETQYF+X+TCRBJ02-05	unresolved	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCCGGGGGGACTAGCGGTACAGATACGCAGTATTTTGGCCCA	CASSLAGGTSGTDTQYF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	51				TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	0	0	5	3	4	1	18	35	50	39	51	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03				01,02								CASSLAGGTSGTDTQYF+X+TCRBJ02-03		TCRBD02-01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCTTGGATTACAGCTCTGGAAACACCATATATTTTGGAGAG	CASSLDYSSGNTIYF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	3	3	5	0	5	0	18	32	-1	37	41	TCRBV05,TCRBV11													CASSLDYSSGNTIYF+X+TCRBJ01-03	unresolved	TCRBD01-01*01	TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCKGCYGTGTATKTCTGTGCCAGCAGTTTAAGGCACCAATTTTACGAGCAGTACTTCGGGCCG	CASSLRHQFYEQYF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	42	unresolved						TCRBJ02	TCRBJ02-07	01	2	5	4	4	0	9	18	-1	36	33	45	TCRBV03,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLRHQFYEQYF+X+TCRBJ02-07	unresolved		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGTAGTTTAGTCTTTCGGCTAGCGGGGGGGATAGATACGCAGTATTTTGGCCCA	CASSLVFRLAGGIDTQYF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	54				TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	1	4	0	5	8	2	18	34	54	42	56	TCRBV11,TCRBV12	TCRBV11-03,TCRBV12-02												CASSLVFRLAGGIDTQYF+X+TCRBJ02-03		TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCRTGTATSKCTGTGCTAGCAGCTTAGCGCAGGGGTTGCGGGAAACCCAGTACTTCGGGCCA	CASSLAQGLRETQYF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	45	unresolved						TCRBJ02	TCRBJ02-05	01	0	4	2	8	1	9	18	35	42	36	51	TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLAQGLRETQYF+X+TCRBJ02-05	unresolved		TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
RRGACWCGGCMCTGTATCTCTGYGCCAGCAGCCCGCTTCCCAGGCTCCTCGATGGAACTTCGGCGCC		Out	VDJ	1	10	1.7677839060953188E-4		41	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	6	4	4	17	9	12	20	31	44	40	56	TCRBV05,TCRBV23													X+X+TCRBJ02-04	unresolved	TCRBD01-01*01	TCRBJ02-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
SCTCCCAGACATCTGTGTAYTTSTGYGCCAGCAGTGAAGACAGGGTCTATGGCTACACCTTCGGTTCG	CASSEDRVYGYTF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	39	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	2	3	4	1	1	23	37	45	38	46	TCRBV06,TCRBV10													CASSEDRVYGYTF+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCRGCCATGTATCKCTGTGCCAGCAGCCCCCGCAGACTAGATTTTGAGCAGTACTTCGGGCCG	CASSPRRLDFEQYF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	42	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	2	8	7	7	5	19	31	44	38	49	TCRBV07,TCRBV11					01,02								CASSPRRLDFEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCRGCCATGTATCKCTGTGCCAGCAGCGCCCGACAGGGGGCGACTGGCTACACCTTCGGTTCG	CASSARQGATGYTF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	2	0	7	4	3	19	31	45	35	48	TCRBV07,TCRBV11													CASSARQGATGYTF+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCRGCCMTSTATCKCTGTGCCAGCAGCATACGTAACGTGAACACTGAAGCTTTCTTTGGACAA	CASSIRNVNTEAFF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	42	unresolved						TCRBJ01	TCRBJ01-01	01	4	3	7	0	2	6	19	31	35	33	41	TCRBV05,TCRBV07			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSIRNVNTEAFF+X+TCRBJ01-01	unresolved		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCMTSTATCTCTGTGCCAGCAGCCCCGGGGCCGGAACAGGGGTCGGCGAGCAGTACTTCGGGCCG	CASSPGAGTGVGEQYF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	3	2	6	12	4	19	31	50	43	54	TCRBV05,TCRBV11													CASSPGAGTGVGEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
SGACTCGGCYSTSTATCTCTGTGCCAGCAGCCCTCTAGAGGGACACGGTAACTATGGCTACACCTTCGGTTCG	CASSPLEGHGNYGYTF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	0	6	1	8	3	19	31	45	39	48	TCRBV05,TCRBV07													CASSPLEGHGNYGYTF+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCMTSTATCTCTGTGCCAGCAGCTTTTGGGGGGGCAGAGATACGCAGTATTTTGGCCCA	CASSFWGGRDTQYF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	42	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	2	9	0	5	2	3	19	33	42	35	45	TCRBV05,TCRBV11													CASSFWGGRDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCRGCCMTGTATCKCTGTGCCAGCAGCCCGGGAGGCCAGTCCTACGAGCAGTACTTCGGGCCG	CASSPGGQSYEQYF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	42	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	4	8	1	1	1	4	19	31	39	32	43	TCRBV05,TCRBV07													CASSPGGQSYEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCRGCCMTGTATCKCTGTGCCAGCAGCTTTCCATTCTGGGGGAAGGACACTGAAGCTTTCTTTGGACAA	CASSFPFWGKDTEAFF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	48	unresolved						TCRBJ01	TCRBJ01-01	01	2	6	1	3	8	4	19	33	46	41	50	TCRBV05,TCRBV07			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSFPFWGKDTEAFF+X+TCRBJ01-01	unresolved		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGGGGACTCRGCYSTGTATCTCTGTGCCAGCAGCCCAAGGCAGGGGGCCTCCTACGAGCAGTACTTCGGGCCG	CASSPRQGASYEQYF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	4	0	0	6	0	22	34	-1	40	48	TCRBV05,TCRBV07													CASSPRQGASYEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGGGGACTYGGCYGTGTATSTCTGTGCCAGCAGCGACGCGCGGCGGCCAGGATCACCCCTCCACTTTGGGAAC	CASSDARRPGSPLHF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	45	unresolved						TCRBJ01	TCRBJ01-06	01	5	4	4	10	13	1	22	34	51	47	52	TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSDARRPGSPLHF+X+TCRBJ01-06	unresolved		TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGGGGACTYGGCYGTGTATSTCTGTGCCAGCAGCGGACTAGCGGGAGGTGGAGAGACCCAGTACTTCGGGCCA	CASSGLAGGGETQYF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	45	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	5	1	1	4	0	3	22	-1	48	34	51	TCRBV07,TCRBV11													CASSGLAGGGETQYF+X+TCRBJ02-05	unresolved	TCRBD02-01*02	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGTTAGCGGGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	11	1.9445622967048507E-4		43	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	1	5	5	1	1	0	26	42	-1	43	49		TCRBV03-01,TCRBV03-02				01,02								X+TCRBV03-X+TCRBJ02-03	TCRBV03	TCRBD02-01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCGTTCTTGGGACTAGTGACTCTATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	11	1.9445622967048507E-4		47	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	0	8	8	6	7	26	38	52	44	59		TCRBV03-01,TCRBV03-02				01,02								X+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGCGTCAGGACCTACTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CSASVRTYSGANVLTF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	48	TCRBV20						TCRBJ02	TCRBJ02-06	01	3	1	7	0	5	3	26	37	46	42	49		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSASVRTYSGANVLTF+TCRBV20-X+TCRBJ02-06	TCRBV20		TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGATCGCAGGGGAAAGTAGCAATCAGCCCCAGCATTTTGGTGAT	CSARIAGESSNQPQHF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	48	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	3	4	2	0	5	4	26	37	48	42	52		TCRBV20-01,TCRBV20-or09_02												CSARIAGESSNQPQHF+TCRBV20-X+TCRBJ01-05	TCRBV20	TCRBD01-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCCGCAGGTGGTACAAGAGACCCAGTACTTCGGGCCA	CSAPQVVQETQYF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	4	4	2	3	5	26	35	42	38	47		TCRBV20-01,TCRBV20-or09_02												CSAPQVVQETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGGGGGGGCTAGCGGGAGTGGGCAGTACTTCGGCGCC	CSGGASGSGQYF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	36	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-04	01	7	4	2	13	6	4	26	33	49	39	53		TCRBV20-01,TCRBV20-or09_02												CSGGASGSGQYF+TCRBV20-X+TCRBJ02-04	TCRBV20	TCRBD02-01*02	TCRBJ02-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCACCAACCAGACATCTRTGTAYCTCTRTGCCAGCAGTTCTACCGGGACACCAACCTACGAGCAGTACTTCGGGCCG	XASSSTGTPTYEQYF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	0	6	2	5	4	25	38	49	43	53	TCRBV26,TCRBV28													XASSSTGTPTYEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAGCCCCGGCGCCAGACTACGAGCAGTACTTCGGGCCG	CASSQAPAPDYEQYF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	45	unresolved						TCRBJ02	TCRBJ02-07	01	1	4	5	3	9	1	23	39	51	48	52	TCRBV01,TCRBV04			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQAPAPDYEQYF+X+TCRBJ02-07	unresolved		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACACAGGAGGGGAGCACAGATACGCAGTATTTTGGCCCA	CATQEGSTDTQYF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	39	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	10	10	0	0	3	1	24	32	41	35	42		TCRBV24-01,TCRBV24-or09_02												CATQEGSTDTQYF+TCRBV24-X+TCRBJ02-03	TCRBV24	TCRBD02-01*02	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGACACCACAGTGGGTCGGGAGACCCAGTACTTCGGGCCA	CATSDTTVGRETQYF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	45	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	4	3	5	5	4	8	24	38	46	42	54		TCRBV24-01,TCRBV24-or09_02												CATSDTTVGRETQYF+TCRBV24-X+TCRBJ02-05	TCRBV24	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTCGCCGGGGAGACCCAGTACTTCGGGCCA	CATSDFAGETQYF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	39	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	1	8	4	5	3	0	24	41	-1	44	48		TCRBV24-01,TCRBV24-or09_02				01,02								CATSDFAGETQYF+TCRBV24-X+TCRBJ02-05	TCRBV24	TCRBD02-01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCACCAGTTGAGGGGGGAGGTATGGCTACACCTTCGGTTCG	CATS*GGRYGYTF	Stop	VDJ	1	11	1.9445622967048507E-4		39	unresolved						TCRBJ01	TCRBJ01-02	01	6	5	1	5	2	4	24	36	44	38	48	TCRBV24,TCRBV27			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CATS*GGRYGYTF+X+TCRBJ01-02	unresolved		TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGCCGCTATTGGGGGCCCAAAGGGGATGAGCAGTTCTTCGGGCCA	CASSRYWGPKGDEQFF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	48	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	6	0	8	8	9	26	37	51	45	60		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASSRYWGPKGDEQFF+TCRBV12-X+TCRBJ02-01	TCRBV12	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AAYCMRGRGACWCAGCWSKGTATTTYTGTGCCAGCAGCGTAGGGGGCGTCGGTTTGGTTGGCGAGCAGTACTTCGGGCCG	CASSVGGVGLVGEQYF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	5	0	6	3	14	26	37	47	40	61	TCRBV12,TCRBV21													CASSVGGVGLVGEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTTGAGACAGGGACAGGCGAGCAGTACTTCGGGCCG	CASSFETGTGEQYF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	42	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	0	4	6	7	0	26	40	-1	47	55		TCRBV12-03,TCRBV12-04												CASSFETGTGEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAMGACTCGGCCCTGTATCTCTGTGCCAGCAGCTCCAGCCGAGACGAGACCCAGTACTTCGGGCCA	CASSSSRDETQYF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	39	unresolved						TCRBJ02	TCRBJ02-05	01	3	2	7	5	8	0	20	33	-1	41	44	TCRBV04,TCRBV05			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSSRDETQYF+X+TCRBJ02-05	unresolved		TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGKGACTCKGCYSTGTATYTCTGTGCCAGCAGCTACTATCCCCGGGTCCGGGGGGATGAGCAGTTCTTCGGGCCA	CASSYYPRVRGDEQFF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	48	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	5	8	1	8	15	0	26	38	-1	53	60	TCRBV03,TCRBV05													CASSYYPRVRGDEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGGACTCSGCCGTGTATSTCTGTGCCAGCAGCTTAACGGGAAGTTACTCTGGAAACACCATATATTTTGGAGAG	CASSLTGSYSGNTIYF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	48	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-03	01	2	8	3	0	1	5	20	35	41	36	46	TCRBV07,TCRBV11													CASSLTGSYSGNTIYF+X+TCRBJ01-03	unresolved	TCRBD02-01*02	TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGCCCCTCAAACAGGGGGGATGAAAAACTGTTTTTTGGCAGT	CSASPSNRGDEKLFF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	45	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	3	3	1	6	8	1	26	37	53	45	54		TCRBV20-01,TCRBV20-or09_02												CSASPSNRGDEKLFF+TCRBV20-X+TCRBJ01-04	TCRBV20	TCRBD01-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTGAGGGACTAGGCTACAATGAGCAGTTCTTCGGGCCA	CSASEGLGYNEQFF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	42	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	3	0	8	3	3	1	26	37	48	40	49		TCRBV20-01,TCRBV20-or09_02				01,02								CSASEGLGYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTGGCAGGGGGATCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CSASGRGISGANVLTF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	48	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	3	4	1	0	3	2	26	37	47	40	49		TCRBV20-01,TCRBV20-or09_02												CSASGRGISGANVLTF+TCRBV20-X+TCRBJ02-06	TCRBV20	TCRBD01-01*01	TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TSRGGGACTCAGCTKTGTAYTTCTGTGCCAGCAGCTCCCTAACAGGGGAGGCGTCTAAAGAGACCCAGTACTTCGGGCCA	CASSSLTGEASKETQYF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	51	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	6	3	2	3	7	9	22	33	47	40	56	TCRBV09,TCRBV12													CASSSLTGEASKETQYF+X+TCRBJ02-05	unresolved	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
SRGGGACTYRGCTGTGTAYYTCTGTGCCAGCAGCTTAGTCGCTGGGGGCGAAGCTTTCTTTGGACAA	CASSLVAGGEAFF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	39	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	6	0	8	5	0	22	38	-1	43	49	TCRBV07,TCRBV12													CASSLVAGGEAFF+X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCAGTGCGGCGGACCGCGGGCCCCAGCATTTTGGTGAT	CASSAADRGPQHF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	39	TCRBV12						TCRBJ01	TCRBJ01-05	01	5	1	7	9	5	5	22	34	43	39	48		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSAADRGPQHF+TCRBV12-X+TCRBJ01-05	TCRBV12		TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTGCAGGGGAACAATGAGCAGTTCTTCGGGCCA	CATSDLQGNNEQFF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	0	4	2	5	0	1	24	-1	48	42	49		TCRBV24-01,TCRBV24-or09_02												CATSDLQGNNEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTCATTGCAGGGGGTCTCCTACGAGCAGTACTTCGGGCCG	CASSSLQGVSYEQYF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	4	1	0	5	1	18	31	43	36	44	TCRBV07,TCRBV11													CASSSLQGVSYEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTAGCGGGCCCCGGTGGTGAGACCCAGTACTTCGGGCCA	CASSLAGPGGETQYF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	0	8	0	5	0	9	18	-1	39	35	48	TCRBV07,TCRBV11													CASSLAGPGGETQYF+X+TCRBJ02-05	unresolved	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCTTTAGCGGGAGAGCTTCCCACGAGCAGTACTTCGGGCCG	CASSFSGRASHEQYF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	45	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	3	5	2	5	0	8	18	-1	41	32	49	TCRBV07,TCRBV11													CASSFSGRASHEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCRTGTATSKCTGTGCCAGGGGTCGGGACAAGGTCCTGGTGGGGCTGTGACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	12	2.1213406873143826E-4		56	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	9	0	6	3	5	19	18	26	37	31	56	TCRBV07,TCRBV11,TCRBV12													X+X+TCRBJ02-03	unresolved	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGGGACTCRGCCGTGTATSTCTRYGCCAGCAGCCGGTGGTATCCGAACACCGGGGAGCTGTTTTTTGGAGAA	XASSRWYPNTGELFF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	45	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	5	8	5	0	0	7	22	-1	37	34	44	TCRBV07,TCRBV11,TCRBV17					01,02								XASSRWYPNTGELFF+X+TCRBJ02-02	unresolved	TCRBD02-01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GRGACWCRGCMMTGTATCKCTGYGCCAGCAGCTTAGGGACGGTACAAGAGACCCAGTACTTCGGGCCA	CASSLGTVQETQYF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	42	unresolved						TCRBJ02	TCRBJ02-05	01	1	1	7	2	0	4	19	-1	39	35	43	TCRBV07,TCRBV23			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGTVQETQYF+X+TCRBJ02-05	unresolved		TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCMTGTATCTCTGTGCCAGCAGCCAAGGCGGGCAGTCCTACGAGCAGTACTTCGGGCCG	CASSQGGQSYEQYF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	42	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	1	7	4	1	0	3	19	-1	40	35	43	TCRBV04,TCRBV11					01,02								CASSQGGQSYEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGGGGACTCRGCYGTGTATSTCTGTGCCAGCAGCTTGGATGCTAATAGGGACTATGGCTACACCTTCGGTTCG	CASSLDANRDYGYTF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	45	unresolved						TCRBJ01	TCRBJ01-02	01	3	5	3	3	10	0	22	36	-1	46	50	TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLDANRDYGYTF+X+TCRBJ01-02	unresolved		TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGGRGACWYGGCWSTGTATCTCTGYGCCAGCGCCGACAGGGGCTTAGTTGTAAACCCTTACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	12	2.1213406873143826E-4		52	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	8	2	2	5	3	17	22	31	42	34	59	TCRBV07,TCRBV23													X+X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACYSRGGGACTCAGCTKTGTATTTYTGTGCCAGCAGTACCCACACAGGGATCGGGCCCTACGAGCAGTACTTCGGGCCG	CASSTHTGIGPYEQYF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	3	3	2	6	7	26	38	50	44	57	TCRBV09,TCRBV12													CASSTHTGIGPYEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTGAAGGGACAGGCTACGAGCAGTACTTCGGGCCG	CASSEGTGYEQYF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	39	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	0	4	3	3	0	26	38	-1	41	49		TCRBV12-03,TCRBV12-04												CASSEGTGYEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTGGCACCGGGCCCTGGAAAGGGGAGACCCAGTACTTCGGGCCA	CASSGTGPWKGETQYF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	48	TCRBV12						TCRBJ02	TCRBJ02-05	01	5	5	3	5	17	0	26	38	-1	55	59		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSGTGPWKGETQYF+TCRBV12-X+TCRBJ02-05	TCRBV12		TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTCCCAGACATCTGTGTACTTCTGTGCCAGCAGAAGAGGACAGGGATCCTATGGCTACACCTTCGGTTCG	CASRRGQGSYGYTF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	42				TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	1	3	4	4	3	24	35	47	39	50	TCRBV06,TCRBV10	TCRBV06-01,TCRBV06-05,TCRBV06-06,TCRBV10-03												CASRRGQGSYGYTF+X+TCRBJ01-02		TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTCCCAGACATCTGTGTACTTCTGTGCCAGCAGTCCCCCACTAACGGGAGGGCACACCTACAAGCAGTACTTCGGGCCA	CASSPPLTGGHTYKQYF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	51				TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	5	8	0	11	10	12	24	36	54	46	66	TCRBV06,TCRBV10	TCRBV06-01,TCRBV06-05,TCRBV06-06,TCRBV10-03												CASSPPLTGGHTYKQYF+X+TCRBJ02-05		TCRBD02-01*02	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTCCCAGACATCTGTGTACTTCTGTGCCAGCAGTTCTGAGGGGGACACTGAAGCTTTCTTTGGACAA	CASSSEGDTEAFF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	39	TCRBV06			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	5	1	3	3	0	24	37	-1	40	46		TCRBV06-05,TCRBV06-06												CASSSEGDTEAFF+TCRBV06-X+TCRBJ01-01	TCRBV06	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCGTACTATGGCTACACCTTCGGTTCG	CASSPYYGYTF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	33	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	4	8	6	3	0	1	26	-1	41	39	42		TCRBV03-01,TCRBV03-02				01,02								CASSPYYGYTF+TCRBV03-X+TCRBJ01-02	TCRBV03	TCRBD02-01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGGGGGGGATTAAGGGGCACAGATACGCAGTATTTTGGCCCA	CASRGGLRGTDTQYF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	45	TCRBV03			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	6	9	1	1	0	8	26	-1	43	37	51		TCRBV03-01,TCRBV03-02												CASRGGLRGTDTQYF+TCRBV03-X+TCRBJ02-03	TCRBV03	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTACAACGGGTAGCGGGGCCCTATAATTCACCCCTCCACTTTGGGAAC		Out	VDJ	1	13	2.2981190779239146E-4		49	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-06	01	4	5	3	2	7	1	26	36	51	43	52		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ01-06	TCRBV20	TCRBD02-01*01	TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGACCGTAGGGCTGGCAATCAGCCCCAGCATTTTGGTGAT	CSARDRRAGNQPQHF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	45	TCRBV20						TCRBJ01	TCRBJ01-05	01	0	5	3	2	4	3	26	40	48	44	51		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARDRRAGNQPQHF+TCRBV20-X+TCRBJ01-05	TCRBV20		TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATCAGGTCGGGAATGGCTACACCTTCGGTTCG	CSARDQVGNGYTF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	39	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	0	8	3	6	6	0	26	40	-1	46	51		TCRBV20-01,TCRBV20-or09_02												CSARDQVGNGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD02-01*02	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGCGACAGCTACATACGAGCAGTACTTCGGGCCG	CSARATATYEQYF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	2	5	4	1	5	26	39	45	40	50		TCRBV20-01,TCRBV20-or09_02												CSARATATYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTCGGCAGAAGAACATTGAAGCTTTCTTTGGACAA	CSASRQKNIEAFF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	39	TCRBV20						TCRBJ01	TCRBJ01-01	01	3	3	6	7	11	1	26	37	51	48	52		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSASRQKNIEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGRAGACWCRGCMCTGTATCTCTGCGCCAGCAGCCAAGATGGGGCAGGGGGCGTGAAAAACACCATATATTTTGGAGAG	CASSQDGAGGVKNTIYF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	51	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	0	4	0	6	5	5	23	40	53	45	58	TCRBV04,TCRBV23													CASSQDGAGGVKNTIYF+X+TCRBJ01-03	unresolved	TCRBD01-01*01	TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCAGTTCGTCTAGCGGGAGGAGTAGGGAGCAGTTCTTCGGGCCA	CASSSSSGRSREQFF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	45	TCRBV12			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	4	4	1	10	3	6	22	35	49	38	55		TCRBV12-03,TCRBV12-04												CASSSSSGRSREQFF+TCRBV12-X+TCRBJ02-01	TCRBV12	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGCCCCGGGGGGGGGCCGAGCACAGATACGCAGTATTTTGGCCCA	CATSPGGGPSTDTQYF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	48	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	7	8	0	0	3	5	24	35	46	38	51		TCRBV24-01,TCRBV24-or09_02												CATSPGGGPSTDTQYF+TCRBV24-X+TCRBJ02-03	TCRBV24	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCCCATTTTATTTCCCCAACACTGAAGCTTTCTTTGGACAA	CASPFYFPNTEAFF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	42	TCRBV24						TCRBJ01	TCRBJ01-01	01	11	4	6	2	3	12	24	31	36	34	48		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASPFYFPNTEAFF+TCRBV24-X+TCRBJ01-01	TCRBV24		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGAAGGGCAAAAAAGTCGTCCGGTTCCAGACCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	13	2.2981190779239146E-4		53							TCRBJ02	TCRBJ02-07	01	5	4	5	2	21	1	18	29	53	50	54	TCRBV05,TCRBV11,TCRBV12	TCRBV05-03,TCRBV11-03,TCRBV12-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+X+TCRBJ02-07			TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCCCTCCTAGCGGGGATCGACCAATCCTACGAGCAGTACTTCGGGCCG	CASSLALLAGIDQSYEQYF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	57				TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	0	4	3	1	4	9	18	35	48	39	57	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03												CASSLALLAGIDQSYEQYF+X+TCRBJ02-07		TCRBD02-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTCTATCTCTGTGCCAGCAGCCTGGACAGGGATTCTGGAAACACCATATATTTTGGAGAG	CASSLDRDSGNTIYF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	45	TCRBV05			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	0	3	3	1	0	2	19	-1	41	35	43		TCRBV05-06,TCRBV05-07												CASSLDRDSGNTIYF+TCRBV05-X+TCRBJ01-03	TCRBV05	TCRBD01-01*01	TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGCGTAGCCCCTACTAGGCACGAGCAGTACTTCGGGCCG	CASSVAPTRHEQYF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	42	TCRBV12			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	6	3	8	5	10	2	26	37	52	47	54		TCRBV12-03,TCRBV12-04,TCRBV12-05				01,02								CASSVAPTRHEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTCGTCCCACGGACGGGTAAATCTGAAGCTTTCTTTGGACAA	CASSFVPRTGKSEAFF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	48	TCRBV12						TCRBJ01	TCRBJ01-01	01	3	1	7	6	8	8	26	40	52	48	60		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSFVPRTGKSEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCACAAAGCGGCTAGCGGATTCCTACAATGAGCAGTTCTTCGGGCCA	CASTKRLADSYNEQFF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	48	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	7	4	5	1	8	2	24	34	49	42	51	TCRBV06,TCRBV10					01,02								CASTKRLADSYNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAGGCCACGCGGGACAGGGCTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	14	2.474897468533447E-4		50	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	0	3	0	8	0	26	40	-1	48	57		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCAATCGGGACTAGCGGGATTCTTGGTGGGGCCAACGTCCTGACTTTCGGGGCC	CSAIGTSGILGGANVLTF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	54	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-06	01	6	0	3	3	4	7	26	34	51	38	58		TCRBV20-01,TCRBV20-or09_02												CSAIGTSGILGGANVLTF+TCRBV20-X+TCRBJ02-06	TCRBV20	TCRBD02-01*02	TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCTATGACGGGACCCGCATCTTTCAAGAGACCCAGTACTTCGGGCCA	CSAYDGTRIFQETQYF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	48	TCRBV20						TCRBJ02	TCRBJ02-05	01	6	0	7	2	7	10	26	34	46	41	56		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAYDGTRIFQETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20		TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGAGAACAGGGGGAACACTGAAGCTTTCTTTGGACAA	CSARENRGNTEAFF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	3	2	1	2	0	26	40	-1	42	49		TCRBV20-01,TCRBV20-or09_02												CSARENRGNTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATCGAGGAGGATATGGCTACACCTTCGGTTCG	CSARDRGGYGYTF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	39	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	0	10	1	5	4	1	26	40	49	44	50		TCRBV20-01,TCRBV20-or09_02												CSARDRGGYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD02-01*02	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTTCTGGGAACACAGCCGGGGAGCTGTTTTTTGGAGAA	CSASSGNTAGELFF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	42	TCRBV20						TCRBJ02	TCRBJ02-02	01	3	0	8	6	4	6	26	37	45	41	51		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSASSGNTAGELFF+TCRBV20-X+TCRBJ02-02	TCRBV20		TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGGGACTCRGCYGTGTAYKTCTGTGCCAGCAGCTTAGGCGGCCAGGTGAACACTGAAGCTTTCTTTGGACAA	CASSLGGQVNTEAFF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	45	unresolved						TCRBJ01	TCRBJ01-01	01	1	4	4	0	5	0	22	38	-1	43	47	TCRBV11,TCRBV12			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGGQVNTEAFF+X+TCRBJ01-01	unresolved		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCCGCCTCTCAGTAGGGGGTAGCGAGCAGTACTTCGGGCCG	CASRLSVGGSEQYF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	11	5	1	6	13	3	24	31	50	44	53		TCRBV24-01,TCRBV24-or09_02												CASRLSVGGSEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCCGTTATGACAGCTCCAACTATGGCTACACCTTCGGTTCG	CASRYDSSNYGYTF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	8	2	5	2	7	4	19	27	39	34	43	TCRBV07,TCRBV11													CASRYDSSNYGYTF+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCRTGTATSKCTGTGCAAGTCGCTTTGACGGTTATGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	14	2.474897468533447E-4		43	unresolved						TCRBJ01	TCRBJ01-01	01	3	2	7	0	1	5	18	32	36	33	41	TCRBV07,TCRBV12			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+X+TCRBJ01-01	unresolved		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGGAGGACTCRGCCRTGTAYKTCTGTGCCAGCAGCACGACAGGGAAGATTTTTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	14	2.474897468533447E-4		44	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	2	3	4	2	8	18	30	39	32	47	TCRBV02,TCRBV11													X+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGACWCGGCMSTGTATSTCTGYGCCAGCAGCCAAGAAATAGAACTGTCCTACGAGCAGTACTTCGGGCCG	CASSQEIELSYEQYF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	45	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	0	3	10	1	6	1	18	35	44	41	45	TCRBV04,TCRBV11,TCRBV23					01,02								CASSQEIELSYEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCCCAGACGGGGGGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSPDGGNTGELFF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	45	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	5	8	2	1	5	0	18	30	-1	35	41	TCRBV07,TCRBV11													CASSPDGGNTGELFF+X+TCRBJ02-02	unresolved	TCRBD02-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCCCATTACAGGGGGCGGGGAATGAGCAGTTCTTCGGGCCA	CASSPLQGAGNEQFF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	3	0	7	5	4	18	30	44	35	48	TCRBV05,TCRBV11													CASSPLQGAGNEQFF+X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTCCCAGTGGGGGGCAGCGGGTCGGAGCTCCTACAATGAGCAGTTCTTCGGGCCA	CASSSQWGAAGRSSYNEQFF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	60	unresolved						TCRBJ02	TCRBJ02-01	01	4	6	0	0	7	12	18	31	44	38	56	TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSQWGAAGRSSYNEQFF+X+TCRBJ02-01	unresolved		TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTAGGAAGGGGGTTTCCCTACGAGCAGTACTTCGGGCCG	CASSLGRGFPYEQYF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	5	1	2	2	4	18	34	42	36	46	TCRBV07,TCRBV11													CASSLGRGFPYEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATSTCTGTGCCAGCAGCTTCCGGACTAGCGAAACCGGGGAGCTGTTTTTTGGAGAA	CASSFRTSETGELFF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	45	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	3	1	6	5	2	2	18	32	43	34	45	TCRBV07,TCRBV11					01,02								CASSFRTSETGELFF+X+TCRBJ02-02	unresolved	TCRBD02-01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGACWCGGCMSTGTATCTCTGYGCCAGCAGCCTACCGGGTCCATGGGGCTACACCTTCGGTTCG	CASSLPGPWGYTF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	39	unresolved			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	6	8	4	8	5	7	20	31	40	36	47	TCRBV07,TCRBV23					01,02								CASSLPGPWGYTF+X+TCRBJ01-02	unresolved	TCRBD02-01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
SGACTCGGCYRTGTATCTCTGTGCCAGCAGCCGTGGGACAGCGAACACTGAAGCTTTCTTTGGACAA	CASSRGTANTEAFF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	0	5	1	3	1	19	31	41	34	42	TCRBV07,TCRBV11													CASSRGTANTEAFF+X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCRGCCATGTATCKCTGTGCCAGCAGCTTGGCAGGGGCGGGTTTAACTAATGAAAAACTGTTTTTTGGCAGT	CASSLAGAGLTNEKLFF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	51	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	3	4	2	1	2	7	19	33	41	35	48	TCRBV07,TCRBV11													CASSLAGAGLTNEKLFF+X+TCRBJ01-04	unresolved	TCRBD01-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCMTSTATCTCTGTGCCAGCAGCCAACCGTGGGCCACCGGGGAGCTGTTTTTTGGAGAA	CASSQPWATGELFF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	4	8	0	4	7	0	19	31	-1	38	42	TCRBV05,TCRBV11													CASSQPWATGELFF+X+TCRBJ02-02	unresolved	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGGGGACTCRGCYGTGTATSTCTGTGCCAGCAGCGCAGGGACAGGGGGCCACTACGAGCAGTACTTCGGGCCG	CASSAGTGGHYEQYF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	0	0	3	3	2	22	34	49	37	51	TCRBV07,TCRBV11													CASSAGTGGHYEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ARRRRGACTCAGCYGYGTATCTCTRCGCCAGCAGCCAAGGATTTTCGGGCACTGAAGCTTTCTTTGGACAA	XASSQGFSGTEAFF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	42	unresolved			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	1	8	4	4	6	0	23	39	-1	45	49	TCRBV01,TCRBV04					01,02								XASSQGFSGTEAFF+X+TCRBJ01-01	unresolved	TCRBD02-01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCACCAACCAGACATCTRTGTAYCTCTRTGCCAGCAGTTTAGCCCGATCGGGTGGAAACACCATATATTTTGGAGAG	XASSLARSGGNTIYF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	45	unresolved			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-03	01	4	5	7	3	0	9	27	-1	44	40	53	TCRBV26,TCRBV28					01,02								XASSLARSGGNTIYF+X+TCRBJ01-03	unresolved	TCRBD02-01	TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCGTCACAAGGGTTGACTGAAGCTTTCTTTGGACAA	CASSPSQGLTEAFF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	42	TCRBV03						TCRBJ01	TCRBJ01-01	01	4	5	3	5	7	3	26	39	50	46	53		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPSQGLTEAFF+TCRBV03-X+TCRBJ01-01	TCRBV03		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCTCCAACAGGGGAGATACGCAGTATTTTGGCCCA	CASSSNRGDTQYF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	39	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	3	2	5	4	0	26	38	-1	42	49		TCRBV03-01,TCRBV03-02												CASSSNRGDTQYF+TCRBV03-X+TCRBJ02-03	TCRBV03	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCTCCTATAGCGGGTGGAACACAGATACGCAGTATTTTGGCCCA	CASSSYSGWNTDTQYF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	48	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	5	5	4	2	5	5	26	38	50	43	55		TCRBV03-01,TCRBV03-02				01,02								CASSSYSGWNTDTQYF+TCRBV03-X+TCRBJ02-03	TCRBV03	TCRBD02-01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGGACTCSGCCGTGTATSTCTGTGCCAGCAGCTTGCTAGCGGGGGGCCTTAGCTCCTACAATGAGCAGTTCTTCGGGCCA	CASSLLAGGLSSYNEQFF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	54	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	3	4	1	0	1	6	20	34	46	35	52	TCRBV07,TCRBV11													CASSLLAGGLSSYNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCACCGGGACAGGGCCCTACGAGCAGTACTTCGGGCCG	CSATGTGPYEQYF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	0	3	2	4	1	26	34	47	38	48		TCRBV20-01,TCRBV20-or09_02												CSATGTGPYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCAGTTGGGGGGTCTACATGAACACTGAAGCTTTCTTTGGACAA	CSASWGVYMNTEAFF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	45	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	6	9	1	0	5	6	26	34	45	39	51		TCRBV20-01,TCRBV20-or09_02												CSASWGVYMNTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD02-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGCTCCAAACTTGTGGCTACACCTTCGGTTCG		Out	VDJ	1	15	2.6516758591429784E-4		35	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	3	3	10	7	6	2	26	37	46	43	48		TCRBV20-01,TCRBV20-or09_02				01,02								X+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD02-01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTTTGGGACTAGCGGGGCTCCAAGAGACCCAGTACTTCGGGCCA	CSALGLAGLQETQYF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	45	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	5	0	3	1	2	2	26	35	50	37	52		TCRBV20-01,TCRBV20-or09_02												CSALGLAGLQETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGTCATACCCGGGCCTCTCAATCAGCCCCAGCATTTTGGTGAT	CSVIPGPLNQPQHF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	42	TCRBV20						TCRBJ01	TCRBJ01-05	01	7	8	0	3	8	4	26	33	45	41	49		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSVIPGPLNQPQHF+TCRBV20-X+TCRBJ01-05	TCRBV20		TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGTTACCCCCTGGGACAGAACCTACGAGCAGTACTTCGGGCCG	CSVTPWDRTYEQYF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	7	0	5	2	9	2	26	33	49	42	51		TCRBV20-01,TCRBV20-or09_02												CSVTPWDRTYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCAGGGACGGTACCCTAGGCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASRDGTLGSGANVLTF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	51	TCRBV12						TCRBJ02	TCRBJ02-06	01	6	1	7	0	0	11	22	-1	37	33	48		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRDGTLGSGANVLTF+TCRBV12-X+TCRBJ02-06	TCRBV12		TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGCCCCCATGAGGGGCGGTATGGCTACACCTTTGGTTCG	CASSPHEGRYGYTF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	42	unresolved						TCRBJ01	TCRBJ01-02	01	7	5	2	20	8	18	24	35	48	43	66	TCRBV24,TCRBV27			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPHEGRYGYTF+X+TCRBJ01-02	unresolved		TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTAACCGTCCGGGACAGGGAGTCGTCTATGGCTACACCTTCGGTTCG	CASSNRPGQGVVYGYTF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	51	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	0	3	4	8	6	24	36	53	44	59		TCRBV24-01,TCRBV24-or09_02												CASSNRPGQGVVYGYTF+TCRBV24-X+TCRBJ01-02	TCRBV24	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTGGGGGACTAGCGGGAGATACGCAGTATTTTGGCCCA	CASSGGLAGDTQYF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	42	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	5	0	4	5	1	0	24	37	-1	38	50		TCRBV24-01,TCRBV24-or09_02				01,02								CASSGGLAGDTQYF+TCRBV24-X+TCRBJ02-03	TCRBV24	TCRBD02-01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTCCGGGGTAGCGGGGTCTGGGGGGCCAACGTCCTGACTTTCGGGGCC	CASSFRGSGVWGANVLTF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	54	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-06	01	6	5	3	4	8	5	24	36	52	44	57		TCRBV24-01,TCRBV24-or09_02												CASSFRGSGVWGANVLTF+TCRBV24-X+TCRBJ02-06	TCRBV24	TCRBD02-01*01	TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCGACTCCCACGGCGGGGCAACCGGGGAGCTGTTTTTTGGAGAA	CASDSHGGATGELFF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	45	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	8	7	3	5	10	2	23	32	48	42	50	TCRBV06,TCRBV10													CASDSHGGATGELFF+X+TCRBJ02-02	unresolved	TCRBD02-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCKGCYRTGTATYKCTGTGCCAGCAGCTCCTCGGGGGGTGCTGGAAACACCATATATTTTGGAGAG	CASSSSGGAGNTIYF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	45	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-03	01	4	8	1	2	3	2	18	31	41	34	43	TCRBV03,TCRBV07													CASSSSGGAGNTIYF+X+TCRBJ01-03	unresolved	TCRBD02-01*01	TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGGGACTCAGCCGTGTATCTCTACGCCAGCAGCCCCGAGGGGTCCTACGAGCAGTACTTCGGGCCG	YASSPEGSYEQYF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	39							TCRBJ02	TCRBJ02-07	01	5	5	2	1	4	0	22	34	-1	38	43	TCRBV07,TCRBV17	TCRBV07-03,TCRBV17-01		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									YASSPEGSYEQYF+X+TCRBJ02-07			TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGGGACTCAGCYSTGTACTTCTGTGCCAGTTACCGGGTCCCAAACACCGGGGAGCTGTTTTTTGGAGAA	CASYRVPNTGELFF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	42	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	9	8	4	2	4	5	20	28	36	32	41	TCRBV12,TCRBV13					01,02								CASYRVPNTGELFF+X+TCRBJ02-02	unresolved	TCRBD02-01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCGGCCGTGTATGTCTGTGCCAGCAGCTTAGATTGTCGGGCGGACTAGCGGGCCAAAGTTAGCACAGATACGCAGTATTTTGGCCCA	CASSLDCRAD*RAKVSTDTQYF	Stop	VDJ	1	15	2.6516758591429784E-4		66	TCRBV11			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	0	1	4	0	9	8	15	32	52	41	60		TCRBV11-02,TCRBV11-03				01,02								CASSLDCRAD*RAKVSTDTQYF+TCRBV11-X+TCRBJ02-03	TCRBV11	TCRBD02-01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGCCCCGGGACAGTGTTGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSPGTVLNTGELFF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	48	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	6	0	5	1	4	4	26	37	48	41	52		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASSPGTVLNTGELFF+TCRBV12-X+TCRBJ02-02	TCRBV12	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGCGTAACGGCTAGCGGGGGGCCCACAGATACGCAGTATTTTGGCCCA	CASSVTASGGPTDTQYF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	51	TCRBV12			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	6	4	1	2	8	2	26	37	56	45	58		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASSVTASGGPTDTQYF+TCRBV12-X+TCRBJ02-03	TCRBV12	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACYSRGGGACTCAGCTKTGTATTTYTGTGCCAGCAGCTCAATAGGGACATATGGAAACACCATATATTTTGGAGAG	CASSSIGTYGNTIYF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	6	0	6	3	7	2	26	37	50	44	52	TCRBV09,TCRBV12													CASSSIGTYGNTIYF+X+TCRBJ01-03	unresolved	TCRBD01-01*01	TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGGGGGACAGTGAACACTGAAGCTTTCTTTGGACAA	CASRGTVNTEAFF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	39	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	0	5	0	1	0	26	37	-1	38	45		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASRGTVNTEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTCCCCGATAGCGGGAGACTTATGGAATGAGCAGTTCTTCGGGCCA	CASSSPIAGDLWNEQFF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	51	TCRBV12			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	4	5	2	7	6	8	26	39	54	45	62		TCRBV12-03,TCRBV12-04												CASSSPIAGDLWNEQFF+TCRBV12-X+TCRBJ02-01	TCRBV12	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTATGGGCGACAGGGGTTAGTGAGCTTTCTTTGGACAA		Out	VDJ	1	16	2.82845424975251E-4		44	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	2	2	10	5	6	26	41	54	46	60		TCRBV12-03,TCRBV12-04												X+TCRBV12-X+TCRBJ01-01	TCRBV12	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTCACTCGCGGGGTAGGCAACGAGCAGTACTTCGGGCCG	CASSFTRGVGNEQYF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	45	TCRBV12			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	3	7	3	5	5	6	26	40	51	45	57		TCRBV12-03,TCRBV12-04												CASSFTRGVGNEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12	TCRBD02-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AAYCMRGRGACWCAGCWSKGTATTTYTGTGCCAGCAGTTTGATTCATTGGGGGGGGACCTACGAGCAGTACTTCGGGCCG	CASSLIHWGGTYEQYF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	48	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	3	9	0	2	8	2	26	40	55	48	57	TCRBV12,TCRBV21													CASSLIHWGGTYEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGAACCGACAGGCGAAATAATTCACCCCTCCACTTTGGGAAC		Out	VDJ	1	16	2.82845424975251E-4		50	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	0	2	4	5	3	4	26	43	52	46	56		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ01-06	TCRBV03	TCRBD01-01*01	TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAATAGCCTCGGAGGACCTACAATGAGCAGTTCTTCGGGCCA	CASSQ*PRRTYNEQFF	Stop	VDJ	1	16	2.82845424975251E-4		48	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	2	10	1	2	7	1	26	41	53	48	54		TCRBV03-01,TCRBV03-02												CASSQ*PRRTYNEQFF+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCAGATATGGCCGGAGTCAGCCCCAGCATTTTGGTGAT	CASRYGRSQPQHF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	39	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-05	01	6	10	2	6	8	0	22	33	-1	41	45	TCRBV02,TCRBV12													CASRYGRSQPQHF+X+TCRBJ01-05	unresolved	TCRBD02-01*02	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCAGTGAAGGGAAGGTGGCCCCGGGCGAGCAGTACTTCGGGCCG	CASSEGKVAPGEQYF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	45	TCRBV12						TCRBJ02	TCRBJ02-07	01	5	0	8	6	3	13	22	34	41	37	54		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSEGKVAPGEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCACCAGTGATTTGCCGTTCAAGTCATGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	16	2.82845424975251E-4		50	unresolved						TCRBJ01	TCRBJ01-01	01	0	4	6	0	5	5	23	41	48	46	53	TCRBV24,TCRBV27			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+X+TCRBJ01-01	unresolved		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGAGGGCCGGGACCTCACAGATACGCAGTATTTTGGCCCA	CATSEGRDLTDTQYF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	45	TCRBV24						TCRBJ02	TCRBJ02-03	01	4	0	7	2	5	2	24	38	48	43	50		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CATSEGRDLTDTQYF+TCRBV24-X+TCRBJ02-03	TCRBV24		TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTCCCTACAGGGGGTCGACGAGCAGTACTTCGGGCCG	CASSSLQGVDEQYF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	3	1	5	5	3	24	36	49	41	52		TCRBV24-01,TCRBV24-or09_02												CASSSLQGVDEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTATAGGGCCGCGGGAGCACCGGGGAGCTGTTTTTTGGAGAA	CASSL*GRGSTGELFF	Stop	VDJ	1	16	2.82845424975251E-4		48	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	6	7	2	4	10	0	24	36	-1	46	53		TCRBV24-01,TCRBV24-or09_02												CASSL*GRGSTGELFF+TCRBV24-X+TCRBJ02-02	TCRBV24	TCRBD02-01*02	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAAGACTCGGCCSTGTATSTCTGTGCCAGCAGCTCAGGGAAGTAGGGACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	16	2.82845424975251E-4		41	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	4	3	5	1	8	21	33	39	34	47	TCRBV04,TCRBV11													X+X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCCCCCGGACTAGTGGGAGCGGTGAGACCCAGTACTTCGGGCCA	CASSPRTSGSGETQYF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	48	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	5	1	8	5	4	10	18	30	41	34	51	TCRBV07,TCRBV11					01,02								CASSPRTSGSGETQYF+X+TCRBJ02-05	unresolved	TCRBD02-01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGACWCGGCMSTGTATSTCTGYGCCAGCAGCTTAGCGGGTGGACAGTTTAACTATGGCTACACCTTCGGTTCG	CASSLAGGQFNYGYTF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	48	unresolved			unresolved			TCRBJ01	TCRBJ01-02	01	6	5	4	1	2	9	20	31	40	33	49	TCRBV07,TCRBV11,TCRBV23			TCRBD01,TCRBD02										CASSLAGGQFNYGYTF+X+TCRBJ01-02	unresolved	unresolved	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
SGACTCGGCYRTGTATCTCTGTGCCAGCAGCCCACGGCGCCTTGGAGATACGCAGTATTTTGGCCCA	CASSPRRLGDTQYF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	42	unresolved						TCRBJ02	TCRBJ02-03	01	5	9	0	5	4	7	19	31	38	35	45	TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPRRLGDTQYF+X+TCRBJ02-03	unresolved		TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCRGCCMTSTATCKCTGTGCCAGCATGGGAACAAAAACGCCTGAGTGAAAGACCTATGGCTACACCTTCGGTTCG	CASMGTKTPE*KTYGYTF	Stop	VDJ	1	16	2.82845424975251E-4		54	unresolved						TCRBJ01	TCRBJ01-02	01	6	0	8	4	1	23	19	29	34	30	57	TCRBV05,TCRBV07			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASMGTKTPE*KTYGYTF+X+TCRBJ01-02	unresolved		TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGGGGACTYRGCYSTGTAYYTCTGTGCCAGCACGAGGCAGCGCACAGATACGCAGTATTTTGGCCCA	CASTRQRTDTQYF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	39	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	7	11	1	1	1	4	22	32	37	33	41	TCRBV07,TCRBV13													CASTRQRTDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01*02	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TYRGGRGACWCAGCWYKGTATTTCTGTGCCAGCAGTGGAATAAATGAAAAACTGTTTTTTGGCAGT	CASSGINEKLFF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	36	unresolved						TCRBJ01	TCRBJ01-04	01	5	1	8	5	1	3	23	34	38	35	41	TCRBV09,TCRBV21			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSGINEKLFF+X+TCRBJ01-04	unresolved		TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTCCCAGACATCTGTGTACTTCTGTGCCAGCAGTGACGTTATCTAGCGGGGCCGGGGAGTTCTTCGGGCCA		Out	VDJ	1	17	3.005232640362042E-4		43				TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	3	4	3	14	6	6	24	38	53	44	59	TCRBV06,TCRBV10	TCRBV06-01,TCRBV10-03												X+X+TCRBJ02-01		TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAATTTGAGGCGGGCCACAATCTCTAAAGCAGATACGCAGTATTTTGGCCCA	CASNLRRATISKADTQYF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	54	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	7	7	4	4	7	15	26	36	48	43	63		TCRBV03-01,TCRBV03-02				01,02								CASNLRRATISKADTQYF+TCRBV03-X+TCRBJ02-03	TCRBV03	TCRBD02-01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGTTTCACTAGCGGGCGGCAATGAGCAGTTCTTCGGGCCA	CASSQVSLAGGNEQFF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	48	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	1	3	4	6	4	3	26	42	55	46	58		TCRBV03-01,TCRBV03-02				01,02								CASSQVSLAGGNEQFF+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCACCCGATCAGGGAGCTACTGGAAACACCATATATTTTGGAGAG	CSAPDQGATGNTIYF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	45	TCRBV20						TCRBJ01	TCRBJ01-03	01	6	4	3	2	7	5	26	34	46	41	51		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAPDQGATGNTIYF+TCRBV20-X+TCRBJ01-03	TCRBV20		TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCAGGACAGGGCATCCTACGAGCAGTACTTCGGGCCG	CSAQDRASYEQYF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	1	3	1	3	2	26	34	45	37	47		TCRBV20-01,TCRBV20-or09_02												CSAQDRASYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCGGGCAGGACTCTGTGGGGGATTTCGAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	17	3.005232640362042E-4		55	TCRBV20						TCRBJ02	TCRBJ02-02	01	6	6	1	0	15	4	26	34	54	49	58		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV20-X+TCRBJ02-02	TCRBV20		TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTACCCGGGACAGGGGGCCGGAAGGCTACACCTTCGGTTCG	CSATRDRGPEGYTF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	0	0	8	3	5	26	36	51	39	56		TCRBV20-01,TCRBV20-or09_02												CSATRDRGPEGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCACGGCCAGGAGACTAACACTGAAGCTTTCTTTGGACAA	CSAHGQETNTEAFF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	42	TCRBV20						TCRBJ01	TCRBJ01-01	01	5	4	4	2	6	5	26	35	45	41	50		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAHGQETNTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCARCCARACAKCTWTGTACYTCTGTGCCAGCAGTGTAACCGGGACTAGCCATGAGCAGTTCTTCGGGCCA	CASSVTGTSHEQFF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	42	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	13	0	7	8	15	1	25	28	52	43	53	TCRBV22,TCRBV28					01,02								CASSVTGTSHEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGGGACTCRGCYGTGTAYKTCTGTGCCAGCAGTCTCCGGGACATAAGCATTTATGGCTACACCTTCGGTTCG	CASSLRDISIYGYTF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	0	6	5	4	8	22	34	44	38	52	TCRBV11,TCRBV12													CASSLRDISIYGYTF+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTCGAGACTCGCCTCCAGTACTTCGGGCCG	CATSDFETRLQYF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	39	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	1	2	10	10	3	6	24	41	48	44	54		TCRBV24-01,TCRBV24-or09_02				01,02								CATSDFETRLQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTCGGCCGGGGAGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	17	3.005232640362042E-4		43	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-05	01	6	8	3	1	5	0	24	36	-1	41	46		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ01-05	TCRBV24	TCRBD02-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTAGGTACCGACATGAATGAGCAGTTCTTCGGGCCA	CASSLGTDMNEQFF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	2	6	7	9	2	24	36	49	45	51		TCRBV24-01,TCRBV24-or09_02												CASSLGTDMNEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTTGGGACAGGCACAGATACGCAGTATTTTGGCCCA	CASSFGTGTDTQYF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	6	0	5	1	3	0	24	36	-1	39	46		TCRBV24-01,TCRBV24-or09_02												CASSFGTGTDTQYF+TCRBV24-X+TCRBJ02-03	TCRBV24	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGTCAGCAGTTTTCGACAGGGTATGAATTCACCCCTCCACTTTGGGAAC	CVSSFRQGMNSPLHF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	45	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	6	2	3	7	4	4	24	36	47	40	51		TCRBV24-01,TCRBV24-or09_02												CVSSFRQGMNSPLHF+TCRBV24-X+TCRBJ01-06	TCRBV24	TCRBD01-01*01	TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATCTCTGTGCCAGCAGCTTGGGGACAGACTTTAGCACAGATACGCAGTATTTTGGCCCA	CASSLGTDFSTDTQYF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	48				TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	0	1	5	0	0	5	18	-1	40	34	45	TCRBV05,TCRBV07	TCRBV05-08,TCRBV07-02												CASSLGTDFSTDTQYF+X+TCRBJ02-03		TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ARRRRGACTCAGCYGYGTATCTCTRCGCCAGCAGCCAAGTGGGGAGCTCCTACAATGAGCAGTTCTTCGGGCCA	XASSQVGSSYNEQFF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	45	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	1	9	2	0	2	0	22	38	-1	40	45	TCRBV01,TCRBV04													XASSQVGSSYNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTCTATCTCTGTGCCAGCAGCTTGCACAGCGGGGGGGTCGATGAGCAGTTCTTCGGGCCA	CASSLHSGGVDEQFF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	45	TCRBV05			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	1	6	0	8	3	3	19	34	47	37	50		TCRBV05-06,TCRBV05-07												CASSLHSGGVDEQFF+TCRBV05-X+TCRBJ02-01	TCRBV05	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGCCCCGCCTCCTACGAGCAGTACTTCGGGCCG	CASSPASYEQYF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	36	TCRBV12						TCRBJ02	TCRBJ02-07	01	6	10	0	0	4	0	26	37	-1	41	43		TCRBV12-03,TCRBV12-04,TCRBV12-05		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPASYEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTCCTCAAGTGGGGCGGGCCTACGAGCAGTACTTCGGGCCG	CASSPQVGRAYEQYF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	45	TCRBV12						TCRBJ02	TCRBJ02-07	01	5	7	0	2	8	3	26	38	51	46	54		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPQVGRAYEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGTTTAAGGGACAGGGATATGGCTACACCTTCGGTTCG		Out	VDJ	1	18	3.182011030971574E-4		41	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	0	3	5	1	1	26	41	51	42	52		TCRBV12-03,TCRBV12-04												X+TCRBV12-X+TCRBJ01-02	TCRBV12	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTAGAGGCCAGTCGTACGGATTCACCCCTCCACTTTGGGAAC	CASSLEASRTDSPLHF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	48	TCRBV12						TCRBJ01	TCRBJ01-06	01	1	4	5	8	4	8	26	42	49	46	57		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLEASRTDSPLHF+TCRBV12-X+TCRBJ01-06	TCRBV12		TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTCGCAGGGTGGGGTGGCTACACCTTCGGTTCG	CASSFAGWGGYTF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	39	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	4	3	7	2	5	26	40	47	42	52		TCRBV12-03,TCRBV12-04												CASSFAGWGGYTF+TCRBV12-X+TCRBJ01-02	TCRBV12	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCAGGGTGACTAGCGGGGTACTCTCTGGGGCCAATGTCCTGACTTTCGGGGCC	CASRVTSGVLSGANVLTF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	54	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-06	01	6	2	3	13	3	17	24	35	49	38	66	TCRBV06,TCRBV10													CASRVTSGVLSGANVLTF+X+TCRBJ02-06	unresolved	TCRBD02-01*01	TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGACGGAAACTATAATTCACCCCTCCACTTTGGGAAC	CASSQDGNYNSPLHF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	45	TCRBV03						TCRBJ01	TCRBJ01-06	01	0	1	8	3	1	2	26	43	47	44	49		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQDGNYNSPLHF+TCRBV03-X+TCRBJ01-06	TCRBV03		TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCGGACTTGGCATCATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	18	3.182011030971574E-4		41	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	5	1	10	5	0	7	26	-1	43	38	50		TCRBV03-01,TCRBV03-02				01,02								X+TCRBV03-X+TCRBJ01-05	TCRBV03	TCRBD02-01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCGGCGGACATCGGGAGACCCAGTACTTCGGGCCA	CSAGGHRETQYF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	36	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	6	1	6	5	4	4	26	34	43	38	47		TCRBV20-01,TCRBV20-or09_02												CSAGGHRETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGGGGTTCACAGGGGGTTGAACACCGGGGAGCTGTTTTTTGGAGAA	CSARGVHRGLNTGELFF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	51	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	1	3	1	1	6	2	26	39	53	45	55		TCRBV20-01,TCRBV20-or09_02												CSARGVHRGLNTGELFF+TCRBV20-X+TCRBJ02-02	TCRBV20	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCTGACATCTGGCTATGGCTACACCTTCGGTTCG	CSALTSGYGYTF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	36	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	2	6	4	2	5	26	35	41	37	46		TCRBV20-01,TCRBV20-or09_02												CSALTSGYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCWMCCAGACATCTRTGTACYTSTGTGCCAGCAGTTACCCCGGACAGGGGATGACCGGGGAGCTGTTTTTTGGAGAA	CASSYPGQGMTGELFF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	4	1	2	5	5	3	25	38	52	43	55	TCRBV06,TCRBV28													CASSYPGQGMTGELFF+X+TCRBJ02-02	unresolved	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGTTTATTCCGCAGGGGAAACACTGAAGCTTTCTTTGGACAA	CASSLFRRGNTEAFF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	4	2	2	4	1	23	39	49	43	50	TCRBV24,TCRBV27													CASSLFRRGNTEAFF+X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTACCACCAGTGATGCACAGGGGGCCTACGAGCAGTACTTCGGGCCG	CTTSDAQGAYEQYF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	3	1	2	2	0	24	39	-1	41	49		TCRBV24-01,TCRBV24-or09_02												CTTSDAQGAYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGAGATACGATAGGAGCTTGCGAGCAGTACTTCGGGCCG		Out	VDJ	1	18	3.182011030971574E-4		44	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	4	10	2	6	9	4	24	38	51	47	55		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTGCAGGGCGCGAAGGGCTACACCTTCGGTTCG	CATSDLQGAKGYTF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	4	3	8	0	7	24	-1	47	42	54		TCRBV24-01,TCRBV24-or09_02												CATSDLQGAKGYTF+TCRBV24-X+TCRBJ01-02	TCRBV24	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTATCACTAGCGTTGAAGACCCAGTACTTCGGGCCA	CASSLSLALKTQYF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	42				TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	6	3	6	6	5	4	24	36	48	41	52	TCRBV24,TCRBV27	TCRBV24-01,TCRBV24-or09_02,TCRBV27-01				01,02								CASSLSLALKTQYF+X+TCRBJ02-05		TCRBD02-01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCTTAGTTGCAGGCGGAAACACCATATATTTTGGAGAG	CASSLVAGGNTIYF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	0	4	4	4	3	1	19	35	42	38	43	TCRBV07,TCRBV11													CASSLVAGGNTIYF+X+TCRBJ01-03	unresolved	TCRBD01-01*01	TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATCTCTGTGCCAGCAGCTTGGGTGGAGGGAACAATGAGCAGTTCTTCGGGCCA	CASSLGGGNNEQFF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	42				TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	0	10	0	5	2	1	18	34	42	36	43	TCRBV05,TCRBV07	TCRBV05-08,TCRBV07-02												CASSLGGGNNEQFF+X+TCRBJ02-01		TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCCCCTCCGTGGGGGGGTTGAACACTGAAGCTTTCTTTGGACAA	CASSPSVGGLNTEAFF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	48	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	5	9	0	0	8	1	18	30	45	38	46	TCRBV07,TCRBV11													CASSPSVGGLNTEAFF+X+TCRBJ01-01	unresolved	TCRBD02-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ARRRRGACTCAGCYGYGTATCTCTRCGCCAGCAGCCAAGACAGAAACACAGATACACAGTATTTTGGCCCA	XASSQDRNTDTQYF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	0	3	5	12	7	5	22	39	50	46	55	TCRBV01,TCRBV04													XASSQDRNTDTQYF+X+TCRBJ02-03	unresolved	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCRGCCATGTATCKCTGTGCCAGCACCTCTACTTCGGACCTCCCCGAGCAGTACTTCGGGCCG	CASTSTSDLPEQYF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	42	unresolved						TCRBJ02	TCRBJ02-07	01	7	1	7	6	10	5	19	29	43	39	48	TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASTSTSDLPEQYF+X+TCRBJ02-07	unresolved		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGTACYSKMKSASWCAKCYRTGTACTTCTGTGCCAGCAGCGTAGGGGGGTGGAGGGGACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	18	3.182011030971574E-4		46	unresolved						TCRBJ01	TCRBJ01-01	01	6	5	1	3	3	9	28	39	48	42	57	TCRBV02,TCRBV06			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+X+TCRBJ01-01	unresolved		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGGCGGGACAGAAATACGAGCAGTACTTCGGGCCG		Out	VDJ	1	19	3.358789421581106E-4		38	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	0	5	4	2	3	26	37	46	39	49		TCRBV12-03,TCRBV12-04,TCRBV12-05												X+TCRBV12-X+TCRBJ02-07	TCRBV12	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTATAACGGATAGAATCCAATGGTTCACCCCTCCACTTTGGGAAC	CASSL*RIESNGSPLHF	Stop	VDJ	1	19	3.358789421581106E-4		51	TCRBV12						TCRBJ01	TCRBJ01-06	01	2	1	8	9	4	13	26	41	48	45	61		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSL*RIESNGSPLHF+TCRBV12-X+TCRBJ01-06	TCRBV12		TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTCCCAGACATCTGTGTACTTCTGTGCCAGCAGTGACTCTACAGGGATGGGGTCGAACACTGAAGCTTTCTTTGGACAA	CASSDSTGMGSNTEAFF	In	VDJ	1	19	3.358789421581106E-4	4.066084574559151E-4	51				TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	3	3	1	4	8	24	38	48	42	56	TCRBV06,TCRBV10	TCRBV06-01,TCRBV06-04,TCRBV06-05,TCRBV06-06,TCRBV10-03												CASSDSTGMGSNTEAFF+X+TCRBJ01-01		TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGTAMSCTCYCAGACATCTGTGTACTTCTGTGCCAGCAGTGATGGCGGGGGGGCTAGCACAGATACGCAGTATTTTGGCCCA	CASSDGGGASTDTQYF	In	VDJ	1	19	3.358789421581106E-4	4.066084574559151E-4	48	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	3	7	0	0	2	2	24	38	49	40	51	TCRBV06,TCRBV10													CASSDGGGASTDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CTMSCTCYCAGACWTCTGTKTACTTCTGTGCCAGCGAGCGGGACAGGAATGAGCAGTTCTTCGGGCCA	CASERDRNEQFF	In	VDJ	1	19	3.358789421581106E-4	4.066084574559151E-4	36	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	10	0	4	7	6	0	24	31	-1	37	45	TCRBV06,TCRBV10													CASERDRNEQFF+X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCACGTCCTGACCGGGACGGTTTATGGCTACACCTTCGGTTCG	CASSHVLTGTVYGYTF	In	VDJ	1	19	3.358789421581106E-4	4.066084574559151E-4	48	TCRBV03						TCRBJ01	TCRBJ01-02	01	3	0	7	5	10	4	26	40	55	50	59		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSHVLTGTVYGYTF+TCRBV03-X+TCRBJ01-02	TCRBV03		TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCATTTGGGGCTTTATGGATACTACGAGCAGTACTTCGGGCCG	CASSHLGLYGYYEQYF	In	VDJ	1	19	3.358789421581106E-4	4.066084574559151E-4	48	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	7	0	3	3	10	26	40	48	43	58		TCRBV03-01,TCRBV03-02												CASSHLGLYGYYEQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCTCCGGACAGGGGGCGCTTCTATGGCTACACCTTCGGTTCG		Out	VDJ	1	19	3.358789421581106E-4		47	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	1	0	4	3	4	26	39	53	42	57		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ01-02	TCRBV03	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTACACCCCGGACTAGCGGGAGGGGGTACGAGCAGTACTTCGGGCCG	CSASTPRTSGRGYEQYF	In	VDJ	1	19	3.358789421581106E-4	4.066084574559151E-4	51	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	3	1	0	4	8	2	26	37	60	45	62		TCRBV20-01,TCRBV20-or09_02												CSASTPRTSGRGYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCACCCCGCTCCTAGGGGGCCGGGAGTACTTCGGGCCG	CASTPLLGGREYF	In	VDJ	1	19	3.358789421581106E-4	4.066084574559151E-4	39	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	7	5	0	11	10	4	22	32	49	42	53		TCRBV12-03,TCRBV12-04												CASTPLLGGREYF+TCRBV12-X+TCRBJ02-07	TCRBV12	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTAGGGGGGAGATTACCAAGAGACCCAGTACTTCGGGCCA	CATSD*GGDYQETQYF	Stop	VDJ	1	19	3.358789421581106E-4		48	TCRBV24						TCRBJ02	TCRBJ02-05	01	2	5	1	0	0	6	24	-1	46	40	52		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CATSD*GGDYQETQYF+TCRBV24-X+TCRBJ02-05	TCRBV24		TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCAGCTTCGAGGGGGGGCTGAACACTGAAGCTTTCTTTGGACAA	CASSFEGGLNTEAFF	In	VDJ	1	19	3.358789421581106E-4	4.066084574559151E-4	45	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	6	9	0	0	6	1	23	34	47	40	48	TCRBV06,TCRBV10													CASSFEGGLNTEAFF+X+TCRBJ01-01	unresolved	TCRBD02-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TYRGRRGACWCAGCMMKGTAYTTCTGTGCCAGCAGCCTCTTAGGGGGTAGGAAAGCCCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	19	3.358789421581106E-4		49	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	5	5	1	6	5	9	24	36	47	41	56	TCRBV02,TCRBV21													X+X+TCRBJ02-02	unresolved	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AAYCMRGRGACWCAGCWSKGTATTTYTGTGCCAGCAGTCCCGGACAGGGGGCCCACGAGCAGTACTTCGGGCCG	CASSPGQGAHEQYF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	1	0	5	3	2	26	38	52	41	54	TCRBV12,TCRBV21													CASSPGQGAHEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCGTAAGCGGGCCTTTTGGCTACACCTTCGGTTCG	CASSVSGPFGYTF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	39	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	5	6	4	7	3	5	26	38	47	41	52		TCRBV03-01,TCRBV03-02				01,02								CASSVSGPFGYTF+TCRBV03-X+TCRBJ01-02	TCRBV03	TCRBD02-01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCGAGGACCCTACTTAGCACAGATACGCAGTATTTTGGCCCA	CSARTLLSTDTQYF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	42	TCRBV20						TCRBJ02	TCRBJ02-03	01	6	1	7	0	2	7	26	34	40	36	47		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARTLLSTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20		TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCGTCAATCCAAAAACATTCAGTACTTCGGCGCC		Out	VDJ	1	20	3.5355678121906376E-4		34	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	6	4	6	2	2	2	26	34	38	36	40		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-04	TCRBV20	TCRBD01-01*01	TCRBJ02-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGACTACAGGGCTGGGGCCAACGTCCTGACTTTCGGGGCC	CSARDYRAGANVLTF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	45	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	0	3	3	2	2	0	26	40	-1	42	48		TCRBV20-01,TCRBV20-or09_02												CSARDYRAGANVLTF+TCRBV20-X+TCRBJ02-06	TCRBV20	TCRBD01-01*01	TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGTTTGGGGACACGGCGAAACTATGGCTACACCTTCGGTTCG	CASSLGTRRNYGYTF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	45	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	0	6	2	1	6	22	36	43	37	49		TCRBV12-03,TCRBV12-04												CASSLGTRRNYGYTF+TCRBV12-X+TCRBJ01-02	TCRBV12	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGGGGACAGCCGAACACCGGGGAGCTGTTTTTTGGAGAA	CASRGQPNTGELFF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	7	0	5	0	0	1	24	-1	42	35	43	TCRBV24,TCRBV27													CASRGQPNTGELFF+X+TCRBJ02-02	unresolved	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCAGGCCTATGGGGCTAGCGGGAGATACGCAGTATTTTGGCCCA	CASRPMGLAGDTQYF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	45	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	6	4	4	5	10	0	23	34	-1	44	52	TCRBV06,TCRBV10					01,02								CASRPMGLAGDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGYGACTCKGCTGTGTATYTCTGTGCCAGCAGCAGCTTGAGGGGGGCCGGCGAGCAGTACTTCGGGCCG	CASSSLRGAGEQYF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	42	unresolved						TCRBJ02	TCRBJ02-07	01	4	5	1	6	6	5	19	31	43	37	48	TCRBV03,TCRBV07			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSLRGAGEQYF+X+TCRBJ02-07	unresolved		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTACTGACAATCTCGACAAAGTCGGGCCAACGTCCTGACTTTCGGGGCC	CASSY*QSRQSRANVLTF	Stop	VDJ	1	20	3.5355678121906376E-4		54	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	4	2	6	5	3	14	18	31	38	34	52	TCRBV07,TCRBV11													CASSY*QSRQSRANVLTF+X+TCRBJ02-06	unresolved	TCRBD01-01*01	TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCGGCTAAGGGAAACACCATATATTTTGGAGAG	CASSLAAKGNTIYF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	42							TCRBJ01	TCRBJ01-03	01	0	9	0	4	0	4	18	-1	38	35	42	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLAAKGNTIYF+X+TCRBJ01-03			TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCCTCTATCTCTGTGCCAGCAGCTTGGGGCCCCAGGTGTCTAATGAAAAACTGTTTTTTGGCAGT	CASSLGPQVSNEKLFF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	48	TCRBV05			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	0	4	4	3	5	3	19	35	44	40	47		TCRBV05-06,TCRBV05-07												CASSLGPQVSNEKLFF+TCRBV05-X+TCRBJ01-04	TCRBV05	TCRBD01-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TYRGGRGACWCAGCWYKGTATTTCTGTGCCAGCAGCTTAGGCCGTGGCAGGGGAAACTATGGCTACACCTTCGGTTCG	CASSLGRGRGNYGYTF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	4	2	2	11	1	24	36	53	47	54	TCRBV09,TCRBV21													CASSLGRGRGNYGYTF+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TYRGRRGACWCAGCMMKGTAYTTCTGTGCCAGCAGTGCTCGGACAGGAGACACTGAAGCTTTCTTTGGACAA	CASSARTGDTEAFF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	1	4	3	5	2	24	35	47	40	49	TCRBV02,TCRBV21													CASSARTGDTEAFF+X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCTGTGTACTTSTGTGCCACCTACCCCTGGACTAGCGGGAGGGTAACCCCCCTTAACGCGAGAACTCGTCCCTTCGGGCCA	CATYPWTSGRVTPLNARTRPF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	63	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02			10	1	0	18	9	28	12	19	43	28	71	TCRBV06,TCRBV10							TCRBJ02-01,TCRBJ02-05						CATYPWTSGRVTPLNARTRPF+X+TCRBJ02-X	unresolved	TCRBD02-01*02	TCRBJ02	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGGRGGACTCAGCYWTGTAYTTCTGTGCCAGCAGAGGGACTAGCGGGAGAAAAGATACGCAGTATTTTGGCCCA	CASRGTSGRKDTQYF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	45	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	5	0	2	5	1	3	23	34	49	35	52	TCRBV02,TCRBV09													CASRGTSGRKDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01*02	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCAGCTTCTACATCTGCAGTGCTACAAAACCGGGACTAGCGGGGGCACACGTTTCCTACAATGAGCAGTTCTTCGGGCCA	CSATKPGLAGAHVSYNEQFF	In	VDJ	1	21	3.71234620280017E-4	4.4940934771443245E-4	60	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	4	0	2	1	7	8	15	25	46	32	54		TCRBV20-01,TCRBV20-or09_02												CSATKPGLAGAHVSYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCGGGGGGTTTACGGCACCTCTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	21	3.71234620280017E-4		47	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	6	8	1	0	1	12	26	34	42	35	54		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTTCCCTGGCGGGAGCCACTGGAGACAATGAGCAGTTCTTCGGGCCA	CSASLAGATGDNEQFF	In	VDJ	1	21	3.71234620280017E-4	4.4940934771443245E-4	48	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	5	7	2	5	6	9	26	35	48	41	57		TCRBV20-01,TCRBV20-or09_02												CSASLAGATGDNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGTTTCTCCGGGTGGCCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSFSGWPGANVLTF	In	VDJ	1	21	3.71234620280017E-4	4.4940934771443245E-4	48	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-06	01	3	8	4	2	3	4	23	37	44	40	48	TCRBV24,TCRBV27					01,02								CASSFSGWPGANVLTF+X+TCRBJ02-06	unresolved	TCRBD02-01	TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGCTTAGTTACAACGGAGCCCTCTCTCAACTAATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	21	3.71234620280017E-4		58				TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-04	01	1	10	2	0	7	8	23	39	50	46	58	TCRBV07,TCRBV12	TCRBV07-04,TCRBV12-03,TCRBV12-04												X+X+TCRBJ01-04		TCRBD02-01*02	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTTAGGACAGGGGGAGACTATGAGCAGTTCTTCGGGCCA	CATSDFRTGGDYEQFF	In	VDJ	1	21	3.71234620280017E-4	4.4940934771443245E-4	48	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	1	1	1	8	2	5	24	41	53	43	58		TCRBV24-01,TCRBV24-or09_02												CATSDFRTGGDYEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTACCCAGGACTAGCCGGATTGAATGAGCAGTTCTTCGGGCCA	CASSYPGLAGLNEQFF	In	VDJ	1	21	3.71234620280017E-4	4.4940934771443245E-4	48	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	4	1	7	7	5	7	18	31	44	36	51	TCRBV07,TCRBV11					01,02								CASSYPGLAGLNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTAGTAACGAAAGGCACAGATACGCAGTATTTTGGCCCA	CASSLVTKGTDTQYF	In	VDJ	1	21	3.71234620280017E-4	4.4940934771443245E-4	45	unresolved						TCRBJ02	TCRBJ02-03	01	1	2	8	1	4	3	18	34	40	38	43	TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLVTKGTDTQYF+X+TCRBJ02-03	unresolved		TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCMTSTATCTCTGTGCCAGCAGCACCCACTCCGGGACTAGCGAAGATACGCAGTATTTTGGCCCA	CASSTHSGTSEDTQYF	In	VDJ	1	21	3.71234620280017E-4	4.4940934771443245E-4	48	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	4	0	6	5	9	1	19	31	50	40	51	TCRBV05,TCRBV11					01,02								CASSTHSGTSEDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACYSRGGGACTCAGCTKTGTATTTYTGTGCCAGCAGAGGGATGAACACTGAAGCTTTCTTTGGACAA	CASRGMNTEAFF	In	VDJ	1	21	3.71234620280017E-4	4.4940934771443245E-4	36	unresolved						TCRBJ01	TCRBJ01-01	01	5	0	8	0	1	0	23	34	-1	35	39	TCRBV09,TCRBV12			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRGMNTEAFF+X+TCRBJ01-01	unresolved		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTCCCAGACATCTGTGTACTTCTGTGCCAGCACTCGAAACGCGGGAGTTTACCACAATGAGCAGTTCTTCGGGCCA	CASTRNAGVYHNEQFF	In	VDJ	1	22	3.8891245934097015E-4	4.7080979284369113E-4	48				TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	7	7	2	5	8	6	24	34	49	42	55	TCRBV06,TCRBV10	TCRBV06-01,TCRBV06-05,TCRBV06-06,TCRBV10-03												CASTRNAGVYHNEQFF+X+TCRBJ02-01		TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCGAAGGGGTATCCATGGCTACACCTTCGGTTCG	CASSRRGIHGYTF	In	VDJ	1	22	3.8891245934097015E-4	4.7080979284369113E-4	39	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	5	2	6	2	5	26	39	46	41	51		TCRBV03-01,TCRBV03-02												CASSRRGIHGYTF+TCRBV03-X+TCRBJ01-02	TCRBV03	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGAGCCGGGGGCAGGAGGCTACACCTTCGGTTCG	CSAREPGAGGYTF	In	VDJ	1	22	3.8891245934097015E-4	4.7080979284369113E-4	39	TCRBV20						TCRBJ01	TCRBJ01-02	01	0	6	0	8	3	4	26	40	49	43	53		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAREPGAGGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20		TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATTCGGAGTCGATGGGGCAGTACTTCGGGCCG	CSARDSESMGQYF	In	VDJ	1	22	3.8891245934097015E-4	4.7080979284369113E-4	39	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	0	10	2	9	3	8	26	40	47	43	55		TCRBV20-01,TCRBV20-or09_02												CSARDSESMGQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGTTCCAGGAGGGGGCGGGAGAGCAGTACTTCGGGCCG	CSARFQEGAGEQYF	In	VDJ	1	22	3.8891245934097015E-4	4.7080979284369113E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	5	0	7	8	4	26	37	52	45	56		TCRBV20-01,TCRBV20-or09_02												CSARFQEGAGEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
SRGGGACTCAGCTGTGTAYYTCTGTGCCAGCAGCTTAGATTACTCGGGGGCCCAGTACTTCGGGCCA	CASSLDYSGAQYF	In	VDJ	1	22	3.8891245934097015E-4	4.7080979284369113E-4	39	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	1	8	2	9	6	0	22	38	-1	44	50	TCRBV07,TCRBV12													CASSLDYSGAQYF+X+TCRBJ02-05	unresolved	TCRBD02-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCGCTACCAGGGACTCTTACGAGCAGTACTTCGGGCCG	CATATRDSYEQYF	In	VDJ	1	22	3.8891245934097015E-4	4.7080979284369113E-4	39	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	9	0	10	4	7	2	24	33	46	40	48		TCRBV24-01,TCRBV24-or09_02				01,02								CATATRDSYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCACCGAAATCGGCATGAACACTGAAGCTTTCTTTGGACAA	CASTEIGMNTEAFF	In	VDJ	1	22	3.8891245934097015E-4	4.7080979284369113E-4	42	TCRBV24						TCRBJ01	TCRBJ01-01	01	11	9	0	0	11	1	24	31	45	42	46		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASTEIGMNTEAFF+TCRBV24-X+TCRBJ01-01	TCRBV24		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGACWCGGCMSTGTATSTCTGYGCCAGCAGCCCAGCCCCGGACAGTTTTTACGAGCAGTACTTCGGGCCG	CASSPAPDSFYEQYF	In	VDJ	1	22	3.8891245934097015E-4	4.7080979284369113E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	1	5	4	8	4	18	30	44	38	48	TCRBV11,TCRBV23													CASSPAPDSFYEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCRGCCRTGTATSKCTGTGCCAGCAGTATAGCGGGAGCCACCGGGGAGCTGTTTTTTGGAGAA	CASSIAGATGELFF	In	VDJ	1	22	3.8891245934097015E-4	4.7080979284369113E-4	42	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	6	5	2	4	2	1	19	30	41	32	42	TCRBV07,TCRBV11													CASSIAGATGELFF+X+TCRBJ02-02	unresolved	TCRBD02-01*02	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTGGACAGGGGGCCTAAACACTGAAGCTTTCTTTGGACAA	CASSWTGGLNTEAFF	In	VDJ	1	23	4.0659029840192336E-4	4.922102379729498E-4	45	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	1	0	2	0	3	26	-1	50	39	53		TCRBV12-03,TCRBV12-04												CASSWTGGLNTEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTACGGACAGGGAATGAAAAACTGTTTTTTGGCAGT	CASSLRTGNEKLFF	In	VDJ	1	23	4.0659029840192336E-4	4.922102379729498E-4	42	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	2	1	3	5	1	0	26	41	-1	42	50		TCRBV12-03,TCRBV12-04												CASSLRTGNEKLFF+TCRBV12-X+TCRBJ01-04	TCRBV12	TCRBD01-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CTMSCTCYCAGACWTCTGTKTACTTCTGTGCCAGCAGGGGAGAGCACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	23	4.0659029840192336E-4		37	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	6	9	2	4	0	2	24	-1	40	35	42	TCRBV06,TCRBV10													X+X+TCRBJ02-02	unresolved	TCRBD02-01*02	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCATTATTTGGAGCTGTTTTTTGGAGAA	CASSHYLELFF	In	VDJ	1	23	4.0659029840192336E-4	4.922102379729498E-4	33	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	3	5	9	10	1	3	26	40	43	41	46		TCRBV03-01,TCRBV03-02				01,02								CASSHYLELFF+TCRBV03-X+TCRBJ02-02	TCRBV03	TCRBD02-01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCTGGTGCGAAAAGCCTACAATGAGCAGTTCTTCGGGCCA	CASSLVRKAYNEQFF	In	VDJ	1	23	4.0659029840192336E-4	4.922102379729498E-4	45	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	4	7	6	2	4	5	26	39	46	43	51		TCRBV03-01,TCRBV03-02				01,02								CASSLVRKAYNEQFF+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCATACGGACATCGCCCTGAAAAACTGTTTTTTGGCAGT	CSAYGHRPEKLFF	In	VDJ	1	23	4.0659029840192336E-4	4.922102379729498E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	6	1	6	7	4	6	26	34	43	38	49		TCRBV20-01,TCRBV20-or09_02												CSAYGHRPEKLFF+TCRBV20-X+TCRBJ01-04	TCRBV20	TCRBD01-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCAGACAGGGGGCTAGAGAGACCCAGTACTTCGGGCCA	CSARQGARETQYF	In	VDJ	1	23	4.0659029840192336E-4	4.922102379729498E-4	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	2	4	0	4	0	3	26	-1	46	38	49		TCRBV20-01,TCRBV20-or09_02												CSARQGARETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCCTGACATCGATACTGAAGCTTTCTTTGGACAA	CSAPDIDTEAFF	In	VDJ	1	23	4.0659029840192336E-4	4.922102379729498E-4	36	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	2	6	5	4	5	26	34	42	38	47		TCRBV20-01,TCRBV20-or09_02												CSAPDIDTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGAGGGGGAACGGGTCTATGGCTACACCTTCGGTTCG	CSAREGERVYGYTF	In	VDJ	1	23	4.0659029840192336E-4	4.922102379729498E-4	42	TCRBV20						TCRBJ01	TCRBJ01-02	01	0	6	1	4	0	7	26	-1	45	40	52		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAREGERVYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20		TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATACCCTGTTTTCAGGGGAAAAACTGTTTTTTGGCAGT	CSARDTLFSGEKLFF	In	VDJ	1	23	4.0659029840192336E-4	4.922102379729498E-4	45	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	0	4	3	8	11	0	26	40	-1	51	56		TCRBV20-01,TCRBV20-or09_02												CSARDTLFSGEKLFF+TCRBV20-X+TCRBJ01-04	TCRBV20	TCRBD01-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTACCGCAGGGAACTGGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	1	23	4.0659029840192336E-4		46	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	3	4	3	2	5	2	26	37	47	42	49		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-06	TCRBV20	TCRBD01-01*01	TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCARCCARACMKCTYTGTACTTCTGTGCCAGCATTCCAGGGGGTGTCAGAAACACCATATATTTTGGAGAG	CASIPGGVRNTIYF	In	VDJ	1	23	4.0659029840192336E-4	4.922102379729498E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	13	4	1	5	10	5	25	28	45	38	50	TCRBV22,TCRBV27													CASIPGGVRNTIYF+X+TCRBJ01-03	unresolved	TCRBD01-01*01	TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATCCATCACCAGTCGAGGATACGCAGTATTTTGGCCCA	CATSDPSPVEDTQYF	In	VDJ	1	23	4.0659029840192336E-4	4.922102379729498E-4	45	TCRBV24						TCRBJ02	TCRBJ02-03	01	3	4	5	6	7	5	24	39	49	46	54		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CATSDPSPVEDTQYF+TCRBV24-X+TCRBJ02-03	TCRBV24		TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTCTATTGCCCGACAGGAGAGTGGGGGGCTACACCTTCGGTTCG		Out	VDJ	1	23	4.0659029840192336E-4		53	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	1	2	4	8	9	9	24	41	56	50	65		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ01-02	TCRBV24	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTCGAGTCCTGGGAACTATGGCTACACCTTCGGTTCG	CASSSSPGNYGYTF	In	VDJ	1	23	4.0659029840192336E-4	4.922102379729498E-4	42	TCRBV24						TCRBJ01	TCRBJ01-02	01	6	0	9	2	9	0	24	36	-1	45	48		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSSPGNYGYTF+TCRBV24-X+TCRBJ01-02	TCRBV24		TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACYSRGGGACTCAGCTKTGTATTTYTGTGCCAGCAGCAAGGGACTYCAGAGCACAGATACGCAGTATTTTGGCCCA	CASSKGLQSTDTQYF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	45	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	6	0	10	0	3	4	26	37	46	40	50	TCRBV09,TCRBV12					01,02								CASSKGLQSTDTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTAYTTYTGTGCCAGCAGCAGCCTTCCAGGACAGTTTGAAGCTTTCTTTGGACAA	CASSSLPGQFEAFF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	42	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	1	5	7	10	2	26	37	53	47	55		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASSSLPGQFEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGCGGGACTTTCGGGGAGCTGTTTTTTGGAGAA	CASSGTFGELFF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	36	TCRBV12			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	6	0	10	7	1	2	26	37	44	38	46		TCRBV12-03,TCRBV12-04,TCRBV12-05				01,02								CASSGTFGELFF+TCRBV12-X+TCRBJ02-02	TCRBV12	TCRBD02-01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCGAACATAAGGACAGTTTATGGCTACACCTTCGGTTCG	CASSPNIRTVYGYTF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	45	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	1	5	5	9	2	26	39	54	48	56		TCRBV03-01,TCRBV03-02												CASSPNIRTVYGYTF+TCRBV03-X+TCRBJ01-02	TCRBV03	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCGATGTACAGCGGGAGAGAGATACGCAGTATTTTGGCCCA	CSADVQRERDTQYF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	42	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	6	6	2	5	8	2	26	34	50	42	52		TCRBV20-01,TCRBV20-or09_02												CSADVQRERDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*02	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGACGGGGGGCCCTAGCGGCTAGCACAGATACGCAGTATTTTGGCCCA	CSARRGALAASTDTQYF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	51	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	2	4	5	0	9	2	26	38	54	47	56		TCRBV20-01,TCRBV20-or09_02				01,02								CSARRGALAASTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTTCCAGGGGGCCCGAGCAGTACTTCGGGCCG	CSASRGPEQYF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	33	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	4	0	6	2	1	26	35	45	37	46		TCRBV20-01,TCRBV20-or09_02												CSASRGPEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGTTACAACAGGGGGGTTACTATGGCTACACCTTCGGTTCG		Out	VDJ	1	24	4.2426813746287653E-4		40	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	7	3	1	3	5	3	26	33	46	38	49		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCARCCAGACMKMTCTKTACYWCTGTGCCAGCAGTCCTACAGGGCTAAGAACTGAAGCTTTCTTTGGACAA	CASSPTGLRTEAFF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	3	3	5	5	6	22	32	43	37	49	TCRBV08,TCRBV24													CASSPTGLRTEAFF+X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCMRGRGACWCAGCWSKGTAYTTCTGTGCCAGCAGCCAGGAAGGCCCGGGAGATACGCAGTATTTTGGCCCA	CASSQEGPGDTQYF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	42	unresolved						TCRBJ02	TCRBJ02-03	01	6	4	4	5	1	10	22	33	38	34	48	TCRBV12,TCRBV21			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQEGPGDTQYF+X+TCRBJ02-03	unresolved		TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTATAGGGGGCTGCTCCGGGGAGCTGTTTTTTGGAGAA	CATSIGGCSGELFF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	6	5	0	6	2	4	24	36	45	38	49		TCRBV24-01,TCRBV24-or09_02												CATSIGGCSGELFF+TCRBV24-X+TCRBJ02-02	TCRBV24	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCACCTCACCGGACAGGGTTATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	24	4.2426813746287653E-4		41	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	9	1	3	6	5	2	24	33	46	38	48	TCRBV24,TCRBV27													X+X+TCRBJ01-04	unresolved	TCRBD01-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTACAGGGCCTTCCTACGAGCAGTACTTTGGGCCG	CASSTGPSYEQYF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	39	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	3	3	19	0	21	24	-1	42	36	63		TCRBV24-01,TCRBV24-or09_02												CASSTGPSYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAAGAAGGCCGGGGTACCGGGGAGCTGTTTTTTGGAGAA	CASSQEGRGTGELFF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	45				TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	0	8	3	5	4	1	18	35	44	39	45	TCRBV04,TCRBV11	TCRBV04-02,TCRBV11-03												CASSQEGRGTGELFF+X+TCRBJ02-02		TCRBD02-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TYRGGRGACWCAGCWYKGTATTTCTGTGCCAGCAGGGGACTAGCGGGAAGGGAGACCCAGTACTTCGGGCCA	CASRGLAGRETQYF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	42	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	6	0	3	5	0	3	24	-1	48	35	51	TCRBV09,TCRBV21													CASRGLAGRETQYF+X+TCRBJ02-05	unresolved	TCRBD02-01*02	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCTGCTGTGTATTTCTGTGCCAGCAGCAAAGATTTTCACGGGACTAGCGGGAGGTGCCAAGAGACCCAGTACTTCGGGCCA	CASSKDFHGTSGRCQETQYF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	60	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	0	0	1	1	7	2	15	32	54	39	56		TCRBV03-01,TCRBV03-02												CASSKDFHGTSGRCQETQYF+TCRBV03-X+TCRBJ02-05	TCRBV03	TCRBD02-01*02	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TYRGGRGACWCAGCWYKGTATTTCTGTGCCAGCAGCCCCGGGACTAGCGGGACCAATGAGCAGTTCTTCGGGCCA	CASSPGTSGTNEQFF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	45	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	4	0	3	6	3	1	23	35	51	38	52	TCRBV09,TCRBV21													CASSPGTSGTNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGAGGGTGGCAGGGGGGATACTCTCTGGAAACACCATATATTTTGGAGAG		Out	VDJ	1	24	4.2426813746287653E-4		58	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	0	4	1	0	6	6	23	40	53	46	59		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ01-03	TCRBV03	TCRBD01-01*01	TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGACGACTTGGTGGGGGCATAAGGCGAGCAGTACTTCGGGCCG	CASSQDDLVGA*GEQYF	Stop	VDJ	1	25	4.4194597652382975E-4		51	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	6	0	6	9	6	26	43	58	52	64		TCRBV03-01,TCRBV03-02												CASSQDDLVGA*GEQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCACCTCTAGCGGGAGCGGCCGAGCAGTACTTCGGGCCG		Out	VDJ	1	25	4.4194597652382975E-4		44	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	3	4	2	6	3	4	26	40	53	43	57		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGACCGAGCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CSARPSSGANVLTF	In	VDJ	1	25	4.4194597652382975E-4	5.350111282314672E-4	42	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-06	01	2	11	2	0	2	0	26	38	-1	40	43		TCRBV20-01,TCRBV20-or09_02												CSARPSSGANVLTF+TCRBV20-X+TCRBJ02-06	TCRBV20	TCRBD02-01*02	TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCTCCGACAGGGAAGAGATAGTGGCTACACCTTCGGTTCG	CSALRQGRDSGYTF	In	VDJ	1	25	4.4194597652382975E-4	5.350111282314672E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	2	3	7	4	9	26	35	46	39	55		TCRBV20-01,TCRBV20-or09_02												CSALRQGRDSGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTCCGCTATGAAGGCCACCTATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	25	4.4194597652382975E-4		47	TCRBV24						TCRBJ01	TCRBJ01-05	01	6	5	4	5	9	6	24	36	48	45	54		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV24-X+TCRBJ01-05	TCRBV24		TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCTACCAGTGATGGACAGGGATTCGGGGAAAAACTGTTTTTTGGCAGT	CATSDGQGFGEKLFF	In	VDJ	1	25	4.4194597652382975E-4	5.350111282314672E-4	45	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	3	1	3	8	0	7	24	-1	47	39	54		TCRBV24-01,TCRBV24-or09_02												CATSDGQGFGEKLFF+TCRBV24-X+TCRBJ01-04	TCRBV24	TCRBD01-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCMTSTATCTCTGTGCCAGCAGCTTAATTCAGGGGAGCTCTGGAAACACCATATATTTTGGAGAG	CASSLIQGSSGNTIYF	In	VDJ	1	25	4.4194597652382975E-4	5.350111282314672E-4	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	2	4	2	0	4	2	19	33	43	37	45	TCRBV05,TCRBV11													CASSLIQGSSGNTIYF+X+TCRBJ01-03	unresolved	TCRBD01-01*01	TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCAGCTTCTACATCTGCAGTGCTACAGGGATTAGGCAGGGGCCTTACTGGAGCTCCTACAATGAGCAGTTCTTCGGGCCA	CSATGIRQGPYWSSYNEQFF	In	VDJ	1	26	4.596238155847829E-4	5.564115733607259E-4	60	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	4	4	2	0	11	11	15	25	42	36	53		TCRBV20-01,TCRBV20-or09_02												CSATGIRQGPYWSSYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGCAACAGCATATGGCTACACCTTCGGTTCG	CASSQATAYGYTF	In	VDJ	1	26	4.596238155847829E-4	5.564115733607259E-4	39	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	1	3	5	5	2	2	26	42	48	44	50		TCRBV03-01,TCRBV03-02												CASSQATAYGYTF+TCRBV03-X+TCRBJ01-02	TCRBV03	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCGGGGAGAGACCCAGTACTTCGGGCCA	CASSRGETQYF	In	VDJ	1	26	4.596238155847829E-4	5.564115733607259E-4	33	TCRBV03						TCRBJ02	TCRBJ02-05	01	4	6	2	4	0	0	26	-1	-1	39	43		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSRGETQYF+TCRBV03-X+TCRBJ02-05	TCRBV03		TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATAGGATGGATCAGCCCCAGCATTTTGGTGAT	CSARDRMDQPQHF	In	VDJ	1	26	4.596238155847829E-4	5.564115733607259E-4	39	TCRBV20						TCRBJ01	TCRBJ01-05	01	0	1	8	5	2	3	26	40	45	42	48		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARDRMDQPQHF+TCRBV20-X+TCRBJ01-05	TCRBV20		TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGACAGAAAAGGACAAGACTCACAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	26	4.596238155847829E-4		49	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	7	1	6	2	8	7	24	35	48	43	55		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ02-05	TCRBV24	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATCTTCTAGCGGGGGGAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	26	4.596238155847829E-4		50	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	3	4	2	1	3	0	24	39	-1	42	52		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ02-02	TCRBV24	TCRBD02-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCTCCGGGACAGGGGGGTACGAGCAGTACTTCGGGCCG	CATSGTGGYEQYF	In	VDJ	1	26	4.596238155847829E-4	5.564115733607259E-4	39	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	9	0	1	4	3	1	24	33	47	36	48		TCRBV24-01,TCRBV24-or09_02												CATSGTGGYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTGACCCTAGGGGGCCCCCCCTACAATGAGCAGTTCTTCGGGCCA	CASSLTLGGPPYNEQFF	In	VDJ	1	26	4.596238155847829E-4	5.564115733607259E-4	51	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	5	0	2	8	4	24	36	51	44	55		TCRBV24-01,TCRBV24-or09_02												CASSLTLGGPPYNEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTGAAGACAGCAGCTTCTACATCTGCAGTGCCAGACAGGGGACTAGCGGGCCTGGGGAGTTCACCTACGAGCAGTATTTTGGGCCG	CSARQGTSGPGEFTYEQYF	In	VDJ	1	26	4.596238155847829E-4	5.564115733607259E-4	57	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	2	0	4	19	3	30	24	36	51	39	81		TCRBV20-01,TCRBV20-or09_02				01,02								CSARQGTSGPGEFTYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGGGGACTYGGCYGTGTATSTCTGTGTCAGCAGCTCTAGCGGGAGTGACACCGGGGAGCTGTTTTTTGGAGAA	CVSSSSGSDTGELFF	In	VDJ	1	26	4.596238155847829E-4	5.564115733607259E-4	45	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	3	5	2	3	0	2	22	-1	45	36	47	TCRBV07,TCRBV11													CVSSSSGSDTGELFF+X+TCRBJ02-02	unresolved	TCRBD02-01*02	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTAGGCCCTAACACTGAAGCTTTCTTTGGACAA	CASSLGPNTEAFF	In	VDJ	1	27	4.7730165464573613E-4	5.778120184899846E-4	39	TCRBV12						TCRBJ01	TCRBJ01-01	01	1	10	0	2	0	3	26	-1	44	42	47		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGPNTEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCTTGGGACTAGCGGGAGCCTACAATGAGCAGTTCTTCGGGCCA	CSALGLAGAYNEQFF	In	VDJ	1	27	4.7730165464573613E-4	5.778120184899846E-4	45	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	6	0	2	2	3	0	26	34	-1	37	51		TCRBV20-01,TCRBV20-or09_02												CSALGLAGAYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCGAAACCGGGGGCCCTCTCCTACGAGCAGTACTTCGGGCCG	CSAKPGALSYEQYF	In	VDJ	1	27	4.7730165464573613E-4	5.778120184899846E-4	42	TCRBV20						TCRBJ02	TCRBJ02-07	01	6	6	0	0	6	3	26	34	46	40	49		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAKPGALSYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGAGGGACTAGCGATTTATGAGCAGTTCTTCGGGCCA	CSAREGLAIYEQFF	In	VDJ	1	27	4.7730165464573613E-4	5.778120184899846E-4	42	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	0	0	6	8	0	4	26	-1	50	40	54		TCRBV20-01,TCRBV20-or09_02				01,02								CSAREGLAIYEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGCCCTCAATGAGCAGTTCTTCGGGCCA	CSARALNEQFF	In	VDJ	1	27	4.7730165464573613E-4	5.778120184899846E-4	33	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	1	4	10	6	2	0	26	39	-1	41	43		TCRBV20-01,TCRBV20-or09_02				01,02								CSARALNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTCAAACAGTTTCTTCCTACAATGAGCAGTTCTTCGGGCCA	CSASQTVSSYNEQFF	In	VDJ	1	27	4.7730165464573613E-4	5.778120184899846E-4	45	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	3	5	1	4	5	26	37	45	41	50		TCRBV20-01,TCRBV20-or09_02												CSASQTVSSYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTCTTCGGGCAACTAATGAAAAACTGTTTTTTGGCAGT	CSASLRATNEKLFF	In	VDJ	1	27	4.7730165464573613E-4	5.778120184899846E-4	42	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-04	01	3	8	4	0	4	0	26	37	-1	41	45		TCRBV20-01,TCRBV20-or09_02				01,02								CSASLRATNEKLFF+TCRBV20-X+TCRBJ01-04	TCRBV20	TCRBD02-01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCCCTTGGGGCAGGGGGACACCGGGGAGCTGTTTTTTGGAGAA	CSAPLGQGDTGELFF	In	VDJ	1	27	4.7730165464573613E-4	5.778120184899846E-4	45	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	5	4	1	3	9	0	26	35	-1	44	51		TCRBV20-01,TCRBV20-or09_02												CSAPLGQGDTGELFF+TCRBV20-X+TCRBJ02-02	TCRBV20	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGGGGACAGGGGGGAACCTACGAGCAGTACTTCGGGCCG	CASRGQGGTYEQYF	In	VDJ	1	27	4.7730165464573613E-4	5.778120184899846E-4	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	7	0	1	2	0	3	24	-1	46	35	49		TCRBV24-01,TCRBV24-or09_02												CASRGQGGTYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ARRRRGACTCAGCYGYGTATCTCTRCGCCAGCAGCCAAGGTTGGAACGGGGGAAACACCGGGGAGCTGTTTTTTGGAGAA	XASSQGWNGGNTGELFF	In	VDJ	1	27	4.7730165464573613E-4	5.778120184899846E-4	51	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	1	8	2	2	7	1	22	38	51	45	52	TCRBV01,TCRBV04													XASSQGWNGGNTGELFF+X+TCRBJ02-02	unresolved	TCRBD02-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCACGCATGTAGACAATGAGCAGTTCTTCGGGCCA	CASTHVDNEQFF	In	VDJ	1	28	4.949794937066893E-4	5.992124636192433E-4	36	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	7	5	8	5	6	0	26	36	-1	42	45		TCRBV03-01,TCRBV03-02				01,02								CASTHVDNEQFF+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGAGGGCCAGGGGTTGACTGAGCAGTTCTTCGGGCCA	CASSQEGQGLTEQFF	In	VDJ	1	28	4.949794937066893E-4	5.992124636192433E-4	45	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	0	4	2	9	4	5	26	43	53	47	58		TCRBV03-01,TCRBV03-02												CASSQEGQGLTEQFF+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCAAGTGGGGGACTAGCGGTGAATGAGCAGTTCTTCGGGCCA	CSASGGLAVNEQFF	In	VDJ	1	28	4.949794937066893E-4	5.992124636192433E-4	42	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	0	5	7	6	2	26	34	51	40	53		TCRBV20-01,TCRBV20-or09_02				01,02								CSASGGLAVNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCGCCTACCTGGACGGATGAAAAACTGTTTTTTGGCAGT	CSAPTWTDEKLFF	In	VDJ	1	28	4.949794937066893E-4	5.992124636192433E-4	39	TCRBV20						TCRBJ01	TCRBJ01-04	01	6	1	7	6	8	2	26	34	46	42	48		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAPTWTDEKLFF+TCRBV20-X+TCRBJ01-04	TCRBV20		TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGCGCTCCGGGACAACAACCTTTACACCTTCGGTTCG	CSARALRDNNLYTF	In	VDJ	1	28	4.949794937066893E-4	5.992124636192433E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	1	0	6	11	6	8	26	39	51	45	59		TCRBV20-01,TCRBV20-or09_02												CSARALRDNNLYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGTCTGGTCGGGGGGGCTTGGCACAGATACGCAGTATTTTGGCCCA	CSVWSGGLGTDTQYF	In	VDJ	1	28	4.949794937066893E-4	5.992124636192433E-4	45	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	7	8	0	1	6	4	26	33	47	39	51		TCRBV20-01,TCRBV20-or09_02												CSVWSGGLGTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGTTAACCCGGGACTCCTTTGGAAACACCATATATTTTGGAGAG		Out	VDJ	1	28	4.949794937066893E-4		47	unresolved			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-03	01	4	0	10	3	5	4	23	36	47	41	51	TCRBV24,TCRBV27					01,02								X+X+TCRBJ01-03	unresolved	TCRBD02-01	TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTCTTCTAACACAGATACGCAGTATTTTGGCCCA	CASSSSNTDTQYF	In	VDJ	1	28	4.949794937066893E-4	5.992124636192433E-4	39	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	6	4	9	2	4	1	24	36	43	40	44		TCRBV24-01,TCRBV24-or09_02				01,02								CASSSSNTDTQYF+TCRBV24-X+TCRBJ02-03	TCRBV24	TCRBD02-01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTCCGGGGGGCCCACGAGCAGTACTTCGGGCCG	CASSFRGAHEQYF	In	VDJ	1	28	4.949794937066893E-4	5.992124636192433E-4	39	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	6	8	1	5	3	3	24	36	46	39	49		TCRBV24-01,TCRBV24-or09_02												CASSFRGAHEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD02-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCAGTGGTGACGGGGCGTCACCCCTCCACTTTGGGAAC	CASSGDGASPLHF	In	VDJ	1	28	4.949794937066893E-4	5.992124636192433E-4	39	unresolved						TCRBJ01	TCRBJ01-06	01	5	7	0	10	6	1	23	35	46	41	47	TCRBV06,TCRBV10			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSGDGASPLHF+X+TCRBJ01-06	unresolved		TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGGGACTCAGCCGTGTATCTCTACGCCAGCAGCCGCCGGGGACTAGCGGGAGGGTCCACAGATACGCAGTATTTTGGCCCA	YASSRRGLAGGSTDTQYF	In	VDJ	1	28	4.949794937066893E-4	5.992124636192433E-4	54				TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	5	0	0	2	5	2	22	34	55	39	57	TCRBV07,TCRBV17	TCRBV07-03,TCRBV17-01												YASSRRGLAGGSTDTQYF+X+TCRBJ02-03		TCRBD02-01*02	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAGGCTAGATGGGGGGTGAATGAGCAGTTCTTCGGGCCA	CASSQARWGVNEQFF	In	VDJ	1	29	5.126573327676425E-4	6.20612908748502E-4	45	TCRBV03			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	3	9	1	7	8	2	26	40	54	48	56		TCRBV03-01,TCRBV03-02												CASSQARWGVNEQFF+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCGCGGGGGGTACCCTTACAGATACGCAGTATTTTGGCCCA	CASSAGGTLTDTQYF	In	VDJ	1	29	5.126573327676425E-4	6.20612908748502E-4	45	TCRBV03			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	5	7	1	3	0	7	26	-1	46	38	53		TCRBV03-01,TCRBV03-02												CASSAGGTLTDTQYF+TCRBV03-X+TCRBJ02-03	TCRBV03	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCCGGACGGATACTCTGGAAACACCATATATTTTGGAGAG	CSAPDGYSGNTIYF	In	VDJ	1	29	5.126573327676425E-4	6.20612908748502E-4	42	TCRBV20						TCRBJ01	TCRBJ01-03	01	6	1	7	0	3	5	26	34	41	37	46		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAPDGYSGNTIYF+TCRBV20-X+TCRBJ01-03	TCRBV20		TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGGCGGCACCCCCTAACTATGGCTACACCTTCGGTTCG	CSARAAPPNYGYTF	In	VDJ	1	29	5.126573327676425E-4	6.20612908748502E-4	42	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	3	7	5	0	1	6	26	37	42	38	48		TCRBV20-01,TCRBV20-or09_02				01,02								CSARAAPPNYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD02-01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTATCCAGTGCCTATGGCTACACCTTCGGTTCG	CASSLSSAYGYTF	In	VDJ	1	29	5.126573327676425E-4	6.20612908748502E-4	39				TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	4	5	4	5	3	24	36	44	41	47	TCRBV24,TCRBV27	TCRBV24-01,TCRBV24-or09_02,TCRBV27-01												CASSLSSAYGYTF+X+TCRBJ01-02		TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AAYCMRGRGACWCAGCWSKGTATTTYTGTGCCAGACGGACAGCTCCAGGCAGCTACGAGCAGTACTTCGGGCCG	CARRTAPGSYEQYF	In	VDJ	1	30	5.303351718285957E-4	6.420133538777606E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	12	1	5	3	5	10	26	31	42	36	52	TCRBV12,TCRBV21													CARRTAPGSYEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGTTGGCGGCCAGCGGGAGGTTCAGTACTTCGGGCCG	CASSQVGGQREVQYF	In	VDJ	1	30	5.303351718285957E-4	6.420133538777606E-4	45	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	1	6	1	10	9	2	26	42	60	51	62		TCRBV03-01,TCRBV03-02												CASSQVGGQREVQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGGCCCCTAGCGGGGACGTACAATGAGCAGTTCTTCGGGCCA	CASRPLAGTYNEQFF	In	VDJ	1	30	5.303351718285957E-4	6.420133538777606E-4	45	TCRBV03			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	6	4	3	4	4	3	26	37	50	41	53		TCRBV03-01,TCRBV03-02												CASRPLAGTYNEQFF+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGGGGGAACGAACACTGAAGCTTTCTTTGGACAA	CSARGGTNTEAFF	In	VDJ	1	30	5.303351718285957E-4	6.420133538777606E-4	39	TCRBV20						TCRBJ01	TCRBJ01-01	01	1	0	8	1	1	2	26	39	44	40	46		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARGGTNTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGCCATACCCGGACTAGCGGGAGCCACAATGAGCAGTTCTTCGGGCCA	CATSHTRTSGSHNEQFF	In	VDJ	1	30	5.303351718285957E-4	6.420133538777606E-4	51	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	7	1	2	5	8	2	24	35	56	43	58		TCRBV24-01,TCRBV24-or09_02												CATSHTRTSGSHNEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCAGTCGGGGGCCCGACCGCTACGAGCAGTACTTCGGGCCG	CASSRGPDRYEQYF	In	VDJ	1	30	5.303351718285957E-4	6.420133538777606E-4	42	unresolved						TCRBJ02	TCRBJ02-07	01	5	6	0	3	1	7	23	35	42	36	49	TCRBV06,TCRBV10			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSRGPDRYEQYF+X+TCRBJ02-07	unresolved		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTGAAGACAGCAGCTTCTACATCTGCAGTGCCATCCGAAGGACTAGCCCGCCCCTAAGAGAGGACGGGGAGCTGTTTTTTGGAGAA	CSAIRRTSPPLREDGELFF	In	VDJ	1	30	5.303351718285957E-4	6.420133538777606E-4	57	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	6	1	7	7	8	17	24	32	48	40	65		TCRBV20-01,TCRBV20-or09_02				01,02								CSAIRRTSPPLREDGELFF+TCRBV20-X+TCRBJ02-02	TCRBV20	TCRBD02-01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCRGCCRTGTATSKCTGTGCCAGCAGCTACCTTCAGGGGGCTAGCAATGAGCAGTTCTTCGGGCCA	CASSYLQGASNEQFF	In	VDJ	1	30	5.303351718285957E-4	6.420133538777606E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	4	4	0	6	5	3	18	31	44	36	47	TCRBV07,TCRBV11													CASSYLQGASNEQFF+X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCKGCYGTGTATKTCTGTGCCAGCAGCTTACACAGGGAAGTCGCTGGCTACACCTTCGGTTCG	CASSLHREVAGYTF	In	VDJ	1	30	5.303351718285957E-4	6.420133538777606E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	3	3	7	1	7	18	33	40	34	47	TCRBV03,TCRBV11													CASSLHREVAGYTF+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AAYCMRGRGACWCAGCWSKGTATTTYTGTGCCAGCAGCTGGGCTGGAGGTGGAAACACCATATATTTTGGAGAG	CASSWAGGGNTIYF	In	VDJ	1	31	5.480130108895489E-4	6.634137990070194E-4	42	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-03	01	6	10	1	3	7	0	26	37	-1	44	49	TCRBV12,TCRBV21													CASSWAGGGNTIYF+X+TCRBJ01-03	unresolved	TCRBD02-01*02	TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCGACTAGCGGGAGAAAAAGAGACCCAGTACTTCGGGCCA	CSARLAGEKETQYF	In	VDJ	1	31	5.480130108895489E-4	6.634137990070194E-4	42	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	6	2	2	3	2	3	26	34	48	36	51		TCRBV20-01,TCRBV20-or09_02												CSARLAGEKETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*02	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGCGTGACGGGCACTGGAAACACCATATATTTTGGAGAG	CSASVTGTGNTIYF	In	VDJ	1	31	5.480130108895489E-4	6.634137990070194E-4	42	TCRBV20						TCRBJ01	TCRBJ01-03	01	3	8	0	2	6	1	26	37	47	43	48		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSASVTGTGNTIYF+TCRBV20-X+TCRBJ01-03	TCRBV20		TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TTSTGTGCCAGCAGTCCTACCGACCAAACAGGGTATCCGAGCGGGACCACCTACAATGAGCAGTTCTTCGGGCCA	CASSPTDQTGYPSGTTYNEQFF	In	VDJ	1	31	5.480130108895489E-4	6.634137990070194E-4	66	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	5	6	3	2	24	3	3	15	46	39	49	TCRBV06,TCRBV24													CASSPTDQTGYPSGTTYNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGAAACCTATGAAGCTTTCTTTGGACAA	CSARETYEAFF	In	VDJ	1	32	5.65690849950502E-4	6.84814244136278E-4	33	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	0	4	9	7	3	0	26	40	-1	43	46		TCRBV20-01,TCRBV20-or09_02				01,02								CSARETYEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD02-01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGACCCTAGCGGGGCTAGCACAGATACGCAGTATTTTGGCCCA	CSARDPSGASTDTQYF	In	VDJ	1	32	5.65690849950502E-4	6.84814244136278E-4	48	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	0	4	3	0	2	2	26	40	51	42	53		TCRBV20-01,TCRBV20-or09_02												CSARDPSGASTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTGCAGGACAGGGAGTATATGAAAAACTGTTTTTTGGCAGT	CSASAGQGVYEKLFF	In	VDJ	1	32	5.65690849950502E-4	6.84814244136278E-4	45	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	3	1	3	6	4	5	26	37	49	41	54		TCRBV20-01,TCRBV20-or09_02												CSASAGQGVYEKLFF+TCRBV20-X+TCRBJ01-04	TCRBV20	TCRBD01-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCTGGGGGGACAGACGGTATTCTGAAGACCCAGTACTTCGGGCCA	CASSLAGGTDGILKTQYF	In	VDJ	1	32	5.65690849950502E-4	6.84814244136278E-4	54				TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	0	0	5	6	4	12	18	35	46	39	58	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03												CASSLAGGTDGILKTQYF+X+TCRBJ02-05		TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGACTTAGCGGTCCCCAGACCTACGAGCAGTACTTCGGGCCG	CASRLSGPQTYEQYF	In	VDJ	1	33	5.833686890114552E-4	7.062146892655367E-4	45	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	6	5	5	2	3	8	26	37	46	40	54		TCRBV03-01,TCRBV03-02				01,02								CASRLSGPQTYEQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGATAGCAGGTCTACAATGAAACAGTTCTTCGGGCCA	CASSQDSRSTMKQFF	In	VDJ	1	33	5.833686890114552E-4	7.062146892655367E-4	45	TCRBV03						TCRBJ02	TCRBJ02-01	01	0	4	4	13	3	12	26	43	50	46	62		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQDSRSTMKQFF+TCRBV03-X+TCRBJ02-01	TCRBV03		TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGTCAGCAGCCAAAAGGGACTACGATACTCTAGTGAGCAGTTCTTCGGGCCA	CVSSQKGLRYSSEQFF	In	VDJ	1	33	5.833686890114552E-4	7.062146892655367E-4	48	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	2	0	9	9	2	11	26	41	50	43	61		TCRBV03-01,TCRBV03-02				01,02								CVSSQKGLRYSSEQFF+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCGGGGGACGCCCGGAATTCACCCCTCCACTTTGGGAAC	CSAGDARNSPLHF	In	VDJ	1	33	5.833686890114552E-4	7.062146892655367E-4	39	TCRBV20						TCRBJ01	TCRBJ01-06	01	6	0	7	7	2	6	26	34	41	36	47		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAGDARNSPLHF+TCRBV20-X+TCRBJ01-06	TCRBV20		TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTGGCCCGGGGGCCTACGAGCAGTACTTCGGGCCG	CSASGPGAYEQYF	In	VDJ	1	33	5.833686890114552E-4	7.062146892655367E-4	39	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	3	8	2	2	5	0	26	37	-1	42	48		TCRBV20-01,TCRBV20-or09_02												CSASGPGAYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGCCAAAGGGACACAGAAAAACTGTTTTTTGGCAGT	CASSQRDTEKLFF	In	VDJ	1	34	6.010465280724084E-4	7.276151343947955E-4	39	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	6	0	6	8	5	2	26	37	48	42	50		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASSQRDTEKLFF+TCRBV12-X+TCRBJ01-04	TCRBV12	TCRBD01-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTTTTACAGGGAATCCCGGGGAGCTGTTTTTTGGAGAA	CATSFTGNPGELFF	In	VDJ	1	34	6.010465280724084E-4	7.276151343947955E-4	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	6	3	3	6	3	4	24	36	45	39	49		TCRBV24-01,TCRBV24-or09_02												CATSFTGNPGELFF+TCRBV24-X+TCRBJ02-02	TCRBV24	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTATCCTACTCGCCGGGACAGGGGGCTCTGGGGAGCTGTTTTTTGGAGAA	CASSILLAGTGGSGELFF	In	VDJ	1	34	6.010465280724084E-4	7.276151343947955E-4	54	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	6	0	0	8	12	3	24	36	60	48	63		TCRBV24-01,TCRBV24-or09_02												CASSILLAGTGGSGELFF+TCRBV24-X+TCRBJ02-02	TCRBV24	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGACWCGGCMSTGTATSTCTGYGCCAGCAGCCAATTTGAAGGCGGCAATCAGCCCCAGCATTTTGGTGAT	CASSQFEGGNQPQHF	In	VDJ	1	34	6.010465280724084E-4	7.276151343947955E-4	45	unresolved						TCRBJ01	TCRBJ01-05	01	5	5	4	2	8	2	18	30	41	38	43	TCRBV11,TCRBV23			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQFEGGNQPQHF+X+TCRBJ01-05	unresolved		TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCRGCCATGTATCKCTGTGCCAGCCGATATCTAGCGGGAGGCAACAATGAGCAGTTCTTCGGGCCA	CASRYLAGGNNEQFF	In	VDJ	1	34	6.010465280724084E-4	7.276151343947955E-4	45	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	8	4	1	5	6	2	19	28	45	34	47	TCRBV07,TCRBV11													CASRYLAGGNNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTGAGCAGGTTGCAAAACTGTTTTTTGGCAGT	CASSEQVAKLFF	In	VDJ	1	35	6.187243671333617E-4	7.490155795240541E-4	36	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	5	4	4	10	3	4	26	38	45	41	49		TCRBV12-03,TCRBV12-04												CASSEQVAKLFF+TCRBV12-X+TCRBJ01-04	TCRBV12	TCRBD01-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAAAAGGGAGCAGAGCCAAAAACATTCAGTACTTCGGCGCC	CASSQKGSRAKNIQYF	In	VDJ	1	35	6.187243671333617E-4	7.490155795240541E-4	48	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-04	01	2	9	2	0	3	3	26	41	49	44	52		TCRBV03-01,TCRBV03-02												CASSQKGSRAKNIQYF+TCRBV03-X+TCRBJ02-04	TCRBV03	TCRBD02-01*02	TCRBJ02-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCCAAGCCCCTCAGACAGAGGGTACGACGAGCAGTACTTCGGGCCG	CSAPSPSDRGYDEQYF	In	VDJ	1	35	6.187243671333617E-4	7.490155795240541E-4	48	TCRBV20						TCRBJ02	TCRBJ02-07	01	6	2	5	5	13	8	26	34	52	47	60		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSAPSPSDRGYDEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTACCAACCCTACTACCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CSATNPTTSGANVLTF	In	VDJ	1	35	6.187243671333617E-4	7.490155795240541E-4	48	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-06	01	4	3	9	0	8	1	26	36	48	44	49		TCRBV20-01,TCRBV20-or09_02				01,02								CSATNPTTSGANVLTF+TCRBV20-X+TCRBJ02-06	TCRBV20	TCRBD02-01	TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CACCARCCARACMKCTYTGTACTTCTGTGCCACCAGTGAGCGGACAGGGGGCTACGAGCAGTACTTCGGGCCG	CATSERTGGYEQYF	In	VDJ	1	35	6.187243671333617E-4	7.490155795240541E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	1	1	3	4	0	23	35	-1	39	49	TCRBV22,TCRBV27													CATSERTGGYEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCAGGGTACACCGGGGAGCTGTTTTTTGGAGAA	CASSLAGYTGELFF	In	VDJ	1	35	6.187243671333617E-4	7.490155795240541E-4	42							TCRBJ02	TCRBJ02-02	01	0	5	3	3	0	1	18	-1	39	35	40	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLAGYTGELFF+X+TCRBJ02-02			TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCRGGRGACWCAGCWSKGTATYTCTGTGCCAGCAGCGGACATACAGGGCTCTACAATGAGCAGTTCTTCGGGCCA	CASSGHTGLYNEQFF	In	VDJ	1	35	6.187243671333617E-4	7.490155795240541E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	3	3	3	6	2	24	36	48	42	50	TCRBV07,TCRBV21													CASSGHTGLYNEQFF+X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTCAAACCCGGACAGGGCCCCTCTACGAGCAGTACTTCGGGCCG	CASSQTRTGPLYEQYF	In	VDJ	1	36	6.364022061943148E-4	7.704160246533128E-4	48	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	1	3	3	7	5	26	38	53	45	58		TCRBV12-03,TCRBV12-04												CASSQTRTGPLYEQYF+TCRBV12-X+TCRBJ02-07	TCRBV12	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTCTACACGTTACGCACTGAAGCTTTCTTTGGACAA	CASSFYTLRTEAFF	In	VDJ	1	36	6.364022061943148E-4	7.704160246533128E-4	42	TCRBV12						TCRBJ01	TCRBJ01-01	01	3	3	6	4	2	7	26	40	45	42	52		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSFYTLRTEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAACCAAGAGGACTAGCGGAACTACGAGCAGTACTTCGGGCCG	CASNQED*RNYEQYF	Stop	VDJ	1	36	6.364022061943148E-4		45	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	0	1	5	3	0	2	26	-1	53	43	55		TCRBV03-01,TCRBV03-02				01,02								CASNQED*RNYEQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCTACAGGGAAAGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	36	6.364022061943148E-4		40	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	3	3	0	2	2	26	35	43	37	45		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGGGCTGTAGCGGGAGGGCCTATTCACGTAGCAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	36	6.364022061943148E-4		55	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	5	5	0	6	6	13	26	35	52	41	65		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGTTCCCGGGACAGGGGGGAGAGAGACCCAGTACTTCGGGCCA	CSAVPGTGGRETQYF	In	VDJ	1	36	6.364022061943148E-4	7.704160246533128E-4	45	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	0	1	4	6	3	26	35	52	41	55		TCRBV20-01,TCRBV20-or09_02												CSAVPGTGGRETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCCCTCGTTGGGGGAAGAAATTCACCCCTCCACTTTGGGAAC	CASSPLVGGRNSPLHF	In	VDJ	1	37	6.54080045255268E-4	7.918164697825714E-4	48	TCRBV03						TCRBJ01	TCRBJ01-06	01	4	6	1	7	8	4	26	39	52	47	56		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPLVGGRNSPLHF+TCRBV03-X+TCRBJ01-06	TCRBV03		TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCCTGTCGGCAGCGGAGGGGGGGGTGAAAAACTGTTTTTTGGCAGT	CSAPVGSGGGGEKLFF	In	VDJ	1	37	6.54080045255268E-4	7.918164697825714E-4	48	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-04	01	5	9	0	7	15	1	26	35	57	50	58		TCRBV20-01,TCRBV20-or09_02												CSAPVGSGGGGEKLFF+TCRBV20-X+TCRBJ01-04	TCRBV20	TCRBD02-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GMGACWCGGCWSTGTATCTCTGYGCCAGCAGCTTGGGCGGGGGGAACAATGAGCAGTTCTTCGGGCCA	CASSLGGGNNEQFF	In	VDJ	1	37	6.54080045255268E-4	7.918164697825714E-4	42	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	2	7	1	5	2	1	19	33	43	35	44	TCRBV07,TCRBV23													CASSLGGGNNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCACAGGGGGCGTCCTACGAGCAGTACTTCGGGCCG	CASSLAQGASYEQYF	In	VDJ	1	37	6.54080045255268E-4	7.918164697825714E-4	45				TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	3	0	1	0	1	18	-1	44	35	45	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03												CASSLAQGASYEQYF+X+TCRBJ02-07		TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCMRGRGACWCAGCWSKGTAYTTCTGTGCCAGCAGCGTTACCCCGGAGAGCGAGCAGTACTTCGGGCCG	CASSVTPESEQYF	In	VDJ	1	37	6.54080045255268E-4	7.918164697825714E-4	39	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	5	10	2	6	8	2	24	36	48	44	50	TCRBV12,TCRBV21													CASSVTPESEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCAAGAGAGTTAGCCCCTAACAATGAGCAGTTCTTCGGGCCA	CSARELAPNNEQFF	In	VDJ	1	38	6.717578843162212E-4	8.132169149118302E-4	42	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	0	5	7	5	2	5	26	40	46	42	51		TCRBV20-01,TCRBV20-or09_02				01,02								CSARELAPNNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCATTTGGGAGGGACGGTAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	38	6.717578843162212E-4		44	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-05	01	5	9	0	4	5	5	26	35	47	40	52		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ01-05	TCRBV20	TCRBD02-01*02	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTTTACAGGGAGCAAGAGACCCAGTACTTCGGGCCA	CATSDFYREQETQYF	In	VDJ	1	38	6.717578843162212E-4	8.132169149118302E-4	45	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	1	3	3	2	2	2	24	41	49	43	51		TCRBV24-01,TCRBV24-or09_02												CATSDFYREQETQYF+TCRBV24-X+TCRBJ02-05	TCRBV24	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCACAGGGGACTGAAGCTTTCTTTGGACAA	CASSPQGTEAFF	In	VDJ	2	40	7.071135624381275E-4	8.560178051703475E-4	36	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	3	2	5	1	0	26	39	-1	40	47		TCRBV03-01,TCRBV03-02												CASSPQGTEAFF+TCRBV03-X+TCRBJ01-01	TCRBV03	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTATAGCATACCGGGGGGGCCGAACAGATACGCAGTATTTTGGCCCA	CSAIAYRGGRTDTQYF	In	VDJ	2	40	7.071135624381275E-4	8.560178051703475E-4	48	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	4	8	0	3	8	4	26	36	52	44	56		TCRBV20-01,TCRBV20-or09_02												CSAIAYRGGRTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGGGGGGGAGTCACCCCTCCACTTTGGGAAC	CSAGGESPLHF	In	VDJ	2	40	7.071135624381275E-4	8.560178051703475E-4	33	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-06	01	5	9	0	10	0	2	26	-1	42	35	44		TCRBV20-01,TCRBV20-or09_02												CSAGGESPLHF+TCRBV20-X+TCRBJ01-06	TCRBV20	TCRBD02-01*01	TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTTAAAAATCCGGGGGAACGCGAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	2	41	7.247914014990807E-4		50	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	5	8	2	0	8	4	26	35	49	43	53		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-02	TCRBV20	TCRBD02-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACYSRGGGACTCAGCTKTGTATTTYTGTGCCAGCAGTGTTTTGGAAACCTCCTACAATGAGCAGTTCTTCGGGCCA	CASSVLETSYNEQFF	In	VDJ	2	42	7.42469240560034E-4	8.988186954288649E-4	45	unresolved						TCRBJ02	TCRBJ02-01	01	5	1	8	0	5	3	26	38	46	43	49	TCRBV09,TCRBV12			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSVLETSYNEQFF+X+TCRBJ02-01	unresolved		TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCTTTCGGGGGGGCCGGGAGACCCAGTACTTCGGGCCA	CASSFRGGRETQYF	In	VDJ	2	42	7.42469240560034E-4	8.988186954288649E-4	42	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	2	8	0	5	1	4	19	33	42	34	46	TCRBV07,TCRBV11													CASSFRGGRETQYF+X+TCRBJ02-05	unresolved	TCRBD02-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGCGTAGGACTAGCGGGACCCGAAGTATTTTGGCCCA	CASSQA*D*RDPKYF	Stop	VDJ	2	43	7.601470796209872E-4		45	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	1	1	3	13	4	5	26	42	58	46	63		TCRBV03-01,TCRBV03-02												CASSQA*D*RDPKYF+TCRBV03-X+TCRBJ02-03	TCRBV03	TCRBD02-01*02	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGCTACGGGAGCTCCTACAATGAGCAGTTCTTCGGGCCA	CSASYGSSYNEQFF	In	VDJ	2	43	7.601470796209872E-4	9.202191405581236E-4	42	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	3	8	2	0	3	0	26	37	-1	40	46		TCRBV20-01,TCRBV20-or09_02												CSASYGSSYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGGACCCTCGGCTAGTTGGGGAGCAGTTCTTCGGGCCA	CSARDPRLVGEQFF	In	VDJ	2	43	7.601470796209872E-4	9.202191405581236E-4	42	TCRBV20						TCRBJ02	TCRBJ02-01	01	3	1	7	10	0	15	26	-1	41	37	56		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARDPRLVGEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20		TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAGACGTAGCGGGGGGCATCCGGAATACGCAGTATTTTGGCCCA	CASSQDVAGGIRNTQYF	In	VDJ	2	43	7.601470796209872E-4	9.202191405581236E-4	51	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	0	5	1	7	2	8	23	40	52	42	60	TCRBV01,TCRBV04													CASSQDVAGGIRNTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TSRRGGACTCAGCYRTGTACTTCTGTGCCAGCGTTCGGGACAGTACTCACAATGAGCAGTTCTTCGGGCCA	CASVRDSTHNEQFF	In	VDJ	2	45	7.955027577428935E-4	9.63020030816641E-4	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	8	0	5	5	4	5	22	31	42	35	47	TCRBV02,TCRBV12													CASVRDSTHNEQFF+X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCCCAGCCCCGGACAGCTTCTACGAGCAGTACTTCGGGCCG	CASSPAPDSFYEQYF	In	VDJ	2	45	7.955027577428935E-4	9.63020030816641E-4	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	1	5	3	8	3	18	30	44	38	47	TCRBV07,TCRBV11													CASSPAPDSFYEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TYRGGRGACWCAGCWYKGTATTTCTGTGCCAGCAGTGAAGCAACCGGACTAGCGGGAGAAGGGACCGGGGAGCTGTTTTTTGGAGAA	CASSEATGLAGEGTGELFF	In	VDJ	2	45	7.955027577428935E-4	9.63020030816641E-4	57	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	6	1	2	5	10	5	24	35	58	45	63	TCRBV09,TCRBV21													CASSEATGLAGEGTGELFF+X+TCRBJ02-02	unresolved	TCRBD02-01*02	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGGACCCGACAGGGAGCCGGAGACCCAGTACTTCGGGCCA	CSAGPDREPETQYF	In	VDJ	2	46	8.131805968038467E-4	9.844204759458996E-4	42	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	2	3	5	6	5	26	35	48	41	53		TCRBV20-01,TCRBV20-or09_02												CSAGPDREPETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAATTCTAGCGGGAGAAGATACGCAGTATTTTGGCCCA	CSARILAGEDTQYF	In	VDJ	2	47	8.308584358647998E-4	0.0010058209210751584	42	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	2	4	2	5	3	1	26	38	51	41	52		TCRBV20-01,TCRBV20-or09_02												CSARILAGEDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*02	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTGGGACAGGAGGGTACACTGAAGCTTTCTTTGGACAA	CASSGTGGYTEAFF	In	VDJ	2	47	8.308584358647998E-4	0.0010058209210751584	42	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	1	4	3	0	5	24	-1	44	37	49		TCRBV24-01,TCRBV24-or09_02												CASSGTGGYTEAFF+TCRBV24-X+TCRBJ01-01	TCRBV24	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGACWCGGCMSTGTATSTCTGYGCCAGCAGCTTGGATTCGGGGGTCTATGGCTACACCTTCGGTTCG	CASSLDSGVYGYTF	In	VDJ	2	47	8.308584358647998E-4	0.0010058209210751584	42	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	3	8	2	4	5	1	18	32	43	37	44	TCRBV11,TCRBV23													CASSLDSGVYGYTF+X+TCRBJ01-02	unresolved	TCRBD02-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCAACAGGCGACGGAAGCTTTCTTTGGACAA	CSAQQATEAFF	In	VDJ	2	48	8.485362749257531E-4	0.001027221366204417	33	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	3	4	8	2	5	26	35	42	37	47		TCRBV20-01,TCRBV20-or09_02												CSAQQATEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCWMCCAGACAKCTSTKTACTTSTGTGCCAGCAGYAAGTTTAGCGGGATTTCCTACAATGAGCAGTTCTTCGGGCCA	CASSKFSGISYNEQFF	In	VDJ	2	48	8.485362749257531E-4	0.001027221366204417	48	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	7	5	3	1	6	2	24	35	49	41	51	TCRBV06,TCRBV24													CASSKFSGISYNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATCCCGGGACGGCCTACGAGCAGTACTTCGGGCCG	CSARDPGTAYEQYF	In	VDJ	2	49	8.662141139867063E-4	0.0010486218113336758	42	TCRBV20						TCRBJ02	TCRBJ02-07	01	0	0	7	2	4	2	26	40	49	44	51		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARDPGTAYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCTTGAAAGGGACAGGGCTGTCCTATGGCTACACCTTCGGTTCG	CSALKGTGLSYGYTF	In	VDJ	2	50	8.838919530476595E-4	0.0010700222564629343	45	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	0	3	4	7	5	26	34	50	41	55		TCRBV20-01,TCRBV20-or09_02												CSALKGTGLSYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCCTAAGGCGGGGGATTCCTACAATGAGCAGTTCTTCGGGCCA	CSAPKAGDSYNEQFF	In	VDJ	2	51	9.015697921086126E-4	0.001091422701592193	45	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	6	7	2	1	7	2	26	34	48	41	50		TCRBV20-01,TCRBV20-or09_02												CSAPKAGDSYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCGGGAGGGCCGGGGGAGCAGTACTTCGGGCCG	CASSLAGGPGEQYF	In	VDJ	2	51	9.015697921086126E-4	0.001091422701592193	42				TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	0	9	0	7	0	6	18	-1	42	35	48	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03												CASSLAGGPGEQYF+X+TCRBJ02-07		TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCTTAGGGCTGGGACAGGGCAGGTTATCCCAGTACTTCGGGCCA	CASSLGLGQGRLSQYF	In	VDJ	2	51	9.015697921086126E-4	0.001091422701592193	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	1	0	3	9	4	8	18	34	47	38	55	TCRBV05,TCRBV11													CASSLGLGQGRLSQYF+X+TCRBJ02-05	unresolved	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCMRGRGACWCAGCWSKGTAYTTCTGTGCCAGCAGTGGCCCCAGGGTAGGGGGCGGCCACACAGATACGCAGTATTTTGGCCCA	CASSGPRVGGGHTDTQYF	In	VDJ	2	51	9.015697921086126E-4	0.001091422701592193	54	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	6	5	0	2	12	5	24	35	54	47	59	TCRBV12,TCRBV21													CASSGPRVGGGHTDTQYF+X+TCRBJ02-03	unresolved	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCTACAACCCGCCCATGGGGGCTACACCTTCGGTTCG	CSALQPAHGGYTF	In	VDJ	2	52	9.192476311695658E-4	0.0011128231467214518	39	TCRBV20						TCRBJ01	TCRBJ01-02	01	6	0	9	8	16	0	26	34	-1	50	53		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSALQPAHGGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20		TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGTGGCGGGGGGGCACCAAGAGACCCAGTACTTCGGGCCA	CSARVAGGHQETQYF	In	VDJ	2	52	9.192476311695658E-4	0.0011128231467214518	45	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	1	7	0	0	2	1	26	39	50	41	51		TCRBV20-01,TCRBV20-or09_02												CSARVAGGHQETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATTCCAGGGACACTGAAGCTTTCTTTGGACAA	CSARDSRDTEAFF	In	VDJ	2	53	9.36925470230519E-4	0.0011342235918507105	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	4	3	3	3	0	26	40	-1	43	48		TCRBV20-01,TCRBV20-or09_02												CSARDSRDTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCAGACGGGACAGTGAGTATTATCAGCCCCAGCATTTTGGTGAT	CASRRDSEYYQPQHF	In	VDJ	2	54	9.546033092914723E-4	0.0011556240369799693	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	0	5	5	2	8	24	35	44	37	52	TCRBV06,TCRBV10													CASRRDSEYYQPQHF+X+TCRBJ01-05	unresolved	TCRBD01-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGATCGGGAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	2	55	9.722811483524254E-4		43	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	0	8	5	1	1	0	26	43	-1	44	47		TCRBV03-01,TCRBV03-02				01,02								X+TCRBV03-X+TCRBJ02-02	TCRBV03	TCRBD02-01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCGGGACTAGCGGGCCCAGAGACCCAGTACTTCGGGCCA	CASSPGLAGPETQYF	In	VDJ	2	55	9.722811483524254E-4	0.0011770244821092278	45	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-05	01	4	0	4	4	1	3	26	39	52	40	55		TCRBV03-01,TCRBV03-02				01,02								CASSPGLAGPETQYF+TCRBV03-X+TCRBJ02-05	TCRBV03	TCRBD02-01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCGGCCMTSTATCKCTGTGCCAGCAGCGGTGGGACTAGCGGGCACAATGAGCAGTTCTTCGGGCCA	CASSGGTSGHNEQFF	In	VDJ	2	55	9.722811483524254E-4	0.0011770244821092278	45	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	4	0	4	5	3	1	19	31	46	34	47	TCRBV05,TCRBV07					01,02								CASSGGTSGHNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTACCGACAACGGACAGCCCCAGCATTTTGGTGAT		Out	VDJ	2	56	9.899589874133787E-4		41	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	2	2	6	7	2	5	26	41	47	43	52		TCRBV12-03,TCRBV12-04												X+TCRBV12-X+TCRBJ01-05	TCRBV12	TCRBD01-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGAAATCTGGAGCTCCTACAATGAGCAGTTCTTCGGGCCA	CASSQEIWSSYNEQFF	In	VDJ	2	56	9.899589874133787E-4	0.0011984249272384865	48	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	0	10	2	0	5	0	26	43	-1	48	52		TCRBV03-01,TCRBV03-02												CASSQEIWSSYNEQFF+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAGGGACCGGCCGCGGGCCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	2	56	9.899589874133787E-4		47	TCRBV03						TCRBJ02	TCRBJ02-07	01	3	0	7	2	0	11	26	-1	45	40	56		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV03-X+TCRBJ02-07	TCRBV03		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTCGGACTAGCGGGGGAAGAATCTACAATGAGCAGTTCTTCGGGCCA	CSARTSGGRIYNEQFF	In	VDJ	2	56	9.899589874133787E-4	0.0011984249272384865	48	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	5	1	2	3	1	6	26	35	49	36	55		TCRBV20-01,TCRBV20-or09_02												CSARTSGGRIYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAGAYAGAAACACAGATACGCAGTATTTTGGCCCA	CASSQDRNTDTQYF	In	VDJ	2	56	9.899589874133787E-4	0.0011984249272384865	42	unresolved			unresolved			TCRBJ02	TCRBJ02-03	01	0	5	8	2	0	3	23	-1	43	40	46	TCRBV01,TCRBV04			TCRBD01,TCRBD02										CASSQDRNTDTQYF+X+TCRBJ02-03	unresolved	unresolved	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCMRGRGACWCAGCWSKGTAYTTCTGTGCCAGCAGTGAAGCGTGAGGAGGGGCGAACACTGAAGCTTTCTTTGGACAA	CASSEA*GGANTEAFF	Stop	VDJ	2	56	9.899589874133787E-4		48	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	5	10	0	1	9	2	22	34	49	43	51	TCRBV12,TCRBV21													CASSEA*GGANTEAFF+X+TCRBJ01-01	unresolved	TCRBD02-01*02	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTTGTCTAGCGGGTCGAGTAGGATACGCAGTATTTTGGCCCA		Out	VDJ	2	57	0.0010076368264743318		46	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	6	4	4	6	3	8	24	36	47	39	55		TCRBV24-01,TCRBV24-or09_02				01,02								X+TCRBV24-X+TCRBJ02-03	TCRBV24	TCRBD02-01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTCGGCAGGGCTCTCCTACGAGCAGTACTTCGGGCCG	CATSDSAGLSYEQYF	In	VDJ	2	58	0.001025314665535285	0.001241225817497004	45	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	4	3	0	3	2	24	40	48	43	50		TCRBV24-01,TCRBV24-or09_02												CATSDSAGLSYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
SGACTCGGCYSTSTATCTCTGTGCCAGCAGCCAGGACACAGCCTACAATGAGCAGTTCTTCGGGCCA	CASSQDTAYNEQFF	In	VDJ	2	58	0.001025314665535285	0.001241225817497004	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	4	1	6	2	2	3	19	31	38	33	41	TCRBV05,TCRBV07													CASSQDTAYNEQFF+X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGCGACAGGGGGGTTCCAAGAGACCCAGTACTTCGGGCCA	CATSATGGFQETQYF	In	VDJ	2	60	0.0010606703436571913	0.0012840267077555213	45	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	2	1	1	1	3	24	37	47	38	50		TCRBV24-01,TCRBV24-or09_02												CATSATGGFQETQYF+TCRBV24-X+TCRBJ02-05	TCRBV24	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGACCCGGGACGGTCAATCAGCCCCAGCATTTTGGTGAT	CASRPGTVNQPQHF	In	VDJ	2	60	0.0010606703436571913	0.0012840267077555213	42	TCRBV24						TCRBJ01	TCRBJ01-05	01	7	0	7	3	4	3	24	35	44	39	47		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASRPGTVNQPQHF+TCRBV24-X+TCRBJ01-05	TCRBV24		TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTATCGAAGTGGTGGGCAGGGGGAACTATGGCTACACCTTCGGTTCG		Out	VDJ	2	61	0.0010783481827181445		53				TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	4	1	2	16	0	24	36	-1	52	59	TCRBV24,TCRBV27	TCRBV24-01,TCRBV24-or09_02,TCRBV27-01												X+X+TCRBJ01-02		TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTATGGGCAGGGGGCTCGGCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSLWAGGSAGANVLTF	In	VDJ	2	61	0.0010783481827181445	0.00130542715288478	54	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	6	4	0	2	7	4	24	36	51	43	55		TCRBV24-01,TCRBV24-or09_02												CASSLWAGGSAGANVLTF+TCRBV24-X+TCRBJ02-06	TCRBV24	TCRBD01-01*01	TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCCCACCCCCCGGGCGTAGAAAAACTGTTTTTTGGCAGT	CASSPHPPGVEKLFF	In	VDJ	2	62	0.0010960260217790978	0.0013268275980140387	45	TCRBV03						TCRBJ01	TCRBJ01-04	01	4	8	0	8	10	3	26	39	53	49	56		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPHPPGVEKLFF+TCRBV03-X+TCRBJ01-04	TCRBV03		TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCATGGGACTAGCGGGAGATTCCTACAATGAGCAGTTCTTCGGGCCA	CASMGLAGDSYNEQFF	In	VDJ	2	62	0.0010960260217790978	0.0013268275980140387	48	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	7	0	2	1	1	2	23	33	48	34	50	TCRBV06,TCRBV10													CASMGLAGDSYNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACYSRGGGACTCAGCTKTGTATTTYTGTGCCAGCAGCTTTGGGTCTTACAATGAGCAGTTCTTCGGGCCA	CASSFGSYNEQFF	In	VDJ	2	63	0.001113703860840051	0.0013482280431432975	39	unresolved						TCRBJ02	TCRBJ02-01	01	6	0	9	4	4	3	26	37	44	41	47	TCRBV09,TCRBV12			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSFGSYNEQFF+X+TCRBJ02-01	unresolved		TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTGTCACAGGGTTCGGCTACACCTTCGGTTCG	CASSVTGFGYTF	In	VDJ	2	63	0.001113703860840051	0.0013482280431432975	36	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	3	3	8	3	3	26	38	47	41	50		TCRBV12-03,TCRBV12-04												CASSVTGFGYTF+TCRBV12-X+TCRBJ01-02	TCRBV12	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTCGGACTACCGGATTGGTGCCGGCTCGGGCCA		Out	VDJ	2	64	0.001131381699901004		41	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02			2	1	9	20	1	16	24	40	47	41	63		TCRBV24-01,TCRBV24-or09_02				01,02		TCRBJ02-01,TCRBJ02-05						X+TCRBV24-X+TCRBJ02-X	TCRBV24	TCRBD02-01	TCRBJ02	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTTCGAACAGGCGGGATCAAAACTACGAGCAGTACTTCGGGCCG	CATSSNRRDQNYEQYF	In	VDJ	2	64	0.001131381699901004	0.001369628488272556	48	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	6	7	3	3	8	6	24	36	50	44	56		TCRBV24-01,TCRBV24-or09_02												CATSSNRRDQNYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATCCGAGTAGCGGGGTCCCTACTGCGGAGACCCAGTACTTCGGGCCA	CSARDPSSGVPTAETQYF	In	VDJ	2	65	0.0011490595389619573	0.0013910289334018147	54	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	0	5	3	5	6	11	26	40	54	46	65		TCRBV20-01,TCRBV20-or09_02												CSARDPSSGVPTAETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TYRGGRGACWCAGCWYKGTATTTCTGTGCCAGCAGCGTAGAGACAGGCGGCCAAGAGACCCAGTACTTCGGGCCA	CASSVETGGQETQYF	In	VDJ	3	66	0.0011667373780229104	0.0014124293785310734	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	2	4	1	5	3	24	36	47	41	50	TCRBV09,TCRBV21													CASSVETGGQETQYF+X+TCRBJ02-05	unresolved	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTCCGGACCTTTCGCAGAGTTACAATGAGCAGTTCTTCGGGCCA	CASSPDLSQSYNEQFF	In	VDJ	3	67	0.0011844152170838638	0.0014338298236603322	48	TCRBV24						TCRBJ02	TCRBJ02-01	01	6	1	7	4	2	12	24	36	42	38	54		TCRBV24-01,TCRBV24-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPDLSQSYNEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24		TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TGGAGGACTCRGCCATGTAYYKCTGTGCCAGCAGCTTGATGGAGGGGGCGATGGGTGCAATGAAGCTTTCTTTGGACAA		Out	VDJ	3	68	0.0012020930561448169		50	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	5	0	7	8	11	23	34	49	42	60	TCRBV02,TCRBV07													X+X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGGGAGAAACTAGCGGGGAAAAACAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	3	70	0.0012374487342667233		49	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	5	3	3	2	7	5	26	35	52	42	57		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGAACTGCCCGGGACAGGGACAGCCAAAAACATTCAGTACTTCGGCGCC	CSARELPGTGTAKNIQYF	In	VDJ	3	71	0.0012551265733276764	0.001519431604177367	54	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	0	0	3	0	7	2	26	40	56	47	58		TCRBV20-01,TCRBV20-or09_02												CSARELPGTGTAKNIQYF+TCRBV20-X+TCRBJ02-04	TCRBV20	TCRBD01-01*01	TCRBJ02-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGTATTTCTGTGCCAGCAGCTTTTTAATGGATCGACCATCTTCGTTGAGTAATCTTGGAAACACCATATATTTTGGAGAG	CASSFLMDRPSSLSNLGNTIYF	In	VDJ	3	71	0.0012551265733276764	0.001519431604177367	66	TCRBV21						TCRBJ01	TCRBJ01-03	01	5	1	8	3	8	24	8	20	31	28	55		TCRBV21-or09_02,TCRBV21-01		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSFLMDRPSSLSNLGNTIYF+TCRBV21-X+TCRBJ01-03	TCRBV21		TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAAGAAGGGGGTTTGGCAGGGGAGTACTTCGGGCCG	CASSQEGGLAGEYF	In	VDJ	3	75	0.001325837929571489	0.0016050333846944016	42				TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	4	2	11	11	0	18	35	-1	46	52	TCRBV04,TCRBV11	TCRBV04-02,TCRBV11-03												CASSQEGGLAGEYF+X+TCRBJ02-07		TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGRGACWCRGCMSTGTATCTCTRCGCCAGCAGCCAAGATCGGAATTCAGATACGCAGTATTTTGGCCCA	XASSQDRNSDTQYF	In	VDJ	3	76	0.0013435157686324424	0.0016264338298236604	42	unresolved						TCRBJ02	TCRBJ02-03	01	0	1	8	4	2	3	22	39	44	41	47	TCRBV04,TCRBV23			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									XASSQDRNSDTQYF+X+TCRBJ02-03	unresolved		TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TTTCTGTGCCAGCAGTGAATGGGGTCGCCCGACCCCAGTGACTAGCGGGAGGACGCCGGGCAGCAGTACTTCGGGCCG		Out	VDJ	3	76	0.0013435157686324424		68	TCRBV21			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	6	2	1	8	24	9	4	15	52	39	61		TCRBV21-or09_02,TCRBV21-01												X+TCRBV21-X+TCRBJ02-07	TCRBV21	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGACTCRGCCRTGTATSKCTGTGCCAGCAGCTTATTTGGTGGGGGCCCCAATGAGCAGTTCTTCGGGCCA	CASSLFGGGPNEQFF	In	VDJ	3	78	0.0013788714467543488	0.0016692347200821776	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	2	6	0	6	6	2	18	33	45	39	47	TCRBV07,TCRBV11													CASSLFGGGPNEQFF+X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGGGGACTYGGCYSTSTATCTCTGTGCCAGCAGCTTACTGGGACAGGGAGGGAACACTGAAGCTTTCTTTGGACAA	CASSLLGQGGNTEAFF	In	VDJ	3	79	0.001396549285815302	0.0016906351652114363	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	0	3	1	4	3	22	35	48	39	51	TCRBV05,TCRBV07													CASSLLGQGGNTEAFF+X+TCRBJ01-01	unresolved	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCCAAGACGCGGGGGGGCCCGCAGATACGCAGTATTTTGGCCCA	CASSQDAGGPADTQYF	In	VDJ	3	84	0.001484938481120068	0.0017976373908577298	48	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	0	7	0	4	1	4	23	40	50	41	54	TCRBV01,TCRBV04													CASSQDAGGPADTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGCCTAGGGACAGGGTCCTCCTACGAGCAGTACTTCGGGCCG	CASSLGTGSSYEQYF	In	VDJ	3	87	0.0015379719983029275	0.001861838726245506	45	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	7	0	3	0	4	2	24	35	48	39	50		TCRBV24-01,TCRBV24-or09_02												CASSLGTGSSYEQYF+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCAACCGGGACAGAGACTACGAGCAGTACTTCGGGCCG	CASSNRDRDYEQYF	In	VDJ	3	88	0.0015556498373638806	0.0018832391713747645	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	0	5	3	4	3	19	31	42	35	45	TCRBV07,TCRBV11													CASSNRDRDYEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCARCAGCCATTCAGTCCCGCCCTACGAGCAGTACTTCGGGCCG	CAXSHSVPPYEQYF	In	VDJ	3	89	0.001573327676424834	0.0019046396165040233	42	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	4	5	2	2	6	26	40	45	42	51		TCRBV03-01,TCRBV03-02												CAXSHSVPPYEQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGTTTAACCGGGACCGTCTATGGCTACACCTTCGGTTCG	CASSLTGTVYGYTF	In	VDJ	3	89	0.001573327676424834	0.0019046396165040233	42	unresolved						TCRBJ01	TCRBJ01-02	01	6	0	7	4	6	3	24	36	47	42	50	TCRBV24,TCRBV27			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLTGTVYGYTF+X+TCRBJ01-02	unresolved		TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCATAGCGGACAGGGGTCTTCAAGAGACCCAGTACTTCGGGCCA	CASSIADRGLQETQYF	In	VDJ	3	89	0.001573327676424834	0.0019046396165040233	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	0	1	2	2	0	4	18	-1	44	35	48	TCRBV07,TCRBV11													CASSIADRGLQETQYF+X+TCRBJ02-05	unresolved	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGACTCGGCYGTGTATSTCTGTGCCAGAAGCTTGGAAGAGCGGGGGACCCCTCGGGACGAGCAGTACTTCGGGCCG	CARSLEERGTPRDEQYF	In	VDJ	3	90	0.001591005515485787	0.001926040061633282	51	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	0	6	2	5	3	10	18	34	45	37	55	TCRBV05,TCRBV07													CARSLEERGTPRDEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACMKCTCTKTACTTCTGTGCCAGCAGTTCCCTCTCCTACGAGCAGTACTTCGGGCCG	CASSSLSYEQYF	In	VDJ	3	91	0.0016086833545467401	0.0019474405067625407	36	unresolved			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	6	4	10	0	3	0	24	36	-1	39	41	TCRBV24,TCRBV27					01,02								CASSSLSYEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGGACAGGGTAGGGAATGGCTACACCTTCGGTTCG	CSARDRVGNGYTF	In	VDJ	4	92	0.0016263611936076935	0.0019688409518917992	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	3	1	3	6	0	6	26	-1	45	37	51		TCRBV20-01,TCRBV20-or09_02												CSARDRVGNGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGAAAGCCTCGGACAGGGGTTCAGAACACGTATGGCTACACCTTCGGTTCG	CASRKPRTGVQNTYGYTF	In	VDJ	4	97	0.0017147503889124594	0.0020758431775380927	54	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	1	2	5	8	11	26	37	54	45	65		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASRKPRTGVQNTYGYTF+TCRBV12-X+TCRBJ01-02	TCRBV12	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTCAGTGGGGAGGGGCGAATGAAAAACTGTTTTTTGGCAGT	CASSQWGGANEKLFF	In	VDJ	4	100	0.001767783906095319	0.0021400445129258687	45	TCRBV12			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-04	01	5	9	0	5	5	3	26	38	50	43	53		TCRBV12-03,TCRBV12-04												CASSQWGGANEKLFF+TCRBV12-X+TCRBJ01-04	TCRBV12	TCRBD02-01*02	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTAGCGGGAGGGCATTCAGACAATGAGCAGTTCTTCGGGCCA	CASSLAGGHSDNEQFF	In	VDJ	4	103	0.0018208174232781785	0.002204245848313645	48	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	0	9	0	5	0	7	18	-1	42	35	49	TCRBV07,TCRBV11													CASSLAGGHSDNEQFF+X+TCRBJ02-01	unresolved	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGGGTCGCGCGAGCTTTCCTACGAGCAGTACTTCGGGCCG	CSARGSRELSYEQYF	In	VDJ	4	111	0.001962240135765804	0.0023754494093477145	45	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	1	6	7	1	9	2	26	39	51	48	53		TCRBV20-01,TCRBV20-or09_02				01,02								CSARGSRELSYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGAAGCCCCTTATCAGGTATATATGGCTACACCTTCGGTTCG	CARSPLSGIYGYTF	In	VDJ	4	112	0.0019799179748267574	0.002396849854476973	42				TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	4	4	5	7	4	18	30	41	37	45	TCRBV05,TCRBV11	TCRBV05-03,TCRBV11-03												CARSPLSGIYGYTF+X+TCRBJ01-02		TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCRTGTATSKCTGTGCCAGCAGCTTAGTAGGAGCCACCCTGGCAGATACGCAGTATTTTGGCCCA	CASSLVGATLADTQYF	In	VDJ	4	113	0.0019975958138877103	0.002418250299606232	48	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	1	10	2	4	2	9	18	34	40	36	49	TCRBV07,TCRBV11													CASSLVGATLADTQYF+X+TCRBJ02-03	unresolved	TCRBD02-01*02	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGCCTCTGGGGCTAGCGGGGGGGCTGGTAGGGCAGTTCTTCGGGCCA	CSARPLGLAGGLVGQFF	In	VDJ	4	117	0.002068307170131523	0.0025038520801232665	51	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	3	4	0	12	10	8	26	37	59	47	67		TCRBV20-01,TCRBV20-or09_02												CSARPLGLAGGLVGQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ARRRRGACTCAGCYGYGTATCTCTRCGCCAGCAGCCAAGAAACAGGCGTCTACGAGCAGTACTTCGGGCCG	XASSQETGVYEQYF	In	VDJ	4	117	0.002068307170131523	0.0025038520801232665	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	0	3	4	3	1	3	22	39	45	40	48	TCRBV01,TCRBV04													XASSQETGVYEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTCCGAGGACAGGGGGCGAGGCTACACCTTCGGTTCG	CATSDSEDRGRGYTF	In	VDJ	4	118	0.0020859850091924765	0.0025252525252525255	45	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	1	0	8	4	2	24	40	55	44	57		TCRBV24-01,TCRBV24-or09_02												CATSDSEDRGRGYTF+TCRBV24-X+TCRBJ01-02	TCRBV24	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGAACGGACTAGCCGGGGGATCAATGAGCAGTTCTTCGGGCCA	CSARERTSRGINEQFF	In	VDJ	5	122	0.002156696365436289	0.00261085430576956	48	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	0	1	7	6	2	8	26	40	50	42	58		TCRBV20-01,TCRBV20-or09_02				01,02								CSARERTSRGINEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTAGCCGCATGCGGGAGGGCCTTTCCAATGAGCAGTTCTTCGGGCCA	CSSRMREGLSNEQFF	In	VDJ	5	123	0.0021743742044972422	0.0026322547508988185	45	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	8	7	0	6	8	6	26	32	49	40	55		TCRBV20-01,TCRBV20-or09_02												CSSRMREGLSNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGAGGGGACAGGGTCCAACACTGAAGCTTTCTTTGGACAA	CATSEGTGSNTEAFF	In	VDJ	5	129	0.0022804412388629613	0.002760657421674371	45	TCRBV24			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	0	3	2	1	3	24	38	48	39	51		TCRBV24-01,TCRBV24-or09_02												CATSEGTGSNTEAFF+TCRBV24-X+TCRBJ01-01	TCRBV24	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGATGTGCTACGAGCAGTACTTCGGGCCG		Out	VJ	5	144	0.002545608824777259		37	TCRBV03						TCRBJ02	TCRBJ02-07	01	0	0	0	3	0	4	26	-1	43	-1	47		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ02-07	TCRBV03		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TCTGTGTACTTSTGTGCCACCTACCCCTGGACTAGCGGGAGGGTAACCCCCCCTAACGCGAGAACTCGTCCCTTCGGGCCA	CATYPWTSGRVTPPNARTRPF	In	VDJ	6	154	0.002722387215386791	0.003295668549905838	63	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02			10	1	0	18	9	28	12	19	43	28	71	TCRBV06,TCRBV10							TCRBJ02-01,TCRBJ02-05						CATYPWTSGRVTPPNARTRPF+X+TCRBJ02-X	unresolved	TCRBD02-01*02	TCRBJ02	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TYRGGRGACWCAGCWYKGTATTTCTGTGCCAGCAGCCCACGAGGATCCAGCGGGAGCTCCTACGAGCAGTACTTCGGGCCG	CASSPRGSSGSSYEQYF	In	VDJ	6	154	0.002722387215386791	0.003295668549905838	51	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	4	6	2	0	12	0	23	35	-1	47	55	TCRBV09,TCRBV21													CASSPRGSSGSSYEQYF+X+TCRBJ02-07	unresolved	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGCAATCAGCCCCAGCATTTTGGTGAT		Out	VJ	6	157	0.0027754207325696506		35	TCRBV03						TCRBJ01	TCRBJ01-05	01	3	0	0	1	0	0	26	-1	-1	-1	40		TCRBV03-01,TCRBV03-02												X+TCRBV03-X+TCRBJ01-05	TCRBV03		TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGACTCGGCYGTGTATSTCTGTGCCAGCAGCTCGAGCTCCGGGACCCTTGGGAGAAGATACACCTTCGGTTCG	CASSSSSGTLGRRYTF	In	VDJ	6	158	0.002793098571630604	0.0033812703304228727	48	unresolved						TCRBJ01	TCRBJ01-02	01	4	0	7	11	8	13	18	31	44	39	57	TCRBV07,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSSSGTLGRRYTF+X+TCRBJ01-02	unresolved		TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGACGTGGGACGGCGACACTGAAGCTTTCTTTGGACAA		Out	VDJ	6	167	0.0029521991231791825		38	unresolved						TCRBJ01	TCRBJ01-01	01	9	0	7	3	4	4	23	31	40	35	44	TCRBV06,TCRBV10			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+X+TCRBJ01-01	unresolved		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTGAATTACAGGGGTAATGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	7	171	0.0030229104794229954		40	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	5	3	2	8	5	4	26	35	47	40	51		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ02-02	TCRBV20	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGGGAGGGTCGAGCGGTAACTCCTACGAGCAGTACTTCGGGCCG	CSARGGSSGNSYEQYF	In	VDJ	7	172	0.0030405883184839487	0.0036808765622324945	48	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	3	9	0	0	0	11	26	-1	44	37	55		TCRBV20-01,TCRBV20-or09_02												CSARGGSSGNSYEQYF+TCRBV20-X+TCRBJ02-07	TCRBV20	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTAAGGACATCTAGCACAGATACGCAGTATTTTGGCCCA	CASSLRTSSTDTQYF	In	VDJ	7	180	0.003182011030971574	0.003852080123266564	45	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	2	1	6	0	1	3	26	41	47	42	50		TCRBV12-03,TCRBV12-04												CASSLRTSSTDTQYF+TCRBV12-X+TCRBJ02-03	TCRBV12	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTAAAATGGACGGGACTTAATACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	7	185	0.00327040022627634		50	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	0	10	4	11	3	24	36	53	47	56		TCRBV24-01,TCRBV24-or09_02				01,02								X+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAACCCGCTAGCGGGGCGTTAAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	7	194	0.003429500777824919		43	unresolved			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	10	4	3	3	5	5	23	30	44	35	49	TCRBV06,TCRBV10													X+X+TCRBJ02-05	unresolved	TCRBD02-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTCCGCAGGGACTGTACAATGAGCAGTTCTTCGGGCCA	CATSPQGLYNEQFF	In	VDJ	7	195	0.0034471786168858718	0.004173086800205444	42	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	0	10	4	5	1	24	36	47	41	48		TCRBV24-01,TCRBV24-or09_02				01,02								CATSPQGLYNEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGCAGACTAGCGGGAGTCATGAACACCGGGGAGCTGTTTTTTGGAGAA	CSASRLAGVMNTGELFF	In	VDJ	8	199	0.0035178899731296846	0.004258688580722479	51	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	3	2	2	1	2	4	26	37	51	39	55		TCRBV20-01,TCRBV20-or09_02												CSASRLAGVMNTGELFF+TCRBV20-X+TCRBJ02-02	TCRBV20	TCRBD02-01*02	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACYSRGGGACTCAGCTKTGTATTTYTGTGCCAGCAGCCCTACCCTGGGTACTGAAGCTTTCTTTGGACAA	CASSPTLGTEAFF	In	VDJ	8	200	0.003535567812190638	0.004280089025851737	39	unresolved						TCRBJ01	TCRBJ01-01	01	4	0	9	5	8	1	23	35	46	43	47	TCRBV09,TCRBV12			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPTLGTEAFF+X+TCRBJ01-01	unresolved		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGATCCCTAGCGGGAAGCACAGATACGCAGTATTTTGGCCCA	CSARSLAGSTDTQYF	In	VDJ	9	232	0.00410125866214114	0.004964903269988016	45	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	2	4	3	0	3	0	26	38	-1	41	50		TCRBV20-01,TCRBV20-or09_02												CSARSLAGSTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01*02	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTACGGGGGGGAGGCAGATACGCAGTATTTTGGCCCA	CASSYGGEADTQYF	In	VDJ	9	233	0.004118936501202093	0.0049863037151172745	42	TCRBV12			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	4	8	0	4	1	3	26	39	48	40	51		TCRBV12-03,TCRBV12-04												CASSYGGEADTQYF+TCRBV12-X+TCRBJ02-03	TCRBV12	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ARRRRGACTCAGCYGYGTATCTCTRCGCCAGCAGCCAGGGGCAGGGGGCCGCCTACGAGCAGTACTTCGGGCCG	XASSQGQGAAYEQYF	In	VDJ	10	266	0.004702305190213548	0.005692518404382811	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	4	0	2	4	2	23	37	49	41	51	TCRBV01,TCRBV04,TCRBV07,TCRBV17													XASSQGQGAAYEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGAACCTGGACTAGCGGGAGTCCCGCCGACGCGAGCAGTACTTCGGGCCG		Out	VDJ	11	288	0.005091217649554518		55	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	4	1	2	6	4	11	24	38	55	42	66		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ02-07	TCRBV24	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGAAATCCGTTCAGGGGACATGAACACTGAAGCTTTCTTTGGACAA	CSAREIRSGDMNTEAFF	In	VDJ	11	289	0.0051088954886154715	0.006184728642355761	51	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	0	0	6	0	11	0	26	40	-1	51	57		TCRBV20-01,TCRBV20-or09_02												CSAREIRSGDMNTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATTTAAGAGTTAGTGAGCAGTTCTTCGGGCCA	CATSDLRVSEQFF	In	VDJ	13	353	0.006240277188516476	0.0075543571306283175	39	TCRBV24			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	1	5	8	9	6	0	24	41	-1	47	50		TCRBV24-01,TCRBV24-or09_02				01,02								CATSDLRVSEQFF+TCRBV24-X+TCRBJ02-01	TCRBV24	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCCAACCAGACAGCTCTTTACTTCTGTGCCAGCAGTTTATGGGGCCGCGGGGGCACCGGGGAGCTGTTTTTTGGAGAA	CASSLWGRGGTGELFF	In	VDJ	17	446	0.007884316221185123	0.009544598527649375	48	TCRBV24			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	6	7	2	4	10	0	24	36	-1	46	53		TCRBV24-01,TCRBV24-or09_02												CASSLWGRGGTGELFF+TCRBV24-X+TCRBJ02-02	TCRBV24	TCRBD02-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGCGGGCTACACCGGGGAGCTGTTTTTTGGAGAA	CASSLAGYTGELFF	In	VDJ	17	447	0.007901994060246076	0.009565998972778635	42				TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	0	8	0	3	0	1	18	-1	39	35	40	TCRBV07,TCRBV11	TCRBV07-02,TCRBV11-03												CASSLAGYTGELFF+X+TCRBJ02-02		TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGAAAGGGGACCGGGACGGACGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSQERGPGRTNTGELFF	In	VDJ	18	466	0.008237873002404186	0.009972607430234549	57	TCRBV03						TCRBJ02	TCRBJ02-02	01	0	0	7	0	3	9	24	41	49	44	58		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQERGPGRTNTGELFF+TCRBV03-X+TCRBJ02-02	TCRBV03		TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCCGTATAGAGCCGGGGAGCTGTTTTTTGGAGAA	CASSPYRAGELFF	In	VDJ	47	1238	0.021885164757460048	0.026493751070022255	39	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	4	5	8	6	4	2	26	39	46	43	48		TCRBV03-01,TCRBV03-02				01,02								CASSPYRAGELFF+TCRBV03-X+TCRBJ02-02	TCRBV03	TCRBD02-01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CAGCCAGACCTATCTGTACCACTGTGCCAGCTCGGGAGGCGGTGCTTACAATGAGCAGTTCTTCGGGCCA	CASSGGGAYNEQFF	In	VDJ	1	26	4.596238155847829E-4	5.564115733607259E-4	42	TCRBV08	TCRBV08-02	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	5	8	1	4	1	7	22	31	39	32	46														CASSGGGAYNEQFF+TCRBV08-02+TCRBJ02-01	TCRBV08-02*01	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATCTCTGTGCCAGCAGCGCCTTACAGGGAGCGTCGGAGACCCAGTACTTCGGGCCA	CASSALQGASETQYF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	45	TCRBV07	TCRBV07-02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	3	3	5	5	7	18	30	41	35	48														CASSALQGASETQYF+TCRBV07-02+TCRBJ02-05	TCRBV07-02*01	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGAAGGCTAGCGGGGACGGGCAGTACTTCGGGCCG		Out	VDJ	1	8	1.414227124876255E-4		43	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	0	4	3	9	3	4	18	35	47	38	51														X+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATSTCTGTGCCAGCAGCTTGCCTCTACCGGGAGTAGACCCAGATACGCAGTATTTTGGCCCA	CASSLPLPGVDPDTQYF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	51	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	3	8	2	4	8	6	18	32	46	40	52														CASSLPLPGVDPDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGAAATGCCCGGGGCCAAAGCGGCCCAGTACTTCGGGCCA		Out	VDJ	1	9	1.591005515485787E-4		43	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-05	01	6	7	0	9	8	8	18	29	42	37	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01		TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCACCCTGGCAGGCCAAAAACATTCAGTACTTCGGCGCC	CASSPPWQAKNIQYF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	5	4	5	1	9	0	18	30	-1	39	42														CASSPPWQAKNIQYF+TCRBV11-03+TCRBJ02-04	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCCCCCATGGCGGGGGGCTTCTTTGAGCAGTTCTTCGGGCCA	CASSPPMAGGFFEQFF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	5	7	1	9	9	6	18	30	47	39	53														CASSPPMAGGFFEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTACCGGGACAACAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	9	1.591005515485787E-4		43	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	2	0	6	3	2	1	18	33	41	35	42														X+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTACCGGGACAGGTTTAATTTCGATTCACTGAAGCTTTCTTTGGACAA	CASSLPGQV*FRFTEAFF	Stop	VDJ	1	9	1.591005515485787E-4		54	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	0	4	4	2	13	18	33	43	35	56														CASSLPGQV*FRFTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTTAAGGGATGGAACACTGAAGCTTTCTTTGGACAA	CASSFKGWNTEAFF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	42	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-01	01	3	0	8	1	3	2	18	32	39	35	41				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSFKGWNTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATCTCTGTGCCAGCAGCTTGGGCGTTACAGGGGCTAAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	10	1.7677839060953188E-4		49	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	3	2	2	7	3	18	32	46	39	49														X+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCGTAGGACAGGGGCGGCCGGGGAGCTGTTTTTTGGAGAA	CASSRRTGAAGELFF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	5	1	2	6	4	3	18	30	43	34	46														CASSRRTGAAGELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATSTCTGTGCCAGCAGCGTGGACAGGGCTTCATTCTATGGCTACACCTTCGGTTCG	CASSVDRASFYGYTF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	1	3	4	2	7	18	30	40	32	47														CASSVDRASFYGYTF+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGGTTCCGGACTAACCAAGGCCTACGAGCAGTACTTCGGGCCG	CASSLGSGLTKAYEQYF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	51	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	1	1	9	2	5	7	18	34	45	39	52						01,02								CASSLGSGLTKAYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTCCCGAACATGAACACTGAAGCTTTCTTTGGACAA	CASSFPNMNTEAFF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	3	6	0	5	0	18	32	-1	37	40														CASSFPNMNTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATSTCTGTGCCAGCAGCTTTATAAGCGGATCGTTGAACATGAAAGTGGCTGAAGCTTTCTTTGGACAA	CASSFISGSLNMKVAEAFF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	57	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	3	6	5	6	4	20	18	32	41	36	61						01,02								CASSFISGSLNMKVAEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD02-01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCACGCCGACAGGGGGAAGAGAGACCCAGTACTTCGGGCCA	CASTPTGGRETQYF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	7	2	1	4	4	3	18	28	41	32	44														CASTPTGGRETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCACTACAGAGGGTATCCTACGAGCAGTACTTCGGGCCG	CASSSLQRVSYEQYF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	4	11	0	1	7	2	18	31	43	38	45														CASSSLQRVSYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTCCGAGCGGGGTTTAGGAAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	11	1.9445622967048507E-4		46	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	3	6	3	7	3	7	18	32	42	35	49														X+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGAAGGTCAGGGGCACTGAAGCTTTCTTTGGACAA	CASSLKVRGTEAFF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	4	2	4	6	0	18	32	-1	38	44														CASSLKVRGTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGGTAGGAGAGAGAGCTCCTATAATTCACCCCTCCACTTTGGGAAC	CASSLGRRESSYNSPLHF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	54	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-06	01	3	10	2	0	5	6	18	32	41	37	47														CASSLGRRESSYNSPLHF+TCRBV11-03+TCRBJ01-06	TCRBV11-03*01	TCRBD02-01*02	TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCAACCGGGACAGGGTGCGGGAGATCCAGTACTTCGGGCCA	CASSNRDRVREIQYF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	5	0	3	10	4	10	18	30	43	34	53														CASSNRDRVREIQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCGGGCCGAATGAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	12	2.1213406873143826E-4		41	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-01	01	5	8	0	0	1	4	18	30	35	31	39				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAATGATAGAGAACACCGGGGAGCTGTTTTTTGGAGAA	CASSLMIENTGELFF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	2	5	8	1	4	1	18	33	40	37	41						01,02								CASSLMIENTGELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01	TCRBD02-01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGTATGGGGGGTCCCCGGGGAGCTGTTTTTTGGAGAA	CASSLVWGVPGELFF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	1	9	1	6	3	3	18	34	43	37	46														CASSLVWGVPGELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATSTCTGTGCTAGCAGCTTAATTTCAGAGAGTGGGGCCTGAAGCTTTCTTTGGACAA		Out	VDJ	1	12	2.1213406873143826E-4		46	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	7	0	6	12	0	18	33	-1	45	50														X+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCACAGGGACAGGGTATACCGGGGAGCTGTTTTTTGGAGAA	CASSTGTGYTGELFF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	5	0	3	5	3	3	18	30	42	33	45														CASSTGTGYTGELFF+TCRBV11-03+TCRBJ02-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCGAAGGGCAGGGGACACTGAAGCTTTCTTTGGACAA	CASSRRAGDTEAFF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	4	2	3	7	0	18	30	-1	37	43														CASSRRAGDTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCTCCGACTAGCGAGAGATACGCAGTATTTTGGCCCA	CASSLRLARDTQYF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	5	2	6	5	4	2	18	30	42	34	44						01,02								CASSLRLARDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCTCGGGGGGGACTTTACAATGAGCAGTTCTTCGGGCCA	CASSSRGGLYNEQFF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	4	8	0	4	2	4	18	31	41	33	45														CASSSRGGLYNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGAGTGCAGGGGAACTAGAGTTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	13	2.2981190779239146E-4		53	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	0	4	2	4	3	9	18	35	44	38	53														X+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGGGACCGGGACAGGGGACTACGAGCAGTACTTCGGGCCG	CASSLGTGTGDYEQYF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	48	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	0	2	3	5	1	18	34	49	39	50														CASSLGTGTGDYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGGGACTAGCTCCTACGAGCAGTACTTCGGGCCG	CASSLGTSSYEQYF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	3	0	8	0	1	0	18	32	-1	33	41						01,02								CASSLGTSSYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATSTCTGTGCCAGCAGCCAAAGGAGGGGTGGGCACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	14	2.474897468533447E-4		43	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	5	10	0	4	4	5	18	30	40	34	45														X+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD02-01*02	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCACGGACAGGGACCCTCTGGAAACACCATATATTTTGGAGAG	CASSHGQGPSGNTIYF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	48	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	5	1	3	0	3	3	18	30	41	33	44														CASSHGQGPSGNTIYF+TCRBV11-03+TCRBJ01-03	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCTTAGCGGGGGGGGAGACAATGAGCAGTTCTTCGGGCCA	CASSLSGGGDNEQFF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	5	5	0	5	2	3	18	30	43	32	46														CASSLSGGGDNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTACCGGGATTTGGAGAGACCCAGTACTTCGGGCCA	CASSLPGFGETQYF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	2	8	3	4	1	5	18	33	39	34	44														CASSLPGFGETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGGAGGCGGGTTGAACACTGAAGCTTTCTTTGGACAA	CASSLGGGLNTEAFF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-01	01	1	7	4	0	3	1	18	34	42	37	43						01,02								CASSLGGGLNTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD02-01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGATAGGGGGGGAATACGAGCAGTACTTCGGGCCG	CASSLIGGEYEQYF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	3	9	0	4	4	2	18	32	43	36	45														CASSLIGGEYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCGGGGGACTAGCGGGGTTCACAGATACGCAGTATTTTGGCCCA	CASGGLAGFTDTQYF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	8	0	3	2	2	2	18	27	42	29	44														CASGGLAGFTDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCGGGGACTAGCGGGAGTGAGACCCAGTACTTCGGGCCA	CASSSGTSGSETQYF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	4	0	2	5	2	1	18	31	47	33	48														CASSSGTSGSETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCAAAACTAGCGGGGGTTACTACAATGAGCAGTTCTTCGGGCCA	CASSKTSGGYYNEQFF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	5	3	2	3	3	3	18	30	44	33	47														CASSKTSGGYYNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAAAATTGGGGGACAGATACGCAGTATTTTGGCCCA	CASSQNWGTDTQYF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	42	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-03	01	5	6	1	3	7	0	18	30	-1	37	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQNWGTDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01		TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCCGGGACAGGGGGAGGCAATGAGCAGTTCTTCGGGCCA	CASSSGTGGGNEQFF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	4	0	1	6	2	3	18	31	44	33	47														CASSSGTGGGNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCCGTGCAGGGAGGTAGCGGCTACGAGCAGTACTTCGGGCCG	CASSSVQGGSGYEQYF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	4	5	5	3	13	0	18	31	-1	44	50						01,02								CASSSVQGGSGYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAAACAGGCTTAATTCACCCCTCCACTTTGGGAAC	CASSLNRLNSPLHF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	2	3	4	6	1	2	18	33	39	34	41														CASSLNRLNSPLHF+TCRBV11-03+TCRBJ01-06	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCCAAGCTTAAGGGGACGAGCAGTACTTCGGGCCG		Out	VDJ	1	18	3.182011030971574E-4		41	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	5	2	5	10	0	18	30	-1	40	45														X+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCCCCGGGTGGAGGGGCCAACGTCCTGACTTTCGGGGCC	CASSSPGGGANVLTF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-06	01	4	8	4	4	3	4	18	31	38	34	42						01,02								CASSSPGGGANVLTF+TCRBV11-03+TCRBJ02-06	TCRBV11-03*01	TCRBD02-01	TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGGCGGACCCAGCACGAGCTCTGGAAACACCATATATTTTGGAGAG	CASSLGGPSTSSGNTIYF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	54	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-03	01	3	1	7	0	4	10	18	32	40	36	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGGPSTSSGNTIYF+TCRBV11-03+TCRBJ01-03	TCRBV11-03*01		TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGGGAACGTCCCGAACACTGAAGCTTTCTTTGGACAA	CASSLGNVPNTEAFF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	45	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-01	01	3	0	8	1	1	7	18	32	37	33	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGNVPNTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGGGTTGGGACTAGCGGGAGGCCTTAGCACAGATACGCAGTATTTTGGCCCA	CASSLGLGLAGGLSTDTQYF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	60	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	1	0	1	0	4	4	18	34	53	38	57														CASSLGLGLAGGLSTDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGCGGGGGGCAAAGGAAAAACTGTTTTTTGGCAGT	CASSLRGAKEKLFF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-04	01	3	7	1	8	0	5	18	-1	40	32	45														CASSLRGAKEKLFF+TCRBV11-03+TCRBJ01-04	TCRBV11-03*01	TCRBD02-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGTCAGCAGCCAAGGGGCGGGCCCTTCCTACGAGCAGTACTTCGGGCCG	CVSSQGAGPSYEQYF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	45	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-07	01	5	5	2	1	2	8	18	30	37	32	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CVSSQGAGPSYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGACTCACGGGAAACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	21	3.71234620280017E-4		44	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	0	8	3	2	4	0	18	35	-1	39	44														X+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD02-01*02	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGGGGACGGCTCCTACGAGCAGTACTTCGGGCCG	CASSLGDGSYEQYF	In	VDJ	1	21	3.71234620280017E-4	4.4940934771443245E-4	42	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-07	01	3	0	7	0	2	2	18	32	39	34	41				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLGDGSYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCATGACACCAATAGTTCCGAAGTCGACATAATTCACCCCTCCACTTTGGGAAC		Out	VDJ	1	21	3.71234620280017E-4		55	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	7	2	6	5	1	20	18	28	33	29	53														X+TCRBV11-03+TCRBJ01-06	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCTACAGGGAACTTCCAGACCCAGTACTTCGGGCCA	CASSSTGNFQTQYF	In	VDJ	1	22	3.8891245934097015E-4	4.7080979284369113E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	4	3	3	6	2	7	18	31	39	33	46														CASSSTGNFQTQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCAGACAGGGCGCCGGAAACACCATATATTTTGGAGAG	CASSRQGAGNTIYF	In	VDJ	1	23	4.0659029840192336E-4	4.922102379729498E-4	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	5	2	3	4	1	4	18	30	38	31	42														CASSRQGAGNTIYF+TCRBV11-03+TCRBJ01-03	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCCTTCGACATTAACATGAACACTGAAGCTTTCTTTGGACAA	CASSPFDINMNTEAFF	In	VDJ	1	23	4.0659029840192336E-4	4.922102379729498E-4	48	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	2	6	0	6	6	18	30	40	36	46														CASSPFDINMNTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCACAGCTAGCGGGGGGTACCAAGAGACCCAGTACTTCGGGCCA	CASSTASGGYQETQYF	In	VDJ	1	26	4.596238155847829E-4	5.564115733607259E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	5	4	1	0	4	1	18	30	45	34	46														CASSTASGGYQETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCTCACAGGGACTTCAGCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSSHRDFSSGANVLTF	In	VDJ	1	30	5.303351718285957E-4	6.420133538777606E-4	54	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-06	01	4	3	3	0	3	7	18	31	40	34	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSHRDFSSGANVLTF+TCRBV11-03+TCRBJ02-06	TCRBV11-03*01		TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAAACGGACCGGGGGGCTATAATTCACCCCTCTACTTTGGGAAC	CASSLNGPGGYNSPLYF	In	VDJ	1	33	5.833686890114552E-4	7.062146892655367E-4	51	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-06	01	2	8	1	20	7	17	18	33	47	40	64														CASSLNGPGGYNSPLYF+TCRBV11-03+TCRBJ01-06	TCRBV11-03*01	TCRBD02-01*01	TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATSTCTGTGCCAGCAGCTCCCGATACCGGGGCAGCACTCTGGCGAATCAGCCCCAGCATTTTGGTGAT	CASSSRYRGSTLANQPQHF	In	VDJ	1	34	6.010465280724084E-4	7.276151343947955E-4	57	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-05	01	4	7	0	4	9	12	18	31	45	40	57				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSRYRGSTLANQPQHF+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01		TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTTGTCGCAACTAATGAAAAACTGTTTTTTGGCAGT	CASSFVATNEKLFF	In	VDJ	1	35	6.187243671333617E-4	7.490155795240541E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-04	01	3	8	6	0	3	0	18	32	-1	35	37						01,02								CASSFVATNEKLFF+TCRBV11-03+TCRBJ01-04	TCRBV11-03*01	TCRBD02-01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGYCAGCAGCTTCCTCATCAGCGGGACCCAAGAGACCCAGTACTTCGGGCCA	CXSSFLISGTQETQYF	In	VDJ	1	37	6.54080045255268E-4	7.918164697825714E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	3	6	3	1	7	1	18	32	46	39	47														CXSSFLISGTQETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGTACTAGCGGGTCTTATGGATACGCAGTATTTTGGCCCA	CASSLVLAGLMDTQYF	In	VDJ	1	38	6.717578843162212E-4	8.132169149118302E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	3	3	4	6	3	7	18	32	44	35	51						01,02								CASSLVLAGLMDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGCTGCCGCCGTGGAGTTTTCACCCCTCCACTTTGGGAAC	CASSLAAAVEFSPLHF	In	VDJ	1	39	6.894357233771744E-4	8.346173600410888E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-06	01	3	10	2	9	12	2	18	32	48	44	50														CASSLAAAVEFSPLHF+TCRBV11-03+TCRBJ01-06	TCRBV11-03*01	TCRBD02-01*02	TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCTCTAGCAGAAGGCTACGAGCAGTACTTCGGGCCG	CASSPLAEGYEQYF	In	VDJ	2	41	7.247914014990807E-4	8.774182502996063E-4	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	4	7	3	3	6	18	30	38	33	44						01,02								CASSPLAEGYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATCTCTGTGCCAGCAGCCCGGCGTCGGGGGGGCTCCAAGAGACCCAGTACTTCGGGCCA	CASSPASGGLQETQYF	In	VDJ	2	45	7.955027577428935E-4	9.63020030816641E-4	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	5	8	0	1	7	2	18	30	45	37	47														CASSPASGGLQETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAAGCAGCTCTGGAAACACCATATATTTTGGAGAG	CASSLSSSGNTIYF	In	VDJ	2	48	8.485362749257531E-4	0.001027221366204417	42	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-03	01	2	4	5	0	2	0	18	33	-1	35	38				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLSSSGNTIYF+TCRBV11-03+TCRBJ01-03	TCRBV11-03*01		TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCGGGAAGACCAGCACAGATACGCAGTATTTTGGCCCA	CASSGKTSTDTQYF	In	VDJ	2	56	9.899589874133787E-4	0.0011984249272384865	42	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-03	01	5	0	8	0	0	5	18	-1	34	30	39				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSGKTSTDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01		TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGGGGGCAAGCAGCAACCTACGAGCAGTACTTCGGGCCG	CASRGQAATYEQYF	In	VDJ	2	57	0.0010076368264743318	0.0012198253723677453	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	7	0	2	0	9	18	-1	34	29	43														CASRGQAATYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCTACGCAGGACCACTGCATCGGGGGCTGAAGCTTTCTTTGGACAA	CASSLRRTTASGAEAFF	In	VDJ	2	59	0.0010429925045962382	0.0012626262626262627	51	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	5	8	2	6	19	0	18	30	-1	49	55														CASSLRRTTASGAEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD02-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGTACAGGGGGCCGCCTACGAGCAGTACTTCGGGCCG	CASSLVQGAAYEQYF	In	VDJ	3	68	0.0012020930561448169	0.001455230268789591	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	3	0	2	1	2	18	34	44	35	46														CASSLVQGAAYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTATCCGACAGTAGCAATCAGCCCCAGCATTTTGGTGAT	CASSLSDSSNQPQHF	In	VDJ	3	73	0.0012904822514495829	0.0015622324944358844	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	2	2	5	0	3	0	18	33	-1	36	41														CASSLSDSSNQPQHF+TCRBV11-03+TCRBJ01-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCTATGGGACGAGGTTCGCATTCAGTACTTCGGCGCC	CASSLWDEVRIQYF	In	VDJ	3	74	0.001308160090510536	0.0015836329395651429	42	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-04	01	5	0	7	9	4	8	18	30	39	34	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLWDEVRIQYF+TCRBV11-03+TCRBJ02-04	TCRBV11-03*01		TCRBJ02-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCAGTCCAGGGTGGCGGCGAGCAGTACTTCGGGCCG	CASSPVQGGGEQYF	In	VDJ	3	86	0.0015202941592419744	0.0018404382811162473	42	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	4	3	6	6	6	18	30	41	36	47														CASSPVQGGGEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCGAGCCGATCACTAAGCGGGGGGCGGAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	3	86	0.0015202941592419744		55	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	5	6	1	3	14	3	18	30	53	44	56														X+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGGGATGGACTAGCGGGGTCCTACGAGCAGTACTTCGGGCCG	CASRDGLAGSYEQYF	In	VDJ	3	87	0.0015379719983029275	0.001861838726245506	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	6	1	3	1	4	0	18	29	-1	33	45														CASRDGLAGSYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCTTCAAAGGGTAGCGGGACTTACGAGCAGTACTTCGGGCCG	CASSPSKGSGTYEQYF	In	VDJ	4	99	0.0017501060670343657	0.00211864406779661	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	5	5	3	4	11	2	18	30	49	41	51														CASSPSKGSGTYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGTGGCTAGCGGGAAACCCTACGAGCAGTACTTCGGGCCG	CASSLVASGKPYEQYF	In	VDJ	4	108	0.0019092066185829445	0.0023112480739599386	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	1	4	3	2	3	3	18	34	46	37	49														CASSLVASGKPYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCGGGGGCCTAACTCTGGAAACACCATATATTTTGGAGAG	CASSRGPNSGNTIYF	In	VDJ	4	113	0.0019975958138877103	0.002418250299606232	45	TCRBV11	TCRBV11-03	01				TCRBJ01	TCRBJ01-03	01	5	6	0	0	1	4	18	30	37	31	41				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSRGPNSGNTIYF+TCRBV11-03+TCRBJ01-03	TCRBV11-03*01		TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGGCAGCCGTATTATTACAGCTACGAGCAGTACTTCGGGCCG		Out	VDJ	4	117	0.002068307170131523		50	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	1	3	5	3	14	0	18	34	-1	48	52														X+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCCGGGACTAGCGGGAGGAGTTTTTCTCTACGAGCAGTACTTCGGGCCG		Out	VDJ	5	132	0.002333474756045821		55	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	4	0	1	3	2	9	18	31	48	33	57														X+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTGGATCCCTAGCGGGTACCATGAGCAGTTCTTCGGGCCA	CASSWIPSGYHEQFF	In	VDJ	5	134	0.0023688304341677275	0.0028676596473206644	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	4	4	4	8	6	4	18	31	45	37	49						01,02								CASSWIPSGYHEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCGTCCGGGACAGGGGTGCTCACCCCTCCACTTTGGGAAC		Out	VDJ	10	271	0.004790694385518314		46	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	4	0	2	10	5	3	18	31	46	36	49														X+TCRBV11-03+TCRBJ01-06	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCACCTTCCCCCAGACTAGCGGCCCCGATACGCAGTATTTTGGCCCA	CASTFPQTSGPDTQYF	In	VDJ	12	305	0.005391740913590723	0.0065271357644239	48	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	3	2	5	6	6	4	18	32	47	38	51						01,02								CASTFPQTSGPDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTTTCTAGCGGGACAACAGATACGCAGTATTTTGGCCCA	CASSFSSGTTDTQYF	In	VDJ	13	343	0.006063498797906944	0.0073403526793357305	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	3	4	3	3	2	2	18	32	43	34	45														CASSFSSGTTDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01*02	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTCTTACAGGGGACCAGCTCCTACGAGCAGTACTTCGGGCCG	CASSFLQGTSSYEQYF	In	VDJ	14	374	0.006611511808796493	0.00800376647834275	48	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	3	3	2	0	3	5	18	32	42	35	47														CASSFLQGTSSYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTAGTCTTTCGGCTAGCGGGGGGGATAGATACGCAGTATTTTGGCCCA	CASSLVFRLAGGIDTQYF	In	VDJ	16	425	0.007513081600905106	0.009095189179934942	54	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	1	4	0	5	8	2	18	34	54	42	56														CASSLVFRLAGGIDTQYF+TCRBV11-03+TCRBJ02-03	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGACAGGCAACTAATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	17	453	0.008008061094611794		44	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	3	1	4	0	0	0	18	-1	-1	32	39														X+TCRBV11-03+TCRBJ01-04	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCACTGGGACAGGGACTAGCCAAAAACATTCAGTACTTCGGCGCC		Out	VDJ	25	663	0.011720407297411964		49	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	5	0	3	0	3	3	18	30	42	33	45														X+TCRBV11-03+TCRBJ02-04	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCACCACAGGGGGCCAGTGGAGGGGCTACACCTTCGGTTCG	CASSTTGGQWRGYTF	In	VDJ	30	788	0.013930137180031114	0.016863550761855847	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	3	0	8	3	9	18	30	42	33	51														CASSTTGGQWRGYTF+TCRBV11-03+TCRBJ01-02	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCAACACGAACCTACAGGATTACAATGAGCAGTTCTTCGGGCCA	CASSNTNLQDYNEQFF	In	VDJ	31	809	0.01430137180031113	0.01731296010957028	48	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	3	4	4	11	2	18	30	46	41	48														CASSNTNLQDYNEQFF+TCRBV11-03+TCRBJ02-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGTTTAGCGGGGGGGCTCACCGGGGAGCTGTTTTTTGGAGAA	CASGLAGGLTGELFF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	45	TCRBV12	TCRBV12-05	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-02	01	3	6	0	4	0	2	26	-1	50	40	52														CASGLAGGLTGELFF+TCRBV12-05+TCRBJ02-02	TCRBV12-05*01	TCRBD02-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCACCCCGACGGCGGGAGGCACAGATACGCAGTATTTTGGCCCA	CASTPTAGGTDTQYF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	45	TCRBV12	TCRBV12-05	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	12	7	2	1	13	0	26	31	-1	44	51														CASTPTAGGTDTQYF+TCRBV12-05+TCRBJ02-03	TCRBV12-05*01	TCRBD02-01*02	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGGGAGGAACAGGGTCGGACCGAGACCCAGTACTTCGGGCCA	CASGEEQGRTETQYF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	45	TCRBV12	TCRBV12-05	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	6	3	3	5	6	7	26	37	49	43	56														CASGEEQGRTETQYF+TCRBV12-05+TCRBJ02-05	TCRBV12-05*01	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGTTTGGGGCTTGGGGTGAACACTGAAGCTTTCTTTGGACAA	CASGLGLGVNTEAFF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	45	TCRBV12	TCRBV12-05	01				TCRBJ01	TCRBJ01-01	01	1	6	2	0	5	0	26	42	-1	47	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASGLGLGVNTEAFF+TCRBV12-05+TCRBJ01-01	TCRBV12-05*01		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGTTTAGGACTAAATCAGCCCCAGCATTTTGGTGAT	CASGLGLNQPQHF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	39	TCRBV12	TCRBV12-05	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	3	1	9	4	1	0	26	40	-1	41	47						01,02								CASGLGLNQPQHF+TCRBV12-05+TCRBJ01-05	TCRBV12-05*01	TCRBD02-01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCTCCCGCTACCCAGGGGGCGGAATATTACAGCCCCAGCATTTTGGTGAT	CASSRYPGGGILQPQHF	In	VDJ	1	22	3.8891245934097015E-4	4.7080979284369113E-4	51	TCRBV12	TCRBV12-05	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	12	4	0	7	14	9	26	31	53	45	62														CASSRYPGGGILQPQHF+TCRBV12-05+TCRBJ01-05	TCRBV12-05*01	TCRBD01-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGGCCCCTGAATGGGAATGAGCAGTTCTTCGGGCCA	CASGPLNGNEQFF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	39	TCRBV12	TCRBV12-05	01				TCRBJ02	TCRBJ02-01	01	6	0	9	7	10	0	26	37	-1	47	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASGPLNGNEQFF+TCRBV12-05+TCRBJ02-01	TCRBV12-05*01		TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGTTTGGTACCGGGAGGGGTGGTCGCTGAAGCTTTCTTTGGACAA	CASGLVPGGVVAEAFF	In	VDJ	1	28	4.949794937066893E-4	5.992124636192433E-4	48	TCRBV12	TCRBV12-05	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-01	01	0	8	0	6	2	7	26	43	53	45	60														CASGLVPGGVVAEAFF+TCRBV12-05+TCRBJ01-01	TCRBV12-05*01	TCRBD02-01*02	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGTTTGGTATTTGCTAGCGGGATATTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	28	4.949794937066893E-4		49	TCRBV12	TCRBV12-05	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	0	4	3	4	5	3	26	43	57	48	60														X+TCRBV12-05+TCRBJ02-07	TCRBV12-05*01	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGCTTAAATGACGGCACTGAAGCTTTCTTTGGACAA	CASGLNDGTEAFF	In	VDJ	1	29	5.126573327676425E-4	6.20612908748502E-4	39	TCRBV12	TCRBV12-05	01				TCRBJ01	TCRBJ01-01	01	6	2	7	4	7	2	26	37	47	44	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASGLNDGTEAFF+TCRBV12-05+TCRBJ01-01	TCRBV12-05*01		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGTCCCCCTGGGGTTGGGGGTACCAAAAACATTCAGTACTTCGGCGCC	CASGPPGVGGTKNIQYF	In	VDJ	1	31	5.480130108895489E-4	6.634137990070194E-4	51	TCRBV12	TCRBV12-05	01				TCRBJ02	TCRBJ02-04	01	5	6	1	2	12	2	26	38	55	50	57				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASGPPGVGGTKNIQYF+TCRBV12-05+TCRBJ02-04	TCRBV12-05*01		TCRBJ02-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGTTTCGGTGTTGGTGGATCACCCCTCCACTTTGGGAAC	CASGFGVGGSPLHF	In	VDJ	1	31	5.480130108895489E-4	6.634137990070194E-4	42	TCRBV12	TCRBV12-05	01				TCRBJ01	TCRBJ01-06	01	3	1	8	10	10	0	26	40	-1	50	53				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASGFGVGGSPLHF+TCRBV12-05+TCRBJ01-06	TCRBV12-05*01		TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGATCGACAGCCTACGAGCAGTACTTCGGGCCG	CASGSTAYEQYF	In	VDJ	1	34	6.010465280724084E-4	7.276151343947955E-4	36	TCRBV12	TCRBV12-05	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	2	5	2	3	0	26	37	-1	40	45														CASGSTAYEQYF+TCRBV12-05+TCRBJ02-07	TCRBV12-05*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGTTTGGTATGCGGGCGGCTAGCGGGAGAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	4	94	0.0016617168717295997		58	TCRBV12	TCRBV12-05	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	0	4	3	1	10	0	23	40	-1	50	59														X+TCRBV12-05+TCRBJ02-02	TCRBV12-05*01	TCRBD02-01*02	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGTGGAGGGGGACATGAACACTGAAGCTTTCTTTGGACAA	CASVEGDMNTEAFF	In	VDJ	5	134	0.0023688304341677275	0.0028676596473206644	42	TCRBV12	TCRBV12-05	01				TCRBJ01	TCRBJ01-01	01	7	0	6	0	6	0	26	36	-1	42	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASVEGDMNTEAFF+TCRBV12-05+TCRBJ01-01	TCRBV12-05*01		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGTTTGGCACGCGCGCAGGACACTAGACTTCGGGCCG		Out	VDJ	5	136	0.0024041861122896338		40	TCRBV12	TCRBV12-05	01				TCRBJ02	TCRBJ02-07	01	1	1	6	14	10	4	26	42	57	52	61				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV12-05+TCRBJ02-07	TCRBV12-05*01		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GGGACTCAGCCCTGTACTTCTGTGCCAGCAGCTTAGAGCAGACAGGGAGGACTGAAGCTTTCTTTGGACAA	CASSLEQTGRTEAFF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	45	TCRBV13	TCRBV13-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	2	3	5	4	3	20	36	47	40	50													Vb 23	CASSLEQTGRTEAFF+TCRBV13-01+TCRBJ01-01	TCRBV13-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCCAAGAGTTAGCGGGGGTTTCCTACGAGCAGTACTTCGGGCCG	CASSQELAGVSYEQYF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	48	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	2	5	2	1	4	2	20	35	48	39	50														CASSQELAGVSYEQYF+TCRBV23-01+TCRBJ02-07	TCRBV23-01*01	TCRBD02-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCTTAATGATGCCAGGGAGCAAAGAGCAGTTCTTCGGGCCA	CASSLMMPGSKEQFF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	45	TCRBV23	TCRBV23-01	01				TCRBJ02	TCRBJ02-01	01	6	4	3	10	11	6	20	31	47	42	53				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLMMPGSKEQFF+TCRBV23-01+TCRBJ02-01	TCRBV23-01*01		TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCCAAGATGGGCTAGCAGGTGTCAAAAACATTCAGTACTTTGGCGCC	CASSQDGLAGVKNIQYF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	51	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-04	01	2	4	7	22	6	25	20	35	46	41	71						01,02								CASSQDGLAGVKNIQYF+TCRBV23-01+TCRBJ02-04	TCRBV23-01*01	TCRBD02-01	TCRBJ02-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCGGGACAGGGCAAGAGACCCAGTACTTCGGGCCA	CASSGTGQETQYF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	39	TCRBV23	TCRBV23-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	6	0	3	2	1	0	20	31	-1	32	41														CASSGTGQETQYF+TCRBV23-01+TCRBJ02-05	TCRBV23-01*01	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCCAGTTGCCGGGGAGCTATGGCTACACCTTCGGTTCG	CASSQLPGSYGYTF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	42	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	6	8	3	4	8	2	20	31	44	39	46						01,02								CASSQLPGSYGYTF+TCRBV23-01+TCRBJ01-02	TCRBV23-01*01	TCRBD02-01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCTTGCCGGGGTCGGGTGAGCAGTACTTCGGGCCG	CASSLPGSGEQYF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	39	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	6	8	3	7	5	6	20	31	41	36	47														CASSLPGSGEQYF+TCRBV23-01+TCRBJ02-07	TCRBV23-01*01	TCRBD02-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCTTGGAGGACGAGGGAATCTCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSLEDEGISGANVLTF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	54	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-06	01	6	10	1	0	3	10	20	31	39	34	49														CASSLEDEGISGANVLTF+TCRBV23-01+TCRBJ02-06	TCRBV23-01*01	TCRBD02-01*02	TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGTCAAGATCGGACGGGGTGGCTACACCTTCGGTTCG		Out	VDJ	1	14	2.474897468533447E-4		40	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	2	8	3	7	7	0	20	35	-1	42	47														X+TCRBV23-01+TCRBJ01-02	TCRBV23-01*01	TCRBD02-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCGACCCGAGTAGCGGGGCATACAATGAGCAGTTCTTCGGGCCA	CASSDPSSGAYNEQFF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	48	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	6	5	3	4	9	2	20	31	48	40	50														CASSDPSSGAYNEQFF+TCRBV23-01+TCRBJ02-01	TCRBV23-01*01	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGACACGGCACTGTATCTCTGCGCCAGCGCCCCCGGGCAGTTAGCAATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	17	3.005232640362042E-4		44	TCRBV23	TCRBV23-01	01				TCRBJ01	TCRBJ01-05	01	8	8	0	0	6	3	20	29	39	35	42				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV23-01+TCRBJ01-05	TCRBV23-01*01		TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCTTGACCCCCAGCCAACCCCAGCATTTTGGTGAT	CASSLTPSQPQHF	In	VDJ	1	19	3.358789421581106E-4	4.066084574559151E-4	39	TCRBV23	TCRBV23-01	01				TCRBJ01	TCRBJ01-05	01	6	2	7	10	3	10	20	31	37	34	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLTPSQPQHF+TCRBV23-01+TCRBJ01-05	TCRBV23-01*01		TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGACACGGCACTGTATCTCTGCGCCAACAGTCATCTCCCGGCGGACAGGGGACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	20	3.5355678121906376E-4		52	TCRBV23	TCRBV23-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	3	1	2	3	9	0	20	34	-1	43	52														X+TCRBV23-01+TCRBJ02-02	TCRBV23-01*01	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCTTAGCGCTGGGCAGAAGGTATGGCTATAATTCACCCCTCCACTTTGGGAAC	CASSLALGRRYGYNSPLHF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	57	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-06	01	6	5	6	3	2	17	20	31	38	33	55						01,02								CASSLALGRRYGYNSPLHF+TCRBV23-01+TCRBJ01-06	TCRBV23-01*01	TCRBD02-01	TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGTCAACCAGGACAGGACCCAGCTCCTATAATTCACCCCTCCACTTTGGGAAC		Out	VDJ	1	20	3.5355678121906376E-4		56	TCRBV23	TCRBV23-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	2	1	4	0	3	6	20	35	45	38	51														X+TCRBV23-01+TCRBJ01-06	TCRBV23-01*01	TCRBD01-01*01	TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGTCAATCCCGGGCTAGCGGGGGGACTAATTGGGACCCAGTACTTCGGGCCA		Out	VDJ	1	26	4.596238155847829E-4		55	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	0	4	1	7	5	9	20	37	53	42	62														X+TCRBV23-01+TCRBJ02-05	TCRBV23-01*01	TCRBD02-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGTCAATCTTTATGTCCTGACCTCTGGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	1	29	5.126573327676425E-4		55	TCRBV23	TCRBV23-01	01				TCRBJ02	TCRBJ02-06	01	0	2	7	0	10	0	20	37	-1	47	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV23-01+TCRBJ02-06	TCRBV23-01*01		TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGTCGGATCGAAGGGGACTAGCGGGAGGGCCTGGGAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	30	5.303351718285957E-4		61	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	4	0	0	3	9	6	20	33	58	42	64														X+TCRBV23-01+TCRBJ02-05	TCRBV23-01*01	TCRBD02-01*02	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
GAGACACGGCACTGTATCTCTGCGCCAGCACAAACGGGCCCCCACCGCGGGACAGGGGAGTAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	32	5.65690849950502E-4		56	TCRBV23	TCRBV23-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	7	0	2	7	18	3	20	30	58	48	61														X+TCRBV23-01+TCRBJ02-01	TCRBV23-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCAACGGGACAGGGCGGACACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	8	1.414227124876255E-4		47	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	6	0	3	2	4	4	23	34	47	38	51														X+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGATAACAGACAGGGGTAAACTTTGAATACTGAAGCTTTCTTTGGACAA	CASSDNRQG*TLNTEAFF	Stop	VDJ	1	8	1.414227124876255E-4		54	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	2	2	5	7	12	23	35	50	42	62														CASSDNRQG*TLNTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAAGTTCGATAGGGCTCGAGGCTACACCTTCGGTTCG	CASKFDRARGYTF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	39	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-02	01	7	5	3	8	8	5	23	33	45	41	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASKFDRARGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01		TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCTTAGCGGGGGGTTAAACAATGAGCAGTTCTTCGGGCCA	CASSLSGGLNNEQFF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	5	5	1	5	2	4	23	35	47	37	51														CASSLSGGLNNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACGGGTCTAGCGGCCATAGCACAGATACGCAGTATTTTGGCCCA	CASSYGSSGHSTDTQYF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	51	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	2	4	5	0	4	4	23	38	49	42	53						01,02								CASSYGSSGHSTDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD02-01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGTGGAACCGGCCGACCCCAGTACTTCGGGCCA		Out	VDJ	1	9	1.591005515485787E-4		43	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-05	01	0	1	8	9	2	10	23	40	45	42	55				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01		TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTCAGGGGGGATTGGCGAGCAGTACTTCGGGCCG	CASSSGGIGEQYF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	4	4	1	6	0	6	23	-1	43	36	49														CASSSGGIGEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TTGTGTGCCAGCAGTTACTTTCAAGGGTGAACGAGCCTCCGCGGGAAGGGGGTAGAATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	9	1.591005515485787E-4		70	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-04	01	1	5	1	5	27	3	3	19	52	46	55				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV06-08+TCRBJ01-04	TCRBV06-08*01		TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCACCCAGCCGAGGGTCGGATTTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	10	1.7677839060953188E-4		41	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	10	11	0	4	7	7	23	30	42	37	49														X+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCACTTACTCCGCAGGAAATAGCAATCAGCCCCAGCATTTTGGTGAT	CASTYSAGNSNQPQHF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	48	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	0	4	4	0	2	3	23	40	46	42	49														CASTYSAGNSNQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCCGGACTAGCGGATACGAGCAGTACTTCGGGCCG	CASSRTSGYEQYF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	39	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	6	1	5	4	2	1	23	34	46	36	47						01,02								CASSRTSGYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGTCACCACTCAGGGTTGGAAAACTGTTTTTTGGCAGT	CASRSPLRVGKLFF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	6	4	3	10	9	4	23	34	48	43	52														CASRSPLRVGKLFF+TCRBV06-08+TCRBJ01-04	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTACGACAGGGGCTAACTATGGCTACACCTTCGGTTCG	CASSTTGANYGYTF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	2	2	0	2	0	23	35	-1	37	45														CASSTTGANYGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCCCCCACTAGCGGGAGGGCACACCTACGAGCAGTACTTCGGGCCG	CASSPPLAGGHTYEQYF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	51	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	5	3	0	2	5	4	23	35	53	40	57														CASSPPLAGGHTYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAGGACACCGGACTCTCTGGAAACACCATATATTTTGGAGAG	CASSEDTGLSGNTIYF	In	VDJ	1	10	1.7677839060953188E-4	2.1400445129258688E-4	48	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-03	01	5	1	6	0	2	7	23	35	42	37	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSEDTGLSGNTIYF+TCRBV06-08+TCRBJ01-03	TCRBV06-08*01		TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGCCGACACAGACAAGCTCCTACGAGCAGTACTTCGGGCCG	CASRPTQTSSYEQYF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	2	6	0	3	8	23	34	41	37	49														CASRPTQTSSYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCGACAGGGGGAGATAACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	11	1.9445622967048507E-4		44	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	5	2	1	5	1	5	23	35	45	36	50														X+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCAGGGACGGCCAATCAGCCCCAGCATTTTGGTGAT	CASSYSGTANQPQHF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	45	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-05	01	0	0	7	3	1	3	23	40	46	41	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYSGTANQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01		TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGCGATGCGGCGCACAGATACGCAGTATTTTGGCCCA	CAISAMRRTDTQYF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	5	7	5	1	5	1	23	35	44	40	45						01,02								CAISAMRRTDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD02-01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCACCCTCCGACAGGCGACTGAAGCTTTCTTTGGACAA	CATLRQATEAFF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	36	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	10	2	4	5	6	2	23	30	42	36	44														CATLRQATEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCTCGGGGCAATATAATTCACCCCTCCACTTTGGGAAC	CASSSGQYNSPLHF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	42	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-06	01	6	7	0	4	3	2	23	34	42	37	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSGQYNSPLHF+TCRBV06-08+TCRBJ01-06	TCRBV06-08*01		TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGACTCAGAGGTCCTACAATGAGCAGTTCTTCGGGCCA	CASSYSTQRSYNEQFF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	0	2	10	1	0	6	23	-1	44	40	50						01,02								CASSYSTQRSYNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGACTTGGCGGGGGGGAGGAATGAGCAGTTCTTCGGGCCA	CAISDLAGGRNEQFF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	1	7	0	7	2	3	23	39	50	41	53														CAISDLAGGRNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCACCACTGGTCTGGGTTTTAGCAATCAGCCCCAGCATTTTGGTGAT	CASTTGLGFSNQPQHF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	48	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-05	01	7	0	9	0	10	3	23	33	46	43	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASTTGLGFSNQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01		TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGATTAACAGGGAACACTGAAGCTTTCTTTGGACAA	CASRLTGNTEAFF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	3	4	1	4	0	23	34	-1	38	43														CASRLTGNTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTACACCCGGGACAGCCTGGGGATCAGCCCCAGCATTTTGGTGAT		Out	VDJ	1	13	2.2981190779239146E-4		49	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	5	0	5	5	6	7	23	35	48	41	55														X+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTTGGACCATCCCAACCGGGAGACCCAGTACTTCGGGCCA	CASSLDHPNRETQYF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	45	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-05	01	4	1	7	5	1	12	23	36	41	37	53				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLDHPNRETQYF+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01		TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCCTAACCGGCTTCCGGAGGGGCGAGAGGCAGCCCCAGCATTTTGGTGAT	CASLTGFRRGERQPQHF	In	VDJ	1	13	2.2981190779239146E-4	2.7820578668036295E-4	51	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-05	01	8	10	0	7	13	8	23	32	51	45	59														CASLTGFRRGERQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD02-01*02	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTACCAGCAGTTACCGACAGGAGACGAACACCGGGGAGCTGTTTTTTGGAGAA	CTSSYRQETNTGELFF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	48	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	2	2	4	0	1	3	23	38	45	39	48														CTSSYRQETNTGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAACCCAAGACAGGGATCGAGGGTTGCTTTCTTTGGACAA	CASNPRQGSRVAFF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	7	2	3	11	6	10	23	33	46	39	56														CASNPRQGSRVAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCACCCCAGCCCAGGGGGGATCTGAAGCTTTCTTTGGACAA	CASTPAQGGSEAFF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	7	4	1	6	8	3	23	33	48	41	51														CASTPAQGGSEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGGGACTAGCGGGAGGGTTCGGGATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	14	2.474897468533447E-4		47	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	6	0	0	8	0	6	23	-1	50	34	56														X+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCCGCCGAACCTAGCGGGTCTTATCTTCGGGCCA	CASSPPNLAGLIF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	39	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	4	4	17	9	5	23	35	52	44	57						01,02								CASSPPNLAGLIF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTACCAGCAGTTACCGCTTCGGGGGACACTACGAGCAGTACTTCGGGCCG	CTSSYRFGGHYEQYF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	45	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-07	01	2	0	6	3	8	0	23	38	-1	46	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CTSSYRFGGHYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCGGGGAGCTAACTATGGCTACACCTTCGGTTCG	CASSRGANYGYTF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	39	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	5	8	3	0	0	2	23	-1	40	35	42						01,02								CASSRGANYGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD02-01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGTGGACAGGGGGACATCCGGCAGTACTTCGGGCCG	CASGQGDIRQYF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	36	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	9	1	1	9	1	7	23	31	42	32	49														CASGQGDIRQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCTCGCGGGGCAGCCGAACCCCTCCACTTTGGGAAC	CASSYSRGAAEPLHF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-06	01	0	7	3	12	2	7	23	40	48	42	55														CASSYSRGAAEPLHF+TCRBV06-08+TCRBJ01-06	TCRBV06-08*01	TCRBD02-01*01	TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGGACAGGGGAGCGGGGCCAACGTCCTGACTTTCGGGGCC	CAISGQGSGANVLTF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	5	1	2	4	0	3	23	-1	44	35	47														CAISGQGSGANVLTF+TCRBV06-08+TCRBJ02-06	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCCCGGCAGGAGGCCCCGGGGAGCTGTTTTTTGGAGAA	CAIPAGGPGELFF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	39	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	10	10	1	6	8	2	23	30	43	38	45														CAIPAGGPGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAACCCACTAGCGGGGCGTTAAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	17	3.005232640362042E-4		43	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	10	3	3	3	4	5	23	30	44	34	49														X+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGCACATAGGAGGGGGGCTAATGAAAAACTGTTTTTTGGCAGT	CASSAHRRGANEKLFF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	48	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-04	01	5	5	1	3	9	1	23	35	50	44	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSAHRRGANEKLFF+TCRBV06-08+TCRBJ01-04	TCRBV06-08*01		TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGTCAGCAGTGACGACAGGGAAGAGAAACGAGCAGTACTTCGGGCCG		Out	VDJ	1	17	3.005232640362042E-4		43	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	2	3	5	3	7	23	35	45	38	52														X+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCACCCCAGGGCCGGGACAGGGATTCCATGAGCAGTTCTTCGGGCCA	CASTPGPGQGFHEQFF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	48	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	7	0	3	8	10	5	23	33	52	43	57														CASTPGPGQGFHEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGGAAGAGGGACAGGGGAAGACCTACGAGCAGTACTTCGGGCCG	CASREEGQGKTYEQYF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	48	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	0	2	2	6	4	23	34	50	40	54														CASREEGQGKTYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACGACGGACTAGCGGGGAGGTATTCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	18	3.182011030971574E-4		53	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	2	1	3	3	3	7	23	38	53	41	60														X+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCACACGGGGGGCTAAAGAGACCCAGTACTTCGGGCCA	CAITRGAKETQYF	In	VDJ	1	18	3.182011030971574E-4	3.852080123266564E-4	39	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	10	8	1	3	5	3	23	30	42	35	45														CAITRGAKETQYF+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCACCTTCGCCCAGGCCGTGAGGAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	19	3.358789421581106E-4		46	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-05	01	7	4	4	4	8	8	23	33	45	41	53				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01		TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGATCGGGGACAGGGGGCCTTAGCAATCAGCCCCAGCATTTTGGTGAT	CASRSGTGGLSNQPQHF	In	VDJ	1	19	3.358789421581106E-4	4.066084574559151E-4	51	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-05	01	6	0	0	0	4	2	23	34	50	38	52														CASRSGTGGLSNQPQHF+TCRBV06-08+TCRBJ01-05	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCCCCCGGGACAGGTCTAATTCACCCCTCCACTTTGGGAAC	CASSPRDRSNSPLHF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	6	0	4	6	5	2	23	34	47	39	49														CASSPRDRSNSPLHF+TCRBV06-08+TCRBJ01-06	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCTTCCCTGGTTTTGGGGCGAACACTGAAGCTTTCTTTGGACAA	CASSFPGFGANTEAFF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	48	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	7	0	1	13	0	23	34	-1	47	52														CASSFPGFGANTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCAAGGGACAGGCCTTGGGGGCTATGGCTACACCTTCGGTTCG	CASSQGTGLGGYGYTF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	48	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	0	4	4	3	9	23	35	46	38	55														CASSQGTGLGGYGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCAGACCGTTAGCTCTGGAAACACCATATATTTTGGAGAG	CASSQTVSSGNTIYF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	45	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-03	01	5	2	7	0	2	6	23	35	40	37	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQTVSSGNTIYF+TCRBV06-08+TCRBJ01-03	TCRBV06-08*01		TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGGGGAAGCAGCCCCTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	20	3.5355678121906376E-4		44	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-07	01	5	0	8	0	1	8	23	35	40	36	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACGGAGCAGCTCTTGAGACCCAGTACTTCGGGCCA	CASSYGAALETQYF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	2	10	2	5	0	8	23	-1	42	38	50														CASSYGAALETQYF+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCCGGGACAGAGGAGTCGAGCAGTACTTCGGGCCG	CASSRDRGVEQYF	In	VDJ	1	21	3.71234620280017E-4	4.4940934771443245E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	0	5	6	2	6	23	34	43	36	49														CASSRDRGVEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACGAAGGAGATGGCTACACCTTCGGTTCG	CASSYEGDGYTF	In	VDJ	1	21	3.71234620280017E-4	4.4940934771443245E-4	36	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	2	10	2	6	3	0	23	38	-1	41	45														CASSYEGDGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD02-01*02	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCCCTGGAGGACCAAGAGACCCAGTACTTCGGGCCA	CASSYSLEDQETQYF	In	VDJ	1	21	3.71234620280017E-4	4.4940934771443245E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	0	10	1	0	3	0	23	40	-1	43	48														CASSYSLEDQETQYF+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTAGTACGGGACACTACTACGAGCAGTACTTCGGGCCG	CAISSTGHYYEQYF	In	VDJ	1	21	3.71234620280017E-4	4.4940934771443245E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	5	0	6	3	5	3	23	35	46	40	49														CAISSTGHYYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTACCGGGACTAGCGGGACCGGGGAGCTGTTTTTTGGAGAA	CASSTGTSGTGELFF	In	VDJ	1	22	3.8891245934097015E-4	4.7080979284369113E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	5	0	4	5	3	0	23	35	-1	38	50						01,02								CASSTGTSGTGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD02-01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCACCGTCAGGGGAGCGGGAGAATATGAGCAGTTCTTCGGGCCA	CATVRGAGEYEQFF	In	VDJ	1	23	4.0659029840192336E-4	4.922102379729498E-4	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	10	6	2	8	10	3	23	30	48	40	51														CATVRGAGEYEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCTCCAGGGTGAACACTGAAGCTTTCTTTGGACAA	CASSSRVNTEAFF	In	VDJ	1	23	4.0659029840192336E-4	4.922102379729498E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	4	3	0	3	0	23	34	-1	37	42														CASSSRVNTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGACTGACCGGGACAGGGTTGCATGCTACACCTTCGGTTCG		Out	VDJ	1	23	4.0659029840192336E-4		46	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	1	0	3	9	4	6	23	39	52	43	58														X+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCCAGGAAGCTATAGGCGGGAGTACAGATACGCAGTATTTTGGCCCA	CAIQEAIGGSTDTQYF	In	VDJ	1	23	4.0659029840192336E-4	4.922102379729498E-4	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	10	7	2	3	15	1	23	30	52	45	53														CAIQEAIGGSTDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAACCCGCTAGCGGGGCGTTAAAGAGACCTAGTACTTCGGGCCA		Out	VDJ	1	24	4.2426813746287653E-4		43	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	10	4	3	12	5	14	23	30	44	35	58														X+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCACTGCGGACAGGAAATTTTCCTACGAGCAGTACTTCGGGCCG	CATADRKFSYEQYF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	10	1	4	1	4	6	23	30	41	34	47														CATADRKFSYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGACGCTCTACCGTAGATAGCGCGAGCTCCTACAATGAGCAGTTCTTCGGGCCA	CASRRSTVDSASSYNEQFF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	57	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	6	5	6	0	15	4	23	34	54	49	58						01,02								CASRRSTVDSASSYNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAGGACAGGGGATAAGTAACTATGGCTACACCTTCGGTTCG		Out	VDJ	1	25	4.4194597652382975E-4		47	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	1	2	1	2	5	23	35	46	37	51														X+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGCGCCCCACCCCCCATGAGCAGTTCTTCGGGCCA	CASSYSRPTPHEQFF	In	VDJ	1	25	4.4194597652382975E-4	5.350111282314672E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	0	7	6	8	0	11	23	-1	43	40	54						01,02								CASSYSRPTPHEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGGGGGGGACAGGATCCTATGGCTACACCTTCGGTTCG	CASRGGTGSYGYTF	In	VDJ	1	27	4.7730165464573613E-4	5.778120184899846E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	6	0	4	4	4	3	23	34	46	38	49														CASRGGTGSYGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGGCTCCAGGGGAACCAGTGCTTTCTTTGGACAA	CASSGSRGTSAFF	In	VDJ	1	27	4.7730165464573613E-4	5.778120184899846E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	4	2	11	5	7	23	35	46	40	53														CASSGSRGTSAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACCCAAGCGGGAGTGTCACCGGGGAGCTGTTTTTTGGAGAA	CASSYPSGSVTGELFF	In	VDJ	1	27	4.7730165464573613E-4	5.778120184899846E-4	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	2	6	2	4	3	3	23	38	49	41	52														CASSYPSGSVTGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCGTGGACAGGGGGCGAGTCCCCAATGAGCAGTTCTTCGGGCCA	CASVDRGRVPNEQFF	In	VDJ	1	27	4.7730165464573613E-4	5.778120184899846E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	8	1	0	6	2	7	23	32	45	34	52														CASVDRGRVPNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCGCGGACAGAGATTCACCCCTCCACTTTGGGAAC	CASSADRDSPLHF	In	VDJ	1	29	5.126573327676425E-4	6.20612908748502E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	6	1	5	8	3	2	23	34	43	37	45														CASSADRDSPLHF+TCRBV06-08+TCRBJ01-06	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGCGACTAGCGGGGGTGGAGATACGCAGTATTTTGGCCCA	CASSATSGGGDTQYF	In	VDJ	1	29	5.126573327676425E-4	6.20612908748502E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	5	2	2	5	2	3	23	35	49	37	52														CASSATSGGGDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGCTCTAGCGGGAGGTTTACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	29	5.126573327676425E-4		47	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	5	4	1	3	3	3	23	35	49	38	52														X+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGACAGGTGTCTAATGAAAAACTGTTTTTTGGCAGT	CASRQVSNEKLFF	In	VDJ	1	30	5.303351718285957E-4	6.420133538777606E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	6	3	4	3	0	3	23	-1	39	34	42														CASRQVSNEKLFF+TCRBV06-08+TCRBJ01-04	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTTACGGCGGCTCCTACGAGCAGTACTTCGGGCCG	CAISYGGSYEQYF	In	VDJ	1	30	5.303351718285957E-4	6.420133538777606E-4	39	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	2	7	5	0	1	0	23	38	-1	39	43						01,02								CAISYGGSYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCACTCTAACGGGACAGGGTTACAATGAGCAGTTCTTCGGGCCA	CASTLTGQGYNEQFF	In	VDJ	1	31	5.480130108895489E-4	6.634137990070194E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	7	0	3	4	7	1	23	33	49	40	50														CASTLTGQGYNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGAAGGGGCGGTTTGGGGAACACTGAAGCTTTCTTTGGACAA	CASRRGGLGNTEAFF	In	VDJ	1	31	5.480130108895489E-4	6.634137990070194E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	5	2	1	1	9	23	34	40	35	49														CASRRGGLGNTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGCGGGTATACAATGAGCAGTTCTTCGGGCCA	CASSYSRVYNEQFF	In	VDJ	1	32	5.65690849950502E-4	6.84814244136278E-4	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	0	7	4	4	0	2	23	-1	45	40	47						01,02								CASSYSRVYNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGACTCACTAGCGGGATAGGCAATGAGCAGTTCTTCGGGCCA	CASRLTSGIGNEQFF	In	VDJ	1	33	5.833686890114552E-4	7.062146892655367E-4	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	6	3	3	6	4	4	23	34	48	38	52														CASRLTSGIGNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTCCCAGACGGATTGGACTGAAGCTTTCTTTGGACAA	CASSSQTDWTEAFF	In	VDJ	1	34	6.010465280724084E-4	7.276151343947955E-4	42	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-01	01	4	1	8	5	7	4	23	36	46	43	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSQTDWTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGGGCTTGACAGGGGGCGCGAGCGAGCAGTACTTCGGGCCG	CASRGLTGGASEQYF	In	VDJ	1	36	6.364022061943148E-4	7.704160246533128E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	2	0	6	6	5	23	34	50	40	55														CASRGLTGGASEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGCGGCCACATGGGAGCTATGGCTACACCTTCGGTTCG	CASSYSRPHGSYGYTF	In	VDJ	1	36	6.364022061943148E-4	7.704160246533128E-4	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-02	01	0	9	2	4	10	0	23	40	-1	50	55														CASSYSRPHGSYGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD02-01*02	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTTGAGAGGGGAGACCCAGTACTTCGGGCCA	CASSYLRGETQYF	In	VDJ	1	36	6.364022061943148E-4	7.704160246533128E-4	39	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	1	11	0	5	3	0	23	39	-1	42	47														CASSYLRGETQYF+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGCCCCGGAACGGGGGCGCGTGCCTATGGCTACACCTTCGGTTCG	CASSPGTGARAYGYTF	In	VDJ	1	38	6.717578843162212E-4	8.132169149118302E-4	48	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-02	01	6	6	0	4	9	6	23	34	49	43	55				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPGTGARAYGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01		TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCTATTCGGGGATAGGTGAAGCTTTCTTTGGACAA		Out	VDJ	1	38	6.717578843162212E-4		44	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-01	01	0	8	3	7	4	5	23	40	49	44	54														X+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD02-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGCCCGGGACAGGGACCCGATACGCAGTATTTTGGCCCA	CAISPGQGPDTQYF	In	VDJ	1	38	6.717578843162212E-4	8.132169149118302E-4	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	6	0	3	6	3	4	23	34	46	37	50														CAISPGQGPDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGACACAGGCGCCCGAACACCGGGGAGCTGTTTTTTGGAGAA	CASRHRRPNTGELFF	In	VDJ	1	39	6.894357233771744E-4	8.346173600410888E-4	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	6	3	4	0	2	4	23	34	41	36	45														CASRHRRPNTGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTAACGTGGAGGTGTGGGACACAGATACGCAGTATTTTGGCCCA	CASSNVEVWDTDTQYF	In	VDJ	2	41	7.247914014990807E-4	8.774182502996063E-4	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	5	10	1	2	5	7	23	35	45	40	52														CASSNVEVWDTDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCTCTGGGTTCACCCCTCCACTTTGGGAAC	CASSYSLGSPLHF	In	VDJ	2	41	7.247914014990807E-4	8.774182502996063E-4	39	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-06	01	0	0	9	9	3	0	23	40	-1	43	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYSLGSPLHF+TCRBV06-08+TCRBJ01-06	TCRBV06-08*01		TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGACGGGCTAGGAGACCCAGTACTTCGGGCCA		Out	VDJ	2	42	7.42469240560034E-4		37	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-05	01	5	8	0	5	3	3	23	35	42	38	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01		TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACCAGGGCCGCGGGGAGCTGTTTTTTGGAGAA	CASSYQGRGELFF	In	VDJ	2	43	7.601470796209872E-4	9.202191405581236E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	2	4	3	7	0	3	23	-1	43	38	46														CASSYQGRGELFF+TCRBV06-08+TCRBJ02-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGAACAGGGGGCGGCACTGAAGCTTTCTTTGGACAA	CASRTGGGTEAFF	In	VDJ	2	45	7.955027577428935E-4	9.63020030816641E-4	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	3	0	4	1	2	23	34	44	35	46														CASRTGGGTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGGAAGGGACGGCGAACACTGAAGCTTTCTTTGGACAA	CASSYSEGTANTEAFF	In	VDJ	2	46	8.131805968038467E-4	9.844204759458996E-4	48	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-01	01	0	0	7	1	4	3	23	40	49	44	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYSEGTANTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCCGGTTACACAGGGGGGTGAAACTACGAGCAGTACTTCGGGCCG		Out	VDJ	2	47	8.308584358647998E-4		46	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	8	3	1	3	7	6	23	32	47	39	53														X+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTACTCCCCCCAGGACAAAAAAACTGTTTTTTGGCAGT	CASSTPPRTKKLFF	In	VDJ	2	57	0.0010076368264743318	0.0012198253723677453	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	5	1	6	9	10	1	23	35	50	45	51														CASSTPPRTKKLFF+TCRBV06-08+TCRBJ01-04	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTTTCAAGGGGGTTCGGATGGCTACACCTTCGGTTCG	CASSFQGGSDGYTF	In	VDJ	2	58	0.001025314665535285	0.001241225817497004	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	5	1	6	4	5	23	36	46	40	51														CASSFQGGSDGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAATGATAAGGGACTAGCGGGAGTTGCCGAGCAGTACTTCGGGCCG	CAINDKGLAGVAEQYF	In	VDJ	2	65	0.0011490595389619573	0.0013910289334018147	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	10	0	2	6	10	4	23	30	54	40	58														CAINDKGLAGVAEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAAAAAATCCTGGACTAGCGGGAGGGCCAAAGAGACCCAGTACTTCGGGCCA	CASKKSWTSGRAKETQYF	In	VDJ	3	68	0.0012020930561448169	0.001455230268789591	54	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	7	1	0	3	9	3	23	33	57	42	60														CASKKSWTSGRAKETQYF+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCTCATGGACGAGACTACGAGCAGTACTTCGGGCCG	CASSYSHGRDYEQYF	In	VDJ	3	69	0.00121977089520577	0.0014766307139188494	45	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-07	01	0	1	7	3	4	4	23	40	48	44	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSYSHGRDYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGGACTAGCGGTACCTACGAGCAGTACTTCGGGCCG	CASRTSGTYEQYF	In	VDJ	3	71	0.0012551265733276764	0.001519431604177367	39	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	6	2	5	2	0	2	23	-1	43	34	45						01,02								CASRTSGTYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACGGTTCAGACACTGAAGCTTTCTTTGGACAA	CASSYGSDTEAFF	In	VDJ	3	81	0.0014319049639372084	0.0017334360554699538	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	4	5	3	4	0	23	38	-1	42	45														CASSYGSDTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGTGAAGCGGGAGGCCCCCTAGGAAGACCCAGTACTTCGGGCCA		Out	VDJ	3	82	0.0014495828029981615		49	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	5	6	1	6	4	10	23	35	48	39	58														X+TCRBV06-08+TCRBJ02-05	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACATCGAGGCTAGCGGTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	4	93	0.0016440390326686466		47	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	2	4	5	4	7	0	23	38	-1	45	52						01,02								X+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCTTCTCAGGGTGGGGAGACAGCGAGCAGTACTTCGGGCCG	CASFSGWGDSEQYF	In	VDJ	4	97	0.0017147503889124594	0.0020758431775380927	42	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-07	01	8	2	5	6	15	0	23	32	-1	47	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASFSGWGDSEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCAACGGCAGAATGAAGCTTTCTTTGGACAA	CASSQRQNEAFF	In	VDJ	6	146	0.0025809645028991657	0.0031244649888717687	36	TCRBV06	TCRBV06-08	01				TCRBJ01	TCRBJ01-01	01	5	4	5	7	6	2	23	35	44	41	46				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQRQNEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCCAGCGGGAGCCCTGCGGGAGCAGTACTTCGGGCCG	CASSPAGALREQYF	In	VDJ	12	328	0.005798331211992646	0.00701934600239685	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	5	6	2	7	2	8	23	35	45	37	53														CASSPAGALREQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTCCCCCGTACAACACAGATACGCAGTATTTTGGCCCA	CASSPPYNTDTQYF	In	VDJ	13	336	0.005939753924480272	0.007190549563430919	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	5	3	6	2	7	1	23	35	45	42	46														CASSPPYNTDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCTGTGATTACGGGGGGGCCGGATACAATGAGCAGTTCTTCGGGCCA	CASCDYGGAGYNEQFF	In	VDJ	13	354	0.006257955027577429	0.007575757575757576	48	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	8	8	0	4	8	5	23	32	48	40	53														CASCDYGGAGYNEQFF+TCRBV06-08+TCRBJ02-01	TCRBV06-08*01	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCTGACTTCGCCGGGGAGCAGTACTTCGGGCCG	CASSYSDFAGEQYF	In	VDJ	15	404	0.007141846980625088	0.00864577983222051	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	0	2	10	7	1	8	23	40	45	41	53						01,02								CASSYSDFAGEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACAATGTGCTCGCGGGATTCACAGATACGCAGTATTTTGGCCCA	CASSYNVLAGFTDTQYF	In	VDJ	16	407	0.007194880497807948	0.008709981167608287	51	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	2	7	3	2	9	2	23	38	53	47	55														CASSYNVLAGFTDTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGAAGGCGGGAGTCCCGATTCGAGCAGTACTTCGGGCCG	CASRRRESRFEQYF	In	VDJ	25	663	0.011720407297411964	0.01418849512069851	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	6	7	2	6	3	8	23	34	44	37	52														CASRRRESRFEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACTGGGACTAGCGGGGCGCACAGATACGCAGTATTTTGGCCCA	CASSLGLAGRTDTQYF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	48	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-03	01	4	0	3	1	1	1	24	37	51	38	52													Vb 18	CASSLGLAGRTDTQYF+TCRBV18-01+TCRBJ02-03	TCRBV18-01*01	TCRBD02-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCCCTCGGACGTAACCCTCAAGAGACCCAGTACTTCGGGCCA	CASSLGRNPQETQYF	In	VDJ	1	8	1.414227124876255E-4	1.712035610340695E-4	45	TCRBV18	TCRBV18-01	01				TCRBJ02	TCRBJ02-05	01	6	1	7	2	4	8	24	35	43	39	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSLGRNPQETQYF+TCRBV18-01+TCRBJ02-05	TCRBV18-01*01		TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACAGACAGAGAGCTATAATTCACCCCTCCACTTTGGGAAC	CASSQTESYNSPLHF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	45	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	4	2	5	3	1	4	24	37	43	38	47													Vb 18	CASSQTESYNSPLHF+TCRBV18-01+TCRBJ01-06	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCATTCGGCTTCCAAGAGACCCAGTACTTCGGGCCA	CASSFGFQETQYF	In	VDJ	1	9	1.591005515485787E-4	1.926040061633282E-4	39	TCRBV18	TCRBV18-01	01				TCRBJ02	TCRBJ02-05	01	5	9	0	1	3	2	24	36	42	39	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSFGFQETQYF+TCRBV18-01+TCRBJ02-05	TCRBV18-01*01		TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCAGCTTTCCCAGCGGGGGGGCCCCACAATGAGCAATTCTTCGGGCCA	CASSAFPAGGPHNEQFF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	51	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	5	6	0	16	8	15	24	36	54	44	69													Vb 18	CASSAFPAGGPHNEQFF+TCRBV18-01+TCRBJ02-01	TCRBV18-01*01	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGTCAGCTCCGCGCCTGGGGACTCGGCAACTAATGAAAAACTGTTTTTTGGCAGT	CVSSAPGDSATNEKLFF	In	VDJ	1	11	1.9445622967048507E-4	2.3540489642184556E-4	51	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-04	01	6	0	10	0	8	3	24	35	49	43	52						01,02							Vb 18	CVSSAPGDSATNEKLFF+TCRBV18-01+TCRBJ01-04	TCRBV18-01*01	TCRBD02-01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCAACTAGCGGGAGGGCGATAGATACGCAGTATTTTGGCCCA	CASSTSGRAIDTQYF	In	VDJ	1	12	2.1213406873143826E-4	2.5680534155110427E-4	45	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	5	3	0	5	0	4	24	-1	49	36	53													Vb 18	CASSTSGRAIDTQYF+TCRBV18-01+TCRBJ02-03	TCRBV18-01*01	TCRBD02-01*02	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACCGAGGACCAAATAACCAATCGGACCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	13	2.2981190779239146E-4		56	TCRBV18	TCRBV18-01	01				TCRBJ02	TCRBJ02-07	01	0	1	7	2	2	16	24	41	47	43	63				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	X+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCGCTCGGACAGGGGGCCTAGAACACTGAAGCTTTCTTTGGACAA	CASSPLGQGA*NTEAFF	Stop	VDJ	1	14	2.474897468533447E-4		51	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	1	0	1	4	3	24	38	53	42	56													Vb 18	CASSPLGQGA*NTEAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCAGGGGATAGGAATGAAAAACTGTTTTTTGGCAGT	CASSGDRNEKLFF	In	VDJ	1	14	2.474897468533447E-4	2.9960623180962163E-4	39	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-04	01	5	0	8	5	1	4	24	36	41	37	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSGDRNEKLFF+TCRBV18-01+TCRBJ01-04	TCRBV18-01*01		TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCGACTAGCGGGAGTGGAAATGAGCAGTTCTTCGGGCCA	CASSPTSGSGNEQFF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	45	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	3	2	2	7	0	4	24	-1	50	38	54													Vb 18	CASSPTSGSGNEQFF+TCRBV18-01+TCRBJ02-01	TCRBV18-01*01	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCCCGGGACAGGTCCTACGAGCAGTACTTCGGGCCG	CASSRDRSYEQYF	In	VDJ	1	15	2.6516758591429784E-4	3.210066769388803E-4	39	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	0	4	1	2	0	24	35	-1	37	45													Vb 18	CASSRDRSYEQYF+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACCTGGAGACGCGGCAACTAATGAAAAACTGTTTTTTGGCAGT	CASSPPGDAATNEKLFF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	51	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-04	01	0	7	5	0	7	0	24	41	-1	48	52						01,02							Vb 18	CASSPPGDAATNEKLFF+TCRBV18-01+TCRBJ01-04	TCRBV18-01*01	TCRBD02-01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCATTGACAGGGGGCGAGACCCAGTACTTCGGGCCA	CASSPLTGGETQYF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	42	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	2	2	0	5	2	0	24	39	-1	41	51													Vb 18	CASSPLTGGETQYF+TCRBV18-01+TCRBJ02-05	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCGTCGTTAGATCAGCCCCAGCATTTTGGTGAT	CASSPSLDQPQHF	In	VDJ	1	16	2.82845424975251E-4	3.42407122068139E-4	39	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-05	01	3	5	8	5	5	0	24	38	-1	43	46						01,02							Vb 18	CASSPSLDQPQHF+TCRBV18-01+TCRBJ01-05	TCRBV18-01*01	TCRBD02-01	TCRBJ01-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
TTTCTGTGCCAGCTCACCACCGTGGGTGCCGGGGCCTTACACCCACAACTAATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	16	2.82845424975251E-4		64	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-04	01	0	7	0	0	9	10	4	21	35	30	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	X+TCRBV18-01+TCRBJ01-04	TCRBV18-01*01		TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACTCCAGACAGGGGATGGCTACACCTTCGGTTCG	CASSLQTGDGYTF	In	VDJ	1	17	3.005232640362042E-4	3.6380756719739773E-4	39	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	4	2	2	6	4	0	24	37	-1	41	49													Vb 18	CASSLQTGDGYTF+TCRBV18-01+TCRBJ01-02	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCGGGGCCAGGGTGACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	19	3.358789421581106E-4		43	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	4	3	3	5	2	24	38	48	43	50													Vb 18	X+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACGAGGGACACCCGAGCGAGAGACCCAGTACTTCGGGCCA	CASSRGTPERETQYF	In	VDJ	1	19	3.358789421581106E-4	4.066084574559151E-4	45	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	4	0	6	4	2	8	24	37	45	39	53													Vb 18	CASSRGTPERETQYF+TCRBV18-01+TCRBJ02-05	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACAAGACTACGAGCAGTACTTCGGGCCG	CASSPQDYEQYF	In	VDJ	1	20	3.5355678121906376E-4	4.2800890258517377E-4	36	TCRBV18	TCRBV18-01	01				TCRBJ02	TCRBJ02-07	01	1	2	8	3	2	0	24	40	-1	42	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPQDYEQYF+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACTATATAGGCAAGAGACCCAGTACTTCGGGCCA	CASSLYRQETQYF	In	VDJ	1	21	3.71234620280017E-4	4.4940934771443245E-4	39	TCRBV18	TCRBV18-01	01				TCRBJ02	TCRBJ02-05	01	4	5	4	2	5	0	24	37	-1	42	45				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSLYRQETQYF+TCRBV18-01+TCRBJ02-05	TCRBV18-01*01		TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCAGCTTTCCCAGCGGGGGGGCTCCACAATGAGCAGTTCTTCGGGCCA	CASSAFPAGGLHNEQFF	In	VDJ	1	21	3.71234620280017E-4	4.4940934771443245E-4	51	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	5	6	0	5	8	4	24	36	54	44	58													Vb 18	CASSAFPAGGLHNEQFF+TCRBV18-01+TCRBJ02-01	TCRBV18-01*01	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACAAACCCTTAATGAAAAACTGTTTTTTGGCAGT	CASSQTLNEKLFF	In	VDJ	1	22	3.8891245934097015E-4	4.7080979284369113E-4	39	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-04	01	4	3	7	4	2	3	24	37	41	39	44				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSQTLNEKLFF+TCRBV18-01+TCRBJ01-04	TCRBV18-01*01		TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACTATCCTCCTCACAGGGGATCATGAACACTGAAGCTTTCTTTGGACAA	CASSLSSSQGIMNTEAFF	In	VDJ	1	22	3.8891245934097015E-4	4.7080979284369113E-4	54	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	4	3	2	0	10	4	24	37	54	47	58													Vb 18	CASSLSSSQGIMNTEAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACTACGGACAGGGCGCGACACTGAAGCTTTCTTTGGACAA	CASSPLRTGRDTEAFF	In	VDJ	1	23	4.0659029840192336E-4	4.922102379729498E-4	48	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	1	3	3	3	4	24	40	51	43	55													Vb 18	CASSPLRTGRDTEAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCGTTCGACAGGAGCTCTGGAAACACCATATATTTTGGAGAG	CASSPFDRSSGNTIYF	In	VDJ	1	23	4.0659029840192336E-4	4.922102379729498E-4	48	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	3	2	4	0	4	2	24	38	48	42	50													Vb 18	CASSPFDRSSGNTIYF+TCRBV18-01+TCRBJ01-03	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCATCGGCCAAAATGAGTACGCAGTATTTTGGCCCA	CASSSAKMSTQYF	In	VDJ	1	23	4.0659029840192336E-4	4.922102379729498E-4	39	TCRBV18	TCRBV18-01	01				TCRBJ02	TCRBJ02-03	01	5	9	0	8	2	9	24	36	41	38	50				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSSAKMSTQYF+TCRBV18-01+TCRBJ02-03	TCRBV18-01*01		TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACAGGGGACTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSPQGTGANVLTF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	45	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	1	5	2	2	0	1	24	-1	45	40	46													Vb 18	CASSPQGTGANVLTF+TCRBV18-01+TCRBJ02-06	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCGCCGGGACAACGATACACAGATACGCAGTATTTTGGCCCA	CASSPPGQRYTDTQYF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	48	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	3	0	6	2	3	6	24	38	47	41	53													Vb 18	CASSPPGQRYTDTQYF+TCRBV18-01+TCRBJ02-03	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCGAAAGTGGGGGGGTCGGAGAGACCCAGTACTTCGGGCCA	CAESGGVGETQYF	In	VDJ	1	24	4.2426813746287653E-4	5.136106831022085E-4	39	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	11	9	0	4	6	4	24	30	43	36	47													Vb 18	CAESGGVGETQYF+TCRBV18-01+TCRBJ02-05	TCRBV18-01*01	TCRBD02-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCGGACAGTATCACTGAAGCTTTCTTTGGACAA	CASSPDSITEAFF	In	VDJ	1	25	4.4194597652382975E-4	5.350111282314672E-4	39	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	3	1	5	4	0	3	24	-1	44	38	47													Vb 18	CASSPDSITEAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACCGGCAGGGGCCAACACCGGGGAGCTGTTTTTTGGAGAA	CASSPPAGANTGELFF	In	VDJ	1	27	4.7730165464573613E-4	5.778120184899846E-4	48	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	0	4	2	2	2	2	24	41	49	43	51													Vb 18	CASSPPAGANTGELFF+TCRBV18-01+TCRBJ02-02	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACCGACTAGCGGGAGCTCGACCTACGAGCAGTACTTCGGGCCG	CASSPPTSGSSTYEQYF	In	VDJ	1	28	4.949794937066893E-4	5.992124636192433E-4	51	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	0	2	2	2	0	5	24	-1	53	41	58													Vb 18	CASSPPTSGSSTYEQYF+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACCGTGGGCTAGCGGGAGTTACGAGCAGTACTTCGGGCCG	CASSPPWASGSYEQYF	In	VDJ	1	28	4.949794937066893E-4	5.992124636192433E-4	48	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	0	4	2	4	5	1	24	41	56	46	57													Vb 18	CASSPPWASGSYEQYF+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01	TCRBD02-01*02	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACTACCGCCGATCGGAGCCAAAAACATTCAGTACTTCGGCGCC	CASSPLPPIGAKNIQYF	In	VDJ	1	28	4.949794937066893E-4	5.992124636192433E-4	51	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-04	01	1	8	5	0	10	0	24	40	-1	50	53						01,02							Vb 18	CASSPLPPIGAKNIQYF+TCRBV18-01+TCRBJ02-04	TCRBV18-01*01	TCRBD02-01	TCRBJ02-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACGTCAGGCGGGAGGGCGGACCGGGGAGCTGTTTTTTGGAGAA	CASSPRQAGGRTGELFF	In	VDJ	1	30	5.303351718285957E-4	6.420133538777606E-4	51	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	1	7	0	5	5	3	24	40	54	45	57													Vb 18	CASSPRQAGGRTGELFF+TCRBV18-01+TCRBJ02-02	TCRBV18-01*01	TCRBD02-01*02	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCCGGGCTTGACTACGAGCAGTACTTCGGGCCG	CASSPGLDYEQYF	In	VDJ	1	31	5.480130108895489E-4	6.634137990070194E-4	39	TCRBV18	TCRBV18-01	01				TCRBJ02	TCRBJ02-07	01	3	8	0	3	1	4	24	38	43	39	47				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPGLDYEQYF+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01		TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCTGGAGGGAAGGGGACAGATACGCAGTATTTTGGCCCA	CASSPGGKGTDTQYF	In	VDJ	1	31	5.480130108895489E-4	6.634137990070194E-4	45	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-03	01	3	10	0	3	1	6	24	38	45	39	51													Vb 18	CASSPGGKGTDTQYF+TCRBV18-01+TCRBJ02-03	TCRBV18-01*01	TCRBD02-01*02	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCAGAGGGACAGGGGGATTCACCCCTCCACTTTGGGAAC	CASSEGQGDSPLHF	In	VDJ	1	31	5.480130108895489E-4	6.634137990070194E-4	42	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	5	0	1	8	2	0	24	36	-1	38	49													Vb 18	CASSEGQGDSPLHF+TCRBV18-01+TCRBJ01-06	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCAGAACAGGGGAACCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	34	6.010465280724084E-4		43	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	3	2	2	2	2	24	39	48	41	50													Vb 18	X+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCAGCCTCCGGGGGCGACACTGAAGCTTTCTTTGGACAA	CASSASGGDTEAFF	In	VDJ	1	34	6.010465280724084E-4	7.276151343947955E-4	42	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-01	01	5	6	0	3	6	1	24	36	48	42	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSASGGDTEAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCTCTTCCGGGGGCAGAGAATTCACCCCTCCACTTTGGGAAC	CASSPLPGAENSPLHF	In	VDJ	1	37	6.54080045255268E-4	7.918164697825714E-4	48	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-06	01	3	6	0	7	6	4	24	38	50	44	54				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPLPGAENSPLHF+TCRBV18-01+TCRBJ01-06	TCRBV18-01*01		TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCAACCTTCCCGATAATGAACACTGAAGCTTTCTTTGGACAA	CASSPTFPIMNTEAFF	In	VDJ	2	41	7.247914014990807E-4	8.774182502996063E-4	48	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-01	01	2	2	8	0	8	3	24	39	49	47	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPTFPIMNTEAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACCGGGGACGGCAAGCCATAATGAAAAACTGTTTTTTGGCAGT	CASSPPGTASHNEKLFF	In	VDJ	2	42	7.42469240560034E-4	8.988186954288649E-4	51	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-04	01	0	0	7	4	1	9	24	41	47	42	56				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPPGTASHNEKLFF+TCRBV18-01+TCRBJ01-04	TCRBV18-01*01		TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCCATACCAGGGGAGCTAGCCGGGGAGCTGTTTTTTGGAGAA	CASSPIPGELAGELFF	In	VDJ	2	50	8.838919530476595E-4	0.0010700222564629343	48	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	3	4	2	6	5	6	24	38	49	43	55													Vb 18	CASSPIPGELAGELFF+TCRBV18-01+TCRBJ02-02	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-02*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACCGATCATAAACACTGAAGCTTTCTTTGGACAA	CASSPPIINTEAFF	In	VDJ	2	54	9.546033092914723E-4	0.0011556240369799693	42	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-01	01	0	2	8	2	0	5	24	-1	43	41	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSPPIINTEAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCATCCGGGGGAGCGGTCGAGCAGTACTTCGGGCCG	CASSPSGGAVEQYF	In	VDJ	2	61	0.0010783481827181445	0.00130542715288478	42	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-07	01	2	8	2	6	2	6	24	39	47	41	53													Vb 18	CASSPSGGAVEQYF+TCRBV18-01+TCRBJ02-07	TCRBV18-01*01	TCRBD02-01*01	TCRBJ02-07*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCAAGGCTAGCGGGAGACGAGGAGACCCAGTACTTCGGGCCA	CASSPRLAGDEETQYF	In	VDJ	2	62	0.0010960260217790978	0.0013268275980140387	48	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	2	4	2	5	3	5	24	39	52	42	57													Vb 18	CASSPRLAGDEETQYF+TCRBV18-01+TCRBJ02-05	TCRBV18-01*01	TCRBD02-01*02	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCGGACGAGTACCGCGAAGCTTTCTTTGGACAA	CASSDEYREAFF	In	VDJ	2	62	0.0010960260217790978	0.0013268275980140387	36	TCRBV18	TCRBV18-01	01				TCRBJ01	TCRBJ01-01	01	6	1	7	8	0	9	24	-1	39	35	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSDEYREAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01		TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCTACCAGGGACCCGGCGACTAGCGGGAGAGAGCAGTTCTTCGGGCCA	CASSPTRDPATSGREQFF	In	VDJ	3	71	0.0012551265733276764	0.001519431604177367	54	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	3	2	2	10	15	1	24	38	65	53	66													Vb 18	CASSPTRDPATSGREQFF+TCRBV18-01+TCRBJ02-01	TCRBV18-01*01	TCRBD02-01*02	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGTTCGGGACAGCAAGAGACCCAGTACTTCGGGCCA	CASSGQQETQYF	In	VDJ	3	74	0.001308160090510536	0.0015836329395651429	36	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	9	0	5	2	3	0	24	32	-1	35	42													Vb 18	CASSGQQETQYF+TCRBV18-01+TCRBJ02-05	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-05*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCAGGACAGGGCCCAGATACGCAGTATTTTGGCCCA	CASSPGQGPDTQYF	In	VDJ	3	83	0.0014672606420591146	0.001776236945728471	42	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	2	1	3	4	0	2	24	-1	47	39	49													Vb 18	CASSPGQGPDTQYF+TCRBV18-01+TCRBJ02-03	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACTTGGACAGGTTAATTCACCCCTCCACTTTGGGAAC	CASSLGQVNSPLHF	In	VDJ	3	87	0.0015379719983029275	0.001861838726245506	42	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-06	01	4	1	4	6	2	1	24	37	46	39	47													Vb 18	CASSLGQVNSPLHF+TCRBV18-01+TCRBJ01-06	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-06*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCAGAAGGGGTGAACACTGAAGCTTTCTTTGGACAA	CASSPEGVNTEAFF	In	VDJ	4	92	0.0016263611936076935	0.0019688409518917992	42	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	5	2	0	2	0	24	39	-1	41	46													Vb 18	CASSPEGVNTEAFF+TCRBV18-01+TCRBJ01-01	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCCCCGGGACAGGGCCCAGATACGCAGTATTTTGGCCCA	CASSPGQGPDTQYF	In	VDJ	5	124	0.0021920520435581956	0.0026536551960280774	42	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	6	0	3	4	3	2	24	35	47	38	49													Vb 18	CASSPGQGPDTQYF+TCRBV18-01+TCRBJ02-03	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-03*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCAGCTTTCCCAGCGGGGGGGCCCCACAATGAGCAGTTCTTCGGGCCA	CASSAFPAGGPHNEQFF	In	VDJ	5	136	0.0024041861122896338	0.002910460537579182	51	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	5	6	0	5	8	4	24	36	54	44	58													Vb 18	CASSAFPAGGPHNEQFF+TCRBV18-01+TCRBJ02-01	TCRBV18-01*01	TCRBD02-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACGCCAGGGGGGAATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	7	183	0.0032350445481544336		44	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	1	4	1	5	2	1	24	40	49	42	50													Vb 18	X+TCRBV18-01+TCRBJ01-04	TCRBV18-01*01	TCRBD01-01*01	TCRBJ01-04*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCCCCTGGGCGGTTAGCGGTCCCCTTATCCTACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	22	581	0.010270824494413803		55	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	8	5	5	1	11	8	24	33	50	44	58						01,02							Vb 18	X+TCRBV18-01+TCRBJ02-01	TCRBV18-01*01	TCRBD02-01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCCTTACTTGGGGACAGGCTTTACAATGAGCAGTTCTTCGGGCCA	CASSLLGDRLYNEQFF	In	VDJ	41	1089	0.019251166737378023	0.023305084745762712	48	TCRBV18	TCRBV18-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	6	0	4	4	8	3	24	35	51	43	54													Vb 18	CASSLLGDRLYNEQFF+TCRBV18-01+TCRBJ02-01	TCRBV18-01*01	TCRBD01-01*01	TCRBJ02-01*01	2220A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				2494	2060	398	35	0	1382	1136	218	28	0	56568	46728	9042	798	0	0.116652787	8.96575069	0.110245243	9.28240395				13926	0.148325905	0.0264937505	0.0218851641	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:08	Age (Range):45-65 Years (Late Adulthood),Age:59 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 226,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/paclitaxel then docetaxel	0.8259823351450567	MSKCC- Snyder- P01-02		2066.0	
